



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/11/02
(87) Date publication PCT/PCT Publication Date: 2019/05/09
(85) Entrée phase nationale/National Entry: 2020/04/28
(86) N° demande PCT/PCT Application No.: US 2018/058949
(87) N° publication PCT/PCT Publication No.: 2019/090069
(30) Priorités/Priorities: 2017/11/02 (US62/580,726);
2018/03/14 (US62/643,059)

(51) Cl.Int./Int.Cl. *C07C 235/22* (2006.01),
A61K 31/165 (2006.01), *A61K 31/395* (2006.01),
A61K 31/416 (2006.01), *A61K 31/42* (2006.01),
A61K 31/44 (2006.01), *A61K 31/495* (2006.01),
A61K 31/519 (2006.01), *C07C 317/22* (2006.01),
C07C 323/20 (2006.01), *C07D 213/30* (2006.01),
C07D 213/68 (2006.01), ...

(71) Demandeurs/Applicants:
CALICO LIFE SCIENCES LLC, US;
ABBVIE INC., US

(72) Inventeurs/Inventors:
MARTIN, KATHLEEN ANN, US;
SIDDRAUSKI, CARMELA, US; ...

(54) Titre : **MODULATEURS DE LA VOIE DE REPONSE INTEGREE AU STRESS**

(54) Title: **MODULATORS OF THE INTEGRATED STRESS PATHWAY**

(57) **Abrégé/Abstract:**

Provided herein are compounds, compositions, and methods useful for the modulation of eIF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

(51) Cl.Int./Int.Cl. (suite/continued) *C07D 231/56* (2006.01), *C07D 237/14* (2006.01), *C07D 241/18* (2006.01), *C07D 261/20* (2006.01), *C07D 271/06* (2006.01), *C07D 271/113* (2006.01), *C07D 487/04* (2006.01)

(72) **Inventeurs(suite)/Inventors(continued):** PLIUSHCHEV, MARINA A., US; FROST, JENNIFER M., US; TONG, YUNSONG, US; BLACK, LAWRENCE A., US; XU, XIANGDONG, US; SHI, LEI, US; ZHANG, QINGWEI I., US; CHUNG, SEUNGWON, US; XIONG, ZHAOMING, US; SWEIS, RAMZI FARAH, US; DART, MICHAEL J., US; BROWN, BRIAN S., US; MURAUSKI, KATHLEEN, US

(74) **Agent:** GOWLING WLG (CANADA) LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

09 May 2019 (09.05.2019)



(10) International Publication Number

WO 2019/090069 A1

(51) International Patent Classification:

C07D 213/73 (2006.01) **C07D 471/04** (2006.01)
C07D 317/64 (2006.01) **C07D 261/08** (2006.01)
C07D 231/56 (2006.01) **C07D 261/20** (2006.01)
C07C 311/13 (2006.01) **C07C 235/22** (2006.01)
C07D 401/04 (2006.01) **C07D 271/113** (2006.01)
C07D 237/14 (2006.01) **C07D 213/30** (2006.01)
C07D 237/16 (2006.01) **C07D 213/66** (2006.01)
C07D 405/08 (2006.01) **A61K 31/44** (2006.01)
C07D 241/18 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:

PCT/US2018/058949

(22) International Filing Date:

02 November 2018 (02.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/580,726 02 November 2017 (02.11.2017) US
 62/643,059 14 March 2018 (14.03.2018) US

(71) **Applicants:** **CALICO LIFE SCIENCES LLC** [US/US];
 1170 Veterans Blvd, South San Francisco, CA 94080 (US).
ABBVIE INC. [US/US]; 1 North Waukegan Road, North
 Chicago, IL 60064 (US).

(72) **Inventors:** **MARTIN, Kathleen, Ann**; 3450 Sacramen-
 to Street, San Francisco, CA 94118 (US). **SIDRAUSKI,**
Carmela; 20434 Walnut Ave., Saratoga, CA 95070 (US).
PLIUSHCHEV, Marina, A.; 337 Albert Drive, Vernon
 Hills, IL 60061 (US). **FROST, Jennifer, M.**; 635 York-
 town Lane, Gurnee, IL 60031 (US). **TONG, Yunsong**;
 1408 Braxton Road, Libertyville, IL 60048 (US). **BLACK,**
Lawrence, A.; 150 Puukolii Road, Apt. 33, Lahaina, HI
 96761 (US). **XU, Xiangdong**; 4 River Oaks Circle West,
 Buffalo Grove, IL 60089 (US). **SHI, Lei**; 1908 Trevino
 Terrace, Vernon Hills, IL 60061 (US). **ZHANG, Qing-**
wei, I.; 1820 S Falcon Drive, Libertyville, IL 60048 (US).
CHUNG, Seungwon; 1512 Virginia Avenue, Libertyville,
 IL 60048 (US). **XIONG, Zhaoming**; 37 River Oaks Cir-
 cle East, Buffalo Grove, IL 60089 (US). **SWEIS, Ramzi,**
Farah; 1012 Plaister Avenue, Lake Bluff, IL 60044 (US).
DART, Michael, J.; 844 Yale Lane, Highland Park, IL
 60035 (US). **BROWN, Brian, S.**; 812 Washington St.,
 Evanston, IL 60202 (US). **MURAUSKI, Kathleen**; 1807
 W. Argyle Street, Apt. 404, Chicago, IL 60640 (US).

(74) **Agent:** **MCCARTY, Catherine, M.** et al.; Goodwin Proc-
 ter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) **Designated States** (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
 kind of regional protection available*): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 KM, ML, MR, NE, SN, TD, TG).

Published:— *with international search report (Art. 21(3))*

(54) **Title:** MODULATORS OF THE INTEGRATED STRESS PATHWAY

(57) **Abstract:** Provided herein are compounds, compositions, and methods useful for the modulation of eIF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

WO 2019/090069 A1

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 363

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 363

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

1X

NOTE POUR LE TOME / VOLUME NOTE:

1

- 1 -

MODULATORS OF THE INTEGRATED STRESS PATHWAY

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/580,726, filed
5 November 2, 2017 and U.S. Provisional Application No. 62/643,059, filed March 14, 2018,
which are incorporated herein by reference in their entirety.

BACKGROUND

In metazoa, diverse stress signals converge at a single phosphorylation event at serine 51
10 of a common effector, the translation initiation factor eIF2 α . This step is carried out by four
eIF2 α kinases in mammalian cells: PERK, which responds to an accumulation of unfolded
proteins in the endoplasmic reticulum (ER), GCN2 to amino acid starvation and UV light, PKR
to viral infection and metabolic stress, and HRI to heme deficiency. This collection of signaling
pathways has been termed the “integrated stress response” (ISR), as they converge on the same
15 molecular event. eIF2 α phosphorylation results in an attenuation of translation with
consequences that allow cells to cope with the varied stresses (Wek, R.C. et al, *Biochem Soc
Trans* (2006) 34(Pt 1):7-11).

eIF2 (which is comprised of three subunits, α , β and γ) binds GTP and the initiator Met-
tRNA to form the ternary complex (eIF2-GTP-Met-tRNA_i), which, in turn, associates with the
20 40S ribosomal subunit scanning the 5'UTR of mRNAs to select the initiating AUG codon.
Upon phosphorylation of its α -subunit, eIF2 becomes a competitive inhibitor of its GTP-
exchange factor (GEF), eIF2B (Hinnebusch, A.G. and Lorsch, J.R. *Cold Spring Harbor Perspect
Biol* (2012) 4(10)). The tight and nonproductive binding of phosphorylated eIF2 to eIF2B
prevents loading of the eIF2 complex with GTP, thus blocking ternary complex formation and
25 reducing translation initiation (Krishnamoorthy, T. et al, *Mol Cell Biol* (2001) 21(15):5018-
5030). Because eIF2B is less abundant than eIF2, phosphorylation of only a small fraction of the
total eIF2 has a dramatic impact on eIF2B activity in cells.

eIF2B is a complex molecular machine, composed of five different subunits, eIF2B1
through eIF2B5. eIF2B5 catalyzes the GDP/GTP exchange reaction and, together with a
30 partially homologous subunit eIF2B3, constitutes the “catalytic core” (Williams, D.D. et al, *J
Biol Chem* (2001) 276:24697-24703). The three remaining subunits (eIF2B1, eIF2B2, and


- 2 -

eIF2B4) are also highly homologous to one another and form a “regulatory sub-complex” that provides binding sites for eIF2B’s substrate eIF2 (Dev, K. et al, *Mol Cell Biol* (2010) 30:5218-5233). The exchange of GDP with GTP in eIF2 is catalyzed by its dedicated guanine nucleotide exchange factor (GEF) eIF2B. eIF2B exists as a decamer (B1₂ B2₂ B3₂ B4₂ B5₂) or dimer of two pentamers in cells (Gordiyenko, Y. et al, *Nat Commun* (2014) 5:3902; Wortham, N.C. et al, *FASEB J* (2014) 28:2225-2237). Molecules such as ISRIB interact with and stabilize the eIF2B dimer conformation, thereby enhancing intrinsic GEF activity and making cells less sensitive to the cellular effects of phosphorylation of eIF2 (Sidrauski, C. et al, *eLife* (2015) e07314; Sekine, Y. et al, *Science* (2015) 348:1027-1030). As such, small molecule therapeutics that can modulate eIF2B activity may have the potential to attenuate the PERK branch of the UPR and the overall ISR, and therefore may be used in the prevention and/or treatment of various diseases, such as a neurodegenerative disease, a leukodystrophy, cancer, an inflammatory disease, a musculoskeletal disease, or a metabolic disease.

SUMMARY OF THE INVENTION

The present invention features compounds, compositions, and methods for the modulation of eIF2B (e.g., activation of eIF2B) and the attenuation of the ISR signaling pathway. In some embodiments, the present invention features an eIF2B modulator (e.g., an eIF2B activator) comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof. In other embodiments, the present invention features methods of using a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof for the treatment of a disease or disorder, e.g., a neurodegenerative disease, a leukodystrophy, cancer, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a disease or disorder associated with impaired function of eIF2B or components in the ISR pathway (e.g., eIF2 pathway).

In one aspect, the present invention features a compound of Formula (I):



Formula (I)

- 3 -


or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein D is a bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, bridged bicyclic cycloalkenyl, or cubanyl, wherein each bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, bridged bicyclic cycloalkenyl, or cubanyl is optionally substituted with 1-4 R^X groups; and wherein if the bridged bicyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen moiety may be optionally substituted by R^{N1}; L¹ and L² are each independently C₁-C₆ alkylene, C₂-C₆ alkenylene, 2-7-membered heteroalkylene, O, or NR^C, wherein each C₁-C₆ alkylene, C₂-C₆ alkenylene, or 2-7-membered heteroalkylene is optionally substituted with 1-5 R^L; R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy-C₂-C₆ alkyl, hydroxy-C₂-C₆ alkyl, silyloxy-C₂-C₆ alkyl, G¹-O-C₂-C₆ alkyl, HO₂C-C₁-C₆ alkyl, or C₁-C₆ alkyl-C(O)₂-C₁-C₆ alkyl; each R^L is independently selected from the group consisting of C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, hydroxy-C₁-C₆ alkoxy, halo-C₁-C₆ alkyl, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, HO₂C-C₁-C₆ alkyl, C₁-C₆ alkyl-C(O)₂-C₁-C₆ alkyl, oxo, halo, cyano, -OR^A, -NR^BR^C, -NR^BR^{CC}, -NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -SR^E, -S(O)R^D, -S(O)₂R^D, -OS(O)R^D, -OS(O)₂R^D, and G²; or 2 geminal R^L groups together with the carbon to which they are attached form a cyclopropyl moiety; R^{N1} is selected from the group consisting of hydrogen, C₁-C₆ alkyl, hydroxy-C₂-C₆ alkyl, halo-C₂-C₆ alkyl, amino-C₂-C₆ alkyl, cyano-C₂-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, HO₂C-C₁-C₆ alkyl, C₁-C₆ alkyl-C(O)₂-C₁-C₆ alkyl, phenoxy-C₁-C₆ alkyl (wherein phenoxy is optionally substituted with 1-3 halogens), -C(O)NR^BR^C, -C(O)R^D, -C(O)OR^D, and -S(O)₂R^D; A and W are each independently aryl or 5-6-membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R^Y; each R^X is independently selected from the group consisting of C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkyl-C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkoxy, oxo, halo, cyano, -OR^A, -NR^BR^C, -NR^BR^{CC}, -NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, =CHC(O)OR^D, =CHC(O)OH, -SR^E, -S(O)R^D, -S(O)₂R^D, -OS(O)R^D, -OS(O)₂R^D, and G²; or 2 geminal R^X groups together with the carbon to which they are attached form an oxirane moiety; each R^Y is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, O-C₃-C₆ cycloalkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, hydroxy-C₁-C₆ alkoxy, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, oxo, halo, cyano, -OR^A, -NR^BR^C, -NR^BR^{CC}, -NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)R^D, -S(O)₂R^D, and G¹; or 2 R^Y groups on adjacent atoms,

- 4 -


together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl, heterocyclyl, aryl, or heteroaryl ring optionally substituted with 1-5 R^X ; each G^1 and G^2 is independently C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl, wherein each C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 R^Z ; each R^Z is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, and $-S(O)_2 R^D$; each R^A is independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, $-C(O)NR^B R^C$, $-C(O)R^D$, or $-C(O)OR^D$; each of R^B and R^C is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl; R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with 1-3 R^Z ; each R^{CC} is independently selected from the group consisting of hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, (CO) - C_1 - C_6 alkyl-OH, (CO) - C_1 - C_6 alkyl- C_1 - C_6 alkoxy and 4-6 membered heterocyclyl; wherein the heterocyclyl may optionally be substituted with 1-3 R^Z ; each R^D is independently C_1 - C_6 alkyl, 2-7-membered heteroalkyl, hydroxy- C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl, wherein each C_1 - C_6 alkyl, 2-7-membered heteroalkyl, hydroxy- C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl is optionally substituted with 1-5 R^G ; each R^E is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl; each R^F is independently hydrogen, C_1 - C_6 alkyl, or halo; each R^G is independently aryl or 5-6 membered heteroaryl, wherein each aryl or 5-6 membered heteroaryl is optionally substituted with 1-5 R^H ; each R^H is independently C_1 - C_6 alkyl or halo- C_1 - C_6 alkyl; m is 1 when R^F is hydrogen or C_1 - C_6 alkyl, 3 when R^F is C_1 - C_6 alkyl, or 5 when R^F is halo; t is 0 or 1; and s is 0 or 1.

In some embodiments, D is a bridged bicyclic cycloalkyl, a bridged bicyclic heterocyclyl, or cubanyl, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is a bridged 5-8 membered bicyclic cycloalkyl or heterocyclyl, or cubanyl, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is selected from cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.2.2]oct-2-ene, bicyclo[2.1.1]hexane, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[3.2.1]octane, or 2-azabicyclo[2.2.2]octane, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is selected from cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.1.1]hexane, or bicyclo[3.1.1]heptane, each of which is optionally substituted with 1-4 R^X groups. In some

embodiments, D is selected from:




In some embodiments, D is selected from:




embodiments, D is substituted with 1 or 2 R^X. In some embodiments, R^X is independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkoxy, oxo, halo, cyano, -OR^A, -OS(O)₂R^D, -S(O)₂R^D, -SR^E, NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, =CHC(O)OH, =CHC(O)OR^D, NR^BR^C, NR^BR^{CC}, or G²; or 2 geminal R^X groups together with the carbon to which they are attached form an oxirane moiety. In some embodiments, R^X is independently CH₃, -CH₂OH, -CH₂OCH₃, -CH₂CH₂CH₃, -C(CH₃)₂OH, -O-CH₂-O-CH₃, CH₂CH₂OH, oxo, fluoro, bromo, OH, cyano, OCH₃, NH₂, N(H)CH₂CF₃, N(H)CH₂CH₂OH, N(CH₃)₂, N(CH₃)CH₂CH₂OH, N(CH₃)CH₂CO₂H, N(CH₃)CH₂CH₂CO₂H, NHC(O)CH₃, OC(O)CH₃, C(O)NH₂, OS(O)₂CH₃, -S(O)₂CH₃, -S(O)₂CH₂CH₃, C(O)OH,

- 6 -



In some embodiments, G^2 is oxadiazolyl or tetrazolyl.


In some embodiments, D is substituted with 0 R^X . In some embodiments, D is



In some embodiments, at least one of L^1 and L^2 is independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^L . In some embodiments, one of L^1 and L^2 is independently C_1 - C_6 alkylene or C_2 - C_6 alkenylene and the other of L^1 and L^2 is independently 2-7-membered heteroalkylene, and wherein each C_1 - C_6 alkylene, C_2 - C_6 alkenylene, and 2-7-membered heteroalkylene is optionally substituted by 1-5 R^L .


In some embodiments, each R^L is independently C_1 - C_6 alkyl, OH, oxo, $-C(O)R^D$, cyano, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, $-C(O)OH$, $-NR^B R^C$, $-NR^B R^{CC}$, $-NR^B C(O)R^D$, hydroxy- C_1 - C_6 alkyl, or hydroxy- C_1 - C_6 alkoxy. each R^L is independently CH_3 , oxo, or $C(O)CH_3$.

In some embodiments, each of L^1 and L^2 is independently selected from CH_2O^* , $CH_2CH_2^*$, $CH_2CH_2CH_2^*$, CH_2^* , $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, $NHCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $CH(OH)^*$, $CH(OH)CH_2CH_2^*$, $CH_2CH(OH)^*$, $CH_2NHC(O)^*$, $NHC(O)OCH_2^*$, O^* , NH^* , $S(O)_2CH^*$, $S(O)_2CH_2CH_2^*$, $S(O)_2CH_2CH_2O^*$, $CH_2C(O)^*$, $O-CH_2CH_2^*$, $CH_2N(CH_2CO_2H)^*$, $CH(CO_2H)CH_2CH_2O^*$, $CH_2N(CH_2CO_2C(CH_3)_3)^*$, $CH(CN)CH_2O^*$, $CH_2CH(NH(CH_3))^*$, $CH(OCH_2CH_2OH)^*$,

$CH_2CH(NH(C(O)CH_2OH))^*$, $CH_2CH(NH_2)CH_2^*$, $CH(CH_2CH_2OH)O^*$ or , and “-
 *” indicates the attachment point to A and W, respectively. In some embodiments, L^1 is

- 7 -

independently selected from $\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{CH}_2\text{O}-^*$ or $\text{CH}=\text{CH}-^*$, L^2 is independently selected from $\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{CH}_2-^*$, $\text{CH}_2\text{CH}_2\text{CH}_2-^*$, CH_2-^* , $\text{CH}_2\text{C}(\text{O})-^*$, $\text{CH}=\text{CH}-^*$, $\text{CH}_2\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{OCH}_2-^*$, $\text{CH}_2\text{OCH}_2\text{CH}_2-^*$, $\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{CH}_2\text{OCH}_2-^*$, NHCH_2-^* , $\text{CH}_2\text{NH}-^*$, $\text{CH}_2\text{N}(\text{CH}_3)-^*$, $\text{CH}_2\text{N}(\text{CH}_3)\text{C}(\text{O})-^*$, $\text{CH}_2\text{N}(\text{C}(\text{O})\text{CH}_3)-^*$, $\text{CH}_2\text{CH}(\text{OH})-^*$, $\text{CH}(\text{OH})-^*$, $\text{CH}(\text{OH})\text{CH}_2\text{CH}_2-^*$, $\text{CH}_2\text{CH}(\text{OH})-^*$, $\text{CH}_2\text{NHC}(\text{O})-^*$, $\text{NHC}(\text{O})\text{OCH}_2-^*$, $\text{O}-^*$, $\text{NH}-^*$, $\text{S}(\text{O})_2\text{CH}-^*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2-^*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{C}(\text{O})-^*$, $\text{CH}_2\text{N}(\text{CH}_2\text{CO}_2\text{H})-^*$, $\text{CH}(\text{CO}_2\text{H})\text{CH}_2\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{N}(\text{CH}_2\text{CO}_2\text{C}(\text{CH}_3)_3)-^*$, $\text{CH}(\text{CN})\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{CH}(\text{NH}(\text{CH}_3))-^*$, $\text{CH}(\text{OCH}_2\text{CH}_2\text{OH})-^*$, $\text{CH}_2\text{CH}(\text{NH}(\text{C}(\text{O})\text{CH}_2\text{OH}))-^*$, $\text{CH}_2\text{CH}(\text{NH}_2)\text{CH}_2-^*$, $\text{CH}(\text{CH}_2\text{CH}_2\text{OH})\text{O}-^*$, $\text{CH}_2\text{C}(\text{CH}_3)_2\text{O}-^*$ or




, and “-*” indicates the attachment point to A and W, respectively.

10 In some embodiments, t is 1 and s is 1. In some embodiments, s is 1 and t is 0. In some embodiments, s is 1 and t is 0.

In some embodiments, R^1 and R^2 are each independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, hydroxyl- $\text{C}_2\text{-C}_6$ alkyl, or silyloxy- $\text{C}_2\text{-C}_6$ alkyl. one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ hydroxyl- $\text{C}_2\text{-C}_6$ alkyl, 15 silyloxy- $\text{C}_2\text{-C}_6$ alkyl, $\text{HO}_2\text{C-C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ alkyl- $\text{C}(\text{O})_2\text{-C}_1\text{-C}_6$ alkyl. wherein R^1 and R^2 are each independently hydrogen, $^*\text{-CH}_3$, $^*\text{-CH}_2\text{CH}_2\text{OH}$, $^*\text{-CH}_2\text{CH}_2\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_3$, $^*\text{-CH}_2\text{CO}_2\text{H}$, or $^*\text{-CH}_2\text{C}(\text{O})_2\text{C}(\text{CH}_3)$, and “-*” indicates the attachment point to the nitrogen atom. one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, $^*\text{-CH}_3$, $^*\text{-CH}_2\text{CH}_2\text{OH}$, $^*\text{-CH}_2\text{CH}_2\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_3$, $^*\text{-CH}_2\text{CO}_2\text{H}$, or $^*\text{-CH}_2\text{C}(\text{O})_2\text{C}(\text{CH}_3)$, and 20 “-*” indicates the attachment point to the nitrogen atom. In some embodiments, R^1 and R^2 are each independently hydrogen.

In some embodiments, each A and W is independently phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y . In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, triazinyl, pyrazolyl, 25 pyrimidinyl, triazolyl, oxadiazolyl, oxadiazolonyl, thiazolyl, imidazolyl, pyrimidin-2(1H)-onyl, 1H-benzo[d]imidazolyl, pyrazolo[1,5-a]pyridine, 1H-indazolyl or isoxazolyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently selected from:

- 8 -




- 9 -


In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, O - C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, hydroxy- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B R^{CC}$, $-NR^B C(O)R^D$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some

5 NR^BR^{CC}, -NR^BC(O)R^D, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹. In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, pyrimidinyl, triazinyl, pyrazolyl, triazolyl, oxadiazolyl, oxadiazolonyl, thiazolyl, imidazolyl, or isoxazolyl, each of which is optionally substituted with 1-5 R^Y groups.


In some embodiments, A is selected from:



In some embodiments, W is selected from:



In some embodiments, each R^Y is independently hydrogen, bromo, chloro, fluoro, iodo, cyano, CF₃, CHF₂, CH₂CF₃, CH₃, CH₂CH₃, OH, CH₂OH, C(CH₃)₂OH, OCH₃, OCH₂CH₃, OCHF₂, OCF₃, OCH₂CF₃, OCH₂CH₂OH, CH₂OCH₃, S(O)₂CH₃, S(O)₂CH₂CH₂CH₃, CN, N(CH₃)₂, SF₅, SCH₃, NH₂, NH(C(O)CH₂OH), NH(CH₂CH₂OH), NH(CO)CH₂OCH₃, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(OH)(CH₃)CF₃, S(O)₂CH₃, C(O)CH₃, C(O)OCH₃,



In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y, together with the atoms to which they are attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X. In some embodiments, the 2 R^Y together with the atoms to which they are attached form a phenyl, pyridyl, pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, dioxanyl, dioxolanyl, pyrrolidin-2-onyl, or morpholin-3-onyl ring, each of


- 11 -

which is optionally substituted with 1-5 R^X . In some embodiments, each R^X is independently C_1 - C_6 alkyl, OR^A , or halo. In some embodiments, each R^X is independently CH_3 , OR^A , or fluoro.

In some embodiments, G^1 is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z . In some embodiments, each R^Z is

5 independently C_1 - C_6 alkyl or halo.

In one aspect, the present invention features a compound of Formula (I-b):




Formula (I-b)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or
 10 stereoisomer thereof, wherein D is (1,2,3,4,6,7)-cubane, bicyclo[1.1.1]pentane,
 bicyclo[2.2.2]octane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane,
 bicyclo[3.2.1]octane, or 2-azabicyclo[2.2.2]octane, each of which is optionally substituted with
 1-4 R^X groups; and wherein 2-azabicyclo[2.2.2]octane is substituted on nitrogen by hydrogen or
 CH_3 ; L^1 and L^2 are each independently CH_2O^* , $CH_2CH_2^*$, $CH_2CH_2CH_2^*$, CH_2^* , $CH_2C(O)^*$,
 15 $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$,
 $NHCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$,
 $CH(OH)^*$, $CH(OH)CH_2CH_2^*$, $CH_2CH(OH)^*$, $CH_2NHC(O)^*$, $NHC(O)OCH_2^*$, O^* , NH^* ,
 $S(O)_2CH^*$, $S(O)_2CH_2CH_2^*$, $S(O)_2CH_2CH_2O^*$, or $CH_2C(O)^*$, and “-*” indicates the
 attachment point to A and W, respectively; R^1 and R^2 are each independently hydrogen, CH_3 ,
 20 CH_2CH_2OH , or $CH_2CH_2OSi(CH_3)_2C(CH_3)_3$; A and W are each independently isoxazolyl,
 phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, pyrimidinyl, triazinyl, thiazolyl, triazolyl,
 oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups; each
 R^X is independently selected from CH_3 , $-CH_2OH$, $-C(CH_3)_2OH$, oxo, fluoro, bromo, OH, cyano,
 OCH_3 , NH_2 , $N(CH_3)_2$, $NHC(O)CH_3$, $OC(O)CH_3$, $C(O)NH_2$, $OS(O)_2CH_3$, $-S(O)_2CH_3$, $-S(O)_2$
 25 CH_2CH_3 , $C(O)OH$, $OC(O)R^D$, $-C(O)CH_3$, $-SCH_3$, or G^2 ; each R^Y is independently bromo,
 chloro, fluoro, iodo, CF_3 , CHF_2 , CH_2CF_3 , CH_3 , CH_2CH_3 , OH, CH_2OH , $C(CH_3)_2OH$, OCH_3 ,
 OCH_2CH_3 , OCF_3 , $S(O)_2CH_3$, $S(O)_2CH_2CH_2CH_3$, CN, $N(CH_3)_2$, SF_5 , SCH_3 , NH_2 , $C(CH_3)_3$,
 $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$, $C(OH)(CH_3)CF_3$, $S(O)_2CH_3$, $C(O)CH_3$, $C(O)OCH_3$,
 $C(O)OH$, $OCHF_2$ or G^1 ; or 2 R^Y groups on adjacent atoms, together with the atoms to which
 30 they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, or dioxolanyl ring,

- 12 -

each of which is optionally substituted with 1-2 R^X ; G^1 and G^2 are cyclopropyl, isoxazolyl, phenyl, piperidiny, oxadiazolyl, or tetrazolyl, or pyrazolyl, each of which is optionally substituted with 1-2 R^Z ; each R^D is CH_2O optionally substituted with 1-5 R^G ; each R^G is independently pyridyl optionally substituted with 1-5 R^H ; each R^H is independently CF_3 ; each R^Z is independently CH_3 ; and t is 0 or 1.


In some embodiments, the compound of Formula (I) is a compound of Formula (I-c):



Formula (I-c)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.


In some embodiments, the compound of Formula (I) is a compound of Formula (I-d):



Formula (I-d)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.


In some embodiments, the compound of Formula (I) is a compound of Formula (I-e):



Formula (I-e)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

In some embodiments, the compound of Formula (I) is a compound of Formula (I-f):




Formula (I-f)

- 13 -

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

In some embodiments, the compound of Formula (I) is a compound of Formula (I-g):




5

Formula (I-g)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

In some embodiments, the compound of Formula (I) is a compound of Formula (I-h):




10

Formula (I-h)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

In some embodiments, the compound of Formula (I) is a compound of Formula (I-i):




15

Formula (I-i)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

In some embodiments, the compound of Formula (I) is a compound of Formula (I-j):




20

Formula (I-j)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

In some embodiments, the compound of Formula (I) is a compound of Formula (I-k):


- 14 -



Formula (I-k)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or
 5 stereoisomer thereof.


In some embodiments, the compound of Formula (I) is a compound of Formula (I-l):



Formula (I-l)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or
 10 stereoisomer thereof.

Also disclosed herein is a compound of Formula (II):



Formula (II)

15

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or
 stereoisomer thereof, wherein:

D is a bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl, wherein
 each bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl is optionally
 20 substituted with 1-4 Rˣ groups; and wherein if the bridged bicyclic heterocyclyl contains a
 substitutable nitrogen moiety, the substitutable nitrogen moiety may be optionally substituted by
 R^{N1};

L¹ is C₁-C₆ alkylene, C₂-C₆ alkenylene, 2-7-membered heteroalkylene, O, or NR^C,
 wherein C₁-C₆ alkylene, C₂-C₆ alkenylene, or 2-7-membered heteroalkylene is optionally
 25 substituted with 1-5 Rˣ;

L² is -(C₀-C₂ alkylene)-O-(C₀-C₂ alkylene)-;

- 15 -

R^1 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_2 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, and silyloxy- C_2 - C_6 alkyl;

R^{N1} is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, halo- C_2 - C_6 alkyl, amino- C_2 - C_6 alkyl, cyano- C_2 - C_6 alkyl, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OR^D$,
5 and $-S(O)_2R^D$;

A and W are each independently phenyl or 5-6-membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R^Y ;

each R^X is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl,
10 oxo, halo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BC(O)R^D$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-SR^E$, $-S(O)R^D$, $-S(O)_2R^D$, $-OS(O)R^D$, $-OS(O)_2R^D$, and G^2 ;

each R^Y is independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BC(O)R^D$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)R^D$, $-S(O)_2R^D$, and G^1 ; or
15

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl, heterocyclyl, aryl, or heteroaryl ring optionally substituted with 1-5 R^X ;

each G^1 and G^2 is independently C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-
20 6-membered heteroaryl, wherein each C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 R^Z ;

each R^Z is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BC(O)R^D$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, and $-S(O)_2R^D$;

each R^A is independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, $-C(O)NR^BR^C$, $-C(O)R^D$, or $-C(O)OR^D$;

each of R^B and R^C is independently hydrogen or C_1 - C_6 alkyl; or

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with 1-3 R^Z ;

each R^D is independently C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl,
30 wherein each C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl is optionally substituted with 1-5 R^G ;

- 16 -

each R^E is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl;

each R^F is independently hydrogen, C_1 - C_6 alkyl, or halo;


each R^G is independently aryl or 5-6 membered heteroaryl, wherein each aryl or 5-6 membered heteroaryl is optionally substituted with 1-5 R^H ;

5 each R^H is independently C_1 - C_6 alkyl or halo- C_1 - C_6 alkyl;

m is 1 when R^F is hydrogen or C_1 - C_6 alkyl, 3 when R^F is C_1 - C_6 alkyl, or 5 when R^F is halo; and; and

t is 0 or 1.


In some embodiments D is selected from the group consisting of



embodiments, each R^X is independently selected from the group consisting of oxo, $-OR^A$ (e.g., OH or OCH_3), $-C(O)OH$, $-C(O)OR^D$ (e.g., $-C(O)OCH_3$), halo, and hydroxy- C_1 - C_6 alkyl.


In some embodiments, L^1 is CH_2O-* or CH_2OCH_2-* ; wherein “-*” indicates the attachment point to A. In some embodiments, L^2 is selected from the group consisting of $O-*$,
 15 OCH_2-* , CH_2O-* , OCH_2CH_2-* , CH_2OCH_2-* , and CH_2CH_2O-* ; wherein “-*” indicates the attachment point to W. In some embodiments, R^1 is hydrogen or CH_3 .

In some embodiments, A is selected from the group consisting of:



20 In some embodiments, W is selected from the group consisting of:


- 17 -



wherein R^{N4} is hydrogen or CH_3 .

- 5 In some embodiments, wherein each R^Y is independently hydrogen, chloro, fluoro, CF_3 , CHF_2 , CH_3 , CH_2CH_3 , $CH(CH_3)_2$, OCH_3 , OCF_3 , $OCH(CH_3)_2$, or CN .

In some embodiments, the compound of Formula (II) is a compound of Formula (II-a):



Formula (II-a)

- 10 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein:

D is bicyclo[1.1.1]pentanyl or bicyclo[2.2.2]octanyl, each of which is optionally substituted with 1-4 R^X groups;

L^1 is CH_2O-* or CH_2OCH_2-* , wherein “-*” indicates the attachment point to A;

- 15 L^2 is selected from the group consisting of $O-*$, OCH_2-* , CH_2O-* , OCH_2CH_2-* , CH_2OCH_2-* , and CH_2CH_2O-* ; wherein “-*” indicates the attachment point to W;

A is phenyl or pyridyl, each of which is optionally substituted with 1-5 R^Y groups;

W is phenyl, pyridyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted on one or more available carbons with 1-5 R^Y groups; and wherein pyrazolyl may be optionally

- 20 substituted on an available nitrogen with hydrogen or CH_3 ;

each R^X is independently fluoro, oxo, OH, OCH_3 , $C(O)OH$, or $C(O)OCH_3$;

each R^Y is independently chloro, fluoro, CF_3 , CH_3 , CH_2CH_3 , $CH(CH_3)_2$, OCH_3 , $OCH(CH_3)_2$, or CN ; or

- 18 -

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a furanyl, pyrrolyl, or dioxolanyl ring, each of which is optionally substituted with 1-2 R^X; and R¹ is hydrogen.

5 In some embodiments, the compound of Formula (I) or (II) is selected from a compound set forth in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

10 In some embodiments, the compound of Formula (I) or (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof is formulated as a pharmaceutically acceptable composition comprising a disclosed compound and a pharmaceutically acceptable carrier.

15 In another aspect, the present invention features a method of treating a neurodegenerative disease, a leukodystrophy, a cancer, an inflammatory disease, an autoimmune disease, a viral infection, a skin disease, a fibrotic disease, a hemoglobin disease, a kidney disease, a hearing loss condition, an ocular disease, a musculoskeletal disease, a metabolic disease, or a mitochondrial disease, or a disease or disorder associated with impaired function of eIF2B or components in the ISR pathway (e.g., eIF2 pathway) in a subject, wherein the method comprises administering a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, or a composition thereof, to a subject.

20 In some embodiments, the method comprises the treatment of a neurodegenerative disease. In some embodiments, the neurodegenerative disease comprises a leukodystrophy, a leukoencephalopathy, a hypomyelinating or demyelinating disease, an intellectual disability syndrome, a cognitive impairment, a glial cell dysfunction, or a brain injury (e.g., a traumatic brain injury or toxin induced brain injury). In some embodiments, the neurodegenerative disease comprises vanishing white matter disease, childhood ataxia with CNS hypo myelination, Alzheimer's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker disease, Huntington's disease, dementia (e.g., HIV-associated dementia or Lewy body dementia), kuru, multiple sclerosis, Parkinson's disease, or a prion disease.

30 In some embodiments, the method comprises the treatment of cancer. In some embodiments, the cancer comprises pancreatic cancer, breast cancer, multiple myeloma, or a cancer of the secretory cells.

- 19 -

In some embodiments, the method comprises the treatment of an inflammatory disease. In some embodiments, the inflammatory disease comprises postoperative cognitive dysfunction, arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis), systemic lupus erythematosus (SLE), myasthenia gravis, diabetes (e.g., juvenile onset diabetes or diabetes mellitus type 1), Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma (e.g., allergic asthma), acne vulgaris, celiac disease, chronic prostatitis, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, or atopic dermatitis.

In some embodiments, the method comprises the treatment of a musculoskeletal disease. In some embodiments, the musculoskeletal disease comprises muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, distal muscular dystrophy, congenital muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, or myotonic muscular dystrophy), multiple sclerosis, amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy, spinal cord spasticity, spinal muscle atrophy, myasthenia gravis, neuralgia, fibromyalgia, Machado-Joseph disease, cramp fasciculation syndrome, Friedreich's ataxia, a muscle wasting disorder (e.g., muscle atrophy, sarcopenia, cachexia), an inclusion body myopathy, motor neuron disease, or paralysis.

In some embodiments, the method comprises the treatment of a metabolic disease. In some embodiments, the metabolic disease comprises non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, heart disease, atherosclerosis, arthritis, cystinosis, diabetes (e.g., Type I diabetes, Type II diabetes, or gestational diabetes), phenylketonuria, proliferative retinopathy, or Kearns-Sayre disease.

In some embodiments, the method comprises the treatment of a mitochondrial disease. In some embodiments, the mitochondrial disease is associated with, or is a result of, or is caused by mitochondrial dysfunction, one or more mitochondrial protein mutations, or one or more mitochondrial DNA mutations. In some embodiments, the mitochondrial disease is a mitochondrial myopathy. In some embodiments, the mitochondrial disease is selected from the

- 20 -

group consisting of Barth syndrome, chronic progressive external ophthalmoplegia (cPEO), Kearns-Sayre syndrome (KSS), Leigh syndrome (e.g., MILS, or maternally inherited Leigh syndrome), mitochondrial DNA depletion syndromes (MDDS, e.g., Alpers syndrome), mitochondrial encephalomyopathy (e.g., mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)), mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), myoclonus epilepsy with ragged red fibers (MERRF), neuropathy, ataxia, retinitis pigmentosa (NARP), Leber's hereditary optic neuropathy (LHON), and Pearson syndrome.

In another aspect, the present invention features a method of treating a disease or disorder related to modulation (e.g., a decrease) in eIF2B activity or level, modulation (e.g., a decrease) of eIF2 α activity or level, modulation (e.g., an increase) in eIF2 α phosphorylation, modulation (e.g., an increase) of phosphorylated eIF2 α pathway activity, or modulation (e.g., an increase) of ISR activity in a subject, wherein the method comprises administering a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, or a composition thereof, to a subject. In some embodiments, the disease may be caused by a mutation to a gene or protein sequence related to a member of the eIF2 pathway (e.g., the eIF2 α signaling pathway or ISR pathway).

In another aspect, the present invention features a method of treating cancer in a subject, the method comprising administering to the subject a compound of formula (I) or formula (II) in combination with an immunotherapeutic agent.

DETAILED DESCRIPTION OF THE INVENTION

The present invention features compounds, compositions, and methods comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof for use, e.g., in the modulation (e.g., activation) of eIF2B and the attenuation of the ISR signaling pathway.

Definitions

Chemical Definitions

Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, *Handbook of Chemistry and Physics*, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of

- 21 -

organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, *Organic Chemistry*, University Science Books, Sausalito, 1999; Smith and March, *March's Advanced Organic Chemistry*, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, *Comprehensive Organic Transformations*, VCH Publishers, Inc., New York, 1989; and
5 Carruthers, *Some Modern Methods of Organic Synthesis*, 3rd Edition, Cambridge University Press, Cambridge, 1987.

The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.

10 Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from
15 mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques *et al.*, *Enantiomers, Racemates and Resolutions* (Wiley Interscience, New York, 1981); Wilen *et al.*, *Tetrahedron* 33:2725 (1977); Eliel, *Stereochemistry of Carbon Compounds* (McGraw-Hill, NY, 1962); and Wilen, *Tables of Resolving Agents and Optical Resolutions* p. 268 (E.L. Eliel, Ed.,
20 Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.

As used herein a pure enantiomeric compound is substantially free from other
25 enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, an "S" form of the compound is substantially free from the "R" form of the compound and is, thus, in enantiomeric excess of the "R" form. The term "enantiomerically pure" or "pure enantiomer" denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92%
30 by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 99% by weight, more than 99.5% by weight, or more than 99.9% by weight, of the enantiomer. In

- 22 -

certain embodiments, the weights are based upon total weight of all enantiomers or stereoisomers of the compound.

In the compositions provided herein, an enantiomerically pure compound can be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising enantiomerically pure R-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R-compound. In certain embodiments, the enantiomerically pure R-compound in such compositions can, for example, comprise, at least about 95% by weight R-compound and at most about 5% by weight S-compound, by total weight of the compound. For example, a pharmaceutical composition comprising enantiomerically pure S-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S-compound. In certain embodiments, the enantiomerically pure S-compound in such compositions can, for example, comprise, at least about 95% by weight S-compound and at most about 5% by weight R-compound, by total weight of the compound. In certain embodiments, the active ingredient can be formulated with little or no excipient or carrier.

Compound described herein may also comprise one or more isotopic substitutions. For example, H may be in any isotopic form, including ^1H , ^2H (D or deuterium), and ^3H (T or tritium); C may be in any isotopic form, including ^{12}C , ^{13}C , and ^{14}C ; O may be in any isotopic form, including ^{16}O and ^{18}O ; and the like.

The articles “a” and “an” may be used herein to refer to one or to more than one (*i.e.* at least one) of the grammatical objects of the article. By way of example “an analogue” means one analogue or more than one analogue.

When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example “ $\text{C}_1\text{-C}_6$ alkyl” is intended to encompass, C_1 , C_2 , C_3 , C_4 , C_5 , C_6 , $\text{C}_1\text{-C}_6$, $\text{C}_1\text{-C}_5$, $\text{C}_1\text{-C}_4$, $\text{C}_1\text{-C}_3$, $\text{C}_1\text{-C}_2$, $\text{C}_2\text{-C}_6$, $\text{C}_2\text{-C}_5$, $\text{C}_2\text{-C}_4$, $\text{C}_2\text{-C}_3$, $\text{C}_3\text{-C}_6$, $\text{C}_3\text{-C}_5$, $\text{C}_3\text{-C}_4$, $\text{C}_4\text{-C}_6$, $\text{C}_4\text{-C}_5$, and $\text{C}_5\text{-C}_6$ alkyl.

The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention.

“Alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“ $\text{C}_1\text{-C}_{20}$ alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“ $\text{C}_1\text{-C}_{12}$ alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“ $\text{C}_1\text{-C}_8$ alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“ $\text{C}_1\text{-C}_6$ alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“ $\text{C}_1\text{-C}_5$ alkyl”). In some

- 23 -

embodiments, an alkyl group has 1 to 4 carbon atoms (“C₁-C₄alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C₁-C₃ alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C₁-C₂ alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C₁ alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C₂-C₆alkyl”).

5 Examples of C₁-C₆alkyl groups include methyl (C₁), ethyl (C₂), n-propyl (C₃), isopropyl (C₃), n-butyl (C₄), tert-butyl (C₄), sec-butyl (C₄), iso-butyl (C₄), n-pentyl (C₅), 3-pentanyl (C₅), amyl (C₅), neopentyl (C₅), 3-methyl-2-butanyl (C₅), tertiary amyl (C₅), and n-hexyl (C₆). Additional examples of alkyl groups include n-heptyl (C₇), n-octyl (C₈) and the like. Each instance of an alkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted
10 alkyl”) or substituted (a “substituted alkyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkyl group is unsubstituted C₁₋₁₀ alkyl (e.g., -CH₃). In certain embodiments, the alkyl group is substituted C₁₋₆ alkyl. Common alkyl abbreviations include Me (-CH₃), Et (-CH₂CH₃), iPr (-CH(CH₃)₂), nPr (-CH₂CH₂CH₃), n-Bu (-CH₂CH₂CH₂CH₃), or i-Bu (-CH₂CH(CH₃)₂).

15 The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, -CH₂CH₂CH₂CH₂-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. The term “alkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a
20 divalent radical derived from an alkene. An alkylene group may be described as, e.g., a C₁-C₆-membered alkylene, wherein the term “membered” refers to the non-hydrogen atoms within the moiety.

“Alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds (“C₂-
25 C₂₀ alkenyl”). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C₂-C₁₀ alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C₂-C₈ alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C₂-C₆ alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C₂-C₅ alkenyl”). In some
30 embodiments, an alkenyl group has 2 to 4 carbon atoms (“C₂-C₄ alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C₂-C₃ alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C₂ alkenyl”). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).


- 24 -

Examples of C₂-C₄ alkenyl groups include ethenyl (C₂), 1-propenyl (C₃), 2-propenyl (C₃), 1-butenyl (C₄), 2-butenyl (C₄), butadienyl (C₄), and the like. Examples of C₂-C₆ alkenyl groups include the aforementioned C₂₋₄ alkenyl groups as well as pentenyl (C₅), pentadienyl (C₅), hexenyl (C₆), and the like. Additional examples of alkenyl include heptenyl (C₇), octenyl (C₈), octatrienyl (C₈), and the like. Each instance of an alkenyl group may be independently optionally substituted, *i.e.*, unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents *e.g.*, for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkenyl group is unsubstituted C₂₋₁₀ alkenyl. In certain embodiments, the alkenyl group is substituted C₂₋₆ alkenyl.

“Aryl” refers to a radical of a monocyclic or polycyclic (*e.g.*, bicyclic or tricyclic) 4n+2 aromatic ring system (*e.g.*, having 6, 10, or 14 π electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C₆-C₁₄ aryl”). In some embodiments, an aryl group has six ring carbon atoms (“C₆ aryl”; *e.g.*, phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“C₁₀ aryl”; *e.g.*, naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“C₁₄ aryl”; *e.g.*, anthracyl). An aryl group may be described as, *e.g.*, a C₆-C₁₀-membered aryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety. Aryl groups include, but are not limited to, phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Each instance of an aryl group may be independently optionally substituted, *i.e.*, unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is unsubstituted C₆-C₁₄ aryl. In certain embodiments, the aryl group is substituted C₆-C₁₄ aryl.

In certain embodiments, an aryl group is substituted with one or more of groups selected from halo, C₁-C₈ alkyl, halo-C₁-C₈ alkyl, haloxy-C₁-C₈ alkyl, cyano, hydroxy, alkoxy C₁-C₈ alkyl, and amino.

Examples of representative substituted aryls include the following




wherein one of R⁵⁶ and R⁵⁷ may be hydrogen and at least one of R⁵⁶ and R⁵⁷ is each independently selected from C₁-C₈ alkyl, halo-C₁-C₈ alkyl, 4–10 membered heterocyclyl, alkanoyl, alkoxy-C₁-C₈ alkyl, heteroaryloxy, alkylamino, arylamino, heteroarylamino,

- 25 -

NR⁵⁸COR⁵⁹, NR⁵⁸SOR⁵⁹ NR⁵⁸SO₂R⁵⁹, C(O)Oalkyl, C(O)Oaryl, CONR⁵⁸R⁵⁹, CONR⁵⁸OR⁵⁹, NR⁵⁸R⁵⁹, SO₂NR⁵⁸R⁵⁹, S-alkyl, S(O)-alkyl, S(O)₂-alkyl, S-aryl, S(O)-aryl, S(O)₂-aryl; or R⁵⁶ and R⁵⁷ may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O, or S.

5 Other representative aryl groups having a fused heterocyclyl group include the following:



wherein each W' is selected from C(R⁶⁶)₂, NR⁶⁶, O, and S; and each Y' is selected from carbonyl, NR⁶⁶, O and S; and R⁶⁶ is independently hydrogen, C₁-C₈ alkyl, C₃-C₁₀ cycloalkyl, 4-10 membered heterocyclyl, C₆-C₁₀ aryl, and 5-10 membered heteroaryl.

10 An "arylene" and a "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. Non-limiting examples of heteroaryl groups include pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl, benzodioxanyl, thianaphthanyl, pyrrolopyridinyl, indazolyl, quinolinyl, quinoxalinyl, pyridopyrazinyl, quinazolinonyl, benzoisoxazolyl, imidazopyridinyl, 15 benzofuranyl, benzothienyl, benzothiophenyl, phenyl, naphthyl, biphenyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furylthienyl, pyridyl, pyrimidyl, benzothiazolyl, purinyl, benzimidazolyl, isoquinolyl, thiadiazolyl, oxadiazolyl, pyrrolyl, diazolyl, triazolyl, tetrazolyl, benzothiadiazolyl, isothiazolyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, benzotriazolyl, benzoxazolyl, or quinolyl. The examples above may be 20 substituted or unsubstituted and divalent radicals of each heteroaryl example above are non-limiting examples of heteroarylene.

"Halo" or "halogen," independently or as part of another substituent, mean, unless otherwise stated, a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom. The term "halide" by itself or as part of another substituent, refers to a fluoride, chloride, bromide, or 25 iodide atom. In certain embodiments, the halo group is either fluorine or chlorine.

Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo-C₁-C₆ alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

30 The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a non-cyclic stable straight or branched chain, or combinations thereof,

- 26 -

including at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Exemplary heteroalkyl groups include, but are not limited to: -CH₂-CH₂-O-CH₃, -CH₂-CH₂-NH-CH₃, -CH₂-CH₂-N(CH₃)-CH₃, -CH₂-S-CH₂-CH₃, -CH₂-CH₂-S(O)₂, -S(O)-CH₃, -S(O)₂-CH₂, -CH₂-CH₂-S(O)₂-CH₃, -CH=CH-O-CH₃, -Si(CH₃)₃, -CH₂-CH=N-OCH₃, -CH=CH-N(CH₃)-CH₃, -O-CH₃, and -O-CH₂-CH₃. Up to two or three heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃ and -CH₂-O-Si(CH₃)₃. Where "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as -CH₂O, -NR^BR^C, or the like, it will be understood that the terms heteroalkyl and -CH₂O or -NR^BR^C are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as -CH₂O, -NR^BR^C, or the like.

Similarly, the term "heteroalkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH₂O- and -CH₂CH₂O-. A heteroalkylene group may be described as, e.g., a 2-7-membered heteroalkylene, wherein the term "membered" refers to the non-hydrogen atoms within the moiety. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)₂R'- may represent both -C(O)₂R'- and -R'C(O)₂-.

"Heteroaryl" refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 membered heteroaryl"). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. "Heteroaryl" also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the

- 27 -

number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (*e.g.*, indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, *i.e.*, either the ring bearing a heteroatom (*e.g.*, 2-indolyl) or the ring that does not contain a heteroatom (*e.g.*, 5-indolyl). A heteroaryl group may be described as, *e.g.*, a 6-10-membered heteroaryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.


In some embodiments, a heteroaryl group is a 5–10 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5–8 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5–6 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heteroaryl”). In some embodiments, the 5–6 membered heteroaryl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heteroaryl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Each instance of a heteroaryl group may be independently optionally substituted, *i.e.*, unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. In certain embodiments, the heteroaryl group is unsubstituted 5–14 membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5–14 membered heteroaryl.

Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom

- 28 -

include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiopinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizynyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

Examples of representative heteroaryls include the following formulae:



wherein each Y is selected from carbonyl, N, NR⁶⁵, O, and S; and R⁶⁵ is independently hydrogen, C₁–C₈ alkyl, C₃–C₁₀ cycloalkyl, 4–10 membered heterocyclcyl, C₆–C₁₀ aryl, and 5–10 membered heteroaryl.

“Cycloalkyl” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C₃–C₁₀ cycloalkyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C₃–C₈ cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C₃–C₆ cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C₃–C₆ cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C₅–C₁₀ cycloalkyl”). A cycloalkyl group may be described as, e.g., a C₄–C₇-membered cycloalkyl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety. Exemplary C₃–C₆ cycloalkyl groups include, without limitation, cyclopropyl (C₃), cyclopropenyl

- 29 -

(C₃), cyclobutyl (C₄), cyclobutenyl (C₄), cyclopentyl (C₅), cyclopentenyl (C₅), cyclohexyl (C₆), cyclohexenyl (C₆), cyclohexadienyl (C₆), and the like. Exemplary C₃-C₈ cycloalkyl groups include, without limitation, the aforementioned C₃-C₆ cycloalkyl groups as well as cycloheptyl (C₇), cycloheptenyl (C₇), cycloheptadienyl (C₇), cycloheptatrienyl (C₇), cyclooctyl (C₈), cyclooctenyl (C₈), cubanyl (C₈), bicyclo[1.1.1]pentanyl (C₅), bicyclo[2.2.2]octanyl (C₈), bicyclo[2.1.1]hexanyl (C₆), bicyclo[3.1.1]heptanyl (C₇), and the like. Exemplary C₃-C₁₀ cycloalkyl groups include, without limitation, the aforementioned C₃-C₈ cycloalkyl groups as well as cyclononyl (C₉), cyclononenyl (C₉), cyclodecyl (C₁₀), cyclodecenyl (C₁₀), octahydro-1*H*-indenyl (C₉), decahydronaphthalenyl (C₁₀), spiro[4.5]decanyl (C₁₀), and the like. As the foregoing examples illustrate, in certain embodiments, the cycloalkyl group is either monocyclic (“monocyclic cycloalkyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic cycloalkyl”) and can be saturated or can be partially unsaturated. “Cycloalkyl” also includes ring systems wherein the cycloalkyl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is on the cycloalkyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the cycloalkyl ring system. Each instance of a cycloalkyl group may be independently optionally substituted, *i.e.*, unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is unsubstituted C₃-C₁₀ cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C₃-C₁₀ cycloalkyl.

In some embodiments, “cycloalkyl” is a monocyclic, saturated cycloalkyl group having from 3 to 10 ring carbon atoms (“C₃-C₁₀ cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C₃-C₈ cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C₃-C₆ cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C₅-C₆ cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C₅-C₁₀ cycloalkyl”). Examples of C₅-C₆ cycloalkyl groups include cyclopentyl (C₅) and cyclohexyl (C₆). Examples of C₃-C₆ cycloalkyl groups include the aforementioned C₅-C₆ cycloalkyl groups as well as cyclopropyl (C₃) and cyclobutyl (C₄). Examples of C₃-C₈ cycloalkyl groups include the aforementioned C₃-C₆ cycloalkyl groups as well as cycloheptyl (C₇) and cyclooctyl (C₈). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl

- 30 -

group is unsubstituted C₃-C₁₀ cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C₃-C₁₀ cycloalkyl.

“Heterocyclyl” or “heterocyclic” refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3-10 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is either on the cycloalkyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. A heterocyclyl group may be described as, e.g., a 3-7-membered heterocyclyl, wherein the term “membered” refers to the non-hydrogen ring atoms, i.e., carbon, nitrogen, oxygen, sulfur, boron, phosphorus, and silicon, within the moiety. Each instance of heterocyclyl may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3-10 membered heterocyclyl.

In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In


- 31 -

some embodiments, the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.

5 Exemplary 3–membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenly. Exemplary 4–membered heterocyclyl groups containing one heteroatom include, without limitation, azetidiny, oxetanyl and thietanyl. Exemplary 5–membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl,
10 pyrrolidinyl, dihydropyrrolyl and pyrrolyl–2,5–dione. Exemplary 5–membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin–2–one. Exemplary 5–membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6–membered heterocyclyl groups containing one heteroatom include, without
15 limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl
20 and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary 5–membered heterocyclyl groups fused to a C₆ aryl ring (also referred to herein as a 5,6–bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6–membered heterocyclyl groups fused to an aryl
25 ring (also referred to herein as a 6,6–bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

Particular examples of heterocyclyl groups are shown in the following illustrative examples:

- 32 -



wherein each W is selected from CR^{67} , $\text{C}(\text{R}^{67})_2$, NR^{67} , O, and S; and each Y is selected from NR^{67} , O, and S; and R^{67} is independently hydrogen, C_1 – C_8 alkyl, C_3 – C_{10} cycloalkyl, 4–10 membered heterocyclyl, C_6 – C_{10} aryl, and 5–10-membered heteroaryl. These heterocyclyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl (*e.g.*, amido), aminocarbonylamino, aminosulfonyl, sulfonylamino, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, keto, nitro, thiol, $-\text{S}-\text{alkyl}$, $-\text{S}-\text{aryl}$, $-\text{S}(\text{O})-\text{alkyl}$, $-\text{S}(\text{O})-\text{aryl}$, $-\text{S}(\text{O})_2-\text{alkyl}$, and $-\text{S}(\text{O})_2-\text{aryl}$. Substituting groups include carbonyl or thiocarbonyl which provide, for example, lactam and urea derivatives.

“Nitrogen-containing heterocyclyl” group means a 4- to 7-membered non-aromatic cyclic group containing at least one nitrogen atom, for example, but without limitation, morpholine, piperidine (*e.g.* 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (*e.g.* 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline, pyrazolidine, piperazine, and N-alkyl piperazines such as N-methyl piperazine. Particular examples include azetidine, piperidone and piperazone.

“Amino” refers to the radical $-\text{NR}^{70}\text{R}^{71}$, wherein R^{70} and R^{71} are each independently hydrogen, C_1 – C_8 alkyl, C_3 – C_{10} cycloalkyl, 4–10 membered heterocyclyl, C_6 – C_{10} aryl, and 5–10-membered heteroaryl. In some embodiments, amino refers to NH_2 .

“Cyano” refers to the radical $-\text{CN}$.

“Hydroxy” refers to the radical $-\text{OH}$.

Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (*e.g.*, “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” cycloalkyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group). In general, the term

- 33 -

“substituted”, whether preceded by the term “optionally” or not, means that at least one hydrogen present on a group (*e.g.*, a carbon or nitrogen atom) is replaced with a permissible substituent, *e.g.*, a substituent which upon substitution results in a stable compound, *e.g.*, a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds, such as any of the substituents described herein that result in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.

Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.

A “counterion” or “anionic counterion” is a negatively charged group associated with a cationic quaternary amino group in order to maintain electronic neutrality. Exemplary counterions include halide ions (*e.g.*, F⁻, Cl⁻, Br⁻, I⁻), NO₃⁻, ClO₄⁻, OH⁻, H₂PO₄⁻, HSO₄⁻, sulfonate ions (*e.g.*, methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonic acid-2-sulfonate, and the like), and carboxylate ions (*e.g.*, acetate, ethanoate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, and the like).

The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular

- 34 -

substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al, *Journal of Pharmaceutical Science* 66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder in a first buffer, e.g., in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5, that is combined with a second buffer prior to use.

Thus, the compounds of the present invention may exist as salts, such as with pharmaceutically acceptable acids. The present invention includes such salts. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.

The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent

- 35 -

form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.

In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily
5 undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

10 Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and
15 are intended to be within the scope of the present invention.

As used herein, the term "salt" refers to acid or base salts of the compounds used in the methods of the present invention. Illustrative examples of acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl
20 iodide, ethyl iodide, and the like) salts.

Certain compounds of the present invention possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the
25 scope of the present invention. The compounds of the present invention do not include those which are known in art to be too unstable to synthesize and/or isolate. The present invention is meant to include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or
30 other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

- 36 -

As used herein, the term "isomers" refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.

The term "tautomer," as used herein, refers to one of two or more structural isomers
5 which exist in equilibrium and which are readily converted from one isomeric form to another.

It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.

The terms "treating" or "treatment" refers to any indicia of success in the treatment or
10 amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or
15 subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. For example, certain methods herein treat cancer (e.g. pancreatic cancer, breast cancer, multiple myeloma, cancers of secretory cells), neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, frontotemporal dementia), leukodystrophies (e.g., vanishing white matter disease, childhood ataxia with CNS
20 hypo-myelination), postsurgical cognitive dysfunction, traumatic brain injury, stroke, spinal cord injury, intellectual disability syndromes, inflammatory diseases, musculoskeletal diseases, metabolic diseases, or diseases or disorders associated with impaired function of eIF2B or components in a signal transduction or signaling pathway including the ISR and decreased eIF2 pathway activity). For example certain methods herein treat cancer by decreasing or reducing or
25 preventing the occurrence, growth, metastasis, or progression of cancer or decreasing a symptom of cancer; treat neurodegeneration by improving mental wellbeing, increasing mental function, slowing the decrease of mental function, decreasing dementia, delaying the onset of dementia, improving cognitive skills, decreasing the loss of cognitive skills, improving memory, decreasing the degradation of memory, decreasing a symptom of neurodegeneration or extending
30 survival; treat vanishing white matter disease by reducing a symptom of vanishing white matter disease or reducing the loss of white matter or reducing the loss of myelin or increasing the amount of myelin or increasing the amount of white matter; treat childhood ataxia with CNS

- 37 -

hypo-myelination by decreasing a symptom of childhood ataxia with CNS hypo-myelination or increasing the level of myelin or decreasing the loss of myelin; treat an intellectual disability syndrome by decreasing a symptom of an intellectual disability syndrome, treat an inflammatory disease by treating a symptom of the inflammatory disease; treat a musculoskeletal disease by treating a symptom of the musculoskeletal disease; or treat a metabolic disease by treating a symptom of the metabolic disease. Symptoms of a disease, disorder, or condition described herein (e.g., cancer a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a condition or disease associated with impaired function of eIF2B or components in a signal transduction pathway including the eIF2 pathway, eIF2 α phosphorylation, or ISR pathway) would be known or may be determined by a person of ordinary skill in the art. The term "treating" and conjugations thereof, include prevention of an injury, pathology, condition, or disease (e.g. preventing the development of one or more symptoms of a disease, disorder, or condition described herein).

An "effective amount" is an amount sufficient to accomplish a stated purpose (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, or reduce one or more symptoms of a disease or condition). An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a "therapeutically effective amount." A "prophylactically effective amount" of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

- 38 -

A "reduction" of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).

The term "associated" or "associated with" in the context of a substance or substance activity or function associated with a disease (e.g., a disease or disorder described herein, e.g., cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a disease or disorder associated with impaired function of eIF2B or components in a signal transduction pathway including the eIF2 pathway, eIF2 α phosphorylation, or ISR pathway) means that the disease is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. For example, a symptom of a disease or condition associated with an impaired function of the eIF2B may be a symptom that results (entirely or partially) from a decrease in eIF2B activity (e.g. decrease in eIF2B activity or levels, increase in eIF2 α phosphorylation or activity of phosphorylated eIF2 α or reduced eIF2 activity or increase in activity of phosphorylated eIF2 α signal transduction or the ISR signalling pathway). As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease. For example, a disease associated with decreased eIF2 activity or eIF2 pathway activity, may be treated with an agent (e.g., compound as described herein) effective for increasing the level or activity of eIF2 or eIF2 pathway or a decrease in phosphorylated eIF2 α activity or the ISR pathway. For example, a disease associated with phosphorylated eIF2 α may be treated with an agent (e.g., compound as described herein) effective for decreasing the level of activity of phosphorylated eIF2 α or a downstream component or effector of phosphorylated eIF2 α . For example, a disease associated with eIF2 α , may be treated with an agent (e.g., compound as described herein) effective for increasing the level of activity of eIF2 or a downstream component or effector of eIF2.

"Control" or "control experiment" is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects.

"Contacting" is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including

- 39 -

biomolecules, or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated, however, that the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture. The term "contacting" may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme (e.g. eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway). In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway (e.g. eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway).

As defined herein, the term "inhibition", "inhibit", "inhibiting" and the like in reference to a protein-inhibitor (e.g., antagonist) interaction means negatively affecting (e.g., decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In some embodiments, inhibition refers to reduction of a disease or symptoms of disease. In some embodiments, inhibition refers to a reduction in the activity of a signal transduction pathway or signaling pathway. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In some embodiments, inhibition refers to a decrease in the activity of a signal transduction pathway or signaling pathway (e.g., eIF2B, eIF2 α , or a component of the eIF2 pathway, pathway activated by eIF2 α phosphorylation, or ISR pathway). Thus, inhibition may include, at least in part, partially or totally decreasing stimulation, decreasing or reducing activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein increased in a disease (e.g. eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway, wherein each is associated with cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, or a metabolic disease). Inhibition may include, at least in part, partially or totally decreasing stimulation, decreasing or reducing activation, or deactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein (e.g. eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway) that may modulate the level of another protein or increase cell survival (e.g., decrease in phosphorylated eIF2 α pathway activity may increase cell survival in cells that may or may not have an increase in phosphorylated eIF2 α pathway activity relative to a non-disease control or decrease in eIF2 α pathway activity may increase cell survival in cells

- 40 -

that may or may not have an increase in eIF2 α pathway activity relative to a non-disease control).

As defined herein, the term "activation", "activate", "activating" and the like in reference to a protein-activator (e.g. agonist) interaction means positively affecting (e.g. increasing) the activity or function of the protein (e.g. eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway) relative to the activity or function of the protein in the absence of the activator (e.g. compound described herein). In some embodiments, activation refers to an increase in the activity of a signal transduction pathway or signaling pathway (e.g. eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway). Thus, activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease (e.g. level of eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway associated with cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, or a metabolic disease). Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein (e.g., eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway) that may modulate the level of another protein or increase cell survival (e.g., increase in eIF2 α activity may increase cell survival in cells that may or may not have a reduction in eIF2 α activity relative to a non-disease control).

The term "modulation" refers to an increase or decrease in the level of a target molecule or the function of a target molecule. In some embodiments, modulation of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway may result in reduction of the severity of one or more symptoms of a disease associated with eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway (e.g., cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, or a metabolic disease) or a disease that is not caused by eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway but may benefit from modulation of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway (e.g., decreasing in level or level of activity of eIF2B, eIF2 α or a component of the eIF2 pathway).

The term "modulator" as used herein refers to modulation of (e.g., an increase or decrease in) the level of a target molecule or the function of a target molecule. In embodiments, a modulator of eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway is an anti-

- 41 -

cancer agent. In embodiments, a modulator of eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway is a neuroprotectant. In embodiments, a modulator of eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway is a memory enhancing agent. In embodiments, a modulator of eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway is a memory enhancing agent (e.g., a long term memory enhancing agent). In embodiments, a modulator of eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway is an anti-inflammatory agent. In some embodiments, a modulator of eIF2B, eIF2 α , or component of the eIF2 pathway or ISR pathway is a pain-relieving agent.

"Patient" or "subject in need thereof" refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a compound or pharmaceutical composition, as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human. In some embodiments, a patient is a domesticated animal. In some embodiments, a patient is a dog. In some embodiments, a patient is a parrot. In some embodiments, a patient is livestock animal. In some embodiments, a patient is a mammal. In some embodiments, a patient is a cat. In some embodiments, a patient is a horse. In some embodiments, a patient is bovine. In some embodiments, a patient is a canine. In some embodiments, a patient is a feline. In some embodiments, a patient is an ape. In some embodiments, a patient is a monkey. In some embodiments, a patient is a mouse. In some embodiments, a patient is an experimental animal. In some embodiments, a patient is a rat. In some embodiments, a patient is a hamster. In some embodiments, a patient is a test animal. In some embodiments, a patient is a newborn animal. In some embodiments, a patient is a newborn human. In some embodiments, a patient is a newborn mammal. In some embodiments, a patient is an elderly animal. In some embodiments, a patient is an elderly human. In some embodiments, a patient is an elderly mammal. In some embodiments, a patient is a geriatric patient.

"Disease", "disorder" or "condition" refers to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein. In some embodiments, the compounds and methods described herein comprise reduction or elimination of one or more symptoms of the disease, disorder, or condition, e.g., through administration of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof.

- 42 -

The term "signaling pathway" as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propagated to other signaling pathway components.

"Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

As used herein, the term "administering" means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. By "co-administer" it is meant that a composition described herein is

- 43 -


administered at the same time, just prior to, or just after the administration of one or more additional therapies (e.g., anti-cancer agent, chemotherapeutic, or treatment for a neurodegenerative disease). The compound of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).

The term "eIF2B" as used herein refers to the heteropentameric eukaryotic translation initiation factor 2B. eIF2B is composed of five subunits: eIF2B1, eIF2B2, eIF2B3, eIF2B4 and eIF2B5. eIF2B1 refers to the protein associated with Entrez gene 1967, OMIM 606686, Uniprot Q14232, and/or RefSeq (protein) NP_001405. eIF2B2 refers to the protein associated with Entrez gene 8892, OMIM 606454, Uniprot P49770, and/or RefSeq (protein) NP_055054. eIF2B3 refers to the protein associated with Entrez gene 8891, OMIM 606273, Uniprot Q9NR50, and/or RefSeq (protein) NP_065098. eIF2B4 refers to the protein associated with Entrez gene 8890, OMIM 606687, Uniprot Q9UI10, and/or RefSeq (protein) NP_751945. eIF2B5 refers to the protein associated with Entrez gene 8893, OMIM 603945, Uniprot Q13144, and/or RefSeq (protein) NP_003898.

The terms "eIF2alpha", "eIF2a" or "eIF2 α " are interchangeable and refer to the protein "eukaryotic translation initiation factor 2 alpha subunit eIF2S1". In embodiments, "eIF2alpha", "eIF2a" or "eIF2 α " refer to the human protein. Included in the terms eIF2alpha", "eIF2a" or "eIF2 α " are the wildtype and mutant forms of the protein. In embodiments, "eIF2alpha", "eIF2a" or "eIF2 α " refer to the protein associated with Entrez Gene 1965, OMIM 603907, UniProt P05198, and/or RefSeq (protein) NP_004085. In embodiments, the reference numbers immediately above refer to the protein and associated nucleic acids known as of the date of filing of this application.

Compounds

In one aspect, the present invention features a compound of Formula (I):



Formula (I)

- 44 -

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein D is a bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, bridged bicyclic cycloalkenyl, or cubanyl, wherein each bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, bridged bicyclic cycloalkenyl, or cubanyl is optionally substituted with 1-4

5 R^X groups; and wherein if the bridged bicyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen moiety may be optionally substituted by R^{N1} ; L^1 and L^2 are each independently C_1 - C_6 alkylene, C_2 - C_6 alkenylene, 2-7-membered heteroalkylene, O, or NR^C , wherein each C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or 2-7-membered heteroalkylene is optionally substituted with 1-5 R^L ; R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy-

10 C_2 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, silyloxy- C_2 - C_6 alkyl, G^1 -O- C_2 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, or C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl; each R^L is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkoxy, halo- C_1 - C_6 alkyl, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BR^{CC}$, $-NR^BC(O)R^D$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-$

15 $C(O)OH$, $-C(O)OR^D$, $-SR^E$, $-S(O)R^D$, $-S(O)_2R^D$, $-OS(O)R^D$, $-OS(O)_2R^D$, and G^2 ; or 2 geminal R^L groups together with the carbon to which they are attached form a cyclopropyl moiety; R^{N1} is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, halo- C_2 - C_6 alkyl, amino- C_2 - C_6 alkyl, cyano- C_2 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, phenoxy- C_1 - C_6 alkyl (wherein phenoxy is optionally substituted

20 with 1-3 halogens), $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OR^D$, and $-S(O)_2R^D$; A and W are each independently aryl or 5-6-membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R^Y ; each R^X is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, C_1 - C_6 alkyl- C_1 - C_6 alkoxy, C_1 - C_6 alkoxy- C_1 - C_6

25 alkoxy, oxo, halo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BR^{CC}$, $-NR^BC(O)R^D$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $=CHC(O)OR^D$, $=CHC(O)OH$, $-SR^E$, $-S(O)R^D$, $-S(O)_2R^D$, $-OS(O)R^D$, $-OS(O)_2R^D$, and G^2 ; or 2 geminal R^X groups together with the carbon to which they are attached form an oxirane moiety; each R^Y is independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, O- C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl,



30 hydroxy- C_1 - C_6 alkoxy, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^BR^C$, $-NR^BR^{CC}$, $-NR^BC(O)R^D$, $-C(O)NR^BR^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)R^D$, $-S(O)_2R^D$, and G^1 ; or 2 R^Y groups on adjacent atoms,





- 45 -




together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl, heterocyclyl, aryl, or heteroaryl ring optionally substituted with 1-5 R^X ; each G^1 is independently C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl, wherein each C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 R^Z ; each R^Z is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, and $-S(O)_2 R^D$; each R^A is independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, $-C(O)NR^B R^C$, $-C(O)R^D$, or $-C(O)OR^D$; each of R^B and R^C is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl; R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with 1-3 R^Z ; each R^{CC} is independently selected from the group consisting of hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, (CO) - C_1 - C_6 alkyl-OH, (CO) - C_1 - C_6 alkyl- C_1 - C_6 alkoxy and 4-6 membered heterocyclyl; wherein the heterocyclyl may optionally be substituted with 1-3 R^Z ; each R^D is independently C_1 - C_6 alkyl, 2-7-membered heteroalkyl, hydroxy- C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl, wherein each C_1 - C_6 alkyl, 2-7-membered heteroalkyl, hydroxy- C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl is optionally substituted with 1-5 R^G ; each R^E is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl; each R^F is independently hydrogen, C_1 - C_6 alkyl, or halo; each R^G is independently aryl or 5-6 membered heteroaryl, wherein each aryl or 5-6 membered heteroaryl is optionally substituted with 1-5 R^H ; each R^H is independently C_1 - C_6 alkyl or halo- C_1 - C_6 alkyl; m is 1 when R^F is hydrogen or C_1 - C_6 alkyl, 3 when R^F is C_1 - C_6 alkyl, or 5 when R^F is halo; t is 0 or 1; and s is 0 or 1.



In some embodiments, D is a bridged bicyclic cycloalkyl, a bridged bicyclic heterocyclyl, or cubanyl, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is a bridged 5-8 membered bicyclic cycloalkyl, a bridged bicyclic heterocyclyl, or cubanyl, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is selected from cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.2.2]oct-2-ene, bicyclo[2.1.1]hexane, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[3.2.1]octane, or 2-azabicyclo[2.2.2]octane, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is selected from cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.1.1]hexane, or bicyclo[3.1.1]heptane, each of which is optionally substituted with 1-4

- 46 -




R^X groups. In some embodiments, D is selected from:  $(R^X)_{0-4}$,  $(R^X)_{0-4}$,



embodiments, D is selected from:  $(R^X)_{0-4}$,  $(R^X)_{0-4}$,  $(R^X)_{0-4}$,




- 47 -



substituted with 1 or 2 R^X. In some embodiments, R^X is independently C₁-C₆ alkyl, hydroxy-C₁-

5 C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkoxy, oxo, halo, cyano, -OR^A, -OS(O)₂R^D, -S(O)₂R^D, -SR^E, NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, =CHC(O)OH, =CHC(O)OR^D, NR^BR^C, NR^BR^{CC}, or G²; or 2 geminal R^X groups together with the carbon to which they are attached form an oxirane moiety. In some embodiments, R^X is independently CH₃, -CH₂OH, -CH₂OCH₃, -CH₂CH₂CH₃, -C(CH₃)₂OH, -O-CH₂-O-CH₃,
10 CH₂CH₂OH, oxo, fluoro, bromo, OH, cyano, OCH₃, NH₂, N(H)CH₂CF₃, N(H)CH₂CH₂OH, N(CH₃)₂, N(CH₃)CH₂CH₂OH, N(CH₃)CH₂CO₂H, N(CH₃)CH₂CH₂CO₂H, NHC(O)CH₃, OC(O)CH₃, C(O)NH₂, OS(O)₂CH₃, -S(O)₂CH₃, -S(O)₂CH₂CH₃, C(O)OH, C(O)OCH₃,




and . In some embodiments, R^X is oxo, -OR^A, or NR^BR^C (e.g., oxo, OH, OCH₃, N(CH₃)₂,

15 or OC(O)R^D). In some embodiments, G² is aryl or 5-6 membered heteroaryl. In some
embodiments, G² is oxadiazolyl or tetrazolyl.

- 48 -


In some embodiments, D is substituted with 0 R^X . In some embodiments, D is



In some embodiments, at least one of L^1 and L^2 is independently 2-7-membered heteroalkylene, O, or NR^C , wherein heteroalkylene is optionally substituted by 1-5 R^L . In some
 5 embodiments, at least one of L^1 and L^2 is independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^L . In some embodiments, both L^1 and L^2 are independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^L . In some embodiments, one of L^1 and L^2 is independently C_1 - C_6 alkylene or C_2 - C_6 alkenylene and the other of L^1 and L^2 is independently 2-7-membered heteroalkylene, and wherein each C_1 - C_6 alkylene, C_2 - C_6 alkenylene, and 2-7-
 10 membered heteroalkylene is optionally substituted by 1-5 R^L . In some embodiments, both of L^1 and L^2 are C_1 - C_6 alkylene or C_2 - C_6 alkenylene, and wherein each C_1 - C_6 alkylene, and C_2 - C_6 alkenylene is optionally substituted by 1-5 R^L . In some embodiments, both of L^1 and L^2 are C_2 - C_6 alkenylene, optionally substituted by 1-5 R^L .


In some embodiments, each R^L is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, oxo,
 15 or $-C(O)R^D$ (e.g., CH_3 , OH, oxo, CH_2OH , CH_2OCH_3 , or $C(O)CH_3$). In some embodiments, each R^L is independently C_1 - C_6 alkyl, OH, oxo, $-C(O)R^D$, cyano, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, $-C(O)OH$, $-NR^B R^C$, $-NR^B R^{CC}$, $-NR^B C(O)R^D$, hydroxy- C_1 - C_6 alkyl, or hydroxy- C_1 - C_6 alkoxy. In some embodiments, each R^L is independently CH_3 , oxo, or $C(O)CH_3$.

In some embodiments, each of L^1 and L^2 is independently selected from CH_2O^* ,
 20 $CH_2CH_2^*$, $CH_2CH_2CH_2^*$, CH_2^* , $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$,
 $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, $NHCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$,
 $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $CH(OH)^*$, $CH(OH)CH_2CH_2^*$,
 $CH_2CH(OH)^*$, $CH_2NHC(O)^*$, $NHC(O)OCH_2^*$, O^* , NH^* , $S(O)_2CH^*$, $S(O)_2CH_2CH_2^*$,
 $S(O)_2CH_2CH_2O^*$, $CH_2C(O)^*$, $O-CH_2CH_2^*$, $CH_2N(CH_2CO_2H)^*$, $CH(CO_2H)CH_2CH_2O^*$,
 25 $CH_2N(CH_2CO_2C(CH_3)_3)^*$, $CH(CN)CH_2O^*$, $CH_2CH(NH(CH_3))^*$, $CH(OCH_2CH_2OH)^*$,

$CH_2CH(NH(C(O)CH_2OH))^*$, $CH_2CH(NH_2)CH_2^*$, $CH(CH_2CH_2OH)O^*$ or , and “-
 *” indicates the attachment point to A and W, respectively. In some embodiments, each of L^1

- 49 -

and L^2 is independently selected from $\text{CH}_2\text{O}-*$, CH_2CH_2-* , $\text{CH}_2\text{C}(\text{O})-*$, $\text{CH}=\text{CH}-*$, $\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{OCH}_2-*$, $\text{CH}_2\text{OCH}_2\text{CH}_2-*$, $\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{CH}_2\text{OCH}_2-*$, $\text{CH}_2\text{NH}-*$, $\text{CH}_2\text{N}(\text{CH}_3)-*$, $\text{CH}_2\text{N}(\text{CH}_3)\text{C}(\text{O})-*$, $\text{CH}_2\text{N}(\text{C}(\text{O})\text{CH}_3)-*$, $\text{CH}_2\text{CH}(\text{OH})-*$, $\text{NHC}(\text{O})\text{OCH}_2-*$, or $\text{CH}_2\text{C}(\text{O})-*$, and “-*” indicates the attachment point to A and W, respectively. In some embodiments, L^1 is independently selected from $\text{CH}_2\text{O}-*$ and $\text{CH}=\text{CH}-*$, L^2 is independently selected from $\text{CH}_2\text{O}-*$, CH_2CH_2-* , CH_2-* , $\text{CH}_2\text{C}(\text{O})-*$, $\text{CH}=\text{CH}-*$, $\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{OCH}_2-*$, $\text{CH}_2\text{OCH}_2\text{CH}_2-*$, $\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{CH}_2\text{OCH}_2-*$, NHCH_2-* , $\text{CH}_2\text{NH}-*$, $\text{CH}_2\text{N}(\text{CH}_3)-*$, $\text{CH}_2\text{N}(\text{CH}_3)\text{C}(\text{O})-*$, $\text{CH}_2\text{N}(\text{C}(\text{O})\text{CH}_3)-*$, $\text{CH}_2\text{CH}(\text{OH})-*$, $\text{CH}(\text{OH})-*$, $\text{CH}(\text{OH})\text{CH}_2\text{CH}_2-*$, $\text{CH}_2\text{CH}(\text{OH})-*$, $\text{CH}_2\text{NHC}(\text{O})-*$, $-\text{NHC}(\text{O})\text{OCH}_2-*$, $\text{O}-*$, $\text{NH}-*$, $\text{S}(\text{O})_2\text{CH}_2-*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2-*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2\text{O}-*$, or $\text{CH}_2\text{C}(\text{O})-*$, and “-*” indicates the attachment point to A and W, respectively. In some embodiments, L^1 is independently selected from $\text{CH}_2\text{O}-*$, $\text{CH}_2\text{CH}_2\text{O}-*$ or $\text{CH}=\text{CH}-*$, L^2 is independently selected from $\text{CH}_2\text{O}-*$, CH_2CH_2-* , $\text{CH}_2\text{CH}_2\text{CH}_2-*$, CH_2-* , $\text{CH}_2\text{C}(\text{O})-*$, $\text{CH}=\text{CH}-*$, $\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{OCH}_2-*$, $\text{CH}_2\text{OCH}_2\text{CH}_2-*$, $\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{CH}_2\text{OCH}_2-*$, NHCH_2-* , $\text{CH}_2\text{NH}-*$, $\text{CH}_2\text{N}(\text{CH}_3)-*$, $\text{CH}_2\text{N}(\text{CH}_3)\text{C}(\text{O})-*$, $\text{CH}_2\text{N}(\text{C}(\text{O})\text{CH}_3)-*$, $\text{CH}_2\text{CH}(\text{OH})-*$, $\text{CH}(\text{OH})-*$, $\text{CH}(\text{OH})\text{CH}_2\text{CH}_2-*$, $\text{CH}_2\text{CH}(\text{OH})-*$, $\text{CH}_2\text{NHC}(\text{O})-*$, $\text{NHC}(\text{O})\text{OCH}_2-*$, $\text{O}-*$, $\text{NH}-*$, $\text{S}(\text{O})_2\text{CH}-*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2-*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{C}(\text{O})-*$, $\text{CH}_2\text{N}(\text{CH}_2\text{CO}_2\text{H})-*$, $\text{CH}(\text{CO}_2\text{H})\text{CH}_2\text{CH}_2\text{O}-*$, $\text{CH}_2\text{N}(\text{CH}_2\text{CO}_2\text{C}(\text{CH}_3)_3)-*$, $\text{CH}(\text{CN})\text{CH}_2\text{O}-*$, $\text{CH}_2\text{CH}(\text{NH}(\text{CH}_3))-*$, $\text{CH}(\text{OCH}_2\text{CH}_2\text{OH})-*$, $\text{CH}_2\text{CH}(\text{NH}(\text{C}(\text{O})\text{CH}_2\text{OH}))-*$, $\text{CH}_2\text{CH}(\text{NH}_2)\text{CH}_2-*$, $\text{CH}(\text{CH}_2\text{CH}_2\text{OH})\text{O}-*$, $\text{CH}_2\text{C}(\text{CH}_3)_2\text{O}-*$ or



, and “-*” indicates the attachment point to A and W, respectively.

In some embodiments, t is 1 and s is 1. In some embodiments, s is 1 and t is 0. In some embodiments, s is 0 and t is 0.

In some embodiments, R^1 and R^2 are each independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, hydroxyl- $\text{C}_2\text{-C}_6$ alkyl, or silyloxy- $\text{C}_2\text{-C}_6$ alkyl. In some embodiments, one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ hydroxyl- $\text{C}_2\text{-C}_6$ alkyl, silyloxy- $\text{C}_2\text{-C}_6$ alkyl, $\text{HO}_2\text{C-C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ alkyl- $\text{C}(\text{O})_2\text{-C}_1\text{-C}_6$ alkyl. In some embodiments, R^1 and R^2 are each independently hydrogen, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_3$, $-\text{CH}_2\text{CO}_2\text{H}$, or $-\text{CH}_2\text{C}(\text{O})_2\text{C}(\text{CH}_3)$, and “-” indicates the attachment point to the nitrogen atom. In some embodiments, one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, or $-\text{CH}_2\text{C}(\text{O})_2\text{C}(\text{CH}_3)$.


- 50 -

CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “*-” indicates the attachment point to the nitrogen atom. one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, *-CH₃, *-CH₂CH₂OH, *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, *-CH₂CO₂H, or *-CH₂C(O)₂C(CH₃), and “*-” indicates the attachment point to the nitrogen atom. In some embodiments, R¹ and R² are each independently hydrogen.


In some embodiments, A is phenyl and W is independently phenyl or 5-6-membered heteroaryl. In some embodiments, each A and W is independently phenyl. In some embodiments, A is phenyl and W is 5-6-membered heteroaryl.

In some embodiments, W is a monocyclic 5-6-membered heteroaryl. In some embodiments, 2 R^Y groups on adjacent atoms of W, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl or heterocyclyl optionally substituted with 1-5 R^X forming a bicyclic heteroaryl. In some embodiments, W is a 10-membered heteroaryl, a 9-membered heteroaryl, a 6-membered heteroaryl, or a 5-membered heteroaryl. In some embodiments, W is a heteroaryl containing nitrogen, oxygen or sulfur as allowed by valence.


In some embodiments, each A and W is independently phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y, and each R^Y is independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, triazinyl, pyrazolyl, pyrimidinyl, triazolyl, oxadiazolyl, oxadiazolonyl, thiazolyl, imidazolyl, pyrimidin-2(1H)-onyl, 1H-benzo[d]imidazolyl, pyrazolo[1,5-a]pyridine, 1H-indazolyl or isoxazolyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently selected from:




- 51 -



- 52 -




- In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, O - C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, hydroxy- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B R^{CC}$, $-NR^B C(O)R^D$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, pyrimidinyl, triazinyl, pyrazolyl, triazolyl, oxadiazolyl, oxadiazolonyl, thiazolyl, imidazolyl, or isoxazolyl, each of which is optionally substituted with 1-5 R^Y groups.



In some embodiments, W is selected from:


- 53 -



- 54 -

independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹.

In some embodiments, each R^Y is independently hydrogen, bromo, chloro, fluoro, iodo, cyano, CF₃, CHF₂, CH₂CF₃, CH₃, CH₂CH₃, OH, CH₂OH, C(CH₃)₂OH, OCH₃, OCH₂CH₃, OCHF₂, OCF₃, OCH₂CF₃, OCH₂CH₂OH, CH₂OCH₃, S(O)₂CH₃, S(O)₂CH₂CH₂CH₃, CN, N(CH₃)₂, SF₅, SCH₃, NH₂, NH(C(O)CH₂OH), NH(CH₂CH₂OH), NH(CO)CH₂OCH₃, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(OH)(CH₃)CF₃, S(O)₂CH₃, C(O)CH₃, C(O)OCH₃,


C(O)OH, OCHF₂, G¹, or .

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF₃, CH₃, CH₂CH₃, OCH₃, S(O)₂CH₃, CN, N(CH₃)₂, SF₅, NH₂, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(O)CH₃, C(O)OCH₃, C(O)OH, OCHF₂ or G¹.

In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y, together with the atoms to which they are attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X. In some embodiments, the 2 R^Y together with the atoms to which they are attached form a phenyl, pyridyl, pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, dioxanyl, dioxolanyl, pyrrolidin-2-onyl, or morpholin-3-onyl ring, each of which is optionally substituted with 1-5 R^X. In some embodiments, each R^X is independently C₁-C₆ alkyl, OR^A, or halo. (e.g., CH₃ or fluoro). In some embodiments, each R^X is independently CH₃, OH or fluoro.

In some embodiments, G¹ is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some embodiments, G¹ is cyclopropyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some embodiments, each R^Z is independently C₁-C₆ alkyl or halo. In some embodiments, each R^Z is independently C₁-C₆ alkyl (e.g., CH₃).

In another aspect, the present invention features a compound of Formula (I-a):



Formula (I-a)







- 55 -


or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein D is a bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl, wherein each bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl is optionally substituted with 1-4 R^X groups; L^1 and L^2 are each independently C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or 2-7-membered heteroalkylene, wherein each C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or 2-7-membered heteroalkylene is optionally substituted with 1-5 R^X ; R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_2 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, silyloxy- C_2 - C_6 alkyl; A and W are each independently phenyl or 5-6-membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R^Y ; each R^X is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-SR^E$, $-S(O)R^D$, and $-S(O)_2 R^D$; each R^Y is independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)R^D$, $-S(O)_2 R^D$, and G^1 ; or 2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl, heterocyclyl, aryl, or heteroaryl ring optionally substituted with 1-5 R^X ; each G^1 is independently C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl, wherein each C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 R^Z ; each R^Z is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, and $-S(O)_2 R^D$; each R^A is independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, or $-C(O)OR^D$; each of R^B and R^C is independently hydrogen or C_1 - C_6 alkyl; or R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with 1-3 R^Z ; each R^D is independently C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl, wherein each C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl is optionally substituted with 1-5 R^G ; each R^E is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl; each R^F is independently hydrogen, C_1 - C_6 alkyl, or halo; each R^G is independently aryl or 5-6 membered heteroaryl, wherein each aryl or 5-6 membered heteroaryl is optionally substituted with 1-5 R^H ; each R^H is independently

- 56 -

C₁-C₆ alkyl or halo-C₁-C₆ alkyl; m is 1 when R^F is hydrogen or C₁-C₆ alkyl, 3 when R^F is C₁-C₆ alkyl, or 5 when R^F is halo; and; and t is 0 or 1.

In some embodiments, D is a bridged bicyclic cycloalkyl or cubanyl, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is a bridged 5-8 membered bicyclic cycloalkyl or cubanyl, each of which is optionally substituted with 1-4 R^X groups. In some embodiments, D is selected from cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.1.1]hexane, or bicyclo[3.1.1]heptane, each of which is optionally substituted with 1-4

R^X groups. In some embodiments, D is selected from: , , or . In some embodiments, D is selected from: , , or . In some embodiments, D is substituted with 1 R^X. In some embodiments, R^X is oxo, -OR^A, or NR^BR^C (e.g., oxo, OH, OCH₃, N(CH₃)₂, or OC(O)R^D). In some embodiments, D is substituted with 0 R^X. In some embodiments, D is



In some embodiments, at least one of L¹ and L² is independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^X. In some embodiments, both L¹ and L² are independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^X. In some embodiments, one of L¹ and L² is independently C₁-C₆ alkylene or C₂-C₆ alkenylene and the other of L¹ and L² is independently 2-7-membered heteroalkylene, and wherein each C₁-C₆ alkylene, C₂-C₆ alkenylene, and 2-7-membered heteroalkylene is optionally substituted by 1-5 R^X. In some embodiments, each R^X is independently C₁-C₆ alkyl, oxo, or -C(O)R^D (e.g., CH₃,


- 57 -

oxo, or C(O)CH₃). In some embodiments, each of L¹ and L² is independently selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to A and W, respectively. In some embodiments, L¹ is CH₂O-*, L² is independently selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to A and W, respectively.


In some embodiments, t is 1. In some embodiments, t is 0.

In some embodiments, R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, hydroxyl-C₂-C₆ alkyl, or silyloxy-C₂-C₆ alkyl. In some embodiments, one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, C₁-C₆ alkyl, hydroxyl-C₂-C₆ alkyl, or silyloxy-C₂-C₆ alkyl. In some embodiments, R¹ and R² are each independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “-*” indicates the attachment point to the nitrogen atom. In some embodiments, one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “-*” indicates the attachment point to the nitrogen atom. In some embodiments, R¹ and R² are each independently hydrogen.

In some embodiments, each A and W is independently a phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y groups, and each R^Y is independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently selected from:




- 58 -




- In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y .


10 In some embodiments, A is selected from:



In some embodiments, In some embodiments, W is selected from:



- 59 -




In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF_3 , CH_3 , CH_2CH_3 ,
 5 OCH_3 , $S(O)_2CH_3$, CN , $N(CH_3)_2$, SF_5 , NH_2 , $C(CH_3)_3$, $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$,
 $C(O)CH_3$, $C(O)OCH_3$, $C(O)OH$, $OCHF_2$ or G^1 .

In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent
 atoms, and the 2 R^Y , together with the atoms to which they are attached, form a 3-7-membered
 fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused
 10 heteroaryl ring optionally substituted with 1-5 R^X . In some embodiments, 2 R^Y together with the
 atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, furanyl, or dioxolanyl
 ring, each of which is optionally substituted with 1-5 R^X . In some embodiments, each R^X is
 independently C_1 - C_6 alkyl or halo (*e.g.*, CH_3 or fluoro).

In some embodiments, G^1 is cyclopropyl, isoxazolyl, or pyrazolyl, each of which is
 15 optionally substituted with 1-5 R^Z . In some embodiments, each R^Z is independently C_1 - C_6 alkyl
 (*e.g.*, CH_3).

In some embodiments, the compound of Formula (I) is a compound of Formula (I-b):



Formula (I-b)


20 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or
 stereoisomer thereof,

wherein D is (1,2,3,4,6,7)-cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane,
 bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane, or 2-

- 60 -

azabicyclo[2.2.2]octane, each of which is optionally substituted with 1-4 R^X groups; and wherein 2-azabicyclo[2.2.2]octane is substituted on nitrogen by hydrogen or CH_3 ; L^1 and L^2 are each independently CH_2O -, CH_2CH_2 -, $CH_2CH_2CH_2$ -, CH_2 -, $CH_2C(O)$ -, $CH=CH$ -, CH_2CH_2O -, CH_2OCH_2 -, $CH_2OCH_2CH_2$ -, $CH_2CH_2CH_2O$ -, $CH_2CH_2OCH_2$ -, $NHCH_2$ -, CH_2NH -, $CH_2N(CH_3)$ -, $CH_2N(CH_3)C(O)$ -, $CH_2N(C(O)CH_3)$ -, $CH_2CH(OH)$ -, $CH(OH)$ -, $CH(OH)CH_2CH_2$ -, $CH_2CH(OH)$ -, $CH_2NHC(O)$ -, $NHC(O)OCH_2$ -, O -, NH -, $S(O)_2CH$ -, $S(O)_2CH_2CH_2$ -, $S(O)_2CH_2CH_2O$ -, or $CH_2C(O)$ -, and “-” indicates the attachment point to A and W, respectively; R^1 and R^2 are each independently hydrogen, CH_3 , CH_2CH_2OH , or $CH_2CH_2OSi(CH_3)_2C(CH_3)_3$; A and W are each independently isoxazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, pyrimidinyl, triazinyl, thiazolyl, triazolyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups; each R^X is independently selected from CH_3 , $-CH_2OH$, $-C(CH_3)_2OH$, oxo, fluoro, bromo, OH, cyano, OCH_3 , NH_2 , $N(CH_3)_2$, $NHC(O)CH_3$, $OC(O)CH_3$, $C(O)NH_2$, $OS(O)_2CH_3$, $-S(O)_2CH_3$, $-S(O)_2CH_2CH_3$, $C(O)OH$, $OC(O)R^D$, $-C(O)CH_3$, $-SCH_3$, or G^2 ; each R^Y is independently bromo, chloro, fluoro, iodo, CF_3 , CHF_2 , CH_2CF_3 , CH_3 , CH_2CH_3 , OH, CH_2OH , $C(CH_3)_2OH$, OCH_3 , OCH_2CH_3 , OCF_3 , $S(O)_2CH_3$, $S(O)_2CH_2CH_2CH_3$, CN, $N(CH_3)_2$, SF_5 , SCH_3 , NH_2 , $C(CH_3)_3$, $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$, $C(OH)(CH_3)CF_3$, $S(O)_2CH_3$, $C(O)CH_3$, $C(O)OCH_3$, $C(O)OH$, $OCHF_2$ or G^1 ; or 2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, or dioxolanyl ring, each of which is optionally substituted with 1-2 R^X ; G^1 and G^2 are cyclopropyl, isoxazolyl, phenyl, piperidinyl, oxadiazolyl, or tetrazolyl, or pyrazolyl, each of which is optionally substituted with 1-2 R^Z ; each R^D is CH_2O optionally substituted with 1-5 R^G ; each R^G is independently pyridyl optionally substituted with 1-5 R^H ; each R^H is independently CF_3 ; each R^Z is independently CH_3 ; and t is 0 or 1.

In some embodiments, the compound of Formula (I) is a compound of Formula (I-c):



Formula (I-c)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^1 , L^2 , R^1 , R^2 , A, W, R^X , and t is defined as for Formula (I).

- 61 -

In some embodiments, R^X is C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-OS(O)_2R^D$, $-S(O)_2R^D$, $-SR^E$, $NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $NR^B R^C$, or G^2 (e.g., CH_3 , oxo, fluoro, OH, cyano, OCH_3 , NH_2 , $N(CH_3)_2$, $NHC(O)CH_3$, $OC(O)CH_3$, $C(O)NH_2$, $OS(O)_2CH_3$, $-S(O)_2CH_3$, $-S(O)_2CH_2CH_3$, $C(O)OH$, $OC(O)R^D$, $-C(O)CH_3$, or $-SCH_3$). In some embodiments, R^X is oxo, $-OR^A$, or $NR^B R^C$ (e.g., oxo, OH, OCH_3 , $N(CH_3)_2$, or $OC(O)R^D$). In some

5 embodiments, G^2 is aryl or 5-6 membered heteroaryl (e.g., oxadiazolyl, or tetrazolyl).

In some embodiments, at least one of L^1 and L^2 is independently 2-7-membered heteroalkylene, O, or NR^C , wherein heteroalkylene is optionally substituted by 1-5 R^X . In some

embodiments, at least one of L^1 and L^2 is independently 2-7-membered heteroalkylene optionally

10 substituted by 1-5 R^X . In some embodiments, both L^1 and L^2 are independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^X . In some embodiments, one of L^1 and L^2 is independently C_1 - C_6 alkylene or C_2 - C_6 alkenylene and the other of L^1 and L^2 is independently 2-7-membered heteroalkylene, and wherein each C_1 - C_6 alkylene, C_2 - C_6 alkenylene, and 2-7-membered heteroalkylene is optionally substituted by 1-5 R^X . In some embodiments, both of L^1

15 and L^2 are C_1 - C_6 alkylene or C_2 - C_6 alkenylene, and wherein each C_1 - C_6 alkylene, and C_2 - C_6 alkenylene is optionally substituted by 1-5 R^X . In some embodiments, both of L^1 and L^2 are C_2 - C_6 alkenylene, optionally substituted by 1-5 R^X .

In some embodiments, R^X is C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-OS(O)_2R^D$, $-S(O)_2R^D$, $-SR^E$, $NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $NR^B R^C$, or G^2 (e.g., CH_3 , oxo, fluoro, OH, cyano, OCH_3 , NH_2 , $N(CH_3)_2$, $NHC(O)CH_3$, $OC(O)CH_3$, $C(O)NH_2$, $OS(O)_2CH_3$, $-S(O)_2CH_3$, $-S(O)_2CH_2CH_3$, $C(O)OH$, $OC(O)R^D$, $-C(O)CH_3$, or $-SCH_3$). In some embodiments, R^X is oxo, $-OR^A$, or $NR^B R^C$ (e.g., oxo, OH, OCH_3 , $N(CH_3)_2$, or $OC(O)R^D$). In some

20 embodiments, G^2 is aryl or 5-6 membered heteroaryl (e.g., oxadiazolyl, or tetrazolyl).

In some embodiments, each of L^1 and L^2 is independently selected from CH_2O^* , $CH_2CH_2^*$, $CH_2CH_2CH_2^*$, CH_2^* , $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, $NHCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $CH(OH)^*$, $CH(OH)CH_2CH_2^*$, $CH_2CH(OH)^*$, $CH_2NHC(O)^*$, $NHC(O)OCH_2^*$, O^* , NH^* , $S(O)_2CH^*$, $S(O)_2CH_2CH_2^*$, $S(O)_2CH_2CH_2O^*$, or $CH_2C(O)^*$, and “ $-^*$ ” indicates the attachment point to A and W,

25 respectively. In some embodiments, each of L^1 and L^2 is independently selected from CH_2O^* , $CH_2CH_2^*$, $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$,

30

- 62 -

CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to A and W, respectively. In some embodiments, L¹ is independently selected from CH₂O-* and CH=CH-*, L² is independently selected from CH₂O-*, CH₂CH₂-, CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*,

5 CH₂CH₂OCH₂-, NHCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, CH(OH)-*, CH(OH)CH₂CH₂-, CH₂CH(OH)-*, CH₂NHC(O)-*, -NHC(O)OCH₂-, O-*, NH-*, S(O)₂CH₂-, S(O)₂CH₂CH₂-, S(O)₂CH₂CH₂O-*, or CH₂C(O)-*, and “-*” indicates the attachment point to A and W, respectively. In some embodiments, L¹ is CH₂O-*, L² is independently selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*,

10 CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to A and W, respectively.

In some embodiments, t is 1. In some embodiments, t is 0.

In some embodiments, R¹ and R² are each independently hydrogen, C₁-C₆ alkyl,

15 hydroxyl-C₂-C₆ alkyl, or silyloxy-C₂-C₆ alkyl. In some embodiments, one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, C₁-C₆ alkyl, hydroxyl-C₂-C₆ alkyl, or silyloxy-C₂-C₆ alkyl. In some embodiments, R¹ and R² are each independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “-*” indicates the attachment point to the nitrogen atom. In some embodiments, one of R¹ and R² is

20 independently hydrogen and the other of R¹ and R² is independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “-*” indicates the attachment point to the nitrogen atom. In some embodiments, R¹ and R² are each independently hydrogen.

In some embodiments, A is phenyl and W is independently phenyl or 5-6-membered heteroaryl. In some embodiments, each A and W is independently phenyl. In some

25 embodiments, A is phenyl and W is 5-6-membered heteroaryl.


In some embodiments, W is a monocyclic 5-6-membered heteroaryl. In some embodiments, 2 R^Y groups on adjacent atoms of W, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl or heterocyclyl optionally substituted with 1-5 R^X forming a bicyclic heteroaryl. In some embodiments, W is a 10-membered heteroaryl, a 9-

30 membered heteroaryl, a 6-membered heteroaryl, or a 5-membered heteroaryl. In some embodiments, W is a heteroaryl containing nitrogen, oxygen or sulfur as allowed by valence.


- 63 -

In some embodiments, each A and W is independently phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 .


- 5 In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, triazinyl, triazolyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is
- 10 independently selected from:



- 64 -




In some embodiments, each of A and W is independently selected from:




10 In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5

15 R^Y .



- 66 -



In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl. In some embodiments, each of A and W is optionally substituted with 1-5 R^Y, and each R^Y is independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹.

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF₃, CHF₂, CH₂CF₃, CH₃, CH₂CH₃, C(CH₃)₂OH, OCH₃, OCH₂CH₃, OCF₃, S(O)₂CH₃, S(O)₂CH₂CH₂CH₃, CN, N(CH₃)₂, SF₅, SCH₃, NH₂, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(OH)(CH₃)CF₃, S(O)₂CH₃, C(O)CH₃, C(O)OCH₃, C(O)OH, OCHF₂ or G¹.


In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF₃, CH₃, CH₂CH₃, OCH₃, S(O)₂CH₃, CN, N(CH₃)₂, SF₅, NH₂, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(O)CH₃, C(O)OCH₃, C(O)OH, OCHF₂ or G¹.

In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y, together with the atoms to which they are attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X. In some embodiments, 2 R^Y together with the atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, or dioxolanyl ring, each of which is optionally substituted with 1-5 R^X. In some embodiments, each R^X is independently C₁-C₆ alkyl or halo (*e.g.*, CH₃ or fluoro).

In some embodiments, G¹ is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some embodiments, G¹ is cyclopropyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some embodiments, each R^Z is independently C₁-C₆ alkyl (*e.g.*, CH₃) or halo (*e.g.*, chloro). In some embodiments, each R^Z is independently C₁-C₆ alkyl (*e.g.*, CH₃).

In some embodiments, the compound of Formula (I) is a compound of Formula (I-c):


- 67 -



Formula (I-d)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L¹, L², A, and W, is defined as for Formula (I).

5 In some embodiments, the compound of Formula (I) is a compound of Formula (I-e):



Formula (I-e)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L², A, W, R¹, R² and t is defined as for Formula (I).

10 In some embodiments, L² is C₁-C₆ alkylene, C₂-C₆ alkenylene, or 2-7-membered heteroalkylene optionally substituted by 1-5 R^X. In some embodiments, L² is selected from CH₂O-*, CH₂CH₂-, CH₂CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, NH-*, S(O)₂CH-*, or
15 CH₂C(O)-*, and “-*” indicates the attachment point to W.

C₁-C₆ alkyl, oxo, halo, cyano, -OR^A, -OS(O)₂R^D, -S(O)₂R^D, -SR^E, NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, NR^BR^C, or G² (e.g., CH₃, oxo, fluoro, OH, cyano, OCH₃, NH₂, N(CH₃)₂, NHC(O)CH₃, OC(O)CH₃, C(O)NH₂, OS(O)₂CH₃, -S(O)₂CH₃, -S(O)₂CH₂CH₃, C(O)OH, OC(O)R^D, -C(O)CH₃, or -SCH₃).


20 In some embodiments, L² is selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to W. In some embodiments, L² is selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-,
25 CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to W.

In some embodiments, t is 1. In some embodiments, t is 0.


- 68 -

In some embodiments, R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, hydroxyl- C_2 - C_6 alkyl, or silyloxy- C_2 - C_6 alkyl. In some embodiments, one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, C_1 - C_6 alkyl, hydroxyl- C_2 - C_6 alkyl, or silyloxy- C_2 - C_6 alkyl. In some embodiments, R^1 and R^2 are each independently hydrogen, $^*-CH_3$, $^*-CH_2CH_2OH$, or $^*-CH_2CH_2OSi(CH_3)_2C(CH_3)_3$, and “ $^*-$ ” indicates the attachment point to the nitrogen atom. In some embodiments, one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, $^*-CH_3$, $^*-CH_2CH_2OH$, or $^*-CH_2CH_2OSi(CH_3)_2C(CH_3)_3$, and “ $^*-$ ” indicates the attachment point to the nitrogen atom. In some embodiments, R^1 and R^2 are each independently hydrogen.


In some embodiments, each A and W is independently a phenyl or heteroaryl optionally substituted with 1-5 R^Y groups. In some embodiments, each A and W is independently a phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y groups, and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently selected from:



- 69 -



In some embodiments, each of A and W is independently selected from:




10 In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl,


- 70 -

pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y .

In some embodiments, A is selected from:



In some embodiments, In some embodiments, W is selected from:



In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF_3 , CHF_2 , CH_2CF_3 , CH_3 , CH_2CH_3 , $C(CH_3)_2OH$, OCH_3 , OCH_2CH_3 , OCF_3 , $S(O)_2CH_3$, $S(O)_2CH_2CH_2CH_3$, CN , $N(CH_3)_2$, SF_5 , SCH_3 , NH_2 , $C(CH_3)_3$, $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$, $C(OH)(CH_3)CF_3$, $S(O)_2CH_3$, $C(O)CH_3$, $C(O)OCH_3$, $C(O)OH$, $OCHF_2$ or G^1 .


- 71 -

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF_3 , CH_3 , CH_2CH_3 , OCH_3 , $S(O)_2CH_3$, CN , $N(CH_3)_2$, SF_5 , NH_2 , $C(CH_3)_3$, $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$, $C(O)CH_3$, $C(O)OCH_3$, $C(O)OH$, $OCHF_2$ or G^1 .

In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y , together with the atoms to which they are attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X . In some embodiments, 2 R^Y together with the atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, furanyl, or dioxolanyl ring, each of which is optionally substituted with 1-5 R^X . In some embodiments, each R^X is independently C_1 - C_6 alkyl or halo (e.g., CH_3 or fluoro).

In some embodiments, G^1 is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z . In some embodiments, each R^Z is independently C_1 - C_6 alkyl (e.g., CH_3) or halo (e.g., chloro).

In some embodiments, the compound of Formula (I) is a compound of Formula (I-f):



Formula (I-f)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^2 , W, R^Y , R^1 , R^2 and t is defined as for Formula (I).

In some embodiments, L^2 is C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or 2-7-membered heteroalkylene optionally substituted by 1-5 R^X . In some embodiments, L^2 is 2-7-membered heteroalkylene, O, or NR^C , optionally substituted by 1-5 R^X . In some embodiments, L^2 is selected from CH_2O -, CH_2CH_2 -, $CH_2CH_2CH_2$ -, CH_2 -, $CH_2C(O)$ -, $CH=CH$ -, CH_2CH_2O -, CH_2OCH_2 -, $CH_2OCH_2CH_2$ -, $CH_2CH_2CH_2O$ -, $CH_2CH_2OCH_2$ -, $NHCH_2$ -, CH_2NH -, $CH_2N(CH_3)$ -, $CH_2N(CH_3)C(O)$ -, $CH_2N(C(O)CH_3)$ -, $CH_2CH(OH)$ -, $CH(OH)$ -, $CH(OH)CH_2CH_2$ -, $CH_2CH(OH)$ -, $CH_2NHC(O)$ -, $NHC(O)OCH_2$ -, O -, NH -, $S(O)_2CH$ -, $S(O)_2CH_2CH_2$ -, $S(O)_2CH_2CH_2O$ -, or $CH_2C(O)$ -, and “-” indicates the attachment point to W.

In some embodiments, each R^X is independently C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-OS(O)_2R^D$, $-S(O)_2R^D$, $-SR^E$, $NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $NR^B R^C$, or G^2 .

- 72 -

(*e.g.*, CH₃, oxo, fluoro, OH, cyano, OCH₃, NH₂, N(CH₃)₂, NHC(O)CH₃, OC(O)CH₃, C(O)NH₂, OS(O)₂CH₃, -S(O)₂CH₃, -S(O)₂CH₂CH₃, C(O)OH, OC(O)R^D, -C(O)CH₃, or -SCH₃).

In some embodiments, L² is selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to W. In some embodiments, L² is selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to W.

In some embodiments, t is 1. In some embodiments, t is 0.


In some embodiments, R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, hydroxyl-C₂-C₆ alkyl, or silyloxy-C₂-C₆ alkyl. In some embodiments, one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, C₁-C₆ alkyl, hydroxyl-C₂-C₆ alkyl, or silyloxy-C₂-C₆ alkyl. In some embodiments, R¹ and R² are each independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “*-” indicates the attachment point to the nitrogen atom. In some embodiments, one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “*-” indicates the attachment point to the nitrogen atom. In some embodiments, R¹ and R² are each independently hydrogen.

In some embodiments, each A and W is independently phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y, and each R^Y is independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, triazinyl, triazolyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently selected from:

5


10

- 74 -




- In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y .


10 In some embodiments, A is selected from:



In some embodiments, W is selected from:



- 75 -



In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl. In some embodiments, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 .

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF_3 , CHF_2 , CH_2CF_3 , CH_3 , CH_2CH_3 , $C(CH_3)_2OH$, OCH_3 , OCH_2CH_3 , OCF_3 , $S(O)_2CH_3$, $S(O)_2CH_2CH_2CH_3$, CN , $N(CH_3)_2$, SF_5 , SCH_3 , NH_2 , $C(CH_3)_3$, $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$, $C(OH)(CH_3)CF_3$, $S(O)_2CH_3$, $C(O)CH_3$, $C(O)OCH_3$, $C(O)OH$, $OCHF_2$ or G^1 .


In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF_3 , CH_3 , CH_2CH_3 , OCH_3 , $S(O)_2CH_3$, CN , $N(CH_3)_2$, SF_5 , NH_2 , $C(CH_3)_3$, $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$, $C(O)CH_3$, $C(O)OCH_3$, $C(O)OH$, $OCHF_2$ or G^1 .

- 76 -

In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y , together with the atoms to which they are attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X . In some embodiments, 2 R^Y together with the atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, or dioxolanyl ring, each of which is optionally substituted with 1-5 R^X . In some embodiments, each R^X is independently C_1 - C_6 alkyl or halo (e.g., CH_3 or fluoro).

In some embodiments, G^1 is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z . In some embodiments, G^1 is cyclopropyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z . In some embodiments, each R^Z is independently C_1 - C_6 alkyl (e.g., CH_3) or halo (e.g., chloro). In some embodiments, each R^Z is independently C_1 - C_6 alkyl (e.g., CH_3).


In some embodiments, the compound of Formula (I) is a compound of Formula (I-g):



Formula (I-g)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^1 , L^2 , R^1 , R^2 , A, W, R^X , and t is defined as for Formula (I).


In some embodiments, the compound of Formula (I) is a compound of Formula (I-h):



Formula (I-h)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^2 , R^1 , R^2 , A, W, R^X , and t is defined as for Formula (I).

In some embodiments, the compound of Formula (I) is a compound of Formula (I-i):



Formula (I-i)

- 77 -

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^2 , R^1 , R^2 , W, R^X , R^Y , and t is defined as for Formula (I).

In some embodiments, L^2 is C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or 2-7-membered heteroalkylene optionally substituted by 1-5 R^X . In some embodiments, L^2 is 2-7-membered heteroalkylene, O, or NR^C , optionally substituted by 1-5 R^X . In some embodiments, L^2 is selected from CH_2O^* , $CH_2CH_2^*$, $CH_2CH_2CH_2^*$, CH_2^* , $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, $NHCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $CH(OH)^*$, $CH(OH)CH_2CH_2^*$, $CH_2CH(OH)^*$, $CH_2NHC(O)^*$, $NHC(O)OCH_2^*$, O^* , NH^* , $S(O)_2CH^*$, $S(O)_2CH_2CH_2^*$, $S(O)_2CH_2CH_2O^*$, or $CH_2C(O)^*$, and “-*” indicates the attachment point to W.

In some embodiments, each R^X is independently C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-OS(O)_2R^D$, $-S(O)_2R^D$, $-SR^E$, $NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $NR^B R^C$, or G^2 (e.g., CH_3 , oxo, fluoro, OH, cyano, OCH_3 , NH_2 , $N(CH_3)_2$, $NHC(O)CH_3$, $OC(O)CH_3$, $C(O)NH_2$, $OS(O)_2CH_3$, $-S(O)_2CH_3$, $-S(O)_2CH_2CH_3$, $C(O)OH$, $OC(O)R^D$, $-C(O)CH_3$, or $-SCH_3$).

In some embodiments, L^2 is selected from CH_2O^* , $CH_2CH_2^*$, $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $NHC(O)OCH_2^*$, or $CH_2C(O)^*$, and “-*” indicates the attachment point to W. In some embodiments, L^2 is selected from CH_2O^* , $CH_2CH_2^*$, $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $NHC(O)OCH_2^*$, or $CH_2C(O)^*$, and “-*” indicates the attachment point to W.


In some embodiments, t is 1. In some embodiments, t is 0.

In some embodiments, R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, hydroxyl- C_2 - C_6 alkyl, or silyloxy- C_2 - C_6 alkyl. In some embodiments, one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, C_1 - C_6 alkyl, hydroxyl- C_2 - C_6 alkyl, or silyloxy- C_2 - C_6 alkyl. In some embodiments, R^1 and R^2 are each independently hydrogen, $^*-CH_3$, $^*-CH_2CH_2OH$, or $^*-CH_2CH_2OSi(CH_3)_2C(CH_3)_3$, and “-*” indicates the attachment point to the nitrogen atom. In some embodiments, one of R^1 and R^2 is independently hydrogen and the other of R^1 and R^2 is independently hydrogen, $^*-CH_3$, $^*-$


- 78 -

CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “*-” indicates the attachment point to the nitrogen atom. In some embodiments, R¹ and R² are each independently hydrogen.


In some embodiments, each A and W is independently phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y, and each R^Y is independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, triazinyl, triazolyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently selected from:



- 79 -




In some embodiments, each of A and W is independently selected from:




5 In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 .
 10 In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5
 15 R^Y .

- 80 -


In some embodiments, A is selected from:



In some embodiments, W is selected from:



- 81 -



In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl. In some embodiments, each of A and W is optionally substituted with 1-5 R^Y, and each R^Y is

5 independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹.

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF₃, CHF₂, CH₂CF₃, CH₃, CH₂CH₃, C(CH₃)₂OH, OCH₃, OCH₂CH₃, OCF₃, S(O)₂CH₃, S(O)₂CH₂CH₂CH₃,

10 CN, N(CH₃)₂, SF₅, SCH₃, NH₂, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(OH)(CH₃)CF₃, S(O)₂CH₃, C(O)CH₃, C(O)OCH₃, C(O)OH, OCHF₂ or G¹.

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF₃, CH₃, CH₂CH₃, OCH₃, S(O)₂CH₃, CN, N(CH₃)₂, SF₅, NH₂, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(O)CH₃, C(O)OCH₃, C(O)OH, OCHF₂ or G¹.

15 In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y, together with the atoms to which they are attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X. In some embodiments, 2 R^Y together with the atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, or


20 dioxolanyl ring, each of which is optionally substituted with 1-5 R^X. In some embodiments, each R^X is independently C₁-C₆ alkyl or halo (*e.g.*, CH₃ or fluoro).

In some embodiments, G¹ is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some embodiments, G¹ is cyclopropyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some

25 embodiments, each R^Z is independently C₁-C₆ alkyl (*e.g.*, CH₃) or halo (*e.g.*, chloro). In some embodiments, each R^Z is independently C₁-C₆ alkyl (*e.g.*, CH₃).

In some embodiments, the compound of Formula (I) is a compound of Formula (I-j):


- 82 -



Formula (I-j)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^1 , L^2 , R^1 , R^2 , A, W, R^X , and t is defined as for Formula (I).


In some embodiments, the compound of Formula (I) is a compound of Formula (I-k):



Formula (I-k)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^2 , R^1 , R^2 , A, W, R^X , and t is defined as for Formula (I).

In some embodiments, the compound of Formula (I) is a compound of Formula (I-l):



Formula (I-l)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein each of L^2 , R^1 , R^2 , W, R^X , R^Y , and t is defined as for Formula (I).

In some embodiments, at least one of L^1 and L^2 is independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^X . In some embodiments, both L^1 and L^2 are independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^X . In some embodiments, one of L^1 and L^2 is independently C_1 - C_6 alkylene or C_2 - C_6 alkenylene and the other of L^1 and L^2 is independently 2-7-membered heteroalkylene, and wherein each C_1 - C_6 alkylene, C_2 - C_6 alkenylene, and 2-7-membered heteroalkylene is optionally substituted by 1-5 R^X . In some embodiments, each R^X is independently C_1 - C_6 alkyl, oxo, or $-C(O)R^D$ (e.g., CH_3 , oxo, or $C(O)CH_3$). In some embodiments, each of L^1 and L^2 is independently selected from CH_2O -, CH_2CH_2 -, $CH_2C(O)$ -, $CH=CH$ -, CH_2CH_2O -, CH_2OCH_2 -, $CH_2OCH_2CH_2$ -,

- 83 -

CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to A and W, respectively. In some embodiments, L¹ is CH₂O-*, L² is independently selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to A and W, respectively.

In some embodiments, L² is selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to W. In some embodiments, L² is selected from CH₂O-*, CH₂CH₂-, CH₂C(O)-*, CH=CH-*, CH₂CH₂O-*, CH₂OCH₂-, CH₂OCH₂CH₂-, CH₂CH₂CH₂O-*, CH₂CH₂OCH₂-, CH₂NH-*, CH₂N(CH₃)-*, CH₂N(CH₃)C(O)-*, CH₂N(C(O)CH₃)-*, CH₂CH(OH)-*, NHC(O)OCH₂-, or CH₂C(O)-*, and “-*” indicates the attachment point to W.

In some embodiments, each R^X is independently C₁-C₆ alkyl, oxo, halo, cyano, -OR^A, -OS(O)₂R^D, -S(O)₂R^D, -SR^E, NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, NR^BR^C, or G² (e.g., CH₃, oxo, fluoro, OH, cyano, OCH₃, NH₂, N(CH₃)₂, NHC(O)CH₃, OC(O)CH₃, C(O)NH₂, OS(O)₂CH₃, -S(O)₂CH₃, -S(O)₂CH₂CH₃, C(O)OH, OC(O)R^D, -C(O)CH₃, or -SCH₃).

In some embodiments, t is 1. In some embodiments, t is 0.


In some embodiments, R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, hydroxyl-C₁-C₆ alkyl, or silyloxy-C₁-C₆ alkyl. In some embodiments, one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ hydroxyl-C₁-C₆ alkyl, or silyloxy-C₁-C₆ alkyl. In some embodiments, R¹ and R² are each independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “-*” indicates the attachment point to the nitrogen atom. In some embodiments, one of R¹ and R² is independently hydrogen and the other of R¹ and R² is independently hydrogen, *-CH₃, *-CH₂CH₂OH, or *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, and “-*” indicates the attachment point to the nitrogen atom. In some embodiments, R¹ and R² are each independently hydrogen.

In some embodiments, A is phenyl and W is independently phenyl or 5-6-membered heteroaryl. In some embodiments, each A and W is independently phenyl. In some embodiments, A is phenyl and W is 5-6-membered heteroaryl.


- 84 -

In some embodiments, W is a monocyclic 5-6-membered heteroaryl. In some embodiments, 2 R^Y groups on adjacent atoms of W, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl or heterocyclyl optionally substituted with 1-5 R^X forming a bicyclic heteroaryl. In some embodiments, W is a 10-membered heteroaryl, a 9-membered heteroaryl, a 6-membered heteroaryl, or a 5-membered heteroaryl. In some embodiments, W is a heteroaryl containing nitrogen, oxygen or sulfur as allowed by valence.


In some embodiments, each A and W is independently phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, triazinyl, triazolyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups. In some embodiments, each of A and W is independently selected from:



- 85 -




In some embodiments, each of A and W is independently selected from:




In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 . In some embodiments, A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y .

- 86 -


In some embodiments, A is selected from:



In some embodiments, W is selected from:



- 87 -



In some embodiments, A is phenyl and W is phenyl or 5-6-membered heteroaryl. In some embodiments, each of A and W is optionally substituted with 1-5 R^Y, and each R^Y is independently C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)₂R^D, or G¹.

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF₃, CHF₂, CH₂CF₃, CH₃, CH₂CH₃, C(CH₃)₂OH, OCH₃, OCH₂CH₃, OCF₃, S(O)₂CH₃, S(O)₂CH₂CH₂CH₃, CN, N(CH₃)₂, SF₅, SCH₃, NH₂, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(OH)(CH₃)CF₃, S(O)₂CH₃, C(O)CH₃, C(O)OCH₃, C(O)OH, OCHF₂ or G¹.

In some embodiments, each R^Y is independently chloro, fluoro, iodo, CF₃, CH₃, CH₂CH₃, OCH₃, S(O)₂CH₃, CN, N(CH₃)₂, SF₅, NH₂, C(CH₃)₃, CH(CH₃)₂, CH₂CN, CH₂NH₂, CH(OH)CH₃, C(O)CH₃, C(O)OCH₃, C(O)OH, OCHF₂ or G¹.

In some embodiments, each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y, together with the atoms to which they are attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X. In some embodiments, 2 R^Y together with the atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, or dioxolanyl ring, each of which is optionally substituted with 1-5 R^X. In some embodiments, each R^X is independently C₁-C₆ alkyl or halo (e.g., CH₃ or fluoro).


In some embodiments, G¹ is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some embodiments, G¹ is cyclopropyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z. In some embodiments, each R^Z is independently C₁-C₆ alkyl (e.g., CH₃) or halo (e.g., chloro). In some embodiments, each R^Z is independently C₁-C₆ alkyl (e.g., CH₃).

- 88 -

In some embodiments, the compound of Formula (I) (e.g., a compound of Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j), (I-k) or (I-l)) or a pharmaceutically acceptable salt thereof is formulated as a pharmaceutically acceptable composition comprising a disclosed compound and a pharmaceutically acceptable carrier.

In some embodiments, the compound of Formula (I) (e.g., a compound of Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j), (I-k) or (I-l)) is selected from a compound set forth in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

Also disclosed herein is a compound of Formula (II):



Formula (II)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein:

D is a bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl, wherein each bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl is optionally substituted with 1-4 R^X groups; and wherein if the bridged bicyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen moiety may be optionally substituted by R^{N1};

L¹ is C₁-C₆ alkylene, C₂-C₆ alkenylene, 2-7-membered heteroalkylene, O, or NR^C, wherein C₁-C₆ alkylene, C₂-C₆ alkenylene, or 2-7-membered heteroalkylene is optionally substituted with 1-5 R^X;

L² is -(C₀-C₂ alkylene)-O-(C₀-C₂ alkylene)-;

R¹ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy-C₂-C₆ alkyl, hydroxy-C₂-C₆ alkyl, and silyloxy-C₂-C₆ alkyl;

R^{N1} is selected from the group consisting of hydrogen, C₁-C₆ alkyl, hydroxy-C₂-C₆ alkyl, halo-C₂-C₆ alkyl, amino-C₂-C₆ alkyl, cyano-C₂-C₆ alkyl, -C(O)NR^BC, -C(O)R^D, -C(O)OR^D, and -S(O)₂R^D;

A and W are each independently phenyl or 5-6-membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R^Y;

- 89 -

each R^X is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-SR^E$, $-S(O)R^D$, $-S(O)_2 R^D$, $-OS(O)R^D$, $-OS(O)_2 R^D$, and G^2 ;

5 each R^Y is independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)R^D$, $-S(O)_2 R^D$, and G^1 ; or

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a
10 3-7-membered fused cycloalkyl, heterocyclyl, aryl, or heteroaryl ring optionally substituted with 1-5 R^X ;

each G^1 and G^2 is independently C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl, wherein each C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 R^Z ;

15 each R^Z is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, and $-S(O)_2 R^D$;

each R^A is independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, $-C(O)NR^B R^C$, $-C(O)R^D$, or $-C(O)OR^D$;

20 each of R^B and R^C is independently hydrogen or C_1 - C_6 alkyl; or

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with 1-3 R^Z ;

each R^D is independently C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl, wherein each C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl is optionally
25 substituted with 1-5 R^G ;


each R^E is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl;

each R^F is independently hydrogen, C_1 - C_6 alkyl, or halo;

each R^G is independently aryl or 5-6 membered heteroaryl, wherein each aryl or 5-6 membered heteroaryl is optionally substituted with 1-5 R^H ;

30 each R^H is independently C_1 - C_6 alkyl or halo- C_1 - C_6 alkyl;

m is 1 when R^F is hydrogen or C_1 - C_6 alkyl, 3 when R^F is C_1 - C_6 alkyl, or 5 when R^F is halo; and;




- 91 -

wherein R^{N4} is hydrogen or CH_3 .

In some embodiments, each R^Y is independently hydrogen, chloro, fluoro, CF_3 , CHF_2 , CH_3 , CH_2CH_3 , $CH(CH_3)_2$, OCH_3 , OCF_3 , $OCH(CH_3)_2$, or CN .

In some embodiments, the compound of Formula (II) is a compound of Formula (II-a):



Formula (II-a)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein:

D is bicyclo[1.1.1]pentanyl or bicyclo[2.2.2]octanyl, each of which is optionally substituted with 1-4 R^X groups;

L^1 is CH_2O-^* or $CH_2OCH_2-^*$, wherein “- * ” indicates the attachment point to A;

L^2 is selected from the group consisting of $O-^*$, OCH_2-^* , CH_2O-^* , $OCH_2CH_2-^*$, $CH_2OCH_2-^*$, and $CH_2CH_2O-^*$; wherein “- * ” indicates the attachment point to W;

A is phenyl or pyridyl, each of which is optionally substituted with 1-5 R^Y groups;

W is phenyl, pyridyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted on one or more available carbons with 1-5 R^Y groups; and wherein pyrazolyl may be optionally substituted on an available nitrogen with hydrogen or CH_3 ;

each R^X is independently fluoro, oxo, OH, OCH_3 , $C(O)OH$, or $C(O)OCH_3$;

each R^Y is independently chloro, fluoro, CF_3 , CH_3 , CH_2CH_3 , $CH(CH_3)_2$, OCH_3 , $OCH(CH_3)_2$, or CN ; or

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a furanyl, pyrrolyl, or dioxolanyl ring, each of which is optionally substituted with 1-2 R^X ; and R^1 is hydrogen.

In some embodiments, the compound of Formula (II) (e.g., a compound of Formula (II-a) or a pharmaceutically acceptable salt thereof is formulated as a pharmaceutically acceptable composition comprising a disclosed compound and a pharmaceutically acceptable carrier.

In some embodiments, the compound of Formula (II) (e.g., a compound of Formula (II-a) is selected from a compound set forth in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

Table 1: Exemplary compounds of the invention

















Compound Number	Structure	Compound Number	Structure
100		101	
102		103	
104		105	
106		107	
108		109	
110		111	
112		113	
114		115	
116		117	

- 93 -

Compound Number	Structure	Compound Number	Structure
118		119	
120		121	
122		123	
124		125	
126		127	
128		129	
130		131	
132		133	

- 94 -















Compound Number	Structure	Compound Number	Structure
134		135	
136		137	
138		139	
140		141	
142		143	
144		145	
146		147	
148		149	

Compound Number	Structure	Compound Number	Structure
150		151	
152		153	
154		155	
156		157	
158		159	
160		161	
162		163	
164		165	

Compound Number	Structure	Compound Number	Structure
166		167	
168		169	
170		171	
172		173	
174		175	
176		177	
178		179	
180		181	

Compound Number	Structure	Compound Number	Structure
182		183	
184		185	
186		187	
188		189	
190		191	
192		193	
194		195	
196		197	

- 98 -

Compound Number	Structure	Compound Number	Structure
198		199	
200		201	
202		203	
204		205	
206		207	
208		209	
210		211	

- 99 -

Compound Number	Structure	Compound Number	Structure
212		213	
214		215	
216		217	
218		219	
220		221	
222		223	
224		225	
226		227	
228		229	
230		231	

- 100 -

Compound Number	Structure	Compound Number	Structure
232		233	
234		235	
236		237	
238		239	
240		241	
242		243	
244		245	
246		247	

- 101 -

Compound Number	Structure	Compound Number	Structure
248		249	
250		251	
252		253	
254		255	
256		257	
258		259	
260		261	

- 102 -









Compound Number	Structure	Compound Number	Structure
262		263	
264		265	
266		267	
268		269	
270		271	
272		273	
274		275	
276		277	

Compound Number	Structure	Compound Number	Structure
278		279	
280		281	
282		283	
284		285	
286		287	
288		289	
290		291	
292		293	









- 104 -

Compound Number	Structure	Compound Number	Structure
294		295	
296		297	
298		299	
300		301	
302		303	
304		305	
306		307	

- 105 -

Compound Number	Structure	Compound Number	Structure
308		309	
310		311	
312		313	
314		315	

- 106 -

Compound Number	Structure	Compound Number	Structure
316		317	
318		319	
320		321	
322		323	

- 107 -

Compound Number	Structure	Compound Number	Structure
324		325	
326		327	
328		329	
330		331	









- 108 -

Compound Number	Structure	Compound Number	Structure
332		333	
334		335	
336		337	

- 109 -

Compound Number	Structure	Compound Number	Structure
338		339	
340		341	
342		343	
344		345	

- 110 -

Compound Number	Structure	Compound Number	Structure
346		347	
348		349	
350		351	
352		353	

- 111 -

Compound Number	Structure	Compound Number	Structure
354		355	
356		357	
358		359	
360		361	

- 112 -

Compound Number	Structure	Compound Number	Structure
362		363	
364		365	
366		367	
368		369	

- 113 -

Compound Number	Structure	Compound Number	Structure
370		371	
372		373	
374		375	
376		377	
378		379	

- 114 -

Compound Number	Structure	Compound Number	Structure
380		381	
382		383	
384		385	
386		387	

- 115 -

Compound Number	Structure	Compound Number	Structure
388		389	
390		391	
392		393	
394		395	

- 116 -

Compound Number	Structure	Compound Number	Structure
396		397	
398		399	
400		401	
402		403	

- 117 -

Compound Number	Structure	Compound Number	Structure
404		405	
406		407	
408		409	
410		411	
412		413	

- 118 -

Compound Number	Structure	Compound Number	Structure
414		415	
416		417	
418		419	
420		421	

- 119 -

Compound Number	Structure	Compound Number	Structure
422		423	
424		425	
426		427	

- 120 -

Compound Number	Structure	Compound Number	Structure
428		429	
430		431	
432		433	
434		435	

- 121 -

Compound Number	Structure	Compound Number	Structure
436		437	
438		439	
440		441	
442		443	









- 122 -

Compound Number	Structure	Compound Number	Structure
444		445	
446		447	
448		449	
450		451	

- 123 -

Compound Number	Structure	Compound Number	Structure
452		453	
454		455	
456		457	
458		459	
460		461	











- 124 -

Compound Number	Structure	Compound Number	Structure
462		463	
464		465	
466		467	
468		469	









- 125 -

Compound Number	Structure	Compound Number	Structure
470		471	
472		473	
474		475	
476		477	
478		479	









- 126 -

Compound Number	Structure	Compound Number	Structure
480		481	
482		483	
484		485	
486		487	
488		489	

- 127 -

Compound Number	Structure	Compound Number	Structure
490		491	
492		493	
494		495	
496		497	









- 128 -

Compound Number	Structure	Compound Number	Structure
498		499	
500		501	
502		503	
504		505	

- 129 -

Compound Number	Structure	Compound Number	Structure
506		507	
508		509	
510		511	
512		513	











- 130 -

Compound Number	Structure	Compound Number	Structure
514		515	
516		517	
518		519	
520		521	









- 131 -

Compound Number	Structure	Compound Number	Structure
522		523	
524		525	
526		527	
528		529	









- 132 -

Compound Number	Structure	Compound Number	Structure
530		531	
532		533	
534		535	
536		537	
538		539	

- 133 -

Compound Number	Structure	Compound Number	Structure
540		541	
542		543	
544		545	
546		547	









- 134 -

Compound Number	Structure	Compound Number	Structure
548		549	
550		551	
552		553	
554		555	

- 135 -

Compound Number	Structure	Compound Number	Structure
556		557	
558		559	
560		561	
562		563	

- 136 -

Compound Number	Structure	Compound Number	Structure
564		565	
566		567	
568		569	
570		571	

- 137 -

Compound Number	Structure	Compound Number	Structure
572		573	
574		575	
576		577	
578		579	

- 138 -

Compound Number	Structure	Compound Number	Structure
580		581	
582		583	
584		585	
586		587	









- 139 -

Compound Number	Structure	Compound Number	Structure
588		589	
590		591	
592		593	
594		595	











- 140 -

Compound Number	Structure	Compound Number	Structure
596		597	
598		599	
600		601	
602		603	

- 141 -

Compound Number	Structure	Compound Number	Structure
604		605	
606		607	
608		609	
610		611	

- 142 -

Compound Number	Structure	Compound Number	Structure
612		613	
614		615	
616		617	
618		619	
620		621	

- 143 -

Compound Number	Structure	Compound Number	Structure
622		623	
624		625	
626		627	
628		629	









- 144 -

Compound Number	Structure	Compound Number	Structure
630		631	
632		633	
634		635	
636		637	

- 145 -

Compound Number	Structure	Compound Number	Structure
638		639	
640		641	
642		643	
644		645	

- 146 -

Compound Number	Structure	Compound Number	Structure
646		647	
648		649	
650		651	
652		653	

- 147 -

Compound Number	Structure	Compound Number	Structure
654		655	
656		657	
658		659	
660		661	

- 148 -

Compound Number	Structure	Compound Number	Structure
662		663	
664		665	
666		667	
668		669	

Compound Number	Structure	Compound Number	Structure
670		671	
672		673	
674		675	
676		677	









- 150 -

Compound Number	Structure	Compound Number	Structure
678		679	
680		681	
682		683	
684		685	
686		687	

- 151 -

Compound Number	Structure	Compound Number	Structure
688		689	
690		691	
692		693	
694		695	
696		697	









- 152 -

Compound Number	Structure	Compound Number	Structure
698		699	
700		701	
702		703	
704		705	

- 153 -

Compound Number	Structure	Compound Number	Structure
706		707	
708		709	
710		711	
712		713	
714		715	

- 154 -

Compound Number	Structure	Compound Number	Structure
716		717	
718		719	
720		721	
722		723	

- 155 -

Compound Number	Structure	Compound Number	Structure
724		725	
726		727	
728		729	
730		731	
732		733	

- 156 -

Compound Number	Structure	Compound Number	Structure
734		735	
736		737	
738		739	
740		741	

- 157 -

Compound Number	Structure	Compound Number	Structure
742		743	
744		745	
746		747	
748		749	

- 158 -

Compound Number	Structure	Compound Number	Structure
750		751	
752		753	
754		755	
756		757	

- 159 -

Compound Number	Structure	Compound Number	Structure
758		759	
760		761	
762		763	
764		765	

- 160 -

Compound Number	Structure	Compound Number	Structure
766		767	
768		769	
770		771	
772		773	

- 161 -

Compound Number	Structure	Compound Number	Structure
774		775	
776		777	
778		779	
780		781	

- 162 -

Compound Number	Structure	Compound Number	Structure
782		783	
784		785	
786		787	
788		789	

- 163 -

Compound Number	Structure	Compound Number	Structure
790		791	
792		793	
794		795	
796		797	

- 164 -

Compound Number	Structure	Compound Number	Structure
798		799	
800		801	
802		803	
804		805	

- 165 -

Compound Number	Structure	Compound Number	Structure
806		807	
808		809	
810		811	
812		813	

- 166 -

Compound Number	Structure	Compound Number	Structure
814		815	
816		817	
818		819	
820		821	

- 167 -

Compound Number	Structure	Compound Number	Structure
822		823	
824		825	
826		827	
828		829	

- 168 -

Compound Number	Structure	Compound Number	Structure
830		831	
832		833	
834		835	
836		837	
838		839	

- 169 -

Compound Number	Structure	Compound Number	Structure
840		841	
842		843	
844		845	
846		847	


- 170 -

Compound Number	Structure	Compound Number	Structure
848		849	

Methods of Making Exemplary Compounds

The compounds of the invention may be better understood in connection with the following synthetic schemes and methods which illustrate a means by which the compounds can be

- 5 prepared. The compounds of this invention can be prepared by a variety of synthetic procedures. Representative synthetic procedures are shown in, but not limited to, Schemes 1-29. The variables A, D, W, L¹, L², R¹, and R² are defined as detailed herein, e.g., in the Summary Scheme 1: Representative scheme for synthesis of exemplary compounds of the invention.



- 10 As shown in Scheme 1, compounds of formula (3), when A and W are the same and L¹ and L² are the same, and which are representative of compounds of formula (I), can be prepared from compounds of formula (1). Carboxylic acids of formula (2A) can be coupled with amines of formula (1) under amide bond forming conditions to provide compounds of formula (3). Examples of conditions known to generate amides from a mixture of a carboxylic acid and an

- 171 -


amine include, but are not limited to, adding a coupling reagent such as, but not limited to, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, EDAC or EDCI) or the corresponding hydrochloride salt, 1,3-dicyclohexylcarbodiimide (DCC), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOPCI), *N*-[(dimethylamino)-1*H*-1,2,3-triazolo-[4,5-*b*]pyridin-1-yl)methylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide or 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate or 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU), *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (TBTU), 2-(1*H*-benzo[*d*][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (HBTU), and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P®). The coupling reagents may be added as a solid, a solution, or as the reagent bound to a solid support resin.

In addition to the coupling reagents, auxiliary-coupling reagents may facilitate the coupling reaction. Auxiliary coupling reagents that are often used in the coupling reactions include but are not limited to (dimethylamino)pyridine (DMAP), 1-hydroxy-7-azabenzotriazole (HOAT) and 1-hydroxybenzotriazole (HOBt). The reaction may be carried out optionally in the presence of a base such as, but not limited to, triethylamine, *N,N*-diisopropylethylamine or pyridine. The coupling reaction may be carried out in solvents such as, but not limited to, tetrahydrofuran, *N,N*-dimethylformamide, *N,N*-dimethylacetamide, dimethyl sulfoxide, dichloromethane, and ethyl acetate. The reactions may be carried out at ambient temperature or heated. The heating can be accomplished either conventionally or with microwave irradiation.

Alternatively, acid chlorides of formula (2B) can be reacted with amines of formula (1), optionally in the presence of a base for example, a tertiary amine base such as, but not limited to, triethylamine or *N,N*-diisopropylethylamine or an aromatic base such as pyridine, at room temperature or heated in a solvent such as, but not limited to, dichloromethane to provide amides of formula (3). Amines of formula (1) can also be coupled with acid chlorides of formula (2B) in a mixture of water and dichloromethane in the presence of a base such as but not limited to sodium hydroxide.

- 172 -


Scheme 2: Representative scheme for synthesis of exemplary compounds of the invention.



- As shown in Scheme 2, compounds of formula (3), when A and W are the same or different and L^1 and L^2 are the same or different, and which are representative of compounds of
- 5 formula (I), can be prepared from compounds of formula (1). Amines of formula (1) can be protected with a suitable protecting group (PG) to provide compounds of formula (4). For example, amines of formula (1) can be treated with di-*tert*-butyl dicarbonate at ambient temperature in a solvent such as, but not limited to, tetrahydrofuran to provide compounds of formula (4) wherein PG is $C(O)OC(CH_3)_3$. Carboxylic acids of formula (2A) or acid chlorides
- 10 of formula (2B) can be coupled with amines of formula (4) under amide bond forming conditions described in Scheme 1 to provide compounds of formula (5). The protecting group (PG) in formula (5) can be removed to provide compounds of formula (6). For example, BOC protecting groups can be removed using an acid such as, but not limited to, trifluoroacetic acid or hydrochloric acid in a solvent such as, but not limited to, methanol, 1,4-dioxane or
- 15 dichloromethane, or mixtures thereof. The reaction may be performed at ambient or an elevated temperature. Carboxylic acids of formula (7A) or acid chlorides of formula (7B) can be coupled with amines of formula (6) under amide bond forming conditions described in Scheme 1 to provide compounds of formula (3), which are representative of compounds of formula (I).

- 173 -


Scheme 3: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 3, compounds of formula (9), which are representative of compounds of formula (I) when t is 0, can be prepared from compounds of formula (6).

- 5 Compounds of formula (6), which can be prepared as described in Scheme 2, can be reacted with an aldehyde of formula (8), wherein R^{100} is absent or is alkylene or heteroalkylene, in the presence of a reducing agent such as, but not limited to, sodium triacetoxyborohydride or sodium cyanoborohydride, to provide compounds of formula (9). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, 1,2-dichloroethane,
- 10 dichloromethane, methanol, ethanol, tetrahydrofuran, acetonitrile, or mixtures thereof.


Scheme 4: Representative scheme for synthesis of exemplary compounds of the invention.



- Alternatively, compounds of formula (9), which are representative of compounds of formula (I) when t is 0, can be prepared from compounds of formula (6) as shown in Scheme 4.
- 15 Amines of formula (6) can be reacted with bromides of formula (10), in the presence of a base such as, but not limited to, potassium carbonate, to provide compounds of formula (9). The reaction is typically performed at an elevated temperature in a solvent such as, but not limited to, *N,N*-dimethylformamide or dimethyl sulfoxide.

- 174 -


Scheme 5: Representative scheme for synthesis of exemplary compounds of the invention.



Compounds of formula (13) and compounds of formula (14), which are representative of compounds of formula (I) wherein t is 1, can be prepared as shown in Scheme 5. Amines of formula (6), which can be prepared as described in Scheme 2, can be treated with 2-chloroacetyl chloride in the presence of a base such as, but not limited to, potassium carbonate, to provide compounds of formula (11). The addition is typically performed at low temperature before warming up to ambient temperature in a solvent such as, but not limited to, tetrahydrofuran, water, or mixtures thereof. Alcohols of formula (12A) can be reacted with compounds of formula (11) in the presence of a strong base, such as but not limited to sodium hydride, to provide compounds of formula (13). The reaction is typically performed at ambient temperature in a solvent such as but not limited to *N,N*-dimethylformamide. Alternatively, alcohols of formula (12A) can be reacted with compounds of formula (11) in the presence of a base, such as but not limited to potassium carbonate, optionally with the addition of a catalytic amount of potassium iodide, to provide compounds of formula (13). The reaction is typically performed at an elevated temperature, optionally in a microwave, and in a solvent such as, but not limited to, acetonitrile, acetone, or mixtures thereof. Alcohols of formula (12B), wherein n is 1-6, can be reacted with compounds of formula (11) in the presence of a strong base, such as but not limited to sodium hydride, to provide compounds of formula (14). The reaction is typically performed at ambient temperature in a solvent, such as but not limited to, *N,N*-dimethylformamide.


- 175 -

Scheme 6: Representative scheme for synthesis of exemplary compounds of the invention.



A shown in Scheme 6, compounds of formula (15), which are representative of compounds of formula (I) wherein t is 1 and L² is C₂-C₇ heteroalkylene, can be prepared from compounds of formula (6). Amines of formula (6) can be treated with bis(trichloromethyl) carbonate, followed by alcohols of formula (12B), to provide compounds of formula (15). The reaction is typically performed at ambient temperature in a solvent such as but not limited to tetrahydrofuran.


Scheme 7: Representative scheme for synthesis of exemplary compounds of the invention.



Compounds of formula (18), which are representative of compounds of formula (I) wherein t is 1 and R² is C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, silyloxy-C₁-C₆ alkyl, or C₁-C₆ alkyl-C(O)₂-C₁-C₆ alkyl can be prepared from compounds of formula (6) as shown in Scheme 7. Amines of formula (6) can be alkylated with an alkylating agent of formula (16) wherein X is a halide, in the presence of a base such as, but not limited to, potassium carbonate, to provide compounds of formula (17). The reaction is typically performed at an elevated temperature in a solvent such as, but not limited to, *N,N*-dimethylformamide. Carboxylic acids of formula (7A) or acid chlorides of formula (7B) can be coupled with amines of formula (17) under amide bond forming conditions described in Scheme 1 to provide compounds of formula (18).


- 176 -

Scheme 8: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 8, compounds of formula (20), which are representative of compounds of formula (I) wherein t is 1, can be prepared from amines of formula (6). Amines of formula (6) can be reacted with chloroformates of formula (19) in the presence of a base such as, but not limited to, *N,N*-diisopropylethylamine, to provide compounds of formula (20). The reaction is typically performed at ambient temperature in a solvent such as but not limited to toluene, dichloromethane, or mixtures thereof.


10 Scheme 9: Representative scheme for synthesis of exemplary compounds of the invention.



Compounds of formula (I), wherein R^1 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_2 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, or silyloxy- C_2 - C_6 alkyl, can be prepared from compounds of formula (5) as shown in Scheme 9. Amines of formula (5), which can be prepared as described in Scheme 2, can be alkylated with an alkylating agent of formula (21), wherein X is a halide, in the presence of a base such as but not limited to sodium hydride, to provide compounds of formula (22). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, tetrahydrofuran, *N,N*-dimethylacetamide, *N,N*-dimethylformamide, or mixtures thereof. After removal of the protecting group (PG), compounds of formula (22) can be reacted with carboxylic acids of formula (7A) or acid chlorides of formula (7B) under amide bond forming conditions described in Scheme 2 to provide compounds of formula (I).

- 177 -


Scheme 10: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 10, compounds of formula (25), which are representative of compounds of formula (I) wherein t is 1, can be prepared from compounds of formula (6).

- 5 Amines of formula (6), which can be prepared as described in Scheme 2, can be reacted with 2-hydroxyacetic acid to provide compounds of formula (23) under amide bond forming conditions described in Scheme 2. Compounds of formula (23) can be alkylated with an alkylating agent of formula (24), wherein X is a halide and n is 0-5, in the presence of a base such as but not limited to sodium hydride, to provide compounds of formula (25). The reaction is typically performed
- 10 at an elevated temperature in a solvent such as, but not limited to, tetrahydrofuran *N,N*-dimethylformamide, or mixtures thereof.

Scheme 11: Representative scheme for synthesis of exemplary compounds of the invention.




- 15 Compounds of formula (28), which are representative of compounds of formula (I), wherein t is 1, can be prepared from compounds of formula (23) as shown in Scheme 11. Compounds of formula (23), which can be prepared as described in Scheme 10, can be reacted

- 178 -

with methyl 2-bromoacetate in the presence of a base such as, but not limited to, cesium carbonate to provide compounds of formula (26). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, tetrahydrofuran. Compounds of formula (26) can be treated with aqueous lithium hydroxide to provide compounds of formula (27). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, tetrahydrofuran, methanol, or mixtures thereof. Compounds of formula (27) can be treated with *N*-hydroxyacetimidamide in the presence of a coupling agent such as, but not limited to, 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU), and a base such as, but not limited to, triethylamine, to provide compounds of formula (28). The reaction is typically performed at an elevated temperature in a solvent such as but not limited to acetonitrile.


Scheme 12: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 12, compounds of formula (30), which are representative of compounds of formula (I), can be prepared from compounds of formula (26). Compounds of formula (26), which can be prepared as described in Scheme 11, can be treated with hydrazine monohydrate, to provide compounds of formula (29). The reaction is typically performed at an elevated temperature in a solvent such as, but not limited to, ethanol. Compounds of formula (29) can be treated with 1,1'-carbonyldiimidazole, to provide compounds of formula (30). The reaction is typically performed at an elevated temperature in a solvent such as but not limited to 1,4-dioxane.

- 179 -


Scheme 13: Representative scheme for synthesis of exemplary compounds of the invention.



Scheme 13 describes the synthesis of compounds of formula (I) wherein D is a 2-oxobicyclo[2.2.2]octan-1-yl core. Ethyl 4-amino-2-oxobicyclo[2.2.2]octane-1-carboxylate, which can be prepared as described herein, can be reacted with carboxylic acids of formula (2A) or acid chlorides of formula (2B) under amide bond forming conditions described in Scheme 1 to provide compounds of formula (31). Compounds of formula (31) can be treated with a methanolic solution of sodium hydroxide at ambient temperature to provide compounds of formula (32). Acids of formula (32) can be treated with diphenylphosphoryl azide, in the presence of a base such as but not limited to triethylamine, followed by treatment with *tert*-butanol, to provide compounds of formula (33). The reaction is typically performed at an elevated temperature in a solvent such as, but not limited to, toluene. Compounds of formula (33) can be treated with an acid such as, but not limited to, hydrochloric acid at ambient temperature in a solvent such as, but not limited to, 1,4-dioxane, to provide compounds of formula (34). Compounds of formula (34) can be reacted with carboxylic acids of formula (7A) or acid chlorides of formula (7B) under amide bond forming conditions described in Scheme 2 to provide compounds of formula (I).

- 180 -

Scheme 14: Representative scheme for synthesis of exemplary compounds of the invention.



Scheme 14 describes the synthesis of carboxylic acids (37), (42), and (45), which are representative of acids of formula (2A) and formula (7A).

5 Compounds of formula (35) can be reacted with ethyl 2-hydroxyacetate in the presence of a strong base such as, but not limited to, potassium *tert*-butoxide to provide compounds of formula (36). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, tetrahydrofuran. Compounds of formula (36) can be treated with aqueous lithium hydroxide to provide compounds of formula (37). The reaction is typically performed at
10 ambient temperature in a solvent such as, but not limited to, tetrahydrofuran.

Alcohols of formula (38) can be reacted with *tert*-butyl 2-bromoacetate in the presence of a base such as, but not limited to, potassium carbonate to provide compounds of formula (39). The reaction is typically performed at an elevated temperature in a solvent such as, but not limited to, *N,N*-dimethylformamide. Compounds of formula (39) can be treated with an acid
15 such as, but not limited to, hydrochloric acid to provide compounds of formula (37). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, 1,4-dioxane.


- 181 -

Compounds of formula (40) can be reacted with ethyl 3-bromopropionate in the presence of a strong base such as, but not limited to, sodium hydride, to provide compounds of formula (41). The addition is typically performed at low temperature before warming to ambient temperature, in a solvent such as, but not limited to, tetrahydrofuran. Compounds of formula (41) can be treated with aqueous sodium hydroxide to provide compounds of formula (42). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, tetrahydrofuran.

Carboxylic acids of formula (43) can be reacted with sarcosine methyl ester, under amide bond forming conditions as described in Scheme 1, to provide compounds of formula (44).

Compounds of formula (44) can be treated with aqueous sodium hydroxide to provide compounds of formula (45). The reaction is typically performed at ambient temperature in a solvent such as, but not limited to, ethanol.


Scheme 15: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 15, bromides of formula (47), which are representative of compounds of formula (10) and (24), can be prepared from alcohols of formula (46). Compounds of formula (46) can be reacted with 1,2-dibromoethane in the presence of a base such as, but not limited to, potassium carbonate, to provide compounds of formula (47). The reaction is typically performed at elevated temperature in a solvent such as, but not limited to, acetonitrile.

- 182 -


Scheme 16: Representative scheme for synthesis of exemplary compounds of the invention.



- As shown in Scheme 16, compounds of formula (49), wherein A and W are the same or different and L^1 and L^2 are the same or different, and which are representative of compounds of formula (I), can be prepared from compounds of formula (48). Carboxylic acids of formula (7A) or acid chlorides of formula (7B) can be coupled with amines of formula (48) under amide bond forming conditions described in Scheme 1 to provide compounds of formula (49). Ketones of formula (48) can also be reduced in the presence of a reducing agent such as, but not limited to sodium borohydride in solvents such as a mixture of methanol and dichloromethane to give alcohols of formula (50). Carboxylic acids of formula (7A) or acid chlorides of formula (7B) can be coupled with amines of formula (50) under amide bond forming conditions described in Scheme 1 to provide compounds of formula (51). Ketones of formula (49) can also be reduced in the presence of a reducing agent such as, but not limited to sodium borohydride in solvents such as a mixture of methanol and dichloromethane to give alcohols of formula (51).
- Compounds of formula (48), formula (49), formula (50) and formula (51) can be further derivatized as illustrated in the Examples below.


- 183 -

Scheme 17: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 17, compounds of formula (52) can be transformed to compounds of formula (6) which in turn through the methods described in Schemes 2-8 and 10 can be converted to compounds of formula (I). Accordingly, carboxylic acids of formula (2A) or acid chlorides of formula (2B) can be coupled with amines of formula (50) under amide bond forming conditions described in Scheme 1 followed by ester hydrolysis using conditions known to one of skill in the art to provide compounds of formula (53). Compounds of formula (53) can be reacted under Curtius reaction conditions such as treatment with diphenylphosphoryl azide and triethylamine in heated toluene followed by acid hydrolysis to give compounds of formula (6).

Scheme 18: Representative scheme for synthesis of exemplary compounds of the invention.




As shown in Scheme 18, compounds of formula (6) can be converted to compounds of formula (57) which are representative of compounds of formula (I). Accordingly, compounds of formula (6) can be coupled with protected amino acids of formula (54), wherein PG is suitable amine protecting group, using the amide bond coupling conditions described in Scheme 1 to give

- 184 -

compounds of formula (55). The protecting group, PG, in compounds of formula (55) can be removed under conditions known to one of skill in the art to expose a primary amine that can be coupled with carboxylic acids of formula (56) using the amide bond coupling conditions described in Scheme 1 to give compounds of formula (57).

5


Scheme 19: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 19, compounds of formula (6) can be converted to compounds of formula (59) which are representative of compounds of formula (I). Compounds of formula (6) can be reacted with sulfonyl chlorides of formula (58) in the presence of a base, such as triethylamine, in an optionally warmed solvent, such as but not limited to *N,N*-dimethylformamide, to give compounds of formula (59).

10

Scheme 20: Representative scheme for synthesis of exemplary compounds of the invention.




15

As shown in Scheme 20, compounds of formula (6) can be converted to compounds of formula (61) which are representative of compounds of formula (I). Compounds of formula (6)

- 185 -

can be reacted with isocyanates of formula (60) in the presence of pyridine to give compounds of formula (61).

Scheme 21: Representative scheme for synthesis of exemplary compounds of the invention.




5

As shown in Scheme 21, compounds of formula (6) can be converted to compounds of formula (63) which are representative of compounds of formula (I). Compounds of formula (6) can be reacted with carbamoyl chlorides of formula (62) in the presence of a base, such as *N,N*-diisopropylethylamine, in a solvent, such as tetrahydrofuran, to give compounds of formula (63).

10

Scheme 22: Representative scheme for synthesis of exemplary compounds of the invention.




15

As shown in Scheme 22, compounds of formula (64) can be transformed to compounds of formula (65) which are representative of compounds of formula (I). Compounds of formula (64) can be reduced with indium(III) bromide and triethylsilane (Et_3SiH) in warmed dichloromethane to give compounds of formula (65).


- 186 -

Scheme 23: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 23, compounds of formula (66) can be converted to compounds of formula (1). Accordingly, the ester moiety of compounds of formula (66) can be hydrolyzed under conditions known to one of skill in the art to give the corresponding carboxylic acids. The carboxylic acids can be treated under Curtius reaction conditions to complete the transformation to compounds of formula (67). Compounds of formula (67) can be reacted with di-*tert*-butyl dicarbonate in the presence of a base to give the orthogonally protected bis-amine, (68). Compounds of formula (68) can be converted to compounds of formula (1) under catalytic hydrogenation conditions in the presence of an acid, such as 4 M hydrochloric acid, in a solvent such as warmed dioxane. Compounds of formula (1) can be used as described in Scheme 1 or Scheme 2.

Scheme 24: Representative scheme for synthesis of exemplary compounds of the invention.




As shown in Scheme 24, compounds of formula (68) can be converted to compounds of formula (71). Compounds of formula (68) can be reductively aminated to compounds of formula (69), wherein R^{2b} is optionally substituted C₁-C₆ alkyl. Compounds of formula (69) can be treated under acidic conditions known to one of skill in the art to selectively remove the *tert*-

- 187 -

butoxy carbonyl protecting group and then couple the exposed amine with compounds of formula (2A) using amide bond forming reaction conditions described in Scheme 1 to give compounds of formula (70). Alternatively, acid chlorides of formula (2B) can be coupled with the amines also as described in Scheme 1. The benzyl protecting group of compounds of formula (70) can be removed under catalytic hydrogenation conditions, and then the revealed amine can be coupled with carboxylic acids of formula (7A) to give compounds of formula (71). Compounds of formula (71) can also be obtained by reaction with the corresponding acid chloride with the previously mentioned revealed amine using conditions also described in Scheme 1. Compounds of formula (71) are representative of compounds of formula (I).


Scheme 25: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 25, compounds of formula (72) can be converted to compounds of formula (75). Carboxylic acids of formula (2A) can be coupled with amines of formula (72) under amide bond forming conditions as discussed for Scheme 1 to provide compounds of formula (73). Compounds of formula (73) can be reacted with compounds of formula (74), wherein LG^1 is a leaving group, e.g., halogen or sulfonate, under nucleophilic substitution reaction conditions to give compounds of formula (75). Compounds of formula (73) can be reacted with compounds of formula (74) in the presence of a tertiary amine base, such as 2,6-di-*tert*-butylpyridine, in a solvent such as dichloromethane to give compounds of formula (75). When LG^1 is a halogen, a silver reagent such as silver trifluoromethanesulfonate may be used to increase the reactivity of the halide during nucleophilic substitution compounds of formula (74) such as benzyl halides, for example. Compounds of formula (75) are representative of compounds of Formula (I).

- 188 -


Scheme 26: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 26, compounds of formula (4) can be transformed to compounds of formula (77) which in turn through the last two steps described in Schemes 2 can be converted to compounds of formula (I). Compounds of formula (4), wherein PG is suitable amine protecting group, can be reacted with 2-chloroacetic acid under the amide bond forming conditions described in Scheme 1 to give compound of formula (76). Compounds of formula (76) can be reacted with compounds of formula (38) in the presence of potassium iodide and a base such as potassium carbonate in a heated solvent such as but not limited to acetone to give compounds of formula (77). The heating may be achieved conventionally or with microwave irradiation. After removal of the protecting group (PG) under conditions known to one of skill in the art and dependent upon the particular protecting group from compounds of formula (77), reaction of the resultant amine with carboxylic acids of formula (7A) or acid chlorides of formula (7B) under amide bond forming conditions described in Scheme 1 can provide compounds of formula (I).

- 189 -


Scheme 27: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 27, compounds of formula (4) can be transformed to compounds of formula (79) which in turn through the last two steps described in Schemes 2 can be converted to compounds of formula (I). Compounds of formula (4), wherein PG is suitable amine protecting group, can be reacted with compounds of formula (10) in the presence of a base such as but not limited to cesium carbonate in an optionally warmed solvent such as but not limited to *N,N*-dimethylformamide to give compounds of formula (78). Compounds of formula (78) can be reacted with aldehydes, R^{2c}-CHO, wherein R^{2c} is hydrogen, C₁-C₅ alkyl, C₁-C₆ alkoxy-C₂-C₅ alkyl, hydroxy-C₂-C₅ alkyl, silyloxy-C₂-C₅ alkyl, or C₁-C₅ alkyl-C(O)₂-C₁-C₆ alkyl; under reductive amination conditions such as in the presence of an acid such as trifluoroacetic acid in the presence of sodium borohydride in a solvent such as methanol to give compounds of formula (79). After removal of the protecting group (PG) under conditions known to one of skill in the art and dependent upon the particular protecting group from compounds of formula (79), reaction of the resultant amine with carboxylic acids of formula (2A) or acid chlorides of formula (2B) under amide bond forming conditions described in Scheme 1 can provide compounds of formula (I).


- 190 -

Scheme 28: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 28, compounds of formula (6) can be converted to compounds of formula (3) in one step. Accordingly, amines of formula (6) can be reacted with esters of formula (79) in a heated solvent such as but not limited to toluene to give compounds of formula (3). Compounds of formula (3) are representative of compounds of Formula (I).

Scheme 29: Representative scheme for synthesis of exemplary compounds of the invention.



As shown in Scheme 29, compounds of formula (6) can be converted to compounds of formula (81). Accordingly, amines of formula (6) can be reacted with alcohols of formula (80) and 4-nitrophenyl carbonochloridate in a heated solvent such as but not limited to acetonitrile in the presence of a tertiary amine base such as Hunig's base and an aromatic amine base such as pyridine to give compounds of formula (81). The heating may be accomplished conventionally

- 191 -

or through microwave irradiation. Compounds of formula (81) are representative of compounds of Formula (I).

Pharmaceutical Compositions

5 The present invention features pharmaceutical compositions comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, 10 tautomer, stereoisomer thereof is provided in an effective amount in the pharmaceutical composition. In some embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount.

Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the 15 compound of Formula (I) or Formula (II), (the “active ingredient”) into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit. Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” is a discrete amount of the 20 pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

Relative amounts of a compound of Formula (I) or Formula (II), the pharmaceutically 25 acceptable excipient, and/or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) of a compound of Formula (I) or Formula (II).

30 The term “pharmaceutically acceptable excipient” refers to a non-toxic carrier, adjuvant, diluent, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable excipients useful in the manufacture of the

- 192 -

pharmaceutical compositions of the invention are any of those that are well known in the art of pharmaceutical formulation and include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Pharmaceutically acceptable excipients useful in the manufacture of the pharmaceutical compositions of the invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

Compositions of the present invention may be administered orally, parenterally (including subcutaneous, intramuscular, intravenous and intradermal), by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. In some embodiments, provided compounds or compositions are administrable intravenously and/or orally.

The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraocular, intravitreal, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intraperitoneal intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, subcutaneously, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include

- 193 -

lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. In some embodiments, a provided oral formulation is formulated for immediate release or sustained/delayed release. In some embodiments, the composition is suitable for buccal or sublingual administration, including tablets, lozenges and pastilles. A compound of Formula (I) or Formula (II) may also be in micro-encapsulated form.

The compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Patent Nos. 4,911,920; 5,403,841; 5,212, 162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. *Biomater Sci. Polym. Ed.* 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., *Gao Pharm. Res.* 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. *Pharm. Pharmacol.* 49:669-674, 1997). In another embodiment, the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present

- 194 -

invention into the target cells in vivo. (See, e.g., Al-Muhammed, J. *Microencapsul.* 13:293-306, 1996; Chonn, *Curr. Opin. Biotechnol.* 6:698-708, 1995; Ostro, J. *Hosp. Pharm.* 46: 1576-1587, 1989). The compositions of the present invention can also be delivered as nanoparticles.

Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

In some embodiments, in order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.

Compounds provided herein, e.g., a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof are typically formulated in dosage unit form, e.g., single unit dosage form, for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet

- 195 -

of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.

5 The exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. The desired dosage can be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three
10 weeks, or every four weeks. In certain embodiments, the desired dosage can be delivered using multiple administrations (*e.g.*, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).

 In certain embodiments, an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or
15 stereoisomer thereof for administration one or more times a day may comprise about 0.0001 mg to about 5000 mg, *e.g.*, from about 0.0001 mg to about 4000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a
20 compound per unit dosage form.

 In certain embodiments, a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof may be at dosage levels sufficient to deliver from about 0.001 mg/kg to about 1000
mg/kg, *e.g.*, about 0.001 mg/kg to about 500 mg/kg, about 0.01 mg/kg to about 250 mg/kg, about
25 0.1 mg/kg to about 100 mg/kg, about 0.1 mg/kg to about 50 mg/kg, about 0.1 mg/kg to about 40 mg/kg, about 0.1 mg/kg to about 25 mg/kg, about 0.01 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 10 mg/kg, or about 1 mg/kg to about 50 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.

 It will be appreciated that dose ranges as described herein provide guidance for the
30 administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an

- 196 -

adult.

It will be also appreciated that a compound or composition, e.g., a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof as described herein, can be administered in combination with one or more additional pharmaceutical agents. The compounds or compositions can be administered in combination with additional pharmaceutical agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder, and/or it may achieve different effects.

The compound or composition can be administered concurrently with, prior to, or subsequent to, one or more additional pharmaceutical agents, which may be useful as, *e.g.*, combination therapies. Pharmaceutical agents include therapeutically active agents. Pharmaceutical agents also include prophylactically active agents. Each additional pharmaceutical agent may be administered at a dose and/or on a time schedule determined for that pharmaceutical agent. The additional pharmaceutical agents may also be administered together with each other and/or with the compound or composition described herein in a single dose or administered separately in different doses. The particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional pharmaceutical agents and/or the desired therapeutic and/or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.

Exemplary additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-diabetic agents, anti-inflammatory agents, immunosuppressant agents, and pain-relieving agents. Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells.

- 197 -

Pharmaceutical compositions provided by the present invention include compositions wherein the active ingredient (e.g., compounds described herein, including embodiments or examples) is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose. The actual amount effective for a particular application will depend, inter alia, on the condition being treated. When administered in methods to treat a disease, such compositions will contain an amount of active ingredient effective to achieve the desired result, e.g., modulating the activity of a target molecule (e.g. eIF2B, eIF2 or component of eIF2 α signal transduction pathway or component of phosphorylated eIF2 α pathway or the ISR pathway), and/or reducing, eliminating, or slowing the progression of disease symptoms (e.g. symptoms of cancer a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a disease or disorder associated with impaired function of eIF2B, eIF2 α or a component of the eIF2 pathway or ISR pathway). Determination of a therapeutically effective amount of a compound of the invention is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure herein.

The dosage and frequency (single or multiple doses) administered to a mammal can vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g. a symptom of cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a disease or disorder associated with impaired function of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway), kind of concurrent treatment, complications from the disease being treated or other health-related problems. Other therapeutic regimens or agents can be used in conjunction with the methods and compounds of Applicants' invention. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.

For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.

As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans

- 198 -

can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.

5 Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present invention should be sufficient to affect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of
10 the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate
15 with the severity of the individual's disease state.

Utilizing the teachings provided herein, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative
20 bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.

Also encompassed by the invention are kits (*e.g.*, pharmaceutical packs). The inventive kits may be useful for preventing and/or treating a disease (*e.g.*, cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, a metabolic
25 disease, or other disease or condition described herein).

The kits provided may comprise an inventive pharmaceutical composition or compound and a container (*e.g.*, a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container). In some embodiments, provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive
30 pharmaceutical composition or compound. In some embodiments, the inventive pharmaceutical composition or compound provided in the container and the second container are combined to form one unit dosage form.

- 199 -

Thus, in one aspect, provided are kits including a first container comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, or a pharmaceutical composition thereof. In certain embodiments, the kits are useful in preventing and/or treating a proliferative disease in a subject.

5 In certain embodiments, the kits further include instructions for administering a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, or a pharmaceutical composition thereof, to a subject to prevent and/or treat a disease described herein.

10 **Methods of Treatment**

The present invention features compounds, compositions, and methods comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof. In some embodiments, the compounds, compositions, and methods are used in the prevention or treatment of a disease, disorder, or
15 condition. Exemplary diseases, disorders, or conditions include, but are not limited to a neurodegenerative disease, a leukodystrophy, a cancer, an inflammatory disease, an autoimmune disease, a viral infection, a skin disease, a fibrotic disease, a hemoglobin disease, a kidney disease, a hearing loss condition, an ocular disease, a disease with mutations that leads to UPR induction, a malaria infection, a musculoskeletal disease, a metabolic disease, or a mitochondrial
20 disease.

In some embodiments, the disease, disorder, or condition is related to (e.g., caused by) modulation of (e.g., a decrease in) eIF2B activity or level, eIF2 α activity or level, or a component of the eIF2 pathway or ISR pathway. In some embodiments, the disease, disorder, or condition is related to modulation of a signaling pathway related to a component of the eIF2
25 pathway or ISR pathway (e.g., phosphorylation of a component of the eIF2 pathway or ISR pathway). In some embodiments, the disease, disorder, or condition is related to (e.g., caused by) neurodegeneration. In some embodiments, the disease, disorder, or condition is related to (e.g., caused by) neural cell death or dysfunction. In some embodiments, the disease, disorder, or condition is related to (e.g., caused by) glial cell death or dysfunction. In some embodiments, the
30 disease, disorder, or condition is related to (e.g., caused by) an increase in the level or activity of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway. In some embodiments, the

- 200 -

disease, disorder, or condition is related to (e.g., caused by) a decrease in the level or activity of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway.

In some embodiments, the disease may be caused by a mutation to a gene or protein sequence related to a member of the eIF2 pathway (e.g., eIF2B, eIF2 α , or other component).

- 5 Exemplary mutations include an amino acid mutation in the eIF2B1, eIF2B2, eIF2B3, eIF2B4, eIF2B5 subunits. In some embodiments, an amino acid mutation (e.g., an amino acid substitution, addition, or deletion) in a particular protein that may result in a structural change, e.g., a conformational or steric change, that affects the function of the protein. For example, in some embodiments, amino acids in and around the active site or close to a binding site (e.g., a
- 10 phosphorylation site, small molecule binding site, or protein-binding site) may be mutated such that the activity of the protein is impacted. In some instances, the amino acid mutation (e.g., an amino acid substitution, addition, or deletion) may be conservative and may not substantially impact the structure or function of a protein. For example, in certain cases, the substitution of a serine residue with a threonine residue may not significantly impact the function of a protein. In
- 15 other cases, the amino acid mutation may be more dramatic, such as the substitution of a charged amino acid (e.g., aspartic acid or lysine) with a large, nonpolar amino acid (e.g., phenylalanine or tryptophan) and therefore may have a substantial impact on protein function. The nature of the mutations that affect the structure of function of a gene or protein may be readily identified using standard sequencing techniques, e.g., deep sequencing techniques that are well known in the art.
- 20 In some embodiments, a mutation in a member of the eIF2 pathway may affect binding or activity of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof and thereby modulate treatment of a particular disease, disorder, or condition, or a symptom thereof.

- In some embodiments, an eIF2 protein may comprise an amino acid mutation (e.g., an
- 25 amino acid substitution, addition, or deletion) at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue. In some embodiments, an eIF2 protein may comprise an amino acid substitution at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine,
- 30 leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue. In some embodiments, an eIF2 protein may comprise an amino acid addition at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine,

- 201 -

histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue. In some embodiments, an eIF2 protein may comprise an amino acid deletion at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue.

In some embodiments, the eIF2 protein may comprise an amino acid mutation (e.g., an amino acid substitution, addition, or deletion) at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue in the eIF2B1, eIF2B2, eIF2B3, eIF2B4, eIF2B5 subunits. In some embodiments, the eIF2 protein may comprise an amino acid substitution at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue in the eIF2B1, eIF2B2, eIF2B3, eIF2B4, eIF2B5 subunits. In some embodiments, the eIF2 protein may comprise an amino acid addition at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue in the eIF2B1, eIF2B2, eIF2B3, eIF2B4, eIF2B5 subunits. In some embodiments, the eIF2 protein may comprise an amino acid deletion at an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine residue in the eIF2B1, eIF2B2, eIF2B3, eIF2B4, eIF2B5 subunits. Exemplary mutations include V183F (eIF2B1 subunit), H341Q (eIF2B3), I346T (eIF2B3), R483W (eIF2B4), R113H (eIF2B5), and R195H (eIF2B5).

In some embodiments, an amino acid mutation (e.g., an amino acid substitution, addition, or deletion) in a member of the eIF2 pathway (e.g., an eIF2B protein subunit) may affect binding or activity of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof and thereby modulate treatment of a particular disease, disorder, or condition, or a symptom thereof.

- 202 -

Neurodegenerative Disease

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a neurodegenerative disease. As used herein, the term "neurodegenerative disease" refers to a disease or condition in which the function of a subject's nervous system becomes impaired. Examples of a neurodegenerative disease that may be treated with a compound, pharmaceutical composition, or method described herein include Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, Dystonia, frontotemporal dementia (FTD), Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe disease, kuru, Lewy body dementia, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple system atrophy, Multisystem proteinopathy, Narcolepsy, Neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Schizophrenia, Spinocerebellar ataxia (multiple types with varying characteristics, e.g., Spinocerebellar ataxia type 2 or Spinocerebellar ataxia type 8), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, progressive supranuclear palsy, corticobasal degeneration, adrenoleukodystrophy, X-linked adrenoleukodystrophy, cerebral adrenoleukodystrophy, Pelizaeus-Merzbacher Disease, Krabbe disease, leukodystrophy due to mutation in DARS2 gene (sometimes known as lukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL), DARS2-related spectrum disorders, or Tabes dorsalis.

In some embodiments, the neurodegenerative disease comprises vanishing white matter disease, childhood ataxia with CNS hypo-myelination, a leukodystrophy, a lukoencephalopathy, a hypomyelinating or demyelinating disease, an intellectual disability syndrome (e.g., Fragile X syndrome), Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease, frontotemporal dementia (FTD), Gerstmann-Straussler-Scheinker disease, Huntington's disease, dementia (e.g., HIV-associated dementia or Lewy body dementia), kuru, multiple sclerosis, Parkinson's disease, or a prion disease.

- 203 -

In some embodiments, the neurodegenerative disease comprises vanishing white matter disease, childhood ataxia with CNS hypo-myelination, a leukodystrophy, a leukoencephalopathy, a hypomyelinating or demyelinating disease, or an intellectual disability syndrome (e.g., Fragile X syndrome).

5 In some embodiments, the neurodegenerative disease comprises a psychiatric disease such as agoraphobia, Alzheimer's disease, anorexia nervosa, amnesia, anxiety disorder, attention deficit disorder, bipolar disorder, body dysmorphic disorder, bulimia nervosa, claustrophobia, depression, delusions, Diogenes syndrome, dyspraxia, insomnia, Munchausen's syndrome, narcolepsy, narcissistic personality disorder, obsessive-compulsive disorder, psychosis, phobic
10 disorder, schizophrenia, seasonal affective disorder, schizoid personality disorder, sleepwalking, social phobia, substance abuse, tardive dyskinesia, Tourette syndrome, or trichotillomania.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat vanishing white matter disease. Exemplary methods of treating vanishing
15 white matter disease include, but are not limited to, reducing or eliminating a symptom of vanishing white matter disease, reducing the loss of white matter, reducing the loss of myelin, increasing the amount of myelin, or increasing the amount of white matter in a subject.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat childhood ataxia with CNS hypo-myelination. Exemplary methods of
20 treating childhood ataxia with CNS hypo-myelination include, but are not limited to, reducing or eliminating a symptom of childhood ataxia with CNS hypo-myelination, increasing the level of myelin, or decreasing the loss of myelin in a subject.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat an intellectual disability syndrome (e.g., Fragile X syndrome). Exemplary
25 methods of treating an intellectual disability syndrome include, but are not limited to, reducing or eliminating a symptom of an intellectual disability syndrome.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat neurodegeneration. Exemplary methods of treating neurodegeneration
30 include, but are not limited to, improvement of mental wellbeing, increasing mental function,

- 204 -

slowing the decrease of mental function, decreasing dementia, delaying the onset of dementia, improving cognitive skills, decreasing the loss of cognitive skills, improving memory, decreasing the degradation of memory, or extending survival.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a leukoencephalopathy or demyelinating disease. Exemplary leukoencephalopathies include, but are not limited to, progressive multifocal leukoencephalopathy, toxic leukoencephalopathy, leukoencephalopathy with vanishing white matter, leukoencephalopathy with neuroaxonal spheroids, reversible posterior leukoencephalopathy syndrome, hypertensive leukoencephalopathy, megalencephalic leukoencephalopathy with subcortical cysts, Charcot-Marie-Tooth disorder, and Devic's disease. A leukoencephalopathy may comprise a demyelinating disease, which may be inherited or acquired. In some embodiments, an acquired demyelinating disease may be an inflammatory demyelinating disease (e.g., an infectious inflammatory demyelinating disease or a non-infectious inflammatory demyelinating disease), a toxic demyelinating disease, a metabolic demyelinating disease, a hypoxic demyelinating disease, a traumatic demyelinating disease, or an ischemic demyelinating disease (e.g., Binswanger's disease). Exemplary methods of treating a leukoencephalopathy or demyelinating disease include, but are not limited to, reducing or eliminating a symptom of a leukoencephalopathy or demyelinating disease, reducing the loss of myelin, increasing the amount of myelin, reducing the loss of white matter in a subject, or increasing the amount of white matter in a subject.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a traumatic injury or a toxin-induced injury to the nervous system (e.g., the brain). Exemplary traumatic brain injuries include, but are not limited to, a brain abscess, concussion, ischemia, brain bleeding, cranial fracture, diffuse axonal injury, locked-in syndrome, or injury relating to a traumatic force or blow to the nervous system or brain that causes damage to an organ or tissue. Exemplary toxin-induced brain injuries include, but are not limited to, toxic encephalopathy, meningitis (e.g. bacterial meningitis or viral meningitis), meningoencephalitis, encephalitis (e.g., Japanese encephalitis, eastern equine encephalitis, West Nile encephalitis), Guillan-Barre syndrome, Sydenham's chorea, rabies, leprosy, neurosyphilis, a prion disease, or exposure to a chemical (e.g., arsenic, lead, toluene, ethanol, manganese, fluoride,

- 205 -

dichlorodiphenyltrichloroethane (DDT), dichlorodiphenyldichloroethylene (DDE), tetrachloroethylene, a polybrominated diphenyl ether, a pesticide, a sodium channel inhibitor, a potassium channel inhibitor, a chloride channel inhibitor, a calcium channel inhibitor, or a blood brain barrier inhibitor).

5 In other embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to improve memory in a subject. Induction of memory has been shown to be facilitated by decreased and impaired by increased eIF2 α phosphorylation. Regulators of translation, such as compounds disclosed herein (e.g. a compound of Formula (I) or Formula
10 (II)), could serve as therapeutic agents that improve memory in human disorders associated with memory loss such as Alzheimer's disease and in other neurological disorders that activate the UPR or ISR in neurons and thus could have negative effects on memory consolidation such as Parkinson's disease, schizophrenia, amyotrophic lateral sclerosis (ALS) and prion diseases. In addition, a mutation in eIF2 γ that disrupts complex integrity linked intellectual disability
15 (intellectual disability syndrome or ID) to impaired translation initiation in humans. Hence, two diseases with impaired eIF2 function, ID and VWM, display distinct phenotypes but both affect mainly the brain and impair learning. In some embodiments, the disease or condition is unsatisfactory memory (e.g., working memory, long term memory, short term memory, or memory consolidation).

20 In still other embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used in a method to improve memory in a subject (e.g., working memory, long term memory, short term memory, or memory consolidation). In some embodiments, the subject is human. In some embodiments, the subject is a non-human mammal. In some embodiments, the
25 subject is a domesticated animal. In some embodiments, the subject is a dog. In some embodiments, the subject is a bird. In some embodiments, the subject is a horse. In some embodiments, the patient is a bovine. In some embodiments, the subject is a primate.

Cancer

30 In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof is used to treat cancer. As used herein, "cancer" refers to human cancers and carcinomas, sarcomas,

- 206 -

adenocarcinomas, lymphomas, leukemias, melanomas, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphomas (e.g.,
 5 Burkitt's, Small Cell, and Large Cell lymphomas), Hodgkin's lymphoma, leukemia (including AML, ALL, and CML), and/or multiple myeloma. In some further instances, "cancer" refers to lung cancer, breast cancer, ovarian cancer, leukemia, lymphoma, melanoma, pancreatic cancer, sarcoma, bladder cancer, bone cancer, brain cancer, cervical cancer, colon cancer, esophageal cancer, gastric cancer, liver cancer, head and neck cancer, kidney cancer, myeloma, thyroid
 10 cancer, prostate cancer, metastatic cancer, or carcinoma.

As used herein, the term "cancer" refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemia, lymphoma, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound, pharmaceutical composition, or method provided herein include lymphoma, sarcoma, bladder cancer, bone cancer, brain tumor,
 15 cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g., ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell
 20 lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, glioma, or melanoma. Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma (e.g., WNT-dependent pediatric
 25 medulloblastoma), Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract
 30 cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget's

- 207 -

Disease of the Nipple, Phyllodes Tumors, Lobular Carcinoma, Ductal Carcinoma, cancer of the pancreatic stellate cells, cancer of the hepatic stellate cells, or prostate cancer.

The term "leukemia" refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemmic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocyte leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblasts leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.

The term "sarcoma" generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound, pharmaceutical composition, or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic

- 208 -

sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.

The term "melanoma" is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.

The term "carcinoma" refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epidermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniformi carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lobular carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma,

- 209 -

preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tubular carcinoma, tuberos carcinoma, verrucous carcinoma, or carcinoma villosum.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof is used to treat pancreatic cancer, breast cancer, multiple myeloma, cancers of secretory cells. For example certain methods herein treat cancer by decreasing or reducing or preventing the occurrence, growth, metastasis, or progression of cancer. In some embodiments, the methods described herein may be used to treat cancer by decreasing or eliminating a symptom of cancer. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a cancer described herein (e.g., pancreatic cancer, breast cancer, multiple myeloma, cancers of secretory cells).

In some embodiments, the compounds (compounds described herein, e.g., a compound of Formula (I) or Formula (II)) and compositions (e.g., compositions comprising a compound described herein, e.g., a compound of Formula (I) or Formula (II))) are used with a cancer immunotherapy (e.g., a checkpoint blocking antibody) to treat a subject (e.g., a human subject), e.g., suffering from a disease or disorder described herein (e.g., abnormal cell growth, e.g., cancer (e.g., a cancer described herein)). The methods described herein comprise administering a compound described herein, e.g., a compound of Formula (I) or Formula (II) and an immunotherapy to a subject having abnormal cell growth such as cancer. Exemplary immunotherapies include, but are not limited to the following.

In some embodiments, the immunotherapeutic agent is a compound (e.g., a ligand, an antibody) that inhibits the immune checkpoint blockade pathway. In some embodiments, the immunotherapeutic agent is a compound that inhibits the indoleamine 2,3-dioxygenase (IDO) pathway. In some embodiments, the immunotherapeutic agent is a compound that agonizes the

- 210 -

STING pathway. Cancer immunotherapy refers to the use of the immune system to treat cancer. Three groups of immunotherapy used to treat cancer include cell-based, antibody-based, and cytokine therapies. All groups exploit cancer cells' display of subtly different structures (*e.g.*, molecular structure; antigens, proteins, molecules, carbohydrates) on their surface that can be detected by the immune system. Cancer immunotherapy (*i.e.*, anti-tumor immunotherapy or anti-tumor immunotherapeutics) includes but is not limited to, immune checkpoint antibodies (*e.g.*, PD-1 antibodies, PD-L1 antibodies, PD-L2 antibodies, CTLA-4 antibodies, TIM3 antibodies, LAG3 antibodies, TIGIT antibodies); and cancer vaccines (*i.e.*, anti-tumor vaccines or vaccines based on neoantigens such as a peptide or RNA vaccine).

Cell-based therapies (*e.g.*, cancer vaccines), usually involve the removal of immune cells from a subject suffering from cancer, either from the blood or from a tumor. Immune cells specific for the tumor will be activated, grown, and returned to a subject suffering from cancer where the immune cells provide an immune response against the cancer. Cell types that can be used in this way are *e.g.*, natural killer cells, lymphokine-activated killer cells, cytotoxic T-cells, dendritic cells, CAR-T therapies (*i.e.*, chimeric antigen receptor T-cells which are T-cells engineered to target specific antigens), TIL therapy (*i.e.*, administration of tumor-infiltrating lymphocytes), TCR gene therapy, protein vaccines, and nucleic acid vaccines. An exemplary cell-based therapy is Provenge. In some embodiments, the cell-based therapy is a CAR-T therapy.

Interleukin-2 and interferon-alpha are examples of cytokines, proteins that regulate and coordinate the behavior of the immune system.

Cancer Vaccines with Neoantigens

Neoantigens are antigens encoded by tumor-specific mutated genes. Technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy. Many novel therapeutic approaches are being developed that selectively enhance T cell reactivity against this class of antigens. One approach to target neoantigens is *via* cancer vaccine. These vaccines can be developed using peptides or RNA, *e.g.*, synthetic peptides or synthetic RNA.

- 211 -

Antibody therapies are antibody proteins produced by the immune system and that bind to a target antigen on the surface of a cell. Antibodies are typically encoded by an immunoglobulin gene or genes, or fragments thereof. In normal physiology antibodies are used by the immune system to fight pathogens. Each antibody is specific to one or a few proteins, and those that bind to cancer antigens are used, *e.g.*, for the treatment of cancer. Antibodies are capable of specifically binding an antigen or epitope. (Fundamental Immunology, 3rd Edition, W.E., Paul, ed., Raven Press, N.Y. (1993). Specific binding occurs to the corresponding antigen or epitope even in the presence of a heterogeneous population of proteins and other biologics. Specific binding of an antibody indicates that it binds to its target antigen or epitope with an affinity that is substantially greater than binding to irrelevant antigens. The relative difference in affinity is often at least 25% greater, more often at least 50% greater, most often at least 100% greater. The relative difference can be at least 2-fold, at least 5-fold, at least 10-fold, at least 25-fold, at least 50-fold, at least 100-fold, or at least 1000-fold, for example.

Exemplary types of antibodies include without limitation human, humanized, chimeric, monoclonal, polyclonal, single chain, antibody binding fragments, and diabodies. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, prevent a receptor interacting with its ligand or deliver a payload of chemotherapy or radiation, all of which can lead to cell death. Exemplary antibodies for the treatment of cancer include but are not limited to, Alemtuzumab, Bevacizumab, Bretuximab vedotin, Cetuximab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Ipilimumab, Ofatumumab, Panitumumab, Rituximab, Tositumomab, Trastuzumab, Nivolumab, Pembrolizumab, Avelumab, durvalumab and pidilizumab.

Checkpoint blocking antibodies

The methods described herein comprise, in some embodiments, treating a human subject suffering from a disease or disorder described herein, the method comprising administering a composition comprising a cancer immunotherapy (*e.g.*, an immunotherapeutic agent). In some embodiments, the immunotherapeutic agent is a compound (*e.g.*, an inhibitor or antibody) that inhibits the immune checkpoint blockade pathway. Immune checkpoint proteins, under normal physiological conditions, maintain self-tolerance (*e.g.*, prevent autoimmunity) and protect tissues from damage when the immune system is responding to *e.g.*, pathogenic infection. Immune checkpoint proteins can be dysregulated by tumors as an important immune resistance

- 212 -

mechanism. (Pardoll, Nature Rev. Cancer, 2012, 12, 252-264). Agonists of co-stimulatory receptors or antagonists of inhibitory signals (*e.g.*, immune checkpoint proteins), provide an amplification of antigen-specific T-cell responses. Antibodies that block immune checkpoints do not target tumor cells directly but typically target lymphocyte receptors or their ligands to enhance endogenous antitumor activity.

Exemplary checkpoint blocking antibodies include but are not limited to, anti-CTLA-4, anti-PD-1, anti-LAG3 (*i.e.*, antibodies against lymphocyte activation gene 3), and anti-TIM3 (*i.e.*, antibodies against T-cell membrane protein 3). Exemplary anti-CTLA-4 antibodies include but are not limited to, ipilimumab and tremelimumab. Exemplary anti-PD-1 ligands include but are not limited to, PD-L1 (*i.e.*, B7-H1 and CD274) and PD-L2 (*i.e.*, B7-DC and CD273). Exemplary anti-PD-1 antibodies include but are not limited to, nivolumab (*i.e.*, MDX-1106, BMS-936558, or ONO-4538), CT-011, AMP-224, pembrolizumab (trade name Keytruda), and MK-3475. Exemplary PD-L1-specific antibodies include but are not limited to, BMS936559 (*i.e.*, MDX-1105), MEDI4736 and MPDL-3280A. Exemplary checkpoint blocking antibodies also include but are not limited to, IMP321 and MGA271.

T-regulatory cells (*e.g.*, CD4+, CD25+, or T-reg) are also involved in policing the distinction between self and non-self (*e.g.*, foreign) antigens, and may represent an important mechanism in suppression of immune response in many cancers. T-reg cells can either emerge from the thymus (*i.e.*, “natural T-reg”) or can differentiate from mature T-cells under circumstances of peripheral tolerance induction (*i.e.*, “induced T-reg”). Strategies that minimize the action of T-reg cells would therefore be expected to facilitate the immune response to tumors. (Sutmuller, van Duivenvoorde et al., 2001).

IDO pathway inhibitors

The IDO pathway regulates immune response by suppressing T cell function and enabling local tumor immune escape. IDO expression by antigen-presenting cells (APCs) can lead to tryptophan depletion, and resulting antigen-specific T cell energy and regulatory T cell recruitment. Some tumors even express IDO to shield themselves from the immune system. A compound that inhibits IDO or the IDO pathway thereby activating the immune system to attack the cancer (*e.g.*, tumor in a subject). Exemplary IDO pathway inhibitors include indoximod, epacadostat and EOS200271.

- 213 -

STING pathway agonists

Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation of type I interferons in response to cytosolic nucleic acid ligands. Evidence indicates involvement of the STING pathway in the induction of antitumor immune response. It has been shown that activation of the STING-dependent pathway in cancer cells can result in tumor infiltration with immune cells and modulation of the anticancer immune response. STING agonists are being developed as a class of cancer therapeutics. Exemplary STING agonists include MK-1454 and ADU-S100.

Co-stimulatory antibodies

The methods described herein comprise, in some embodiments, treating a human subject suffering from a disease or disorder described herein, the method comprising administering a composition comprising a cancer immunotherapy (*e.g.*, an immunotherapeutic agent). In some embodiments, the immunotherapeutic agent is a co-stimulatory inhibitor or antibody. In some embodiments, the methods described herein comprise depleting or activating anti-4-1BB, anti-OX40, anti-GITR, anti-CD27 and anti-CD40, and variants thereof.

Inventive methods of the present invention contemplate single as well as multiple administrations of a therapeutically effective amount of a compound as described herein. Compounds, *e.g.*, a compound as described herein, can be administered at regular intervals, depending on the nature, severity and extent of the subject's condition. In some embodiments, a compound described herein is administered in a single dose. In some embodiments, a compound described herein is administered in multiple doses.

Inflammatory Disease

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat an inflammatory disease. As used herein, the term "inflammatory disease" refers to a disease or condition characterized by aberrant inflammation (*e.g.* an increased level of inflammation compared to a control such as a healthy person not suffering from a disease). Examples of inflammatory diseases include postoperative cognitive dysfunction, arthritis (*e.g.*,

- 214 -

rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis), systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, Vitiligo, asthma (e.g., allergic asthma), acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, and atopic dermatitis. Proteins associated with inflammation and inflammatory diseases (e.g. aberrant expression being a symptom or cause or marker of the disease) include interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin- 18 (IL-18), TNF- α (tumor necrosis factor-alpha), and C-reactive protein (CRP).

In some embodiments, the inflammatory disease comprises postoperative cognitive dysfunction, arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis), systemic lupus erythematosus (SLE), myasthenia gravis, diabetes (e.g., juvenile onset diabetes or diabetes mellitus type 1), Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma (e.g., allergic asthma), acne vulgaris, celiac disease, chronic prostatitis, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, or atopic dermatitis.

In some embodiments, the inflammatory disease comprises postoperative cognitive dysfunction, which refers to a decline in cognitive function (e.g. memory or executive function (e.g. working memory, reasoning, task flexibility, speed of processing, or problem solving)) following surgery.

In other embodiments, the method of treatment is a method of prevention. For example, a method of treating postsurgical cognitive dysfunction may include preventing postsurgical cognitive dysfunction or a symptom of postsurgical cognitive dysfunction or reducing the severity of a symptom of postsurgical cognitive dysfunction by administering a compound described herein prior to surgery.

- 215 -

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat an inflammatory disease (e.g., an inflammatory disease described herein) by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat an inflammatory disease (e.g., an inflammatory disease described herein).

10 *Musculoskeletal Diseases*

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a musculoskeletal disease. As used herein, the term "musculoskeletal disease" refers to a disease or condition in which the function of a subject's musculoskeletal system (e.g., muscles, ligaments, tendons, cartilage, or bones) becomes impaired. Exemplary musculoskeletal diseases that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, distal muscular dystrophy, congenital muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy type 1, or myotonic muscular dystrophy type 2), limb girdle muscular dystrophy, multisystem proteinopathy, rhizomelic chondrodysplasia punctata, X-linked recessive chondrodysplasia punctata, Conradi-Hünemann syndrome, Autosomal dominant chondrodysplasia punctata, stress induced skeletal disorders (e.g., stress induced osteoporosis), multiple sclerosis, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy, spinal cord spasticity, spinal muscle atrophy, myasthenia gravis, neuralgia, fibromyalgia, Machado-Joseph disease, Paget's disease of bone, cramp fasciculation syndrome, Freidrich's ataxia, a muscle wasting disorder (e.g., muscle atrophy, sarcopenia, cachexia), an inclusion body myopathy, motor neuron disease, or paralysis.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer

- 216 -

thereof is used to treat a musculoskeletal disease (e.g., a musculoskeletal disease described herein) by decreasing or eliminating a symptom of the disease. In some embodiments, the method of treatment comprises treatment of muscle pain or muscle stiffness associated with a musculoskeletal disease. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a musculoskeletal disease (e.g., a musculoskeletal disease described herein).

Metabolic Diseases

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat metabolic disease. As used herein, the term "metabolic disease" refers to a disease or condition affecting a metabolic process in a subject. Exemplary metabolic diseases that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, heart disease, atherosclerosis, arthritis, cystinosis, diabetes (e.g., Type I diabetes, Type II diabetes, or gestational diabetes), phenylketonuria, proliferative retinopathy, or Kearns-Sayre disease.

In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a metabolic disease (e.g., a metabolic disease described herein) by decreasing or eliminating a symptom of the disease. In some embodiments, the method of treatment comprises decreasing or eliminating a symptom comprising elevated blood pressure, elevated blood sugar level, weight gain, fatigue, blurred vision, abdominal pain, flatulence, constipation, diarrhea, jaundice, and the like. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a metabolic disease (e.g., a musculoskeletal disease described herein).

- 217 -

Mitochondrial Diseases

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat mitochondrial disease. As used herein, the term "mitochondrial disease" refers to a disease or condition affecting the mitochondria in a subject. In some embodiments, the mitochondrial disease is associated with, or is a result of, or is caused by mitochondrial dysfunction, one or more mitochondrial protein mutations, or one or more mitochondrial DNA mutations. In some embodiments, the mitochondrial disease is a mitochondrial myopathy. In some embodiments, mitochondrial diseases, e.g., the mitochondrial myopathy, that may be treated with a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include, e.g., Barth syndrome, chronic progressive external ophthalmoplegia (cPEO), Kearns-Sayre syndrome (KSS), Leigh syndrome (e.g., MILS, or maternally inherited Leigh syndrome), mitochondrial DNA depletion syndromes (MDDS, e.g., Alpers syndrome), mitochondrial encephalomyopathy (e.g., mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)), mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), myoclonus epilepsy with ragged red fibers (MERRF), neuropathy, ataxia, retinitis pigmentosa (NARP), Leber's hereditary optic neuropathy (LHON), and Pearson syndrome.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a mitochondrial disease described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a mitochondrial disease described herein.

Hearing Loss

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat hearing loss. As used herein, the term "hearing loss" or "hearing loss condition" may broadly encompass any damage to the auditory systems, organs, and cells or any impairment of an animal subject's ability to hear sound, as measured by standard methods and

- 218 -

assessments known in the art, for example otoacoustic emission testing, pure tone testing, and auditory brainstem response testing. Exemplary hearing loss conditions that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include, but are not limited to, mitochondrial nonsyndromic hearing loss and deafness, hair cell death, age-related hearing loss, noise-induced hearing loss, genetic or inherited hearing loss, hearing loss experienced as a result of ototoxic exposure, hearing loss resulting from disease, and hearing loss resulting from trauma. In some embodiments, mitochondrial nonsyndromic hearing loss and deafness is a MT-RNR1-related hearing loss. In some embodiments, the MT-RNR1-related hearing loss is the result of amino glycoside ototoxicity. In some embodiments, mitochondrial nonsyndromic hearing loss and deafness is a MT-TS1-related hearing loss. In some embodiments, mitochondrial nonsyndromic hearing loss and deafness is characterized by sensorineural hearing loss.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a hearing loss condition described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a hearing loss condition described herein.

Ocular Disease

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat eye disease. As used herein, the term "ocular disease" may refer to a disease or condition in which the function of a subject's eye becomes impaired. Exemplary ocular diseases and conditions that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include cataracts, glaucoma, endoplasmic reticulum (ER) stress, autophagy deficiency, age-related macular degeneration (AMD), or diabetic retinopathy.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat an ocular disease or condition described herein by decreasing or

- 219 -

eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat an ocular disease or condition described herein.

5

Kidney Diseases

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat kidney disease. As used herein, the term "kidney disease" may refer to a disease or condition in which the function of a subject's kidneys becomes impaired. Exemplary kidney diseases that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include Abderhalden–Kaufmann–Lignac syndrome (Nephropathic Cystinosis), Abdominal Compartment Syndrome, Acetaminophen-induced Nephrotoxicity, Acute Kidney Failure/Acute Kidney Injury, Acute Lobar Nephronia, Acute Phosphate Nephropathy, Acute Tubular Necrosis, Adenine Phosphoribosyltransferase Deficiency, Adenovirus Nephritis, Alagille Syndrome, Alport Syndrome, Amyloidosis, ANCA Vasculitis Related to Endocarditis and Other Infections, Angiomyolipoma, Analgesic Nephropathy, Anorexia Nervosa and Kidney Disease, Angiotensin Antibodies and Focal Segmental Glomerulosclerosis, Antiphospholipid Syndrome, Anti-TNF- α Therapy-related Glomerulonephritis, APOL1 Mutations, Apparent Mineralocorticoid Excess Syndrome, Aristolochic Acid Nephropathy, Chinese Herbal Nephropathy, Balkan Endemic Nephropathy, Arteriovenous Malformations and Fistulas of the Urologic Tract, Autosomal Dominant Hypocalcemia, Bardet-Biedl Syndrome, Bartter Syndrome, Bath Salts and Acute Kidney Injury, Beer Potomania, Beeturia, β -Thalassemia Renal Disease, Bile Cast Nephropathy, BK Polyoma Virus Nephropathy in the Native Kidney, Bladder Rupture, Bladder Sphincter Dyssynergia, Bladder Tamponade, Border-Crossers' Nephropathy, Bourbon Virus and Acute Kidney Injury, Burnt Sugarcane Harvesting and Acute Renal Dysfunction, Byetta and Renal Failure, C1q Nephropathy, C3 Glomerulopathy, C3 Glomerulopathy with Monoclonal Gammopathy, C4 Glomerulopathy, Calcineurin Inhibitor Nephrotoxicity, Callilepis Laureola Poisoning, Cannabinoid Hyperemesis Acute Renal Failure, Cardiorenal syndrome, Carfilzomib-Induced Renal Injury, CFHR5 nephropathy, Charcot–Marie–Tooth Disease with Glomerulopathy, Chinese Herbal Medicines and Nephrotoxicity, Cherry

- 220 -

Concentrate and Acute Kidney Injury, Cholesterol Emboli, Churg–Strauss syndrome, Chyluria, Ciliopathy, Cocaine and the Kidney, Cold Diuresis, Colistin Nephrotoxicity, Collagenofibrotic Glomerulopathy, Collapsing Glomerulopathy, Collapsing Glomerulopathy Related to CMV, Combination Antiretroviral (cART) Related-Nephropathy, Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), Congenital Nephrotic Syndrome, Congestive Renal Failure, Conorenal syndrome (Mainzer-Saldino Syndrome or Saldino-Mainzer Disease), Contrast Nephropathy, Copper Sulphate Intoxication, Cortical Necrosis, Crizotinib-related Acute Kidney Injury, Cryocryoglobulinemia, Cryoglobulinemia, Crystalglobulin-Induced Nephropathy, Crystal-Induced Acute Kidney injury, Crystal-Storing Histiocytosis, Cystic Kidney Disease, Acquired, Cystinuria, Dasatinib-Induced Nephrotic-Range Proteinuria, Dense Deposit Disease (MPGN Type 2), Dent Disease (X-linked Recessive Nephrolithiasis), DHA Crystalline Nephropathy, Dialysis Disequilibrium Syndrome, Diabetes and Diabetic Kidney Disease, Diabetes Insipidus, Dietary Supplements and Renal Failure, Diffuse Mesangial Sclerosis, Diuresis, Djenkol Bean Poisoning (Djenkolism), Down Syndrome and Kidney Disease, Drugs of Abuse and Kidney Disease, Duplicated Ureter, EAST syndrome, Ebola and the Kidney, Ectopic Kidney, Ectopic Ureter, Edema, Swelling, Erdheim-Chester Disease, Fabry’s Disease, Familial Hypocalciuric Hypercalcemia, Fanconi Syndrome, Fraser syndrome, Fibronectin Glomerulopathy, Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy, Fraley syndrome, Fluid Overload, Hypervolemia, Focal Segmental Glomerulosclerosis, Focal Sclerosis, Focal Glomerulosclerosis, Galloway Mowat syndrome, Giant Cell (Temporal) Arteritis with Kidney Involvement, Gestational Hypertension, Gitelman Syndrome, Glomerular Diseases, Glomerular Tubular Reflux, Glycosuria, Goodpasture Syndrome, Green Smoothie Cleanse Nephropathy, HANAC Syndrome, Harvoni (Ledipasvir with Sofosbuvir)-Induced Renal Injury, Hair Dye Ingestion and Acute Kidney Injury, Hantavirus Infection Podocytopathy, Heat Stress Nephropathy, Hematuria (Blood in Urine), Hemolytic Uremic Syndrome (HUS), Atypical Hemolytic Uremic Syndrome (aHUS), Hemophagocytic Syndrome, Hemorrhagic Cystitis, Hemorrhagic Fever with Renal Syndrome (HFRS, Hantavirus Renal Disease, Korean Hemorrhagic Fever, Epidemic Hemorrhagic Fever, Nephropathis Epidemica), Hemosiderinuria, Hemosiderosis related to Paroxysmal Nocturnal Hemoglobinuria and Hemolytic Anemia, Hepatic Glomerulopathy, Hepatic Veno-Occlusive Disease, Sinusoidal Obstruction Syndrome, Hepatitis C-Associated Renal Disease, Hepatocyte Nuclear Factor 1 β -Associated Kidney Disease, Hepatorenal Syndrome, Herbal Supplements and Kidney Disease, High Altitude Renal

- 221 -

Syndrome, High Blood Pressure and Kidney Disease, HIV-Associated Immune Complex Kidney Disease (HIVICK), HIV-Associated Nephropathy (HIVAN), HNF1B-related Autosomal Dominant Tubulointerstitial Kidney Disease, Horseshoe Kidney (Renal Fusion), Hunner's Ulcer, Hydroxychloroquine-induced Renal Phospholipidosis, Hyperaldosteronism, Hypercalcemia, 5 Hyperkalemia, Hypermagnesemia, Hybernemia, Hyperoxaluria, Hyperphosphatemia, Hypocalcemia, Hypocomplementemic Urticarial Vasculitic Syndrome, Hypokalemia, Hypokalemia-induced renal dysfunction, Hypokalemic Periodic Paralysis, Hypomagnesemia, Hyponatremia, Hypophosphatemia, Hypophosphatemia in Users of Cannabis, Hypertension, Hypertension, Monogenic, Iced Tea Nephropathy, Ifosfamide Nephrotoxicity, IgA Nephropathy, 10 IgG4 Nephropathy, Immersion Diuresis, Immune-Checkpoint Therapy-Related Interstitial Nephritis, Infliximab-Related Renal Disease, Interstitial Cystitis, Painful Bladder Syndrome (Questionnaire), Interstitial Nephritis, Interstitial Nephritis, Karyomegalic, Ivemark's syndrome, JC Virus Nephropathy, Joubert Syndrome, Ketamine-Associated Bladder Dysfunction, Kidney Stones, Nephrolithiasis, Kombucha Tea Toxicity, Lead Nephropathy and Lead-Related 15 Nephrotoxicity, Lecithin Cholesterol Acyltransferase Deficiency (LCAT Deficiency), Leptospirosis Renal Disease, Light Chain Deposition Disease, Monoclonal Immunoglobulin Deposition Disease, Light Chain Proximal Tubulopathy, Liddle Syndrome, Lightwood-Albright Syndrome, Lipoprotein Glomerulopathy, Lithium Nephrotoxicity, LMX1B Mutations Cause Hereditary FSGS, Loin Pain Hematuria, Lupus, Systemic Lupus Erythematosus, Lupus Kidney 20 Disease, Lupus Nephritis, Lupus Nephritis with Antineutrophil Cytoplasmic Antibody Seropositivity, Lupus Podocytopathy, Lyme Disease-Associated Glomerulonephritis, Lysinuric Protein Intolerance, Lysozyme Nephropathy, Malarial Nephropathy, Malignancy-Associated Renal Disease, Malignant Hypertension, Malakoplakia, McKittrick-Wheelock Syndrome, MDMA (Molly; Ecstasy; 3,4-Methylenedioxymethamphetamine) and Kidney Failure, Meatal 25 Stenosis, Medullary Cystic Kidney Disease, Urolodulin-Associated Nephropathy, Juvenile Hyperuricemic Nephropathy Type 1, Medullary Sponge Kidney, Megaureter, Melamine Toxicity and the Kidney, MELAS Syndrome, Membranoproliferative Glomerulonephritis, Membranous Nephropathy, Membranous-like Glomerulopathy with Masked IgG Kappa Deposits, MesoAmerican Nephropathy, Metabolic Acidosis, Metabolic Alkalosis, Methotrexate-related 30 Renal Failure, Microscopic Polyangiitis, Milk-alkalai syndrome, Minimal Change Disease, Monoclonal Gammopathy of Renal Significance, Dysproteinemia, Mouthwash Toxicity, MUC1 Nephropathy, Multicystic dysplastic kidney, Multiple Myeloma, Myeloproliferative Neoplasms

- 222 -

and Glomerulopathy, Nail-patella Syndrome, NARP Syndrome, Nephrocalcinosis, Nephrogenic Systemic Fibrosis, Nephroptosis (Floating Kidney, Renal Ptosis), Nephrotic Syndrome, Neurogenic Bladder, 9/11 and Kidney Disease, Nodular Glomerulosclerosis, Non-Gonococcal Urethritis, Nutcracker syndrome, Oligomeganephronia, Orofaciodigital Syndrome, Orotic

5 Aciduria, Orthostatic Hypotension, Orthostatic Proteinuria, Osmotic Diuresis, Osmotic Nephrosis, Ovarian Hyperstimulation Syndrome, Oxalate Nephropathy, Page Kidney, Papillary Necrosis, Papillorenal Syndrome (Renal-Coloboma Syndrome, Isolated Renal Hypoplasia), PARN Mutations and Kidney Disease, Parvovirus B19 and the Kidney, The Peritoneal-Renal Syndrome, POEMS Syndrome, Posterior Urethral Valve, Podocyte Infolding Glomerulopathy,

10 Post-infectious Glomerulonephritis, Post-streptococcal Glomerulonephritis, Post-infectious Glomerulonephritis, Atypical, Post-Infectious Glomerulonephritis (IgA-Dominant), Mimicking IgA Nephropathy, Polyarteritis Nodosa, Polycystic Kidney Disease, Posterior Urethral Valves, Post-Obstructive Diuresis, Preeclampsia, Propofol infusion syndrome, Proliferative Glomerulonephritis with Monoclonal IgG Deposits (Nasr Disease), Propolis (Honeybee Resin)

15 Related Renal Failure, Proteinuria (Protein in Urine), Pseudohyperaldosteronism, Pseudohypobicarbonatemia, Pseudohypoparathyroidism, Pulmonary-Renal Syndrome, Pyelonephritis (Kidney Infection), Pyonephrosis, Pyridium and Kidney Failure, Radiation Nephropathy, Ranolazine and the Kidney, Refeeding syndrome, Reflux Nephropathy, Rapidly Progressive Glomerulonephritis, Renal Abscess, Peripnephric Abscess, Renal Agenesis, Renal

20 Arcuate Vein Microthrombi-Associated Acute Kidney Injury, Renal Artery Aneurysm, Renal Artery Dissection, Spontaneous, Renal Artery Stenosis, Renal Cell Cancer, Renal Cyst, Renal Hypouricemia with Exercise-induced Acute Renal Failure, Renal Infarction, Renal Osteodystrophy, Renal Tubular Acidosis, Renin Mutations and Autosomal Dominant Tubulointerstitial Kidney Disease, Renin Secreting Tumors (Juxtaglomerular Cell Tumor), Reset

25 Osmostat, Retrocaval Ureter, Retroperitoneal Fibrosis, Rhabdomyolysis, Rhabdomyolysis related to Bariatric Surgery, Rheumatoid Arthritis-Associated Renal Disease, Sarcoidosis Renal Disease, Salt Wasting, Renal and Cerebral, Schistosomiasis and Glomerular Disease, Schimke immuno-osseous dysplasia, Scleroderma Renal Crisis, Serpentine Fibula-Polycystic Kidney Syndrome, Exner Syndrome, Sick Cell Nephropathy, Silica Exposure and Chronic Kidney

30 Disease, Sri Lankan Farmers' Kidney Disease, Sjögren's Syndrome and Renal Disease, Synthetic Cannabinoid Use and Acute Kidney Injury, Kidney Disease Following Hematopoietic Cell Transplantation, Kidney Disease Related to Stem Cell Transplantation, TAFRO Syndrome, Tea

- 223 -

and Toast Hyponatremia, Tenofovir-Induced Nephrotoxicity, Thin Basement Membrane Disease, Benign Familial Hematuria, Thrombotic Microangiopathy Associated with Monoclonal Gammopathy, Trench Nephritis, Trigonitis, Tuberculosis, Genitourinary, Tuberous Sclerosis, Tubular Dysgenesis, Immune Complex Tubulointerstitial Nephritis Due to Autoantibodies to the Proximal Tubule Brush Border, Tumor Lysis Syndrome, Uremia, Uremic Optic Neuropathy, Ureteritis Cystica, Ureterocele, Urethral Caruncle, Urethral Stricture, Urinary Incontinence, Urinary Tract Infection, Urinary Tract Obstruction, Urogenital Fistula, Uromodulin-Associated Kidney Disease, Vancomycin-Associated Cast Nephropathy, Vasomotor Nephropathy, Vesicointestinal Fistula, Vesicoureteral Reflux, VGEF Inhibition and Renal Thrombotic Microangiopathy, Volatile Anesthetics and Acute Kidney Injury, Von Hippel-Lindau Disease, Waldenstrom's Macroglobulinemic Glomerulonephritis, Warfarin-Related Nephropathy, Wasp Stings and Acute Kidney Injury, Wegener's Granulomatosis, Granulomatosis with Polyangiitis, West Nile Virus and Chronic Kidney Disease, Wunderlich syndrome, Zellweger Syndrome, or Cerebrohepatorenal Syndrome.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a kidney disease described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a kidney disease described herein.

Skin Diseases

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a skin disease. As used herein, the term "skin disease" may refer to a disease or condition affecting the skin. Exemplary skin diseases that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include acne, alopecia areata, basal cell carcinoma, Bowen's disease, congenital erythropoietic porphyria, contact dermatitis, Darier's disease, disseminated superficial actinic porokeratosis, dystrophic epidermolysis bullosa, eczema (atopic eczema), extra-mammary Paget's disease, epidermolysis bullosa simplex, erythropoietic

- 224 -

protoporphyrin, fungal infections of nails, Hailey-Hailey disease, herpes simplex, hidradenitis suppurativa, hirsutism, hyperhidrosis, ichthyosis, impetigo, keloids, keratosis pilaris, lichen planus, lichen sclerosus, melanoma, melasma, mucous membrane pemphigoid, pemphigoid, pemphigus vulgaris, pityriasis lichenoides, pityriasis rubra pilaris, plantar warts (verrucae), polymorphic light eruption, psoriasis, plaque psoriasis, pyoderma gangrenosum, rosacea, scabies, scleroderma, shingles, squamous cell carcinoma, Sweet's syndrome, urticaria and angioedema and vitiligo.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a skin disease described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a skin disease described herein.

Fibrotic Diseases

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a fibrotic disease. As used herein, the term "fibrotic disease" may refer to a disease or condition that is defined by the accumulation of excess extracellular matrix components. Exemplary fibrotic diseases that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include adhesive capsulitis, arterial stiffness, arthrofibrosis, atrial fibrosis, cardiac fibrosis, cirrhosis, congenital hepatic fibrosis, Crohn's disease, cystic fibrosis, Dupuytren's contracture, endomyocardial fibrosis, glial scar, hepatitis C, hypertrophic cardiomyopathy, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, interstitial lung disease, keloid, mediastinal fibrosis, myelofibrosis, nephrogenic systemic fibrosis, non-alcoholic fatty liver disease, old myocardial infarction, Peyronie's disease, pneumoconiosis, pneumonitis, progressive massive fibrosis, pulmonary fibrosis, radiation-induced lung injury, retroperitoneal fibrosis, scleroderma/systemic sclerosis, silicosis and ventricular remodeling.

- 225 -

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a fibrotic disease described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a fibrotic disease described herein.

Hemoglobin Disorders

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a hemoglobin disease. As used herein, the terms "hemoglobin disease" or "hemoglobin disorder" may refer to a disease or condition characterized by an abnormal production or structure of the hemoglobin protein. Exemplary hemoglobin diseases that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include "dominant" β -thalassemia, acquired (toxic) methemoglobinemia, carboxyhemoglobinemia, congenital Heinz body hemolytic anemia, HbH disease, HbS/ β -thalassemia, HbE/ β -thalassemia, HbSC disease, homozygous α^+ -thalassemia (phenotype of α^0 -thalassemia), Hydrops fetalis with Hb Bart's, sickle cell anemia/disease, sickle cell trait, sickle β -thalassemia disease, α^+ -thalassemia, α^0 -thalassemia, α -Thalassemia associated with myelodysplastic syndromes, α -Thalassemia with mental retardation syndrome (ATR), β^0 -Thalassemia, β^+ -Thalassemia, δ -Thalassemia, γ -Thalassemia, β -Thalassemia major, β -Thalassemia intermedia, $\delta\beta$ -Thalassemia, and $\epsilon\gamma\delta\beta$ -Thalassemia.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a hemoglobin disease described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a hemoglobin disease described herein.

- 226 -

Autoimmune Diseases

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat an autoimmune disease. As used herein, the term "autoimmune disease" may refer to a disease or condition in which the immune system of a subject attacks and damages the tissues of said subject. Exemplary kidney diseases that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include Achalasia, Addison's disease, Adult Still's disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome, Autoimmune angioedema, Autoimmune dysautonomia, Autoimmune encephalomyelitis, Autoimmune hepatitis, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune urticaria, Axonal & neuronal neuropathy (AMAN), Baló disease, Behcet's disease, Benign mucosal pemphigoid, Bullous pemphigoid, Castleman disease (CD), Celiac disease, Chagas disease, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), Cicatricial pemphigoid, Cogan's syndrome, Cold agglutinin disease, Congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn's disease, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressler's syndrome, Endometriosis, Eosinophilic esophagitis (EoE), Eosinophilic fasciitis, Erythema nodosum, Essential mixed cryoglobulinemia, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura (HSP), Herpes gestationis or pemphigoid gestationis (PG), Hidradenitis Suppurativa (HS) (Acne Inversa), Hypogammaglobulinemia, IgA Nephropathy, IgG4-related sclerosing disease, Immune thrombocytopenic purpura (ITP), Inclusion body myositis (IBM), Interstitial cystitis (IC), Juvenile arthritis, Juvenile diabetes (Type 1 diabetes), Juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus, Lyme disease chronic, Meniere's disease, Microscopic polyangiitis (MPA), Mixed connective tissue disease (MCTD), Mooren's

- 227 -

ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neonatal Lupus, Neuromyelitis optica, Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism (PR), PANDAS, Paraneoplastic cerebellar degeneration (PCD), Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis (peripheral uveitis), Parsonnage-Turner syndrome, Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia (PA), POEMS syndrome, Polyarteritis nodosa, Polyglandular syndrome type I, Polyglandular syndrome type II, Polyglandular syndrome type III, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Primary biliary cirrhosis, Primary sclerosing cholangitis, Progesterone dermatitis, Psoriasis, Psoriatic arthritis, Pure red cell aplasia (PRCA), Pyoderma gangrenosum, Raynaud's phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Relapsing polychondritis, Restless legs syndrome (RLS), Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjögren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome (SPS), Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia (SO), Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), Transverse myelitis, Type 1 diabetes, Ulcerative colitis (UC), Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vitiligo, Vogt-Koyanagi-Harada Disease, and Wegener's granulomatosis (or Granulomatosis with Polyangiitis (GPA)).

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat an autoimmune disease described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat an autoimmune disease described herein.

Viral Infections

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a viral infection. Exemplary viral infections that may be treated with a

- 228 -

compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include influenza, human immunodeficiency virus (HIV) and herpes.

In some embodiments, the compound of Formula (I) or Formula (II) or a
5 pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a viral infection described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a
10 composition to treat a viral infection described herein.

Malaria Infection

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer
15 thereof is used to treat a malaria. As used herein, the term "malaria" may refer to a parasitic disease of protozoan of the plasmodium genus that causes infection of red blood cells (RBCs). Exemplary forms of malaria infection that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof include infection caused by Plasmodium vivax, Plasmodium ovale,
20 Plasmodium malariae and Plasmodium falciparum. In some embodiments, the malaria infection that may be treated with a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is resistant/recrudescant malaria.

In some embodiments, the compound of Formula (I) or Formula (II) or a
25 pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a malaria infection described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a
30 composition to treat a malaria infection described herein.

Diseases with Mutations Leading to Unfolded Protein Response (UPR) Induction

- 229 -

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a disease with mutations that leads to UPR induction. Exemplary disease with mutations that lead to UPR induction include Marinesco-Sjogren syndrome, neuropathic pain, diabetic neuropathic pain, noise induced hearing loss, non-syndromic sensorineural hearing loss, age-related hearing loss, Wolfram syndrome, Darier White disease, Usher syndrome, collagenopathies, Thin basement nephropathy, Alport syndrome, skeletal chondrodysplasia, metaphyseal chondrodysplasia type Schmid, and Pseudochondrodysplasia.

In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof is used to treat a disease with mutations that leads to UPR induction described herein by decreasing or eliminating a symptom of the disease. In some embodiments, the compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be used as a single agent in a composition or in combination with another agent in a composition to treat a disease with mutations that leads to UPR induction described herein.

Methods of Modulating Protein Production

In another aspect, disclosed herein is a method of modulating the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in a cell, the method comprising contacting the cell with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, thereby modulating the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell. In some embodiments, contacting the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof with the cell increases the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell. In some embodiments, contacting the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof with the cell decreases the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell.

- 230 -

In another aspect, disclosed herein is a method of preventing or treating a condition, disease or disorder described herein in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, wherein the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof modulates the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof by the patient's cells, thereby treating the condition, disease or disorder. In some embodiments, the condition, disease or disorder is characterized by aberrant expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof by the patient's cells. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof by the patient's cells, thereby treating the condition, disease or disorder. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof decreases the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof by the patient's cells, thereby treating the condition, disease or disorder.

In another aspect, disclosed herein is a method of modulating the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in a cell, the method comprising contacting the cell with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, thereby modulating the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell. In some embodiments, contacting the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof with the cell increases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell. In some embodiments, contacting the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof with the cell

- 231 -

decreases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell.

In another aspect, disclosed herein is a method of preventing or treating a condition, disease or disorder described herein in a patient in need thereof, the method comprising
5 administering to the patient an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, wherein the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof modulates the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any
10 combination thereof by the patients cells, thereby treating the condition, disease or disorder. In some embodiments, the condition, disease or disorder is characterized by aberrant activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the patient's cells. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or
15 stereoisomer thereof increases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the patient's cells, thereby treating the condition, disease or disorder. In some embodiments, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof decreases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway,
20 component of the ISR pathway or any combination thereof in the patient's cells, thereby treating the condition, disease or disorder.

In some embodiments, administering an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, wherein the compound of Formula (I) or Formula (II), or a
25 pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof modulates both the expression and the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the patients cells, thereby treating the condition, disease or disorder.

In some embodiments, the compound of Formula (I) or Formula (II) is chemically
30 modified, prior to (ex vivo) or after (in vivo) contacting with a cell, forming a biologically active compound that modulates the expression and/or activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell. In some

- 232 -

embodiments, the compound of Formula (I) or Formula (II) is metabolized by the patient forming a biologically active compound that modulates the expression and/or activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the patients cells, thereby treating a condition, disease or disorder disclosed herein. In some embodiments, the biologically active compound is the compound of formula (II).

In one aspect, disclosed herein is a method of treating a disease related to a modulation of eIF2B activity or levels, eIF2 α activity or levels, or the activity or levels of a component of the eIF2 pathway or the ISR pathway in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula (I) or Formula (II). In some embodiments, the modulation comprises an increase in eIF2B activity or levels, increase in eIF2 α activity or levels, or increase in activity or levels of a component of the eIF2 pathway or the ISR pathway. In some embodiments, the disease may be caused by a mutation to a gene or protein sequence related to a member of the eIF2 pathway (e.g., the eIF2 α signaling pathway).

Methods of Increasing Protein Activity and Production

In another aspect, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be useful in applications where increasing production output of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof is desirable, such as in vitro cell free systems for protein production.

In some embodiments, the present invention features a method of increasing expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof by a cell or in vitro expression system, the method comprising contacting the cell or in vitro expression system with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof. In some embodiments, the method is a method of increasing the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof by a cell comprising contacting the cell with an effective amount of a compound described herein (e.g., the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof). In other embodiments, the method is a method of increasing the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination

- 233 -

thereof by an in vitro protein expression system comprising contacting the in vitro expression system with a compound described herein (e.g. the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof). In some embodiments, contacting the cell or in vitro expression system with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the cell or in vitro expression system by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%. In some embodiments, contacting the cell or in vitro expression system with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the cell or in vitro expression system by about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 60-fold, about 70-fold, about 80-fold, about 90-fold, about 100-fold, about 200-fold, about 300-fold, about 400-fold, about 500-fold, about 600-fold, about 700-fold, about 800-fold, about 900-fold, about 1000-fold, about 10000-fold, about 100000-fold, or about 1000000-fold.

In some embodiments, the present invention features a method of increasing the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof by a patient cells, the method comprising administering to the patient an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, wherein the patient has been diagnosed with a disease, disorder, or condition disclosed herein and wherein the disease, disorder or condition is characterized by aberrant expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof (e.g., a leukodystrophy, a leukoencephalopathy, a hypomyelinating or demyelinating disease, muscle-wasting disease, or sarcopenia). In some embodiments, administering to the patient in need thereof an effective amount of a compound of Formula (I) or Formula (II), or a

- 234 -

pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof by the patients cells about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%,
5 about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, thereby treating the disease, disorder or condition. In some embodiments, administering to the patient in need thereof an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer
10 thereof increases expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof by the patients cells about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 60-fold, about 70-fold, about 80-fold, about 90-fold, about 100-fold, about 200-fold, about 300-fold, about 400-
15 fold, about 500-fold, about 600-fold about 700-fold, about 800-fold, about 900-fold, about 1000-fold, about 10000-fold, about 100000-fold, or about 1000000-fold, thereby treating the disease, disorder or condition.

In another aspect, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be useful
20 in applications where increasing the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof is desirable.

In some embodiments, the present invention features a method of increasing the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in a cell, the method comprising contacting the cell with an effective
25 amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof. In some embodiments, contacting the cell with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of
30 the ISR pathway or any combination thereof in the cell by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%,

- 235 -

about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%. In some embodiments, contacting the cell with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the cell by about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 60-fold, about 70-fold, about 80-fold, about 90-fold, about 100-fold, about 200-fold, about 300-fold, about 400-fold, about 500-fold, about 600-fold, about 700-fold, about 800-fold, about 900-fold, about 1000-fold, about 10000-fold, about 100000-fold, or about 1000000-fold.

In some embodiments, the present invention features a method of increasing the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, wherein the patient has been diagnosed with a disease, disorder, or condition disclosed herein and wherein the disease, disorder or condition is characterized by lowered levels of protein activity. In some embodiments, administering to the patient in need thereof an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the patient by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, thereby treating the disease, disorder or condition. In some embodiments, administering to the patient in need thereof an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof increases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the patient by about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 60-fold, about 70-fold, about 80-fold, about 90-fold, about 100-fold, about 200-fold, about 300-fold,

- 236 -

about 400-fold, about 500-fold, about 600-fold about 700-fold, about 800-fold, about 900-fold, about 1000-fold, about 10000-fold, about 100000-fold, or about 1000000-fold, thereby treating the disease, disorder or condition.

In some embodiments, the compound of Formula (I) or Formula (II) is chemically modified, prior to (ex vivo) or after (in vivo) contacting with the cell or in vitro expression system, forming a biologically active compound that increases the expression and/or activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cells and/or in vitro expression system. In some embodiments, the compound of Formula (I) or Formula (II) is metabolized by the patient forming a biologically active compound that increases the expression and/or activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the patients cells, thereby treating a condition, disease or disorder disclosed herein. In some embodiments, the biologically active compound is the compound of formula (II).

Methods of Decreasing Protein Activity and Production

In another aspect, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be useful in applications where decreasing production output of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof is desirable.

In some embodiments, the present invention features a method of decreasing expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in a cell, the method comprising contacting the cells with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof. In some embodiments, contacting the cells with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof decreases expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the cell by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%.

In some embodiments, the present invention features a method of decreasing the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway

- 237 -

or any combination thereof in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, wherein the patient has been diagnosed with a disease, disorder, or condition described herein and wherein the disease, disorder or condition is characterized by increased levels of protein production. In some embodiments, administering to the patient in need thereof an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof decreases the expression of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the patient by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, thereby treating the disease, disorder or condition.

In another aspect, the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof may be useful in applications where decreasing the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof is desirable.

In some embodiments, the present invention features a method of decreasing the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in a cell, the method comprising contacting the cell with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof. In some embodiments, contacting the cell with an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof decreases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the cell by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, thereby treating the disease, disorder or condition.

- 238 -

In some embodiments, the present invention features a method of decreasing the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, wherein the patient has been diagnosed with a disease, disorder, or condition described herein and wherein the disease, disorder or condition is characterized by increased levels of protein activity. In some embodiments, administering to the patient in need thereof an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof decreases the activity of eIF2B, eIF2 α , a component of the eIF2 pathway, a component of the ISR pathway or any combination thereof in the patient by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, thereby treating the disease, disorder or condition.

In some embodiments, the compound of Formula (I) or Formula (II) is chemically modified, prior to (ex vivo) or after (in vivo) contacting with a cell, forming a biologically active compound that decreases the expression and/or activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the cell. In some embodiments, the compound of Formula (I) or Formula (II) is metabolized by the patient forming a biologically active compound that decreases the expression and/or activity of eIF2B, eIF2 α , a component of the eIF2 pathway, component of the ISR pathway or any combination thereof in the patients cells, thereby treating a condition, disease or disorder disclosed herein. In some embodiments, the biologically active compound is the compound of Formula (I) or Formula (II).

In some embodiments, the compounds set forth herein are provided as pharmaceutical compositions including a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof and a pharmaceutically acceptable excipient. In embodiments of the method, a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, *N*-oxide or stereoisomer thereof, is co-administered with a second agent (e.g. therapeutic agent). In

- 239 -

other embodiments of the method, a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, is co-administered with a second agent (e.g. therapeutic agent), which is administered in a therapeutically effective amount. In embodiments, the second agent is an agent for improving memory.

Combination Therapy

In one aspect, the present invention features a pharmaceutical composition comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof as well as a second agent (e.g. a second therapeutic agent). In some embodiments, the pharmaceutical composition includes a second agent (e.g. a second therapeutic agent) in a therapeutically effective amount. In some embodiments, the second agent is an agent for treating cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a disease or disorder associated with impaired function of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway.

The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer, a neurodegenerative disease, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a disease or disorder associated with impaired function of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.

In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent. Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one another. In some embodiments, the compounds described herein may be combined with treatments for a cancer, a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, a metabolic disease, or a

- 240 -

disease or disorder associated with impaired function of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway.

In embodiments, the second agent is an anti-cancer agent. In embodiments, the second agent is a chemotherapeutic. In embodiments, the second agent is an agent for improving
 5 memory. In embodiments, the second agent is an agent for treating a neurodegenerative disease. In embodiments, the second agent is an agent for treating a leukodystrophy. In embodiments, the second agent is an agent for treating vanishing white matter disease. In embodiments, the second agent is an agent for treating childhood ataxia with CNS hypo-myelination. In
 10 embodiments, the second agent is an agent for treating an intellectual disability syndrome. In embodiments, the second agent is an agent for treating pancreatic cancer. In embodiments, the second agent is an agent for treating breast cancer. In embodiments, the second agent is an agent for treating multiple myeloma. In embodiments, the second agent is an agent for treating myeloma. In embodiments, the second agent is an agent for treating a cancer of a secretory cell. In
 15 embodiments, the second agent is an agent for reducing eIF2 α phosphorylation. In embodiments, the second agent is an agent for inhibiting a pathway activated by eIF2 α phosphorylation. In embodiments, the second agent is an agent for inhibiting a pathway activated by eIF2 α . In embodiments, the second agent is an agent for inhibiting the integrated stress response. In embodiments, the second agent is an anti-inflammatory agent. In
 20 embodiments, the second agent is an agent for treating postsurgical cognitive dysfunction. In embodiments, the second agent is an agent for treating traumatic brain injury. In embodiments, the second agent is an agent for treating a musculoskeletal disease. In embodiments, the second agent is an agent for treating a metabolic disease. In embodiments, the second agent is an anti-diabetic agent.

25 *Anti-cancer agents*

"Anti-cancer agent" is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic
 properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anti-cancer agent is an agent
 30 identified herein having utility in methods of treating cancer. In some embodiments, an anticancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to,

- 241 -

MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI- 1040, PD035901, selumetinib/ AZD6244, GSK1120212/ trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, 5 mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, chlorambucil, melphalan), ethylenimine and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozocin), triazenes (decabazine), anti-metabolites (e.g., 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, 10 Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP 16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, 15 daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g. cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procabazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), 20 enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossypol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all 25 trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 1 1-7082, PKC412, PD184352, 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; 30 aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense

- 242 -

oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1 ; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstauroporine; 5 beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); 10 castanospermine; cecropin B; cetorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentantraquinones; cycloplata; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; 15 dehydroididemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; 20 etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; 25 idoxifene; idramantone; ilmofofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; 30 leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin;

- 243 -

loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol;

5 mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides;

10 nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic

15 acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin;

20 prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP

25 inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate;

30 sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive

- 244 -

intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans;
 tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur;
 tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide;
 tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin
 5 mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone;
 tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem
 cell factor; translation inhibitors; tretinoin; triacetyluridine; tricyriline; trimetrexate; triptorelin;
 tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex;
 urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide;
 10 variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin;
 vinorelbine; vinoxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin
 stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin;
 acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin;
 ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase;
 15 asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene
 hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium;
 bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin;
 carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin;
 cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin
 20 hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone;
 doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone
 propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin;
 enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride;
 estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate;
 25 etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate;
 fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine
 hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II
 (including recombinant interleukin II, or rIL.sub.2), interferon alfa-2a; interferon alfa-2b;
 interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iprop latin;
 30 irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole
 hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocold;
 maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate;

- 245 -

melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine;
 meturedapa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin;
 mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin;
 ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate;
 5 perfosfamide; pipobroman; pipsulfan; piroxantrone hydrochloride; plicamycin; plomestane;
 porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin;
 puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride;
 semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride;
 spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium;
 10 tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone;
 thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone
 acetate; tricycline phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulazole
 hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine
 sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinylicinate sulfate; vinleurosine
 15 sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin;
 zinzostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate
 the formation or stability of microtubules, (e.g. Taxol (i.e. paclitaxel), Taxotere, compounds
 comprising the taxane skeleton, Erubulazole (i.e. R-55104), Dolastatin 10 (i.e. DLS-10 and NSC-
 376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e.
 20 as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and
 Altorhyrtin C), Spongistatins (e.g. Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4,
 Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin
 hydrochloride (i.e. LU-103793 and SC-D-669356), Epothilones (e.g. Epothilone A, Epothilone
 B, Epothilone C (i.e. desoxyepothilone A or dEpoA), Epothilone D (i.e. KOS-862, dEpoB, and
 25 desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide,
 16-aza-epothilone B, 21 -aminoepothilone B (i.e. BMS-310705), 21-hydroxyepothilone D (i.e.
 Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e. NSC-654663),
 Soblidotin (i.e. TZZ-1027), LS-4559-P (Pharmacia, i.e. LS-4577), LS-4578 (Pharmacia, i.e. LS-
 477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-1 12378 (Aventis), Vincristine
 30 sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e. WS-9885B), GS-164 (Takeda), GS-198
 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e. ILX-651 and LU-
 223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa

- 246 -

Hakko), AM- 132 (Armad), AM- 138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, i.e. AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), T-138067 (Tularik, 5 i.e. T-67, TL-138067 and TI- 138067), COBRA-1 (Parker Hughes Institute, i.e. DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A 1 (i.e. BTO-956 and DIME), DDE- 313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e. SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-569), Narcosine (also known as NSC- 10 5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T- 138026 (Tularik), Monsatrol, Inanocine (i.e. NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tularik, i.e. T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, 15 Desaetyeleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (i.e. NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e. D-81862), A-289099 (Abbott), A-318315 20 (Abbott), HTI-286 (i.e. SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-25041 1 (Sanofi), steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone 25 caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), 30 immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to ¹¹¹In, ⁹⁰Y, or ¹³¹I, etc.), triptolide, homoharringtonine,

- 247 -

dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g. gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbix™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like.

"Chemotherapeutic" or "chemotherapeutic agent" is used in accordance with its plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.

Additionally, the compounds described herein can be co-administered with conventional immunotherapeutic agents including, but not limited to, immunostimulants (e.g., Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alpha- interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody -pseudomonas exotoxin conjugate, etc.), and radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to ^mIn, ⁹⁰Y, or ¹³¹I, etc.).

In a further embodiment, the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as ⁴⁷Sc, ⁶⁴Cu, ⁶⁷Cu, ⁸⁹Sr, ⁸⁶Y, ⁸⁷Y, ⁹⁰Y, ¹⁰⁵Rh, ^mAg, ^mIn, ^{117m}Sn, ¹⁴⁹Pm, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi, optionally conjugated to antibodies directed against tumor antigens.

Additional Agents

In some embodiments, the second agent for use in combination with a compound (e.g., a compound of Formula (I)) or Formula (II), or composition thereof described herein is an agent for use in treating a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, or a metabolic disease. In some embodiments, a second agent for use in combination with a compound (e.g., a compound of Formula (I) or Formula (II)) or composition

- 248 -

thereof described herein is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating a disease, disorder, or condition described herein.

In some embodiments, a second agent for use in treating a neurodegenerative disease, a leukodystrophy, an inflammatory disease, a musculoskeletal disease, or a metabolic disease includes, but is not limited to, an anti-psychotic drug, anti-depressive drug, anti-anxiety drug, analgesic, a stimulant, a sedative, a pain reliever, an anti-inflammatory agent, a benzodiazepine, a cholinesterase inhibitor, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid, a MAO inhibitor, a beta-blocker, a calcium channel blocker, an antacid, or other agent.

Exemplary second agents may include donepezil, galantamine, rivastigmine, memantine, levodopa, dopamine, pramipexole, ropinirole, rotigotine, doxapram, oxazepam, quetiapine, selegiline, rasagiline, entacapone, bengtropine, trihexyphenidyl, riluzole, diazepam, chlorodiazepoxide, lorazepam, alprazolam, buspirone, gepirone, isapirone, hydroxyzine, propranolol, hydroxyzine, midazolam, trifluoperazine, methylphenidate, atomoxetine, methylphenidate, pemoline, perphenazine, divalproex, valproic acid, sertraline, fluoxetine, citalopram, escitalopram, paroxetine, fluvoxamine, trazodone, desvenlafaxine, duloxetine, venlafaxine, amitriptyline, amoxapine, clomipramine, desipramine, imipramine, nortriptyline, protriptyline, trimipramine, maprotiline, bupropion, nefazodone, vortioxetine, lithium, clozapine, fluphenazine, haloperidol, paliperidone, loxapine, thiothixene, pimozide, thioridazine, risperidone, aspirin, ibuprofen, naproxen, acetaminophen, azathioprine, methotrexate, mycophenolic acid, leflunomide, dibenzoylmethane, cilostazol, pentoxifylline, duloxetine, a cannabinoid (e.g. nabilone), simethicone, magaldrate, aluminum salts, calcium salts, sodium salts, magnesium salts, alginic acid, acarbose, albiglutide, alogliptin, metformin, insulin, lisinopril, atenolol, atorvastatin, fluvastatin, lovastatin, pitavastatin, simvastatin, rosuvastatin, and the like.

Naturally derived agents or supplements may also be used in conjunction with a compound of Formula (I) or Formula (II), or a composition thereof to treat a neurodegenerative disease, an inflammatory disease, a musculoskeletal disease, or a metabolic disease. Exemplary naturally derived agents or supplements include omega-3 fatty acids, carnitine, citicoline, curcumin, ginkgo, vitamin E, vitamin B (e.g., vitamin B5, vitamin B6, or vitamin B12), huperzine A, phosphatidylserine, rosemary, caffeine, melatonin, chamomile, St. John's wort, tryptophan, and the like.

- 249 -

EXAMPLES

In order that the invention described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope.

Synthetic Protocols

The compounds provided herein can be prepared from readily available starting materials using modifications to the specific synthesis protocols set forth below that would be well known to those of skill in the art. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by those skilled in the art by routine optimization procedures. General scheme relating to methods of making exemplary compounds of the invention are additionally described in the section entitled Methods of Making Compounds.

Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in Greene *et al.*, *Protecting Groups in Organic Synthesis*, Second Edition, Wiley, New York, 1991, and references cited therein.

Abbreviations

APCI for atmospheric pressure chemical ionization; DCI for desorption chemical ionization; DMSO for dimethyl sulfoxide; ESI for electrospray ionization; HPLC for high performance liquid chromatography; LC/MS for liquid chromatography/mass spectrometry; MS for mass spectrum; NMR for nuclear magnetic resonance; psi for pounds per square inch; and TLC for thin-layer chromatography.

Example 1: *N,N'*-(bicyclo[2.2.2]octane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 100)

- 250 -

A 50 mL round bottom flask, equipped with a magnetic stir bar, was charged with bicyclo[2.2.2]octane-1,4-diamine dihydrochloride (PharmaBlock, CAS#2277-93-2, 100 mg, 0.455 mmol), 2-(4-chloro-3-fluorophenoxy)acetic acid (205 mg, 1.001 mmol), and (1-cyano-2-ethoxy-2-oxoethylidenaminoxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU®, 485 mg, 1.092 mmol). The flask contents were placed under a dry nitrogen atmosphere, and then *N,N*-dimethylformamide (10 mL) was added via syringe. The stirred suspension was chilled to 0 °C, and then *N,N*-diisopropylethylamine (0.66 mL, 3.78 mmol) was introduced dropwise via syringe (reaction mixture turned bright yellow). The reaction mixture was allowed to warm to ambient temperature and stirred for 3 days. The reaction mixture was diluted with water and a white, insoluble solid was collected by filtration. The solid was treated with methanol, and then collected by filtration. The title compound was thus obtained as a white solid (93.5 mg, 40% yield). ¹H NMR (DMSO-*d*₆) δ ppm 7.51-7.44 (m, 4H), 7.02 (dd, *J* = 11.4, 2.9 Hz, 2H), 6.81 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 2H), 4.43 (s, 4H), 1.90 (s, 12H). MS (+ESI) *m/z* 513 (M+H)⁺, MS (-ESI) *m/z* 511 (M-H)⁻.

Example 2: 2-(4-chloro-3-fluorophenoxy)-*N*-[4-(2-{[6-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 101)

Example 2A: tert-butyl (4-aminobicyclo[2.2.2]octan-1-yl)carbamate

Bicyclo[2.2.2]octane-1,4-diamine dihydrochloride (PharmaBlock, CAS#2277-93-2, 200 mg, 1.43 mmol) was dissolved in methanol (5 mL). The solution was basified with 50% aqueous sodium hydroxide. After stirring for 15 minutes (slight exotherm), the mixture was diluted with water and brine and extracted with dichloromethane (3 x 150 mL). The combined organic layers were dried (Na₂SO₄) and filtered. The filtrate was concentrated under reduced pressure to give the free base as a white solid. The free base, bicyclo[2.2.2]octane-1,4-diamine (176 mg, 1.255 mmol), di-*tert*-butyl dicarbonate (274 mg, 1.255 mmol), and tetrahydrofuran (100 mL) were stirred at ambient temperature for 17 hours. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between ethyl acetate and aqueous sodium carbonate. The organic layer was washed with brine, then dried (MgSO₄) and filtered. The filtrate was concentrated under reduced pressure to provide the title intermediate as an off-white solid (258 mg, 86% yield). ¹H NMR (methanol-*d*₄) δ ppm 1.91-1.85 (m, 7H), 1.65-1.60 (m, 2H), 1.40 (s, 12H). MS (DCI-NH₃) *m/z* 241 (M+H)⁺.

Example 2B: tert-butyl (4-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[2.2.2]octan-1-yl)carbamate

- 251 -

A 50 mL round bottom flask, equipped with a magnetic stir bar, was charged with 2-(4-chloro-3-fluorophenoxy)acetic acid (234 mg, 1.144 mmol), *tert*-butyl (4-aminobicyclo[2.2.2]octan-1-yl)carbamate (Example 2A, 250 mg, 1.040 mmol), and COMU® (535 mg, 1.248 mmol). The flask contents were placed under a dry nitrogen atmosphere and *N,N*-dimethylformamide (4 mL) was introduced via syringe. The reaction mixture was then stirred at ambient temperature as *N,N*-diisopropylethylamine (0.545 mL, 3.12 mmol) was added dropwise via syringe. The reaction mixture was stirred at ambient temperature for 19 hours. The reaction mixture was diluted with water (pH = 10). An insoluble beige solid was collected by filtration and rinsed thoroughly with water. The material was purified by column chromatography on an Analogix® IntelliFlash™-310 (Isco RediSep® 40 g silica gel cartridge, 70:30 to 0:100 heptane/ethyl acetate). Fractions #15-31 were combined and concentrated under reduced pressure to give the title intermediate as a white solid (69.5 mg, 15.65% yield). ¹H NMR (CDCl₃) δ ppm 7.31 (t, J = 8.6 Hz, 1H), 6.73 (dd, J = 10.3, 2.9 Hz, 1H), 6.64 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 6.07 (s, 1H), 4.32 (s, 1H), 4.31 (s, 2H), 2.05-1.91 (m, 12H), 1.42 (s, 9H). MS (+ESI) *m/z* 426 (M+H)⁺, *m/z* 853 (2M+H)⁺. MS (-ESI) *m/z* 425 (M-H)⁻.

Example 2C: N-(4-aminobicyclo[2.2.2]octan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride

A 4 mL vial, equipped with a magnetic stir bar, was charged with *tert*-butyl (4-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[2.2.2]octan-1-yl)carbamate (Example 2B, 69 mg, 0.162 mmol). Methanol (1 mL) was added, and the resulting solution was stirred at ambient temperature while 4 M HCl in dioxane (1.2 mL, 4.80 mmol) was added via syringe. The reaction mixture was stirred at ambient temperature for 89 hours. Volatiles were removed under reduced pressure to give the title intermediate as a white solid (58.3 mg, 99% yield). ¹H NMR (methanol-*d*₄) δ ppm 7.36 (t, J = 8.7 Hz, 1H), 6.89 (dd, J = 11.0, 2.9 Hz, 1H), 6.79 (ddd, J = 9.0, 2.9, 1.3 Hz, 1H), 4.43 (s, 2H), 2.15-2.08 (m, 6H), 1.94-1.87 (m, 6H). MS (+ESI) *m/z* 327 (M+H)⁺. MS (-ESI) *m/z* 325 (M-H)⁻.

Example 2D: 2-(4-chloro-3-fluorophenoxy)-N-[4-(2-([6-(trifluoromethyl)pyridin-3-yl]oxy)acetamido)bicyclo[2.2.2]octan-1-yl]acetamide

A 4 mL vial, equipped with a magnetic stir bar, was charged with *N*-(4-aminobicyclo[2.2.2]octan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride (Example 2C, 25 mg, 0.069 mmol), 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid (18.26 mg, 0.083 mmol), and COMU® (41.3 mg, 0.096 mmol). The vial was sealed with a septum screw cap,

- 252 -

and the contents were placed under a dry nitrogen atmosphere. *N,N*-Dimethylformamide (0.5 mL) was introduced via syringe, and the stirred reaction mixture was treated dropwise with *N,N*-diisopropylethylamine (0.1 mL, 0.573 mmol). The reaction mixture was stirred at ambient temperature for 19 hours. An aliquot was partitioned between water and ethyl acetate. The organic layer was checked by TLC (80:20 ethyl acetate/heptane). A major new spot with R_f higher than either starting material was evident. LC/MS confirmed that this major new material had the correct mass for the title compound. The bulk of the reaction was diluted with water and extracted twice with ethyl acetate. The combined organic layers were washed twice with brine, then dried ($MgSO_4$) and filtered. The filtrate was concentrated under reduced pressure to give a pale yellow solid. This crude solid was purified by column chromatography on an Analogix® IntelliFlash™-310 (Isco RediSep® 12 g silica gel cartridge, 70:30 heptane/ethyl acetate) to give a white solid that was stirred with *tert*-butyl methyl ether. The solvent was decanted away, and the solid was dried on a rotary evaporator to provide the title compound as a white solid (11.0 mg, 30.2% yield). 1H NMR ($CDCl_3$) δ ppm 8.43 (d, J = 2.9 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.34-7.28 (m, 2H), 6.73 (dd, J = 10.3, 2.9 Hz, 1H), 6.65 (ddd, J = 8.9, 2.9, 1.3 Hz, 1H), 6.10 (d, J = 2.8 Hz, 2H), 4.45 (s, 2H), 4.33 (s, 2H), 2.08 (s, 12H). MS (+ESI) m/z 530 ($M+H$)⁺. MS (-ESI) m/z 528 ($M-H$)⁻.

Example 3: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(4-chlorophenyl)propanamide (Compound 102)

Example 3A : 3-(4-chlorophenyl)propanoyl chloride

A 50 mL round bottom flask, equipped with a magnetic stir bar, was charged with white crystals of 3-(4-chlorophenyl)propanoic acid (Aldrich, CAS# 2019-34-3, 100 mg, 0.542 mmol). The flask was closed with a septum attached to a bubbler. Anhydrous dichloromethane (2 mL) was introduced via syringe to give a solution that was stirred at ambient temperature. Oxalyl chloride (0.142 mL, 1.625 mmol) was added via syringe, followed by *N,N*-dimethylformamide (0.042 μ L, 0.542 μ mol) at which point gas evolution was evident. The reaction mixture was stirred at ambient temperature for 1 hour. Volatiles were removed under reduced pressure to give a pale yellow oil that was used in the next step.

Example 3B: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(4-chlorophenyl)propanamide

Example 3A was redissolved in dichloromethane (3 mL), and then a suspension of *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride

- 253 -

(Example 112A, 174 mg, 0.542 mmol) in dichloromethane (10 mL) was added to the reaction mixture. This mixture was stirred at ambient temperature under a dry nitrogen atmosphere and triethylamine (0.302 mL, 2.167 mmol) was introduced via syringe. The reaction mixture was stirred at ambient temperature for 20.5 hours. The reaction mixture was treated with aqueous citric acid. The organic layer was washed with brine, then dried (MgSO₄), and filtered. The filtrate was concentrated under reduced pressure to give a beige solid that was treated with *tert*-butyl methyl ether. The insoluble, cream-colored solid was collected by filtration and was purified by column chromatography on an Analogix® IntelliFlash™-310 (Isco RediSep® 24 g silica gel cartridge, 90:10 to 85:15 dichloromethane/acetone, wavelength monitored: 220 nm) to give the title compound as a white solid (97.9 mg, 40% yield). ¹H NMR (DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.40 (s, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.34-7.30 (m, 2H), 7.23-7.19 (m, 2H), 7.07 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.47 (s, 2H), 2.77 (dd, *J* = 8.6, 6.9 Hz, 2H), 2.31 (dd, *J* = 8.5, 7.1 Hz, 2H), 2.20 (s, 6H). MS (+ESI) *m/z* 451 (M+H)⁺. MS (-ESI) *m/z* 449 (M-H)⁻.

Example 4: *N,N'*-(pentacyclo[4.2.0.0^{2,5}.0^{3,8}.0^{4,7}]octane-1,4-diyl)bis[2-(4-chlorophenoxy)-acetamide] (Compound 103)

Example 4A: cubane-1,4-diamine dihydrochloride

A 50 mL round bottom flask, equipped with a magnetic stir bar, was charged with cubane-1,4-dicarboxylic acid (Aldrich, CAS# 32846-66-5, 800 mg, 4.16 mmol), triethylamine (1.16 mL, 8.32 mmol), diphenylphosphoryl azide (1.8 mL, 8.35 mmol), and *t*-butanol (12.8 mL). The flask was fitted with a reflux condenser equipped with a calcium sulfate drying tube, and the reaction mixture was stirred at reflux for 16 hours. The reaction mixture was allowed to cool to ambient temperature, and then poured into saturated aqueous sodium bicarbonate (50 mL). The precipitate was collected by filtration and washed with water. The solid was dissolved in a hot mixture of dichloromethane, tetrahydrofuran, ethyl acetate, and ethanol. This warm solution was dried (MgSO₄) and filtered. The filtrate was concentrated under reduced pressure to give a beige solid that was treated with ether and collected by filtration. The crude, bis-(*tert*-butoxy-carbonyl)-protected intermediate was suspended in methanol (30 mL) and treated with 4 M HCl in dioxane (30 mL, 120 mmol, 47.4 equivalents). The reaction mixture was stirred at ambient temperature for 4 hours. Volatiles were removed under reduced pressure to give a pale brown solid that was washed with diethyl ether and then with ethyl acetate. The solid was dissolved in hot methanol and treated with acetone to induce precipitation. The title intermediate solid was

- 254 -

collected by filtration (125 mg, 14.5% yield). ^1H NMR (methanol- d_4) δ ppm 4.23 (s, 6H). MS (DCI- NH_3) m/z 135 ($\text{M}+\text{H}$) $^+$, m/z 152 ($\text{M}+\text{NH}_4$) $^+$, m/z 169 ($\text{M}+\text{NH}_4+\text{NH}_3$) $^+$.

Example 4B: N,N'-(pentacyclo[4.2.0.0^{2,5}.0^{3,8}.0^{4,7}]octane-1,4-diyl)bis[2-(4-chlorophenoxy)acetamide]

5 A 50 mL round bottom flask, equipped with a magnetic stir bar, was charged with cubane-1,4-diamine dihydrochloride (Example 4A, 77 mg, 0.372 mmol). The flask contents were placed under a dry nitrogen atmosphere, then a solution of 2-(4-chlorophenoxy)acetyl chloride (Aldrich, CAS# 4122-68-3, 160 mg, 0.781 mmol) in dichloromethane (4 mL) was introduced via syringe. This stirred suspension was treated with triethylamine (0.4 mL, 2.87
10 mmol). The reaction mixture was stirred at ambient temperature under a dry nitrogen atmosphere for 17 hours. Volatiles were removed under reduced pressure, and the solid residue was partitioned between *tert*-butyl methyl ether and ice water. Material that was insoluble in either layer was suspected to be product and was collected by filtration. This crude, beige solid was dissolved in a warm mixture of tetrahydrofuran and ethanol. Silica gel (1.2 g) was added,
15 and the solvent was removed in vacuo. This mixture adsorbed to silica gel was placed at the top of a Practichem 4 g silica gel cartridge that had the top 1.6 g of silica gel removed. The cartridge was reassembled and connected to the top of an Isco RediSep® 24 g silica gel cartridge and the assembly was eluted with 100:0 to 90:10 dichloromethane/acetone on an Analogix® IntelliFlash™-310 (wavelength monitored: 220 nm) to provide the title compound as a white
20 solid (25.6 mg, 14.6% yield). ^1H NMR (DMSO- d_6) δ ppm 8.82 (s, 2H), 7.40-7.30 (m, 4H), 6.98 (d, J = 8.9 Hz, 4H), 4.49 (s, 4H), 3.96 (s, 6H). MS (+ESI) m/z 471 ($\text{M}+\text{H}$) $^+$. MS (-ESI) m/z 469 ($\text{M}-\text{H}$) $^-$.

Example 5: N-[3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-3-(4-chloro-6-oxopyridazin-1(6H)-yl)propanamide (Compound 104)

25 *Example 5A: methyl 3-(4-chloro-6-oxopyridazin-1(6H)-yl)propanoate*

A 50 mL round bottom flask, equipped with a magnetic stir bar, was charged with 5-chloropyridazin-3(2H)-one (Maybridge, CAS# 660425-07-0, 350 mg, 2.68 mmol) and cesium carbonate (1310 mg, 4.02 mmol). The vial was sealed with a septum and placed under a dry nitrogen atmosphere, and then *N,N*-dimethylformamide (7 mL) was introduced via syringe. The
30 reaction mixture was vigorously stirred at ambient temperature while methyl 3-bromopropanoate (0.351 mL, 3.22 mmol) was added via syringe. The reaction mixture was stirred at ambient temperature for 22 hours. The reaction mixture was diluted with water, neutralized with aqueous

- 255 -

citric acid, and extracted with ethyl acetate (twice). The combined organic layers were washed with brine, then dried (MgSO₄), and filtered. The filtrate was concentrated under reduced pressure to give a yellow oil that was purified by column chromatography on an Analogix® IntelliFlash™-310 (Isco RediSep® 40 g silica gel cartridge, 70:30 to 65:35 heptane/ethyl acetate) to give the title intermediate as a clear, colorless oil (479 mg, 82% yield). ¹H NMR (CDCl₃) δ ppm 7.72 (d, J = 2.4 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 4.42 (t, J = 7.1 Hz, 2H), 3.70 (s, 3H), 2.83 (t, J = 7.1 Hz, 2H). MS (DCI-NH₃) *m/z* 217 (M+H)⁺, *m/z* 234 (M+NH₄)⁺.

Example 5B: 3-(4-chloro-6-oxopyridazin-1(6H)-yl)propanoic acid

A 50 mL round bottom flask, equipped with a magnetic stir bar, was charged with methyl 3-(4-chloro-6-oxopyridazin-1(6H)-yl)propanoate (Example 5A, 100 mg, 0.462 mmol). Dioxane (2.3 mL) was added, and the resulting solution was stirred at ambient temperature while sulfuric acid, 5 N aqueous (2.3 mL, 11.50 mmol) was added. The reaction mixture was stirred at 50 °C for 17.5 hours. The reaction mixture was concentrated under reduced pressure, and the oily residue was dissolved in dichloromethane. The solution was dried (Na₂SO₄) and filtered. The filtrate was concentrated under reduced pressure to give the title intermediate as a white solid (33.5 mg, 35.8% yield). ¹H NMR (CDCl₃) δ ppm 7.76 (d, J = 2.4 Hz, 1H), 7.01 (d, J = 2.4 Hz, 1H), 4.44 (t, J = 7.0 Hz, 2H), 2.89 (t, J = 7.0 Hz, 2H). MS (DCI-NH₃) *m/z* 203 (M+H)⁺, *m/z* 220 (M+NH₄)⁺.

Example 5C: 3-(4-chloro-6-oxopyridazin-1(6H)-yl)propanoyl chloride

A 4 mL vial, equipped with a magnetic stir bar, was charged with 3-(4-chloro-6-oxopyridazin-1(6H)-yl)propanoic acid (Example 5B, 47.7 mg, 0.235 mmol). The vial was sealed with a septum screw cap vented to a bubbler, and the vial contents were placed under a dry nitrogen atmosphere. Dichloromethane (1 mL) was introduced via syringe, and the stirred reaction mixture was treated with oxalyl chloride (0.1 mL, 1.142 mmol) and catalytic *N,N*-dimethylformamide (0.018 μL, 0.235 μmol). After stirring at ambient temperature for 45 minutes, volatiles were removed under reduced pressure, and the resulting crude acid chloride intermediate was used in the following step.

Example 5D: N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(4-chloro-6-oxopyridazin-1(6H)-yl)propanamide

The acid chloride intermediate, Example 5C, was redissolved in dichloromethane (1 mL). Solid *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride (Example 112A, 76 mg, 0.235 mmol) was added, and the vial was resealed with

- 256 -

the septum screw cap vented to a bubbler. Triethylamine (0.2 mL, 1.435 mmol) was added dropwise via syringe (reaction mixture turns dark). The reaction mixture was vigorously stirred at ambient temperature for 16 hours. The dichloromethane was evaporated, and the residue was treated with pH = 4 water. Insoluble material was collected by filtration and rinsed with water.

5 The remaining solid was purified by column chromatography on an Analogix® IntelliFlash™-310 (Isco RediSep® 12 g silica gel cartridge, 95:5 to 70:30 dichloromethane/acetone, wavelength monitored: 220 nm) to provide 46.9 mg (42.4% yield) of the title compound as a cream-colored solid. ¹H NMR (DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.54 (s, 1H), 8.05 (d, J = 2.4 Hz, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 7.07 (dd, J = 11.4, 2.9 Hz, 1H), 6.85 (ddd, 10 J = 9.0, 2.9, 1.2 Hz, 1H), 4.47 (s, 2H), 4.19 (t, J = 7.3 Hz, 2H), 2.48 (t, J = 7.3 Hz, 2H), 2.20 (s, 6H). MS (+ESI) *m/z* 469 (M+H)⁺. MS (-ESI) *m/z* 467 (M-H)⁻.

Example 6: 2-(3,4-dichlorophenoxy)-N-[3-(2-[[5-(trifluoromethyl)pyrazin-2-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 105)

Example 6A: Ethyl 2-((5-(trifluoromethyl)pyrazin-2-yl)oxy)acetate

15 To a solution of ethyl 2-hydroxyacetate (0.167 mL, 1.762 mmol) in tetrahydrofuran (4 mL) at room temperature was added potassium *tert*-butoxide (1.850 mL, 1.850 mmol). After 10 minutes, 2-bromo-5-(trifluoromethyl)pyrazine (0.2g, 0.881 mmol) in tetrahydrofuran (4 mL) was added. The mixture was stirred at room temperature overnight. The reaction mixture was quenched by addition of water (10 mL), and extracted with ethyl acetate (3 x 30 mL). The 20 organic phase was dried with MgSO₄, filtered and concentrated under reduced pressure. The residue was used in the next step without further purification (215 mg, 0.859 mmol, 98% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (dd, J = 1.4, 0.7 Hz, 1H), 8.63 (d, J = 1.2 Hz, 1H), 5.09 (s, 2H), 4.16 (q, J = 7.1 Hz, 2H), 1.19 (t, J = 7.1 Hz, 3H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ ppm -65.37 MS (ESI+) *m/z* 251 (M+H)⁺.

25 *Example 6B: 2-((5-(trifluoromethyl)pyrazin-2-yl)oxy)acetic acid*

To a solution of ethyl 2-((5-(trifluoromethyl)pyrazin-2-yl)oxy)acetate (215 mg, 0.859 mmol)(crude from previous reaction) in tetrahydrofuran (4 mL) were added lithium hydroxide (82 mg, 3.44 mmol) and water (1.00 mL). The mixture was stirred at room temperature for 2 hours. The reaction mixture diluted with water (2 mL) and extracted with ethyl acetate. The 30 water layer was separated and acidified with 2 N HCl (aq.) to pH=3. The aqueous mixture was extracted with CH₂Cl₂ (2 x 20 mL). The combined organic fractions were dried with MgSO₄, and concentrated under reduced pressure to give the title compound (150mg, 0.675 mmol, 79%

- 257 -

yield). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 13.09 (s, 1H), 8.76 (t, $J = 1.0$ Hz, 1H), 8.60 (d, $J = 1.2$ Hz, 1H), 5.01 (s, 2H). ^{19}F NMR (376 MHz, DMSO- d_6) δ ppm -64.84. MS (ESI+) m/z 223 (M+H) $^+$.

Example 6C: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide hydrochloride

To Example 22A (3.45 g, 15 mmol) in dichloromethane (10 mL)/methanol (1 mL) was added 4 N HCl in dioxane (53.8 mL, 215 mmol). The mixture was stirred at ambient temperature for 1 hour and then concentrated to give 2.91 g of the title compound (100% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 8.90 (m, 4H), 7.55 (d, $J = 8$, 1H), 7.22 (d, $J = 2$, 1H), 6.98 (dd, $J = 8, 2$, 1H), 4.50 (s, 2H), 2.23 (s, 6H). MS (ESI+) m/z 301 (M+H) $^+$.

Example 6D: 2-(3,4-dichlorophenoxy)-N-[3-(2-[(5-(trifluoromethyl)pyrazin-2-yl]oxy)acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide

To a suspension of *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide hydrochloride (0.05 g, 0.148 mmol, Example 6C) in *N,N*-dimethylformamide (1 mL) were added *N,N*-diisopropylethylamine (0.078 mL, 0.444 mmol) and 2-((5-(trifluoromethyl)pyrazin-2-yl)oxy)acetic acid (0.036 g, 0.163 mmol, Example 6B), followed by 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.062 g, 0.163 mmol, HATU). The reaction mixture was stirred 1 hour at room temperature. The reaction mixture was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine. The organic layer was dried with MgSO_4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (24 g) and eluted with heptane and ethyl acetate (0 to 100%) to give 25 mg of the title compound (33.4% yield) as a white solid. ^1H NMR (501 MHz, DMSO- d_6) δ ppm 8.77 (s, 1H), 8.74 (d, $J = 1.2$ Hz, 1H), 8.71 (s, 1H), 8.55 (d, $J = 1.3$ Hz, 1H), 7.54 (d, $J = 8.9$ Hz, 1H), 7.25 (d, $J = 2.9$ Hz, 1H), 6.98 (dd, $J = 9.0, 2.9$ Hz, 1H), 4.85 (s, 2H), 4.48 (s, 2H), 2.24 (s, 6H). ^{19}F NMR (376 MHz, DMSO- d_6) δ ppm -64.74. MS (ESI+) m/z 552 (M+NH $_4$) $^+$.

Example 7: *N,N'*-(bicyclo[1.1.1]pentane-1,3-diyl)bis[2-(3,4-dichlorophenoxy)acetamide] (Compound 106)

To a suspension of *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide hydrochloride (50 mg, 0.148 mmol, Example 6C) in tetrahydrofuran (1 mL)/*N,N*-dimethylformamide (0.1 mL) were added *N,N*-diisopropylethylamine (0.078 mL,

- 258 -

0.444 mmol) and 2-(3,4-dichlorophenoxy)acetic acid (36.0 mg, 0.163 mmol), followed by 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (61.9 mg, 0.163 mmol, HATU). The reaction mixture was stirred 2 hours at room temperature. The white solid was filtered and dried to give 40mg of the title compound (53.6% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.71 (s, 2H), 7.54 (d, *J* = 8.9 Hz, 2H), 7.26 (d, *J* = 2.9 Hz, 2H), 6.98 (dd, *J* = 9.0, 3.0 Hz, 2H), 4.49 (s, 4H), 2.27 (s, 6H). MS (ESI⁺) *m/z* 505 (M+H)⁺, MS (ESI⁺) *m/z* 546 (M+41)⁺.

Example 8: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 107)

To a suspension of Example 112A (30 mg, 0.093 mmol) in *N,N*-dimethylformamide (0.8 mL) were added *N,N*-diisopropylethylamine (0.049 mL, 0.280 mmol) and 2-((5-(trifluoromethyl)pyrazin-2-yl)oxy)acetic acid (22.82 mg, 0.103 mmol, Example 6B), followed by 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (39.1 mg, 0.103 mmol, HATU). The reaction mixture was stirred overnight at room temperature, diluted with water and extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous NaCl. The organic layer was dried with MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by HPLC (Waters XBridgeTM C18 5 μ m OBDTM column, 50 x 100 mm, flow rate 90 mL/minute, 5-95% gradient of CH₃CN in buffer (0.1% CF₃CO₂H/H₂O to give 30 mg of the title compound (65.7% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.78 - 8.72 (m, 2H), 8.70 (s, 1H), 8.56 - 8.53 (m, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.06 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.84 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.85 (s, 2H), 4.47 (s, 2H), 2.24 (s, 6H). MS (ESI⁺) *m/z* 506 (M+NH₄)⁺.

Example 9: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(1*H*-indazol-6-yl)oxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 108)

Example 9A: tert-butyl (3-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate

To a solution of 2-(4-chloro-3-fluorophenoxy)acetic acid (Aldlab Chemicals, 2.01 g, 9.84 mmol) in *N,N*-dimethylformamide (25 mL) was added *N*-ethyl-*N*-isopropylpropan-2-amine (3.96 mL, 22.7 mmol) followed by 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (3.02 g, 7.94 mmol). This mixture was stirred at ambient temperature for 5 minutes, and then *tert*-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (PharmaBlock, 1.5 g, 7.57 mmol) was added. The mixture was allowed to stir at

- 259 -

ambient temperature for 16 hours. The reaction mixture was quenched with saturated, aqueous NH₄Cl (20 mL) and then washed with CH₂Cl₂ (25 mL). The aqueous layer was extracted with CH₂Cl₂ (3 x 5 mL), and the combined organic fractions were dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure. The residue was purified by column chromatography (SiO₂, 10% ethyl acetate/heptanes to 80% ethyl acetate/heptanes) to give the title compound (2.65 g, 6.89 mmol, 91% yield). MS (ESI⁺) *m/z* 402 (M+NH₄)⁺.

Example 9B: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide-2-Trifluoroacetic acid

To a solution of the product of Example 9A (0.79 g, 2.05 mmol) in CH₂Cl₂ (7 mL) at ambient temperature was added trifluoroacetic acid (3.16 mL, 41.1 mmol). The mixture was allowed to stir at ambient temperature for 3 hours. The mixture was concentrated under reduced pressure and azeotroped with toluene to give the title compound (1.06 g, 2.07 mmol, 100% yield) which was carried on to the next step without purification. MS (ESI⁺) *m/z* 285 (M+H)⁺.

Example 9C: tert-butyl 2-((1H-indazol-5-yl)oxy)acetate

To a solution of 6-hydroxy-1H-indazole (0.89 g, 6.64 mmol) and *tert*-butyl bromoacetate (1.07 mL, 7.30 mmol) in dioxane (20 mL) was added potassium bis(trimethylsilyl)amide (1 M in tetrahydrofuran, 7.96 mL, 7.96 mmol). The mixture was then allowed to stir at ambient temperature for 14 hours. The mixture was quenched with saturated, aqueous NH₄Cl (5 mL) and diluted with CH₂Cl₂ (5 mL). The layers were separated, and the aqueous layer was extracted with CH₂Cl₂ (3 x 5 mL). The combined organic fractions were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified via column chromatography (SiO₂, 5% ethyl acetate/heptanes to 100% ethyl acetate) to give the title compound (0.56 g, 2.26 mmol, 34% yield). MS (ESI⁺) *m/z* 249 (M+H)⁺.

Example 9D: 2-((1H-indazol-6-yl)oxy)acetic acid – Trifluoroacetic acid

To a solution of the product of Example 9C (0.56 g, 2.26 mmol) in CH₂Cl₂ (10 mL) at ambient temperature was added trifluoroacetic acid (3.92 mL, 50.9 mmol). The mixture was allowed to stir at ambient temperature for 3 hours, and then it was concentrated under reduced pressure and azeotroped with toluene to give the title compound (0.85 g, 2.36 mmol, >100% yield) which was carried on to the next step without purification. MS (ESI⁺) *m/z* 193 (M+H)⁺.

Example 9E: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(1H-indazol-6-yl)oxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide

- 260 -

To a mixture of the product of Example 9B (0.1 g, 0.195 mmol) and the product of Example 9D (0.090 g, 0.293 mmol) in dimethylacetamide (3 mL) was added *N*-ethyl-*N*-isopropylpropan-2-amine (0.136 mL, 0.780 mmol) followed by 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.078 g, 0.205 mmol).

- 5 This mixture was allowed to stir at ambient temperature for 16 hours, and then it was quenched with saturated, aqueous NaHCO₃ (10 mL) and diluted with CH₂Cl₂ (10 mL). The layers were separated, and the aqueous layer was extracted with CH₂Cl₂ (3 x 3 mL). The combined organic fractions were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified via HPLC (Waters XBridge™ C18 5 μm OBD™ column, 50 x 100
10 mm, flow rate 90 mL/minute, 20-100% gradient of methanol in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)) to give the title compound (0.04, 0.087 mmol, 45% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.82 (s, 1H), 8.71 (d, *J* = 7.7 Hz, 2H), 7.92 (s, 1H), 7.62 (d, *J* = 8.8 Hz, 1H), 7.48 (t, *J* = 8.9 Hz, 1H), 7.05 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.88 (s, 1H), 6.83 (ddt, *J* = 7.5, 4.6, 1.7 Hz, 2H), 4.46 (d, *J* = 3.4 Hz, 4H),
15 2.26 (s, 6H). MS (ESI⁺) *m/z* 459 (M+H)⁺.

Example 10: *N,N'*-(bicyclo[1.1.1]pentane-1,3-diyl)bis{2-[(1*H*-indazol-6-yl)oxy]acetamide} (Compound 109)

*Example 10A: tert-butyl (3-(2-((1*H*-indazol-6-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate*

- 20 To a solution of the product of Example 9D (0.20 g, 0.56 mmol) in dimethylacetamide (4 mL) was added *N*-ethyl-*N*-isopropylpropan-2-amine (0.26 mL, 1.51 mmol) followed by 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.201 g, 0.530 mmol). This mixture was stirred at ambient temperature for 2 minutes then *tert*-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (PharmaBlock, 0.10 g, 0.504 mmol) was
25 added. The mixture was allowed to stir at ambient temperature for 16 hours, and then it was quenched with saturated, aqueous NH₄Cl (10 mL), diluted with CH₂Cl₂ (15 mL), and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (3 x 5 mL), and the combined organic fractions were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by HPLC (Waters XBridge™ C18 5 μm OBD™ column, 50
30 x 100 mm, flow rate 90 mL/minute, 20-100% gradient of methanol in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)) to give the title compound (0.12 g, 0.33 mmol, 65% yield). MS (ESI⁺) *m/z* 373 (M+H)⁺.

- 261 -

Example 10B: 2-((1H-indazol-6-yl)oxy)-N-(3-aminobicyclo[1.1.1]pentan-1-yl)acetamide-3-trifluoroacetic acid

To a solution of the product of Example 10A (0.12 g, 0.33 mmol) in CH₂Cl₂ (3 mL) at ambient temperature was added trifluoroacetic acid (0.51 mL, 6.6 mmol). This mixture was allowed to stir at ambient temperature for 3 hours, and then it was concentrated under reduced pressure and azeotroped with toluene to give the title compound (0.22 g, 0.36 mmol, >100% yield) which was carried on to the next step without purification. MS (ESI⁺) *m/z* 273 (M+H)⁺.

Example 10C: N,N'-(bicyclo[1.1.1]pentane-1,3-diyl)bis{2-[(1H-indazol-6-yl)oxy]acetamide}

To a mixture of the product of Example 10B (0.10 g, 0.16 mmol) and the product of Example 9D (0.055 g, 0.18 mmol) in dimethylacetamide (2 mL) was added *N*-ethyl-*N*-isopropylpropan-2-amine (0.17 mL, 0.98 mmol) followed by 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.065 g, 0.17 mmol). This mixture was allowed to stir at ambient temperature for 16 hours, and it was directly purified via HPLC (Waters XBridgeTM C18 5 μm OBDTM column, 50 x 100 mm, flow rate 90 mL/minute, 20-100% gradient of methanol in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)) to give the title compound (0.055 g, 0.12 mmol, 76% yield). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 12.82 (s, 2H), 8.72 (s, 2H), 7.92 (t, *J* = 1.3 Hz, 2H), 7.62 (d, *J* = 8.8 Hz, 2H), 6.88 (d, *J* = 2.1 Hz, 2H), 6.82 (dd, *J* = 8.8, 2.1 Hz, 2H), 4.47 (s, 4H), 2.27 (s, 6H). MS (ESI⁺) *m/z* 445 (M-H)⁺.

Example 11: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-methyl-1,2-benzoxazol-6-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 110)

Example 11A: tert-butyl 2-((3-methylbenzo[d]isoxazol-6-yl)oxy)acetate

A mixture of 5-hydroxy-3-methylbenzo[d]isoxazole (Chontech, 1.0 g, 6.70 mmol), potassium carbonate (1.85 g, 13.4 mmol) and *tert*-butyl bromoacetate (1.03 mL, 7.04 mmol) in *N,N*-dimethylformamide (20 mL) was warmed to 65 °C and was allowed to stir for 16 hours. The mixture was then quenched with saturated, aqueous NaHCO₃ (10 mL) and diluted with ethyl acetate (10 mL). The layers were separated, and the aqueous layer was extracted with ethyl acetate (3 x 5 mL). The combined organic fractions were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified via column chromatography (SiO₂, 5% ethyl acetate/heptanes to 100% ethyl acetate) to give the title compound (1.45 g, 5.51 mmol, 82% yield). MS (ESI⁺) *m/z* 264 (M+H)⁺.

Example 11B: 2-((3-methylbenzo[d]isoxazol-6-yl)oxy)acetic acid

- 262 -

To a solution of the product of Example 11A (1.7 g, 6.46 mmol) in CH₂Cl₂ (25 mL) at ambient temperature was added trifluoroacetic acid (7.46 mL, 97 mmol). The mixture was allowed to stir at ambient temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was azeotroped with toluene to give the title compound (1.68 g, 6.49 mmol, 100% yield) which was carried on in the next step without purification. MS (ESI⁺) *m/z* 208 (M+H)⁺.

Example 11C: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-methyl-1,2-benzoxazol-6-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide

To a mixture of the product of Example 9B (0.20 g, 0.390 mmol) and the product of Example 11B (0.204 g, 0.51 mmol) in dimethylacetamide (3 mL) was added *N*-ethyl-*N*-isopropylpropan-2-amine (0.272 mL, 1.56 mmol) followed by 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.156 g, 0.410 mmol). This mixture was allowed to stir at ambient temperature for 16 hours then was quenched with saturated, aqueous NaHCO₃ (10 mL) and diluted with CH₂Cl₂ (10 mL). The layers were separated, and the aqueous layer was extracted with CH₂Cl₂ (3 x 3 mL). The combined organic fractions were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified via HPLC (Waters XBridgeTM C18 5 μm OBDTM column, 50 x 100 mm, flow rate 90 mL/minute, 20-100% gradient of methanol in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)) to give the title compound (0.18 g, 0.38 mmol, 97% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.67 (d, *J* = 2.0 Hz, 2H), 7.52 (d, *J* = 8.9 Hz, 1H), 7.46 (t, *J* = 8.9 Hz, 1H), 7.17 (d, *J* = 2.6 Hz, 1H), 7.04 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.96 (dd, *J* = 8.8, 2.6 Hz, 1H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.44 (d, *J* = 6.6 Hz, 4H), 2.54 (s, 3H), 2.24 (s, 6H). MS (ESI⁺) *m/z* 474 (M+H)⁺.

Example 12: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(4-fluoro-1*H*-indazol-6-yl)oxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 111)

*Example 12A: tert-butyl 2-((4-fluoro-1*H*-indazol-6-yl)oxy)acetate*

A mixture of 4-fluoro-1*H*-indazol-6-ol (ArkPharm, Inc., 1.0 g, 6.57 mmol), potassium carbonate (1.82 g, 13.2 mmol) and *tert*-butyl bromoacetate (1.01 mL, 6.90 mmol) in *N,N*-dimethylformamide (15 mL) was warmed to 65 °C and was allowed to stir for 16 hours. The mixture was allowed to cool to ambient temperature and was quenched with saturated, aqueous NaHCO₃ (10 mL) and diluted with ethyl acetate (10 mL). The layers were separated, and the aqueous layer was extracted with ethyl acetate (3 x 5 mL). The combined organic fractions were

- 263 -

dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure. The residue was purified via column chromatography (SiO₂, 5% ethyl acetate/heptanes to 100% ethyl acetate) to give the title compound (0.81 g, 3.04 mmol, 46% yield). MS (ESI⁺) *m/z* 267 (M+H)⁺.

Example 12B: 2-((4-fluoro-1H-indazol-6-yl)oxy)acetic acid

5 To a solution of the product of Example 12A (0.81 g, 3.04 mmol) in CH₂Cl₂ (5 mL) at ambient temperature was added trifluoroacetic acid (2.34 mL, 30.4 mmol). This mixture was allowed to stir at ambient temperature for 4 hours and then was concentrated under reduced pressure. The residue was azeotroped with toluene to give solids which were re-precipitated from ethyl acetate/heptanes to give the title compound (1.31 g, 2.99 mmol, 98% yield). ¹H NMR
10 (400 MHz, DMSO-*d*₆) δ ppm 8.03 (s, 1H), 6.72 (t, *J* = 1.3 Hz, 1H), 6.60 (dd, *J* = 11.7, 1.8 Hz, 1H), 4.75 (s, 2H).

Example 12C: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(4-fluoro-1H-indazol-6-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide

To a mixture of the product of Example 9B (0.15 g, 0.29 mmol) and the product of
15 Example 12B (0.14 g, 0.32 mmol) in *N,N*-dimethylformamide (3 mL) was added *N*-ethyl-*N*-isopropylpropan-2-amine (0.20 mL, 1.17 mmol) followed by 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.18 g, 0.31 mmol). This mixture was allowed to stir at ambient temperature for 16 hours then was quenched with saturated, aqueous NaHCO₃ (10 mL) and diluted with CH₂Cl₂ (10 mL). The layers were
20 separated, and the aqueous layer was extracted with CH₂Cl₂ (3 x 3 mL). The combined organic fractions were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified via column chromatography (SiO₂, 75% ethyl acetate/heptanes) to give the title compound (0.11 g, 0.23 mmol, 79% yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm
13.19 (s, 1H), 8.75 (d, *J* = 12.0 Hz, 2H), 8.06 (s, 1H), 7.50 (t, *J* = 8.9 Hz, 1H), 7.08 (dd, *J* = 11.4,
25 2.8 Hz, 1H), 6.86 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 6.78 (t, *J* = 1.4 Hz, 1H), 6.69 (dd, *J* = 11.6, 1.8 Hz, 1H), 4.52 (s, 2H), 4.49 (s, 2H), 2.28 (s, 6H). MS (ESI⁺) *m/z* 475 (M+H)⁺.

Example 13: *N,N'*-(bicyclo[1.1.1]pentane-1,3-diyl)bis[2-(4-chlorophenoxy)acetamide] (Compound 112)

Bicyclo[1.1.1]pentane-1,3-diamine dihydrochloride (Pharmablock, 2.588 g, 15.13 mmol)
30 in tetrahydrofuran/water (1/1, 60 mL) was treated with potassium carbonate (10.45 g, 76 mmol), cooled to 0°C and then treated with 2-(4-chlorophenoxy)acetyl chloride (4.72 mL, 30.3 mmol). The reaction mixture was stirred at ambient temperature for 2 hours. The precipitate was

- 264 -

collected by filtration, washed with water and hexane, and air dried to provide 5.635 g (86%) of the title compound. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.66 (s, 2H), 7.42 – 7.26 (m, 4H), 7.00 – 6.87 (m, 4H), 4.39 (s, 4H), 2.23 (s, 6H). MS (APCI) m/z 436 ($\text{M}+\text{H}$) $^+$.

Example 14: 2-(4-chlorophenoxy)-N-(3-([2-(4-chlorophenoxy)ethyl]amino)bicyclo-[1.1.1]pentan-1-yl)acetamide (Compound 113)

Example 14A: tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate

tert-Butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate hydrochloride (Pharmablock, 0.469 g, 2 mmol) in tetrahydrofuran/water (1/1, 6 mL) was treated with potassium carbonate (0.732 g, 5.30 mmol), cooled to 0 °C, and then treated with 2-(4-chlorophenoxy)acetyl chloride (0.312 mL, 2 mmol). The reaction mixture was stirred at ambient temperature for 2 hours. The resultant precipitate was collected by filtration, washed with water and hexane, and air dried to provide 0.471 g (57.4%) of the title compound. MS (APCI) m/z 367 ($\text{M}+\text{H}$) $^+$.

Example 14B: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide

A solution of Example 14A (0.471 g, 1.148 mmol) in dioxane (3 mL) was treated with 4 N HCl in dioxane (3 mL) and stirred at 25 °C for 20 hours. The reaction mixture was concentrated to provide 0.347 g (100%) of the title compound. MS (APCI) m/z 267 ($\text{M}+\text{H}$) $^+$.

Example 14C: 2-(4-chlorophenoxy)-N-(3-([2-(4-chlorophenoxy)ethyl]amino)bicyclo-[1.1.1]pentan-1-yl)acetamide

A solution of Example 14B (0.1 g, 0.33 mmol) and 2-(4-chlorophenoxy)acetaldehyde (0.051 g, 0.3 mmol) in methanolic pH4 buffer (2 mL) was stirred at ambient temperature for 1 hour and then treated with sodium cyanoborohydride (0.062 g, 0.99 mmol). The reaction mixture was stirred for 20 hours and then partitioned between dichloromethane (20 mL) and water (20 mL). The aqueous layer was extracted with dichloromethane (3 x 20 mL). The combined organic layers were washed with brine (2 x 30 mL), dried (Na_2SO_4), filtered and concentrated under reduced pressure. The residue was purified by HPLC (Phenomenex® Luna® C18(2) 5 μm 100 Å AXIA™ column 250 mm x 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide 0.076 g (60%) of the title compound. ^1H NMR (501 MHz, $\text{DMSO}-d_6$) δ ppm 8.83 (s, 1H), 7.41 – 7.25 (m, 4H), 7.06 – 6.92 (m, 4H), 4.44 (s, 2H), 4.15 (t, J = 5.1 Hz, 2H), 3.28 – 3.24 (m, 2H), 2.24 (s, 6H). MS (APCI) m/z 422 ($\text{M}+\text{H}$) $^+$.

- 265 -

Example 15: 2-(4-chlorophenoxy)-N-{3-[2-(3-methylphenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 114)

To a solution of 2-(*m*-tolylloxy)acetic acid (13.7 mg, 0.0801 mmol) in *N,N*-dimethylacetamide (0.5 mL) was added *N,N*-diisopropylethylamine (0.052 mL, 0.299 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (71.3 mg, 0.187 mmol) and Example 14B (20.1 mg, 0.0701 mmol). The reaction was stirred at ambient temperature for 18 hours. The crude reaction was purified by HPLC (2-coupled C8 5 μ m 100 Å columns 30 mm \times 75 mm each, flow rate of 50 mL/minute, 5-90% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)). ^1H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.74 (d, *J* = 17.9 Hz, 2H), 7.39 – 7.27 (m, 2H), 7.16 (t, *J* = 8.1 Hz, 1H), 7.05 – 6.91 (m, 2H), 6.86 – 6.64 (m, 3H), 4.39 (d, *J* = 16.7 Hz, 4H), 2.26 (m, 9H). MS (APCI) *m/z* 415.370 (M+H)⁺.

Example 16: 2-(4-chlorophenoxy)-N-{3-[2-(4-methylphenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 115)

The title compound was prepared using the method described in Example 15 by replacing 2-(*m*-tolylloxy)acetic acid with 2-(*p*-tolylloxy)acetic acid (13.7 mg, 0.0801 mmol). ^1H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.38 – 7.27 (m, 2H), 7.12 – 7.05 (m, 2H), 7.00 – 6.94 (m, 2H), 6.86 – 6.81 (m, 2H), 4.38 (d, *J* = 24.1 Hz, 4H), 2.26 (s, 6H), 2.22 (s, 3H). MS (APCI) *m/z* 415.330 (M+H)⁺.

Example 17: 2-(4-chloro-3-methylphenoxy)-N-{3-[2-(4-chlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 116)

The title compound was prepared using the method described in Example 15 by replacing 2-(*m*-tolylloxy)acetic acid with 2-(4-chloro-3-methylphenoxy)acetic acid (16.6 mg, 0.0801 mmol). ^1H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (d, *J* = 7.9 Hz, 2H), 7.37 – 7.25 (m, 3H), 6.97 (m, 3H), 6.97 (dd, *J* = 9.5, 2.8 Hz, 1H), 4.40 (d, *J* = 8.2 Hz, 4H), 2.27 (m, *J* = 5.1 Hz, 9H). MS (APCI) *m/z* 449.2 (M+H)⁺.

Example 18: 2-(4-chlorophenoxy)-N-{3-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 117)

The title compound was prepared using the method described in Example 15 by replacing 2-(*m*-tolylloxy)acetic acid with 2-(3,4-dichlorophenoxy)acetic acid (18.2 mg, 0.0801 mmol). ^1H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.52 (dd, *J* = 8.9, 4.6 Hz, 2H), 7.36 – 7.30 (m, 2H), 7.23 (t, *J* = 3.3 Hz, 1H), 7.00 – 6.94 (m, 4H), 4.44 (d, *J* = 20.4 Hz, 4H), 2.26 (s, 6H). MS (APCI) *m/z* 469.230 (M+H)⁺.

- 266 -

Example 19: 2-(4-chlorophenoxy)-N-{3-[2-(3-chlorophenoxy)acetamido]bicyclo-[1.1.1]pentan-1-yl}acetamide (Compound 118)

The title compound was prepared using the method described in Example 15 by replacing 2-(*m*-tolylloxy)acetic acid with 2-(3-chlorophenoxy)acetic acid (15.4 mg, 0.0801 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.78 (d, J = 5.1 Hz, 2H), 7.36 – 7.27 (m, 3H), 7.06 – 6.88 (m, 6H), 4.43 (d, J = 12.4 Hz, 4H), 2.27 (s, 6H). MS (APCI) *m/z* 435.280 (M+H)⁺.

Example 20: 2-(4-chlorophenoxy)-N-{3-[2-(3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 119)

The title compound was prepared using the method described in Example 15 by replacing 2-(*m*-tolylloxy)acetic acid with 2-(3-fluorophenoxy)acetic acid (14.1 mg, 0.0801 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.37 – 7.28 (m, 3H), 7.00 – 6.93 (m, 2H), 6.85 – 6.75 (m, 3H), 4.43 (d, J = 8.7 Hz, 4H), 2.27 (s, 6H). MS (APCI) *m/z* 419.280 (M+H)⁺.

Example 21: 2-(4-chlorophenoxy)-N-{3-[2-(4-fluorophenoxy)acetamido]bicyclo-[1.1.1]pentan-1-yl}acetamide (Compound 120)

The title compound was prepared using the method described in Example 15 by replacing 2-(*m*-tolylloxy)acetic acid with 2-(4-fluorophenoxy)acetic acid (14.1 mg, 0.0801 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (d, J = 6.9 Hz, 1H), 7.37 – 7.28 (m, 2H), 7.17 – 7.06 (m, 2H), 7.02 – 6.92 (m, 4H), 4.40 (d, J = 10.8 Hz, 4H), 2.26 (s, 6H). MS (APCI) *m/z* 419.260 (M+H)⁺.

Example 22: 2-(4-chloro-3-fluorophenoxy)-N-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 121)

Example 22A: tert-butyl (3-(2-(3,4-dichlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate

To a solution of 2-(3,4-dichlorophenoxy)acetic acid (3.53 g, 15.98 mmol) and *tert*-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (Pharmablock, 3.2 g, 14.53 mmol) in *N,N*-dimethylformamide (50 mL) was added *N,N*-diisopropylethylamine (12.69 mL, 72.6 mmol) and fluoro-*N,N,N,N*-tetramethylformamidinium hexafluorophosphate (8.28 g, 21.79 mmol) at ambient temperature under nitrogen. The resulting mixture was stirred, diluted with water (300 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic layer was washed with brine (3 x 100 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was treated with methyl *tert*-butyl ether (15 mL) and dried under high vacuum to provide 4.2 g (72.3%) of the title compound as a yellow solid. MS (APCI) *m/z* 402 (M+H)⁺.

- 267 -

Example 22B: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide

To a solution of Example 22A (5.5 g, 13.57 mmol) in dichloromethane (100 mL) was added trifluoroacetic acid (30 mL, 389 mmol) at 0 °C. The mixture was stirred at ambient temperature for 12 hours. The mixture was concentrated under reduced pressure, and the residue was diluted with water (300 mL). The aqueous phase was adjusted to pH= 8 with saturated NaHCO₃, and extracted with dichloromethane (4 x 150 mL). The combined organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure to provide 4 g (87%) of the title compound as off white solid. MS (APCI) *m/z* 302 (M+H)⁺.

Example 22C: 2-(4-chloro-3-fluorophenoxy)-N-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide

To a solution of 2-(4-chloro-3-fluorophenoxy)acetic acid (0.033 g, 0.161 mmol) in *N,N*-dimethylformamide (1 mL) was added *N,N*-diisopropylethylamine (0.064 mL, 0.366 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.061 g, 0.161 mmol) and Example 22B (0.044 g, 0.146 mmol). The reaction mixture was stirred at room temperature for 18 hours and concentrated. HPLC purification (Phenomenex® Luna® C18(2) 5 µm 100 Å AXIA™ column 250 mm × 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) afforded the title compound. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.72 (s, 2H), 7.55 (d, *J* = 8.9 Hz, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.26 (d, *J* = 2.9 Hz, 1H), 7.07 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.99 (dd, *J* = 8.9, 2.9 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 1H), 4.49 (s, 2H), 4.48 (s, 2H), 2.27 (s, 6H). MS (APCI) *m/z* 489 (M+H)⁺.

Example 23: 2-(4-chloro-2-fluorophenoxy)-N-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 122)

The title compound was prepared using the method described in Example 22C by replacing 2-(4-chloro-3-fluorophenoxy)acetic acid with 2-(4-chloro-2-fluorophenoxy)acetic acid (33 mg, 0.161 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 – 8.66 (m, 2H), 7.54 (d, *J* = 9.0 Hz, 1H), 7.45 (dd, *J* = 11.2, 2.5 Hz, 1H), 7.26 (d, *J* = 2.9 Hz, 1H), 7.24 – 7.18 (m, 1H), 7.08 (t, *J* = 9.0 Hz, 1H), 6.98 (dd, *J* = 8.9, 2.9 Hz, 1H), 4.54 (s, 2H), 4.48 (s, 2H), 2.25 (s, 6H). MS (APCI) *m/z* 489 (M+H)⁺.

Example 24: N-(3-{[2-(4-chloro-2-fluorophenoxy)ethyl]amino}bicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide (Compound 123)*Example 24A: 1-(2-bromoethoxy)-4-chloro-2-fluorobenzene*

- 268 -

A suspension of 4-chloro-2-fluorophenol (0.88 g, 6 mmol) and potassium carbonate (1.244 g, 9 mmol) in acetonitrile (20 mL) was treated with 1,2-dibromoethane (2.56 mL, 24 mmol) and stirred at 90 °C for 2 days. The reaction mixture was concentrated, washed with water and extracted twice with dichloromethane. The combined organic extracts were dried (Na₂SO₄), filtered, and then concentrated under reduced pressure to provide the title compound. MS (APCI) *m/z* 254 (M+H)⁺.

Example 24B: N-(3-{[2-(4-chloro-2-fluorophenoxy)ethyl]amino}bicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide

A suspension of Example 24A (0.05 g, 0.148 mmol) and Example 22B (0.038 g, 0.148 mmol) in *N,N*-dimethylformamide (1 mL) was treated with potassium carbonate (0.051 g, 0.37 mmol) and stirred at 90 °C for 18 hours. The reaction mixture was concentrated and purified on HPLC (Phenomenex® Luna® C18(2) 5 µm 100 Å AXIA™ column 250 mm × 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.89 (s, 1H), 7.56 (d, *J* = 8.9 Hz, 1H), 7.49 (dd, *J* = 11.0, 1.9 Hz, 1H), 7.33 – 7.21 (m, 3H), 6.99 (dd, *J* = 8.9, 2.9 Hz, 1H), 4.53 (s, 2H), 4.27 (t, *J* = 5.0 Hz, 2H), 2.29 (s, 6H). MS (APCI) *m/z* 475 (M+H)⁺.

Example 25: N-(3-{[2-(4-chloro-3-fluorophenoxy)ethyl]amino}bicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide (Compound 124)

Example 25A: 1-(2-bromoethoxy)-4-chloro-3-fluorobenzene

The title compound was prepared using the method described in Example 24A by replacing 4-chloro-2-fluorophenol with 4-chloro-3-fluorophenol (0.88 g, 6 mmol). MS (APCI) *m/z* 254 (M+H)⁺.

Example 25B: N-(3-{[2-(4-chloro-3-fluorophenoxy)ethyl]amino}bicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide

The title compound was prepared using the method described in Example 24B by replacing 1-(2-bromoethoxy)-4-chloro-2-fluorobenzene with 1-(2-bromoethoxy)-4-chloro-3-fluorobenzene (0.05 g, 0.148 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.91 (s, 1H), 7.59 – 7.50 (m, 2H), 7.26 (d, *J* = 2.9 Hz, 1H), 7.13 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.99 (dd, *J* = 8.9, 2.9 Hz, 1H), 6.90 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.53 (s, 2H), 4.23 (t, *J* = 4.9 Hz, 2H), 2.31 (s, 6H). MS (APCI) *m/z* 475 (M+H)⁺.

Example 26: 2-(3,4-dichlorophenoxy)-N-(3-{[2-(3,4-dichlorophenoxy)ethyl]amino}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 125)

- 269 -

Example 26A: 4-(2-bromoethoxy)-1,2-dichlorobenzene

The title compound was prepared using the method described in Example 24A by replacing 4-chloro-2-fluorophenol with 3,4-dichlorophenol (0.88 g, 6 mmol). MS (APCI) m/z 270 (M+H)⁺.

5 *Example 26B: 2-(3,4-dichlorophenoxy)-N-(3-([2-(3,4-dichlorophenoxy)ethyl]amino)-bicyclo[1.1.1]pentan-1-yl)acetamide*

The title compound was prepared using the method described in Example 24B by replacing 1-(2-bromoethoxy)-4-chloro-2-fluorobenzene with 4-(2-bromoethoxy)-1,2-dichlorobenzene (0.05 g, 0.148 mmol). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.90 (s, 1H),
 10 7.57 (dd, J = 12.2, 8.9 Hz, 2H), 7.28 (dd, J = 18.4, 2.9 Hz, 2H), 7.01 (ddd, J = 18.0, 8.9, 2.9 Hz, 2H), 4.53 (s, 2H), 4.24 (t, J = 5.0 Hz, 2H), 2.30 (s, 6H);). MS (APCI) m/z 491 (M+H)⁺.

Example 27: 2-(4-chloro-3-fluorophenoxy)-N-{3-[2-(4-chloro-3-methoxyphenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 126)

Example 27A: tert-butyl 2-(4-chloro-3-methoxyphenoxy)acetate

15 A solution of 4-chloro-3-methoxyphenol (1g, 6.31 mmol) in *N,N*-dimethylformamide (10 mL) was treated with *tert*-butyl 2-bromoacetate (1.024 mL, 6.94 mmol) and potassium carbonate (1.743 g, 12.61 mmol) and heated at 65 °C for 2 hours. The reaction mixture was diluted with ethyl acetate and washed with water twice. The organic extract was dried (Na₂SO₄), filtered and concentrated to provide 1.72 g (100%) of the title compound. MS (APCI) m/z 273 (M+H)⁺.

20 *Example 27B: 2-(4-chloro-3-methoxyphenoxy)acetic acid*

A solution of Example 27A (1.72 g, 6.31 mmol) in dioxane (8 mL) was treated with 4 N HCl in dioxane (8 mL) and stirred at 25 °C for 4 hours. The reaction mixture was concentrated to provide the title compound (1.365 g, 100%). MS (APCI) m/z 173 (M+H)⁺.

Example 27C: tert-butyl (3-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate

25 To solution of 2-(4-chloro-3-fluorophenoxy)acetic acid (6.09 g, 29.8 mmol) and *tert*-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (Pharmablock, 5.9 g, 29.8 mmol) in *N,N*-dimethylformamide (70 mL) was added *N,N*-diisopropylethylamine (15.59 mL, 89 mmol) and 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (16.97 g, 44.6
 30 mmol) under nitrogen. The resulting mixture was stirred at ambient temperature for 12 hours, diluted with water (300 mL), and extracted with ethyl acetate (3 x 200 mL). The combined organic layer was washed with brine (3 x 100 mL), dried (Na₂SO₄), filtered, and concentrated

- 270 -

under reduced pressure. The residue was treated with methyl *tert*-butyl ether (15 mL), and the resultant solid was dried under high vacuum to provide 6.07 g (53%) of the title compound as a white solid. MS (APCI) m/z 385 (M+H)⁺.

Example 27D: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide

To solution of Example 27C (9 g, 23.39 mmol) in dichloromethane (100 mL) was added trifluoroacetic acid (30 mL, 389 mmol) at 0 °C. The mixture was stirred at ambient temperature for 12 hours. The mixture was concentrated under reduced pressure, and the residue was diluted with water (300 mL). The aqueous phase was adjusted to pH= 8 with NaHCO₃ and then extracted with dichloromethane (4 x 150 mL). The combined organic layer was dried (Na₂SO₄) and concentrated under reduced pressure to provide 6 g (90%) of the title compound as a white solid. MS (APCI) m/z 285 (M+H)⁺

Example 27E: 2-(4-chloro-3-fluorophenoxy)-N-{3-[2-(4-chloro-3-methoxyphenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide

To solution of Example 27B (0.037 g, 0.171 mmol) and Example 27D (0.05 g, 0.156 mmol) in *N,N*-dimethylformamide (1 mL) was added *N,N*-diisopropylethylamine (0.07 mL, 0.39 mmol) and 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.065 g, 0.171 mmol) under nitrogen. The resulting mixture was stirred at ambient temperature for 12 hours and concentrated. The residue was taken into methanol (1 mL)/dimethyl sulfoxide (1 mL), and the precipitate was collected by filtration. The precipitate was washed with methanol (2 mL) and dried under high vacuum to provide the title compound (0.02 g, 27%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.71 (s, 1H), 8.69 (s, 1H), 7.50 (t, *J* = 8.8 Hz, 1H), 7.31 (d, *J* = 8.7 Hz, 1H), 7.07 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.85 (dd, *J* = 8.9, 2.7 Hz, 1H), 6.76 (d, *J* = 2.7 Hz, 1H), 6.54 (dd, *J* = 8.7, 2.7 Hz, 1H), 4.48 (s, 2H), 4.44 (s, 2H), 3.83 (s, 3H), 2.27 (s, 6H). MS (APCI) m/z 484 (M+H)⁺.

Example 28: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[4-(methanesulfonyl)-phenoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 127)

Example 28A: 2-chloro-N-(3-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide

A solution of Example 27D (0.93 g, 2.90 mmol) in tetrahydrofuran (5 mL) and water (5 mL) was treated with potassium carbonate (1 g, 7.24 mmol), cooled to 0 °C and treated with 2-chloroacetyl chloride (0.254 mL, 3.19 mmol). The reaction mixture was stirred at 25 °C for 2

- 271 -

hours and filtered. The precipitate was washed with water and dried in a vacuum oven to provide the title compound (0.853 g, 82%). MS (APCI) m/z 362 (M+H)⁺.

Example 28B: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[4-(methanesulfonyl)phenoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide

5 A suspension of Example 28A (0.03 g, 0.083 mmol), 4-(methylsulfonyl)phenol (28.6 mg, 0.166 mmol), potassium carbonate (0.023 g, 0.166 mmol) and potassium iodide (0.002 g, 0.009 mmol) in acetonitrile (1 mL) was heated in microwave reactor (Personal Chemistry, 300 W) oven at 140 °C for 45 minutes. The reaction mixture was filtered, washed with acetonitrile and the filtrate was concentrated. The residue was purified on HPLC (Phenomenex® Luna® C18(2)
10 5 µm 100 Å AXIA™ column 250 mm × 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide 0.021 g (51%) of the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.77 (s, 1H), 8.71 (s, 1H), 7.92 – 7.81 (m, 2H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.19 – 7.14 (m, 1H), 7.07 (dd, *J* = 11.4, 2.8 Hz, 2H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.57 (s, 2H), 4.48 (s, 2H), 3.16 (s, 3H), 2.27 (s, 6H). MS (APCI) m/z 498
15 (M+H)⁺.

Example 29: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-methylpyridin-2-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 128)

A solution of (6-methylpyridin-2-yl) methanol (39 mg, 6.5 equivalent, 0.31 mmol) in dimethylformamide (0.3 mL) was treated with sodium hydride (10 mg, 0.36 mmol), and the
20 mixture was stirred for 30 minutes. A solution of Example 28A (18 mg, 0.048 mmol) in dimethylformamide (0.250 mL) was added to the mixture. The reaction mixture was stirred for 1 hour, filtered and concentrated to dryness. The residue was dissolved in 1:1 dimethyl sulfoxide/methanol and purified by reverse phase HPLC (2-coupled C8 5 µm 100 Å columns 30 mm × 75 mm each, flow rate of 50 mL/minute, 5-90% gradient of acetonitrile in buffer (0.1%
25 trifluoroacetic acid in water)) to provide the title compound. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.34 (t, *J* = 7.9 Hz, 1H), 7.77 (dd, *J* = 22.4, 7.9 Hz, 2H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.04 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.84 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.82 (s, 2H), 4.45 (s, 2H), 4.04 (s, 2H), 2.69 (s, 3H), 2.26 (s, 6H). MS (APCI+) m/z 448.3 (M+H)⁺.

Example 30: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-fluorophenyl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 129)
30

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with (3-fluorophenyl)methanol (40 mg, 0.31 mmol).

- 272 -

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.79 (s, 1H), 8.47 (s, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.43 – 7.35 (m, 1H), 7.24 – 7.16 (m, 2H), 7.16 – 7.07 (m, 1H), 7.04 (dd, J = 11.3, 2.9 Hz, 1H), 6.84 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.53 (s, 2H), 4.45 (s, 2H), 3.85 (s, 2H), 2.24 (s, 6H). MS (APCI+) *m/z* 451.3 (M+H)⁺.

5 **Example 31: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(4-chlorophenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 130)**

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with (4-chlorophenyl)methanol (45 mg, 0.31 mmol).

10 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.48 (d, J = 8.8 Hz, 1H), 7.46 – 7.36 (m, 4H), 7.11 – 7.03 (m, 1H), 6.90 – 6.83 (m, 1H), 4.50 (s, 2H), 4.45 (s, 2H), 3.83 (s, 2H), 2.24 (s, 6H). MS (APCI+) *m/z* 467.3 (M+H)⁺.

Example 32: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-chlorophenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 131)

15 The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with (3-chlorophenyl)methanol (45 mg, 0.31 mmol).

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.51 – 7.28 (m, 5H), 7.04 (dd, J = 11.3, 2.8 Hz, 1H), 6.84 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 4.51 (s, 2H), 4.45 (s, 2H), 3.85 (s, 2H), 2.24 (s, 6H). MS (APCI+) *m/z* 467.3 (M+H)⁺.

20 **Example 33: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[2-(3-fluorophenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 132)**

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(3-fluorophenyl)ethanol (45 mg, 0.31 mmol).

25 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.47 (t, J = 8.9 Hz, 1H), 7.32 (td, J = 8.1, 6.4 Hz, 1H), 7.12 – 6.97 (m, 4H), 6.84 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.45 (s, 2H), 3.80 (s, 2H), 3.64 (t, J = 6.7 Hz, 2H), 2.85 (t, J = 6.6 Hz, 2H), 2.22 (s, 6H). MS (APCI+) *m/z* 465.3 (M+H)⁺.

Example 34: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[2-(3-chlorophenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 133)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(3-chlorophenyl)ethanol (49 mg, 0.31 mmol).

30 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.48 (d, J = 8.9 Hz, 1H), 7.32 (dd, J = 4.8, 2.9 Hz, 2H), 7.32 – 7.22 (m, 2H), 7.09 – 7.03 (m, 1H), 6.84 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 4.45 (s, 2H), 3.79

- 273 -

(s, 2H), 3.64 (d, J = 6.7 Hz, 2H), 2.85 (d, J = 6.6 Hz, 1H), 2.22 (s, 6H). MS (APCI+) m/z 481.3 (M+H)⁺.

Example 35: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[2-(4-fluorophenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 134)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(4-fluorophenyl)ethanol (44 mg, 0.31 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.48 (d, J = 8.8 Hz, 1H), 7.35 – 7.25 (m, 2H), 7.17 – 7.09 (m, 1H), 7.08 – 7.02 (m, 1H), 6.91 – 6.83 (m, 1H), 4.45 (s, 2H), 3.80 (s, 2H), 3.62 (d, J = 6.8 Hz, 2H), 2.83 (d, J = 6.7 Hz, 1H), 2.21 (s, 6H). MS (APCI+) m/z 465.3 (M+H)⁺.

Example 36: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[2-(4-chlorophenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 135)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(4-chlorophenyl)ethanol (49 mg, 0.31 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.48 (d, J = 8.9 Hz, 1H), 7.33 (d, J = 2.1 Hz, 1H), 7.31 – 7.26 (m, 2H), 7.05 (d, J = 2.8 Hz, 1H), 6.89 – 6.83 (m, 1H), 4.45 (s, 2H), 3.79 (s, 2H), 3.62 (d, J = 6.7 Hz, 2H), 2.83 (d, J = 6.7 Hz, 2H), 2.21 (s, 6H). MS (APCI+) m/z 481.3 (M+H)⁺.

Example 37: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[2-(3-methylphenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 136)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(*m*-tolyl)ethanol (43 mg, 0.31 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.48 (d, J = 8.9 Hz, 1H), 7.17 (d, J = 7.5 Hz, 1H), 7.09 – 7.01 (m, 4H), 6.91 – 6.83 (m, 1H), 4.45 (s, 2H), 3.79 (s, 2H), 3.62 (d, J = 7.0 Hz, 2H), 2.79 (d, J = 6.9 Hz, 2H), 2.26 (d, J = 0.7 Hz, 3H), 2.21 (s, 6H). MS (APCI+) m/z 461.3 (M+H)⁺.

Example 38: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[2-(4-methylphenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 137)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(*p*-tolyl)ethanol (43 mg, 0.31 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.48 (d, J = 8.9 Hz, 1H), 7.11 (dd, J = 8.7, 6.3 Hz, 4H), 7.08 – 7.03 (m, 1H), 6.88 – 6.83 (m, 1H), 4.45 (s, 2H), 3.80 (s, 2H), 3.59 (t, J = 6.9 Hz, 2H), 2.78 (d, J = 6.9 Hz, 2H), 2.25 (s, 3H), 2.23 (s, 1H), 2.20 (s, 6H). MS (APCI+) m/z 461.3 (M+H)⁺.

Example 39: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-cyanophenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 138)

- 274 -

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 3-(hydroxymethyl)benzonitrile (42 mg, 0.31 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.82 (td, J = 1.7, 0.7 Hz, 1H), 7.76 (d, J = 1.3 Hz, 1H), 7.75 – 7.70 (m, 1H), 7.57 (td, J = 7.7, 0.5 Hz, 1H), 7.48 (d, J = 8.9 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.85 (dd, J = 2.9, 1.2 Hz, 1H), 6.83 (dd, J = 2.9, 1.2 Hz, 1H), 4.57 (s, 2H), 4.45 (s, 2H), 3.88 (s, 2H), 2.24 (s, 6H). MS (APCI+) *m/z* 458.3 (M+H)⁺.

Example 40: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(4-cyanophenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 139)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 4-(hydroxymethyl)benzonitrile (42 mg, 0.31 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.87 – 7.79 (m, 2H), 7.57 (h, J = 1.2 Hz, 2H), 7.48 (d, J = 8.9 Hz, 1H), 7.04 (dd, J = 11.3, 2.9 Hz, 1H), 6.92 – 6.83 (m, 1H), 4.61 (s, 2H), 4.45 (s, 2H), 3.88 (s, 2H), 2.24 (s, 6H). MS (APCI+) *m/z* 458.3 (M+H)⁺.

Example 41: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-methylphenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 140)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with *m*-tolylmethanol (38 mg, 0.31 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.48 (d, J = 8.9 Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 7.19 – 7.11 (m, 3H), 7.05 (d, J = 2.9 Hz, 1H), 6.88 – 6.83 (m, 1H), 4.46 (s, 2H), 3.81 (s, 2H), 2.29 (d, J = 0.7 Hz, 3H), 2.24 (s, 6H). MS (APCI+) *m/z* 447.3 (M+H)⁺.

Example 42: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-{[3-(dimethylamino)phenyl]methoxy}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 141)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with (3-(dimethylamino)phenyl)methanol (47 mg, 0.31 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.47 (t, J = 8.9 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 7.04 (dd, J = 11.3, 2.8 Hz, 1H), 6.85 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 6.71 – 6.59 (m, 3H), 4.45 (d, J = 1.7 Hz, 4H), 3.80 (s, 2H), 2.87 (s, 6H), 2.24 (s, 6H). MS (APCI+) *m/z* 476.3 (M+H)⁺.

Example 43: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(4-fluorophenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 142)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with (4-fluorophenyl)methanol (40 mg, 0.31 mmol).

- 275 -

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.47 (t, *J* = 8.9 Hz, 1H), 7.45 – 7.39 (m, 2H), 7.23 – 7.14 (m, 2H), 7.04 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.49 (s, 2H), 4.46 (s, 2H), 3.83 (s, 2H), 2.25 (s, 6H;). MS (APCI+) *m/z* 451.2 (M+H)⁺.

Example 44: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-[2-[4-(dimethylamino)phenyl]ethoxy]-acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 143)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(4-(dimethylamino)phenyl)ethanol (52 mg, 0.31 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.48 (t, *J* = 8.9 Hz, 1H), 7.08 – 7.02 (m, 3H), 6.85 (ddd, *J* = 9.1, 2.9, 1.2 Hz, 1H), 6.73 – 6.64 (m, 2H), 4.45 (s, 2H), 3.79 (s, 2H), 3.56 (t, *J* = 7.0 Hz, 2H), 2.83 (s, 6H), 2.71 (t, *J* = 7.0 Hz, 2H), 2.21 (s, 6H). MS (APCI+) *m/z* 490.3 (M+H)⁺.

Example 45: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(4-methylphenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 144)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with *p*-tolylmethanol (39 mg, 0.31 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.47 (t, *J* = 8.9 Hz, 1H), 7.27 – 7.23 (m, 1H), 7.18 (s, 1H), 7.08 – 7.03 (m, 1H), 6.88 – 6.84 (m, 1H), 4.46 (d, *J* = 3.1 Hz, 4H), 3.80 (s, 2H), 2.29 (s, 3H), 2.24 (s, 6H). MS (APCI+) *m/z* 447.2 (M+H)⁺.

Example 46: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-[2-[3-(dimethylamino)phenyl]ethoxy]-acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 145)

The title compound was prepared according to the method described in Example 29 replacing (6-methylpyridin-2-yl) methanol with 2-(3-(dimethylamino)phenyl)ethanol (52 mg, 0.31 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.48 (t, *J* = 8.9 Hz, 1H), 7.10 (d, *J* = 7.7 Hz, 1H), 7.08 – 7.02 (m, 1H), 6.89 – 6.84 (m, 1H), 6.62 – 6.49 (m, 3H), 4.45 (s, 2H), 3.80 (s, 2H), 3.62 (t, *J* = 6.9 Hz, 2H), 2.86 (s, 6H), 2.77 (t, *J* = 6.9 Hz, 2H), 2.21 (s, 6H). MS (APCI+) *m/z* 490.3 (M+H)⁺.

Example 47: 2-(4-chloro-3-fluorophenoxy)-*N*-{3-[2-(3-chlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 146)

The title compound was prepared using the method described in Example 27E by replacing Example 27B with 2-(3-chlorophenoxy)acetic acid (0.022 g, 0.1 mmol). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.71 (s, 1H), 8.70 (s, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.32 (t, *J* = 8.2 Hz, 1H), 7.10 – 7.04 (m, 1H), 7.02 (ddd, *J* = 7.9, 2.0, 0.9 Hz, 2H), 6.93 (ddd, *J* = 8.3, 2.4, 0.9

- 276 -

Hz, 1H), 6.85 (ddd, $J = 8.9, 2.9, 1.2$ Hz, 1H), 4.48 (s, 2H), 4.46 (s, 2H), 2.27 (s, 6H). MS (APCI) m/z 454.3 (M+H)⁺.

Example 48: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(3-chlorophenoxy)propanamide (Compound 147)

5 The title compound was prepared using the method described in Example 27E by replacing Example 27B with 3-(3-chlorophenoxy)propanoic acid (0.024 g, 0.1 mmol). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.57 (s, 1H), 7.49 (t, $J = 8.9$ Hz, 1H), 7.29 (t, $J = 8.4$ Hz, 1H), 7.07 (dd, $J = 11.4, 2.9$ Hz, 1H), 7.03 – 6.94 (m, 2H), 6.87 (dddd, $J = 23.3, 9.0, 2.6, 1.1$ Hz, 2H), 4.47 (s, 2H), 4.17 (t, $J = 6.2$ Hz, 2H), 2.23 (s, 6H). MS (APCI) m/z 468.3 (M+H)⁺.

10 **Example 49: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-4-(3-chlorophenoxy)butanamide (Compound 148)**

The title compound was prepared using the method described in Example 27E by replacing Example 27B with 4-(3-chlorophenoxy)butanoic acid (0.028 g, 0.1 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.42 (s, 1H), 7.49 (t, $J = 8.9$ Hz, 1H), 7.34 – 7.26 (m, 2H), 7.07 (dd, $J = 11.4, 2.8$ Hz, 1H), 6.98 (dd, $J = 7.0, 1.2$ Hz, 1H), 6.94 – 6.81 (m, 2H), 4.47 (s, 2H), 3.97 (t, $J = 6.4$ Hz, 2H), 2.21 (s, 2H), 2.18 (s, 6H), 1.89 (t, $J = 6.9$ Hz, 2H). MS (APCI) m/z 482.3 (M+H)⁺.

Example 50: 2-(3,4-dichlorophenoxy)-*N*-(3-{2-[2-(4-fluorophenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 149)

20 *Example 50A: 2-chloro-N-(3-(2-(3,4-dichlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide*

The title compound was prepared using the method described in Example 28A by replacing Example 27D with Example 22B (1.118 g, 3.31 mmol) to provide the title compound.

25 *Example 50B: 2-(3,4-dichlorophenoxy)-N-(3-{2-[2-(4-fluorophenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide*

A solution of 2-(4-fluorophenyl)ethanol (54 mg, 0.39 mmol) in dimethylformamide (0.3 mL) was treated with sodium hydride (18 mg, 0.71 mmol) and stirred for 30 minutes. A solution of Example 50A (22.5 mg, 0.060 mmol) in *N,N*-dimethylformamide (0.250 mL) was added to the mixture. The reaction mixture was stirred for 1 hour, filtered and concentrated to dryness.

30 The residue was dissolved in 1:1 dimethyl sulfoxide/methanol and purified by reverse phase HPLC (2-coupled C8 5 μ m 100 Å columns 30 mm \times 75 mm each, flow rate of 50 mL/minute, 5-90% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide the title

- 277 -

compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 (d, J = 8.9 Hz, 1H), 7.33 – 7.28 (m, 1H), 7.25 (dd, J = 11.2, 2.6 Hz, 2H), 7.16 – 7.07 (m, 2H), 7.04 – 6.97 (m, 1H), 4.46 (s, 2H), 3.80 (s, 2H), 3.63 (d, J = 6.8 Hz, 2H), 2.83 (t, J = 6.8 Hz, 2H), 2.22 (s, 6H). MS (APCI+) *m/z* 481.2 (M+H)⁺.

5 **Example 51: 2-(3,4-dichlorophenoxy)-*N*-(3-{2-[2-(3-fluorophenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 150)**

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 2-(3-fluorophenyl)ethanol (54 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 (d, J = 8.9 Hz, 1H), 7.40 – 7.30 (m, 1H), 7.24 (d, J = 2.9 Hz, 1H), 7.14 – 7.07 (m, 2H), 7.07 – 6.96 (m, 2H), 4.46 (s, 2H), 3.80 (s, 2H), 3.65 (t, J = 6.7 Hz, 2H), 2.86 (t, J = 6.6 Hz, 2H), 2.23 (s, 6H). MS (APCI+) *m/z* 481.2 (M+H)⁺.

Example 52: 2-[2-(3-chlorophenyl)ethoxy]-*N*-(3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 151)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 2-(3-chlorophenyl)ethanol (60 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 (d, J = 8.9 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.29 – 7.19 (m, 3H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.46 (s, 2H), 3.80 (s, 2H), 3.65 (t, J = 6.6 Hz, 2H), 2.85 (t, J = 6.6 Hz, 2H), 2.23 (s, 6H). MS (APCI+) *m/z* 497.1 (M+H)⁺.

20 **Example 53: 2-(3,4-dichlorophenoxy)-*N*-(3-{2-[2-(3-methylphenyl)ethoxy]-acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 152)**

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 2-(*m*-tolyl)ethanol (52 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 (d, J = 9.0 Hz, 1H), 7.24 (d, J = 2.9 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 7.08 – 6.96 (m, 4H), 4.46 (s, 2H), 3.80 (s, 2H), 3.62 (t, J = 6.9 Hz, 2H), 2.80 (t, J = 6.9 Hz, 2H), 2.27 (s, 3H), 2.22 (s, 6H). MS (APCI+) *m/z* 477.2 (M+H)⁺.

Example 54: 2-(3,4-dichlorophenoxy)-*N*-(3-{2-[(6-methylpyridin-2-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 153)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with (6-methylpyridin-2-yl)methanol (47 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.24 (t, J = 7.9 Hz, 1H), 7.72 (s, 1H), 7.71 – 7.64 (m, 1H), 7.54 (s, 1H), 7.24 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.79 (s, 2H), 4.47 (s, 2H), 4.03 (s, 2H), 3.16 (s, 1H), 2.66 (s, 3H), 2.27 (s, 7H). MS (APCI+) *m/z* 464.2 (M+H)⁺.

- 278 -

Example 55: 2-(3,4-dichlorophenoxy)-N-(3-{2-[2-(4-methylphenyl)ethoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 154)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 2-(*p*-tolyl)ethanol (53 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.54 (s, 1H), 7.24 (d, J = 2.9 Hz, 1H), 7.16 – 7.07 (m, 4H), 6.98 (dd, J = 8.9, 3.0 Hz, 1H), 4.46 (s, 2H), 3.79 (s, 2H), 3.60 (t, J = 6.9 Hz, 2H), 2.79 (t, J = 6.9 Hz, 2H), 2.26 (s, 3H), 2.21 (s, 6H). MS (APCI+) *m/z* 477.3 (M+H)⁺.

Example 56: 2-[2-(4-chlorophenyl)ethoxy]-N-{3-[2-(3,4-dichlorophenoxy)acetamido]bicyclo-[1.1.1]pentan-1-yl}acetamide (Compound 155)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 2-(4-chlorophenyl)ethanol (61 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 (d, J = 8.9 Hz, 1H), 7.34 (d, J = 6.3 Hz, 2H), 7.29 (d, J = 2.3 Hz, 2H), 7.24 (s, 1H), 7.01 – 6.97 (m, 1H), 4.46 (s, 2H), 3.79 (s, 2H), 3.63 (t, J = 6.7 Hz, 2H), 2.83 (t, J = 6.7 Hz, 2H), 2.22 (s, 6H). MS (APCI+) *m/z* 497.1 (M+H)⁺.

Example 57: 2-[(4-chlorophenyl)methoxy]-N-{3-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 156)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with (4-chlorophenyl)methanol (55 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 (d, J = 9.0 Hz, 1H), 7.45 – 7.35 (m, 4H), 7.24 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.49 (d, J = 16.5 Hz, 4H), 3.84 (s, 2H), 2.25 (s, 6H). MS (APCI+) *m/z* 483.2 (M+H)⁺.

Example 58: 2-(3,4-dichlorophenoxy)-N-(3-{2-[(4-fluorophenyl)methoxy]acetamido}-bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 157)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with (4-fluorophenyl)methanol (49 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 (d, J = 9.0 Hz, 1H), 7.45 – 7.38 (m, 2H), 7.24 (d, J = 2.9 Hz, 1H), 7.22 – 7.14 (m, 2H), 6.98 (dd, J = 8.9, 2.9 Hz, 1H), 4.49 (s, 2H), 4.46 (s, 2H), 3.83 (s, 2H), 2.24 (s, 6H). MS (APCI+) *m/z* 467.2 (M+H)⁺.

Example 59: 2-[(3-chlorophenyl)methoxy]-N-{3-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 158)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with (3-chlorophenyl)methanol (55 mg, 0.39 mmol). ¹H

- 279 -

NMR (400 MHz, DMSO- d_6) δ ppm 7.54 (s, 1H), 7.49 – 7.32 (m, 3H), 7.24 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.52 (s, 2H), 4.47 (s, 2H), 3.86 (s, 2H), 2.25 (s, 6H). MS (APCI+) m/z 483.1 (M+H)⁺.

Example 60: 2-[(4-cyanophenyl)methoxy]-*N*-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 159)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 4-(hydroxymethyl)benzonitrile (52 mg, 0.39 mmol).

¹H NMR (400 MHz, DMSO- d_6) δ ppm 7.87 – 7.78 (m, 2H), 7.65 – 7.50 (m, 3H), 7.24 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.62 (s, 2H), 4.47 (s, 2H), 3.89 (s, 2H), 2.25 (s, 6H). MS (APCI+) m/z 474.2 (M+H)⁺.

Example 61: 2-(3,4-dichlorophenoxy)-*N*-(3-{2-[(4-methylphenyl)methoxy]-acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 160)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with *p*-tolylmethanol (47 mg, 0.39 mmol).

¹H NMR (400 MHz, DMSO- d_6) δ ppm 7.53 (d, J = 9.0 Hz, 1H), 7.24 (dd, J = 5.5, 2.5 Hz, 3H), 7.17 (d, J = 7.8 Hz, 2H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.46 (s, 4H), 3.80 (s, 2H), 2.29 (s, 3H), 2.24 (s, 6H). MS (APCI+) m/z 463.2 (M+H)⁺.

Example 62: 2-[(3-cyanophenyl)methoxy]-*N*-{3-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 161)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 3-(hydroxymethyl)benzonitrile (52 mg, 0.39 mmol).

¹H NMR (400 MHz, DMSO- d_6) δ ppm 7.83 (d, J = 1.5 Hz, 1H), 7.80 – 7.70 (m, 2H), 7.63 – 7.50 (m, 2H), 7.24 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.58 (s, 2H), 4.47 (s, 2H), 3.89 (s, 2H), 2.25 (s, 6H). MS (APCI+) m/z 474.2 (M+H)⁺.

Example 63: 2-(3,4-dichlorophenoxy)-*N*-(3-{2-[(3-methylphenyl)methoxy]-acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 162)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with *m*-tolylmethanol (47 mg, 0.39 mmol).

¹H NMR (400 MHz, DMSO- d_6) δ ppm 7.53 (d, J = 9.0 Hz, 1H), 7.32 – 7.23 (m, 2H), 7.14 (dd, J = 14.7, 6.7 Hz, 3H), 6.98 (dd, J = 8.9, 2.9 Hz, 1H), 4.47 (d, J = 4.1 Hz, 4H), 3.82 (s, 2H), 2.30 (s, 3H), 2.25 (s, 6H). MS (APCI+) m/z 463.2 (M+H)⁺.

- 280 -

Example 64: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-[(3-chlorophenyl)methoxy]propanamide (Compound 163)

Example 64A: ethyl 3-((3-chlorobenzyl)oxy)propanoate

A solution of (3-chlorophenyl)methanol (1 g, 7.01 mmol) in tetrahydrofuran (20 mL) was cooled in an ice bath and treated with sodium hydride (0.365 g, 9.12 mmol), after stirring for 1 hour at 0 °C, ethyl 3-bromopropanoate (1.021 mL, 9.12 mmol) was added. The reaction mixture was stirred at 25 °C for 30 minutes, quenched with aqueous saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with brine (3 x 300 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with 0-30% ethyl acetate in heptane to provide the title compound as a white solid.

Example 64B: 3-((3-chlorobenzyl)oxy)propanoic acid

A solution of Example 64A (0.51 g, 2.101 mmol) in tetrahydrofuran (7 mL) was treated with sodium hydroxide (10.51 mL, 10.51 mmol) and stirred at 25 °C for 18 hours. The reaction mixture was neutralized with 6 N aqueous HCl. The precipitate was washed with water and dried in a vacuum oven to provide the title compound (0.408 g, 90%)

*Example 64C: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-[(3-chlorophenyl)methoxy]propanamide*

The title compound was prepared using the method described in Example 27E by replacing Example 27B with Example 64B (0.032 g, 0.1 mmol). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.47 (s, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.43 – 7.31 (m, 3H), 7.25 (d, *J* = 7.3 Hz, 1H), 7.07 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.91 – 6.82 (m, 1H), 4.47 (s, 2H), 4.46 (s, 2H), 3.62 (t, *J* = 6.3 Hz, 2H), 2.32 (t, *J* = 6.3 Hz, 2H), 2.22 (s, 6H). MS (APCI) *m/z* 482 (M+H)⁺.

Example 65: (3-chlorophenyl)methyl {3-[2-(4-chloro-3-fluorophenoxy)-acetamido]bicyclo[1.1.1]pentan-1-yl}carbamate (Compound 164)

Example 27D (0.1 g, 0.311 mmol) was added to a solution of bis(trichloromethyl) carbonate (0.102 g, 0.342 mmol) in tetrahydrofuran (3 mL) and stirred for 15 minutes. The above solution (1 mL) was added to (3-chlorophenyl)methanol (71.3 mg, 0.500 mmol). The reaction mixture was stirred at 25 °C for 72 hours, concentrated and purified by HPLC (Phenomenex® Luna® C18(2) 5 μm 100 Å AXIA™ column 250 mm × 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide the title compound (0.027g, 59%). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H),

- 281 -

8.06 (s, 1H), 7.49 (t, $J = 8.9$ Hz, 1H), 7.45 – 7.35 (m, 3H), 7.31 (dd, $J = 7.2, 1.9$ Hz, 1H), 7.07 (dd, $J = 11.3, 2.9$ Hz, 1H), 6.85 (ddd, $J = 9.0, 2.9, 1.2$ Hz, 1H), 5.00 (s, 2H), 4.47 (s, 2H), 2.18 (s, 6H). MS (APCI) m/z 454 (M+H)⁺.

Example 66: 2-(3-chlorophenyl)ethyl {3-[2-(4-chloro-3-fluorophenoxy)-

5 acetamido]bicyclo[1.1.1]pentan-1-yl}carbamate (Compound 165)

The title compound was prepared using the method described in Example 65 by replacing (3-chlorophenyl)methanol with 2-(3-chlorophenyl)ethan-1-ol (0.078 g, 0.5 mmol) (0.029 g, 61%). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.67 (s, 1H), 7.86 (s, 1H), 7.49 (t, $J = 8.9$ Hz, 1H), 7.35 – 7.30 (m, 2H), 7.29 – 7.25 (m, 1H), 7.22 (d, $J = 7.5$ Hz, 1H), 7.06 (dd, $J = 11.4, 2.8$ Hz, 1H), 6.92 – 6.79 (m, 1H), 4.46 (s, 2H), 4.14 (s, 2H), 2.87 (s, 2H), 2.15 (s, 6H). MS (APCI) m/z 468 (M+H)⁺.

Example 67: 3-(3-chlorophenyl)propyl {3-[2-(4-chloro-3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}carbamate (Compound 166)

The title compound was prepared using the method described in Example 65 by replacing (3-chlorophenyl)methanol with 3-(3-chlorophenyl)propan-1-ol (0.085 g, 0.5 mmol) (0.031 g, 65%). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.68 (s, 1H), 7.86 (s, 1H), 7.49 (t, $J = 8.9$ Hz, 1H), 7.32 (t, $J = 7.8$ Hz, 1H), 7.28 (d, $J = 1.8$ Hz, 1H), 7.27 – 7.23 (m, 1H), 7.17 (dt, $J = 7.6, 1.3$ Hz, 1H), 7.07 (dd, $J = 11.4, 2.8$ Hz, 1H), 6.85 (ddd, $J = 9.0, 2.9, 1.2$ Hz, 1H), 4.47 (s, 2H), 3.91 (s, 2H), 2.68 – 2.59 (m, 2H), 2.17 (s, 6H), 1.84 (s, 2H). MS (APCI) m/z 482 (M+H)⁺.

20 Example 68: 3-[(3-chlorophenyl)methoxy]-*N*-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}propanamide (Compound 167)

To a solution of Example 64B (9 mg, 0.042 mmol) in *N,N*-dimethylformamide (0.3 mL) was added *N,N*-diisopropylethylamine (0.017 mL, 0.096 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (16 mg, 0.042 mmol) and Example 22B (13 mg, 0.039 mmol). The reaction was stirred at room temperature for 18 hours. The crude reaction was purified by HPLC (Phenomenex® Luna® C18(2) 5 μ m 100 Å AXIA™ column 250 mm \times 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide the title compound (14.2 mg, 74%). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.47 (s, 1H), 7.54 (d, $J = 8.9$ Hz, 1H), 7.42 – 7.31 (m, 3H), 7.29 – 7.23 (m, 2H), 6.98 (dd, $J = 8.9, 2.9$ Hz, 1H), 4.48 (s, 2H), 4.46 (s, 2H), 3.62 (t, $J = 6.3$ Hz, 2H), 2.32 (t, $J = 6.3$ Hz, 2H), 2.22 (s, 6H). MS (APCI) m/z 499 (M+H)⁺.

- 282 -

Example 69: 4-(3-chlorophenoxy)-N-[3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl]butanamide (Compound 168)

The title compound was prepared using the method described in Example 68 by replacing Example 64B with 4-(3-chlorophenoxy)butanoic acid (0.009 g, 0.042 mmol) to provide the title compound (14.3 mg, 75%). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.43 (s, 1H), 7.54 (d, *J* = 8.9 Hz, 1H), 7.29 (t, *J* = 8.3 Hz, 1H), 7.26 (d, *J* = 2.9 Hz, 1H), 7.03 – 6.95 (m, 3H), 6.95 – 6.84 (m, 1H), 4.48 (s, 2H), 3.97 (t, *J* = 6.4 Hz, 2H), 2.21 (s, 6H), 2.19 (d, *J* = 7.4 Hz, 2H), 1.89 (t, *J* = 6.9 Hz, 2H). MS (APCI) *m/z* 499 (M+H)⁺.

Example 70: 3-(3-chlorophenoxy)-N-[3-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]propanamide (Compound 169)

The title compound was prepared using the method described in Example 68 by replacing Example 64B with 3-(3-chlorophenoxy)propanoic acid (0.008 g, 0.042 mmol) to provide the title compound (14.2 mg, 76%). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.57 (s, 1H), 7.54 (d, *J* = 8.9 Hz, 1H), 7.29 (t, *J* = 8.4 Hz, 1H), 7.26 (d, *J* = 2.9 Hz, 1H), 7.04 – 6.95 (m, 3H), 6.94 – 6.85 (m, 1H), 4.48 (s, 2H), 4.17 (t, *J* = 6.2 Hz, 2H), 2.23 (s, 6H);). MS (APCI) *m/z* 485 (M+H)⁺.

Example 71: 2-(3,4-dichlorophenoxy)-N-[3-(2-[2-[3-(dimethylamino)phenyl]ethoxy]-acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 170)

The title compound was prepared according to the method described in Example 50B replacing 2-(4-fluorophenyl)ethanol with 2-(3-(dimethylamino)phenyl)ethanol (63 mg, 0.39 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.54 (d, *J* = 8.9 Hz, 1H), 7.25 (d, *J* = 2.9 Hz, 1H), 7.10 (t, *J* = 7.8 Hz, 1H), 6.99 (dd, *J* = 9.0, 2.9 Hz, 1H), 6.63 – 6.51 (m, 3H), 4.48 (s, 2H), 3.81 (s, 2H), 3.64 (t, *J* = 6.9 Hz, 1H), 2.87 (s, 6H), 2.78 (t, *J* = 6.9 Hz, 2H), 2.23 (s, 6H). MS (APCI+) *m/z* 506.3 (M+H)⁺.

Example 72: 2-(3-chlorophenoxy)-N-[3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 171)

Example 72A: 2-chloro-N-(3-(2-(3,4-dichlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide

The title compound was prepared using the method described in Example 28A by replacing Example 27D with Example 22B (1.118 g, 3.31 mmol) to provide the title compound.

Example 72B: 2-(3-chlorophenoxy)-N-[3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl]acetamide

- 283 -

A solution of Example 72A (37.8 mg, 0.1 mmol) in acetonitrile (1 mL) was added to 3-chlorophenol (0.021 mL, 0.200 mmol) and potassium carbonate (27.6 mg, 0.200 mmol). The reaction mixture was stirred at 80 °C for 2 hours, concentrated and purified by HPLC (Phenomenex® Luna® C18(2) 5 µm 100 Å AXIA™ column 250 mm × 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide the title compound (0.033 g, 70%). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.71 (s, 1H), 8.70 (s, 1H), 7.55 (d, *J* = 8.9 Hz, 1H), 7.32 (t, *J* = 8.1 Hz, 1H), 7.26 (d, *J* = 2.9 Hz, 1H), 7.05 (t, *J* = 2.2 Hz, 1H), 7.02 (ddd, *J* = 7.9, 2.0, 0.9 Hz, 1H), 6.99 (dd, *J* = 8.9, 2.9 Hz, 1H), 6.93 (ddd, *J* = 8.4, 2.4, 0.9 Hz, 1H), 4.49 (s, 2H), 4.47 (s, 2H), 2.27 (s, 6H). MS (APCI) *m/z* 471 (M+H)⁺.

Example 73: (3-chlorophenyl)methyl {3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}carbamate (Compound 172)

Example 22B (0.1 g, 0.296 mmol) was added to a solution of bis(trichloromethyl) carbonate (0.097 g, 0.326 mmol) in tetrahydrofuran (1 mL) and stirred for 15 minutes. This solution (0.25 mL) was added to (3-chlorophenyl)methanol (0.052 g, 0.368 mmol). The reaction mixture was stirred at 25 °C for 18 hours, concentrated and purified by HPLC (Phenomenex® Luna® C18(2) 5 µm 100 Å AXIA™ column 250 mm × 21.2 mm, flow rate 25 mL/minute, 10-80% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid in water)) to provide the title compound (0.016 g, 45%). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.06 (s, 1H), 7.54 (d, *J* = 9.0 Hz, 1H), 7.45 – 7.36 (m, 3H), 7.30 (d, *J* = 7.1 Hz, 1H), 7.26 (d, *J* = 2.9 Hz, 1H), 6.98 (dd, *J* = 8.9, 2.9 Hz, 1H), 5.00 (s, 2H), 4.48 (s, 2H), 2.18 (s, 6H). MS (APCI) *m/z* 471 (M+H)⁺.

Example 74: 2-(3-chlorophenyl)ethyl {3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}carbamate (Compound 173)

The title compound was prepared using the method described in Example 73 by replacing (3-chlorophenyl)methanol with 2-(3-chlorophenyl)ethan-1-ol (0.058 g, 0.386 mmol) (0.019 g, 53%). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.65 (s, 1H), 7.84 (s, 1H), 7.52 (d, *J* = 8.9 Hz, 1H), 7.33 – 7.29 (m, 2H), 7.26 (ddd, *J* = 8.1, 2.1, 1.2 Hz, 1H), 7.24 (d, *J* = 2.9 Hz, 1H), 7.20 (dt, *J* = 7.5, 1.4 Hz, 1H), 6.96 (dd, *J* = 8.9, 2.9 Hz, 1H), 4.46 (s, 2H), 4.13 (s, 2H), 2.85 (s, 2H), 2.13 (s, 6H). MS (APCI) *m/z* 485 (M+H)⁺.

Example 75: 3-(3-chlorophenyl)propyl {3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}carbamate (Compound 174)

- 284 -

The title compound was prepared using the method described in Example 73 by replacing (3-chlorophenyl)methanol with 3-(3-chlorophenyl)propanan-1-ol (0.063 g, 0.386 mmol) (0.0195 g, 53%). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.70 (s, 1H), 7.88 (s, 1H), 7.54 (d, *J* = 8.9 Hz, 1H), 7.32 (t, *J* = 7.7 Hz, 1H), 7.28 (t, *J* = 1.8 Hz, 1H), 7.27 – 7.23 (m, 2H), 7.18 (d, *J* = 7.6 Hz, 1H), 6.98 (dd, *J* = 8.9, 2.9 Hz, 1H), 4.48 (s, 2H), 3.91 (s, 2H), 2.70 – 2.58 (m, 2H), 2.17 (s, 6H), 1.84 (s, 2H). MS (APCI) *m/z* 499 (M+H)⁺.

Example 76: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-{[6-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 175)

Example 76A: tert-butyl 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetate

The title compound was prepared according to the method described in Example 27A replacing 4-chloro-3-methoxyphenol with 6-(trifluoromethyl)pyridin-3-ol (0.8 g, 4.91 mmol). MS (APCI) *m/z* 278 (M+H)⁺.

Example 76B: 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid

The title compound was prepared according to the method described in Example 27B replacing *tert*-butyl 2-(4-chloro-3-methoxyphenoxy)acetate with Example 76A (1.32 g, 4.76 mmol). MS (APCI) *m/z* 222 (M+H)⁺.

*Example 76C: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-{[6-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide*

To a solution of Example 76B (7.57 g, 34.2 mmol) and Example 27D (8.85 g, 31.1 mmol) in *N,N*-dimethylformamide (100 mL) was added *N,N*-diisopropylethylamine (13.59 mL, 78.0 mmol) and 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (13.02 g, 34.20 mmol). The reaction mixture was stirred for 2 hours at 25 °C. The mixture was diluted with water (500 mL), and the resulting mixture was extracted with ethyl acetate (3 x 400 mL). The combined organic layer was washed with brine (3 x 100 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was taken into dichloromethane (200 mL), warmed to reflux to dissolve all solids and left at 25 °C for 18 hours to form a solid. The solid was collected by filtration and washed with small amount of dichloromethane to provide the title compound (9.33 g, yield 61.4%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.81 (s, 1H), 8.72 (s, 1H), 8.47 (d, *J* = 2.8 Hz, 1H), 7.86 (d, *J* = 8.7 Hz, 1H), 7.57 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.07 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.85 (dd, *J* = 9.0, 2.8 Hz, 1H), 4.67 (s, 2H), 4.48 (s, 2H), 2.27 (s, 6H). MS (APCI) *m/z* 489 (M+H)⁺.

- 285 -

Example 77: *N,N'*-(bicyclo[2.1.1]hexane-1,4-diyl)bis[2-(4-chlorophenoxy)acetamide] (Compound 176)

Benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride (MacroChem, 30 mg, 0.106 mmol) was added to trifluoroacetic acid (1 mL, 12.98 mmol) and stirred at 80 °C for 90 minutes. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. To the resulting residue was added *N,N*-dimethylformamide (2.1 mL), triethylamine (0.104 mL, 0.743 mmol), 4-chlorophenoxyacetic acid (Aldrich, 50 mg, 0.265 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (121 mg, 0.318 mmol, HATU) in sequential order. The reaction mixture was then stirred at ambient temperature for 1 hour. The resulting solution was filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 μm OBD™ column, 30 x 100 mm, flow rate 40 mL/minute, 20-100% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to give the title compound (33mg, 0.073 mmol, 68% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.45 (s, 2H), 7.37 – 7.31 (m, 4H), 7.00 – 6.94 (m, 4H), 4.43 (s, 4H), 2.10 – 2.03 (m, 2H), 1.84 – 1.76 (m, 6H). MS (APCI) *m/z* 449 (M+H)⁺.

Example 78 : *N,N'*-(bicyclo[2.1.1]hexane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 177)

The title compound was prepared as described in Example 77, substituting 2-(4-chloro-3-fluorophenoxy)acetic acid (commercially available from Aldlab Chemicals) for 4-chlorophenoxyacetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.48 (s, 2H), 7.49 (t, *J* = 8.9 Hz, 2H), 7.06 (dd, *J* = 11.4, 2.9 Hz, 2H), 6.85 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 2H), 4.48 (s, 4H), 2.12 – 2.04 (m, 2H), 1.85 – 1.76 (m, 6H). MS (APCI) *m/z* 485 (M+H)⁺.

Example 79: *N,N'*-(bicyclo[3.1.1]heptane-1,5-diyl)bis[2-(4-chlorophenoxy)acetamide] (Compound 178)

The title compound was prepared as described in Example 77, substituting benzyl (5-aminobicyclo[3.1.1]heptan-1-yl)carbamate hydrochloride (commercially available from Curpys) for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.22 (s, 2H), 7.38 – 7.29 (m, 4H), 7.00 – 6.92 (m, 4H), 4.40 (s, 4H), 2.20 – 2.12 (m, 4H), 1.78 (dd, *J* = 25.2, 6.9 Hz, 6H). MS (APCI) *m/z* 463 (M+H)⁺.

Example 80: *N,N'*-(bicyclo[3.1.1]heptane-1,5-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 179)

- 286 -

The title compound was prepared as described in Example 77, substituting benzyl (5-aminobicyclo[3.1.1]heptan-1-yl)carbamate hydrochloride (commercially available from Curpys) for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and 2-(4-chloro-3-fluorophenoxy)acetic acid (commercially available from Aldlab Chemicals) for 4-chlorophenoxyacetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.25 (s, 2H), 7.48 (t, J = 8.8 Hz, 2H), 7.04 (dd, J = 11.4, 2.9 Hz, 2H), 6.83 (ddd, J = 8.9, 2.9, 1.2 Hz, 2H), 4.44 (s, 4H), 2.21 – 2.12 (m, 4H), 1.87 – 1.68 (m, 6H). MS (ESI⁺) *m/z* 463 (M+H)⁺.

Example 81: benzyl {4-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.1.1]hexan-1-yl}carbamate (Compound 180)

N,N-Dimethylformamide (9.9 mL), triethylamine (0.97 mL, 6.93 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.489 g, 1.29 mmol, HATU) were added to a mixture of benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride (MacroChem, 0.28 g, 0.99 mmol) and 2-(4-chloro-3-fluorophenoxy)acetic acid (Aldlab Chemicals, 0.223 g, 1.09 mmol) in sequential order. The reaction mixture was then stirred at ambient temperature for 1 hour. The resulting solution was filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridgeTM C18 5 μ m OBDTM column, 30 x 100 mm, flow rate 40 mL/minute, 20-100% gradient of acetonitrile in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)] to give the title compound (0.36 g, 0.83 mmol, 84% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.45 (s, 1H), 7.77 (s, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.39 – 7.28 (m, 5H), 7.06 (dd, J = 11.4, 2.8 Hz, 1H), 6.84 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.99 (s, 2H), 4.47 (s, 2H), 2.14 – 1.95 (m, 2H), 1.83 – 1.65 (m, 6H). MS (DCI) *m/z* 450 (M+NH₄)⁺.

Example 82: benzyl {5-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[3.1.1]heptan-1-yl}carbamate (Compound 181)

The title compound was prepared as described in Example 81, substituting benzyl (5-aminobicyclo[3.1.1]heptan-1-yl)carbamate hydrochloride (commercially available from Curpys) for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.25 (s, 1H), 7.52 – 7.45 (m, 2H), 7.38 – 7.28 (m, 5H), 7.05 (dd, J = 11.4, 2.9 Hz, 1H), 6.83 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 4.97 (s, 2H), 4.44 (s, 2H), 2.25 – 2.14 (m, 2H), 2.08 – 2.01 (m, 2H), 1.83 – 1.69 (m, 6H). MS (DCI) *m/z* 464 (M+NH₄)⁺.

Example 83: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(pyrazolo[1,5-*a*]pyrimidin-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 182)

- 287 -

Example 83A : tert-butyl 2-(pyrazolo[1,5-a]pyrimidin-5-yloxy)acetate

To a solution of pyrazolo[1,5-a]pyrimidin-5-ol (Ark Pharm, 0.25 g, 1.85 mmol) and *tert*-butyl bromoacetate (Combi-Blocks, 0.41 mL, 2.78 mmol) in *N,N*-dimethylformamide (5.0 mL) was added potassium bis(trimethylsilyl)amide (Aldrich, 1.0 M solution in tetrahydrofuran, 3.33 mL). After stirring at ambient temperature for 10 minutes, 30 grams of silica gel was added, and the resulting suspension was concentrated under reduced pressure to a free flowing powder, and the powder was directly purified via flash chromatography (SiO₂, 25-100% ethyl acetate in heptane) to give the title compound (0.26 g, 1.04 mmol, 56% yield). MS (ESI⁺) *m/z* 250 (M+H)⁺.

10 *Example 83B: 2-(pyrazolo[1,5-a]pyrimidin-5-yloxy)acetic acid*

Trifluoroacetic acid (2.0 mL) was added to the product of Example 83A (0.25g, 1.0 mmol). The resulting mixture was stirred at ambient temperature for 18 hours and then concentrated in vacuo to give the title compound (0.2 g, 1.0 mmol, 100% yield). MS (ESI⁺) *m/z* 194 (M+H)⁺.

15 *Example 83C: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(pyrazolo[1,5-a]pyrimidin-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide*

The product of Example 9A (35 mg, 0.091 mmol) was dissolved in trifluoroacetic acid (1.0 mL, 12.98 mmol) and stirred at ambient temperature for 1 hour. The resulting solution was concentrated under reduced pressure and to the residue was added the product of Example 83B (19.3 mg, 0.10 mmol), *N,N*-dimethylformamide (3.0 mL), triethylamine (0.076 mL, 0.546 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (48 mg, 0.13 mmol, HATU) in sequential order. After stirring at ambient temperature for 1 hour, the reaction mixture was filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 μm OBD™ column, 50 x 100 mm, flow rate 90 mL/minute, 5-100% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to give the title compound (31 mg, 0.067 mmol, 74.1% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.84 (s, 1H), 8.71 (s, 1H), 8.54 (d, *J* = 7.9 Hz, 1H), 7.80 (d, *J* = 2.1 Hz, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.07 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.84 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.11 – 6.04 (m, 2H), 4.51 (s, 2H), 4.47 (s, 2H), 2.23 (s, 6H). MS (ESI⁺) *m/z* 460 (M+H)⁺.

30 **Example 84: 2-(4-chloro-3-fluorophenoxy)-N-[3-[2-(3,4-difluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 183)**

- 288 -

The title compound was prepared as described in Example 83C, substituting 2-(3,4-difluorophenoxy)acetic acid (commercially available from Combi-Blocks) for the product of Example 83B. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.72 (s, 1H), 8.70 (s, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.37 (dt, J = 10.6, 9.3 Hz, 1H), 7.13 – 7.05 (m, 2H), 6.85 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 6.80 (dtd, J = 9.2, 3.2, 1.7 Hz, 1H), 4.48 (s, 2H), 4.44 (s, 2H), 2.27 (s, 6H). MS (ESI⁺) *m/z* 455 (M+H)⁺.

Example 85: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-methyl-1H-indazol-6-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 184)

Example 85A: tert-butyl 2-((3-methyl-1H-indazol-6-yl)oxy)acetate

The title compound was prepared as described in Example 83A, substituting 3-methyl-1H-indazol-6-ol (commercially available from Ark Pharm) for pyrazolo[1,5-*a*]pyrimidin-5-ol. MS (ESI⁺) *m/z* 263 (M+H)⁺.

Example 85B: 2-((3-methyl-1H-indazol-6-yl)oxy)acetic acid, trifluoroacetic acid

The title compound was prepared as described in Example 83B, substituting the product of Example 85A for to the product of Example 83A. MS (APCI) *m/z* 207 (M+H)⁺.

Example 85C: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-methyl-1H-indazol-6-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide

The title compound was prepared using the coupling method described in Example 83C, substituting the product of Example 85B for the product of Example 9A and was purified by preparative HPLC [Waters XBridgeTM C18 5 μ m OBDTM column, 30 x 100 mm, flow rate 40 mL/minute, 5-100% gradient of acetonitrile in buffer (carbonic acid buffer prepared by sparging carbon dioxide gas bubbles through deionized water for 15 minutes immediately before use)].

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 12.39 (s, 1H), 8.71 (s, 1H), 8.71 (s, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.06 (dd, J = 11.4, 2.8 Hz, 1H), 6.85 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 6.82 – 6.77 (m, 2H), 4.47 (s, 2H), 4.46 (s, 2H), 2.41 (s, 3H), 2.27 (s, 6H). MS (ESI⁺) *m/z* 473 (M+H)⁺.

Example 86: N,N'-(bicyclo[1.1.1]pentane-1,3-diyl)bis[2-(3,4-difluorophenoxy)acetamide] (Compound 185)

tert-Butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate hydrochloride (Combi-Blocks, 20 mg, 0.085 mmol) was combined with dichloromethane (1.0 mL) and stirred at ambient temperature. Trifluoroacetic acid (1.0 mL, 12.98 mmol) was added, and the resulting solution was stirred at ambient temperature for 20 minutes and then concentrated in vacuo. The resulting

- 289 -

residue was taken up in *N,N*-dimethylformamide (2.0 mL). Triethylamine (0.059 mL, 0.43 mmol), 2-(3,4-difluorophenoxy)acetic acid (Combi-Blocks, 35 mg, 0.187 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (78 mg, 0.204 mmol, HATU) were added in sequential order. After stirring at ambient temperature for 20 minutes, the resulting mixture was filtered through a glass microfiber frit and purified by preparative HPLC [custom packed YMC TriArt™ C18 Hybrid 20 µm column, 30 x 150 mm, flow rate 70 mL/minute, 5-100% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to give the title compound (31mg, 0.071 mmol, 83% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 2H), 7.37 (dt, *J* = 10.7, 9.3 Hz, 2H), 7.09 (ddd, *J* = 12.6, 6.8, 3.0 Hz, 2H), 6.80 (dtd, *J* = 9.2, 3.3, 1.7 Hz, 2H), 4.44 (s, 4H), 2.27 (s, 6H). MS (ESI⁺) *m/z* 439 (M+H)⁺.

Example 87 *N,N'*-(bicyclo[1.1.1]pentane-1,3-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 186)

The title compound was prepared as described in Example 86, substituting 2-(4-chloro-3-fluorophenoxy)acetic acid (commercially available from Aldlab Chemicals) for 2-(3,4-difluorophenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.72 (s, 2H), 7.49 (t, *J* = 8.9 Hz, 2H), 7.07 (dd, *J* = 11.4, 2.9 Hz, 2H), 6.85 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 2H), 4.48 (s, 4H), 2.27 (s, 6H). MS (ESI⁺) *m/z* 468 (M-H)⁺.

Example 88: 2-(4-chloro-3-fluorophenoxy)-*N*-(4-{2-[(1*H*-indazol-6-yl)oxy]acetamido}bicyclo[2.1.1]hexan-1-yl)acetamide (Compound 187)

*Example 88A: tert-butyl 2-((1*H*-indazol-5-yl)oxy)acetate*

The title compound was prepared as described in Example 83A, substituting 6-hydroxy-1*H*-indazole (commercially available from Aldrich) for pyrazolo[1,5-*a*]pyrimidin-5-ol. MS (ESI⁺) *m/z* 249 (M+H)⁺.

*Example 88B: 2-((1*H*-indazol-6-yl)oxy)acetic acid, trifluoroacetic acid*

The title compound was prepared as described in Example 83B, substituting the product of Example 88A for the product of Example 83A. MS (ESI⁺) *m/z* 193 (M+H)⁺.

*Example 88C: *N*-(4-aminobicyclo[2.1.1]hexan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide, trifluoroacetic acid*

The product of Example 81 (110 mg, 0.254 mmol) was dissolved in trifluoroacetic acid (2.0 mL, 26.0 mmol) and stirred at 80 °C in a sealed tube for 3 hours. The reaction mixture was cooled to ambient temperature and then concentrated *in vacuo*. The resulting residue was taken up in methanol (3.0 mL) and was filtered through a glass microfiber frit and purified by

- 290 -

preparative HPLC [custom packed YMC TriArt™ C18 Hybrid 20 µm column, 50 x 150 mm, flow rate 130 mL/minute, 3-60% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to give the title compound (95 mg, 0.230 mmol, 91% yield). MS (ESI⁺) *m/z* 299 (M+H)⁺.

Example 88D: 2-(4-chloro-3-fluorophenoxy)-N-(4-{2-[(1H-indazol-6-yl)oxy]acetamido}bicyclo[2.1.1]hexan-1-yl)acetamide

The title compound was prepared as described in Example 81, substituting the product of Example 88C for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and the product of Example 88B for 2-(4-chloro-3-fluorophenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.81 (br s, 1H), 8.49 (d, J = 3.2 Hz, 2H), 7.94 (s, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.07 (dd, J = 11.4, 2.9 Hz, 1H), 6.92 – 6.81 (m, 3H), 4.49 (s, 2H), 4.48 (s, 2H), 2.11 – 2.06 (m, 2H), 1.85 – 1.78 (m, 6H). MS (ESI⁺) *m/z* 473 (M+H)⁺.

Example 89: 2-(4-chloro-3-fluorophenoxy)-N-[4-(2-{[6-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[2.1.1]hexan-1-yl]acetamide (Compound 188)

The title compound was prepared as described in Example 81, substituting the product of Example 88C for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and the product of Example 76B for 2-(4-chloro-3-fluorophenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.58 (s, 1H), 8.48 (s, 1H), 8.46 (d, J = 2.9 Hz, 1H), 7.88 – 7.85 (m, 1H), 7.56 (dd, J = 8.7, 2.9 Hz, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.07 (dd, J = 11.4, 2.8 Hz, 1H), 6.85 (ddd, J = 9.0, 2.8, 1.2 Hz, 1H), 4.66 (s, 2H), 4.48 (s, 2H), 2.12 – 2.05 (m, 2H), 1.83 – 1.76 (m, 6H). MS (ESI⁺) *m/z* 502 (M+H)⁺.

Example 90: N-(2-{[*tert*-butyl(dimethyl)silyl]oxy}ethyl)-2-(4-chloro-3-fluorophenoxy)-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 189)

*Example 90A: N-{3-[(2-{[*tert*-butyl(dimethyl)silyl]oxy}ethyl)amino]bicyclo[1.1.1]pentan-1-yl]-2-(4-chloro-3-fluorophenoxy)acetamide*

To a mixture of the product of Example 27D (240 mg, 0.76 mmol) and K₂CO₃ (524 mg, 3.79 mmol) was added *N,N*-dimethylformamide (4.0 mL) followed by (2-bromoethoxy)-*tert*-butyldimethylsilane (0.488 mL, 2.28 mmol). The reaction mixture was stirred at 47 °C for 16 hours, filtered through a glass microfiber frit and purified by preparative HPLC [custom packed YMC TriArt™ C18 Hybrid 20 µm column, 30 x 150 mm, flow rate 90 mL/minute, 5-100% gradient of acetonitrile in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)] to give the title compound (0.14 g, 0.32 mmol, 42% yield). ¹H

- 291 -

NMR (501 MHz, DMSO-*d*₆) δ ppm 8.60 (s, 1H), 7.48 (t, *J* = 8.9 Hz, 1H), 7.06 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.84 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 1H), 4.45 (s, 2H), 3.57 (t, *J* = 6.3 Hz, 2H), 2.56 (t, *J* = 6.3 Hz, 2H), 2.27 (br s, 1H), 1.96 – 1.91 (m, 6H), 0.87 – 0.84 (m, 9H), 0.03 (s, 6H). MS (ESI⁺) *m/z* 443 (M+H)⁺.

5 **Example 90B** *N*-(2-([*tert*-butyl(dimethyl)silyl]oxy)ethyl)-2-(4-chloro-3-fluorophenoxy)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]acetamide

The title compound was prepared as described in Example 81, substituting the product of Example 90A for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride. ¹H NMR (400 MHz, DMSO-*d*₆, 120 °C) δ ppm 8.25 (s, 1H), 7.43 – 7.34 (m, 2H), 6.97 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.90 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.83 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.77 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 4.80 (s, 2H), 4.45 (s, 2H), 3.68 (t, *J* = 6.0 Hz, 2H), 3.43 (t, *J* = 6.0 Hz, 2H), 2.38 (s, 6H), 0.87 (s, 9H), 0.04 (s, 6H). MS (ESI⁺) *m/z* 629 (M+H)⁺.

Example 91: 2-(4-chloro-3-fluorophenoxy)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-*N*-(2-hydroxyethyl)acetamide (Compound 190)

15 The product of Example 90 (40 mg, 0.064 mmol) was dissolved in tetrahydrofuran (1.5 mL) and stirred at ambient temperature. Tetra-*n*-butylammonium fluoride (Aldrich, 1 M solution in tetrahydrofuran, 0.32 mL) was added in one portion. After stirring at ambient temperature for 30 minutes, the reaction mixture was concentrated in vacuo. The residue was taken up in methanol (3.0 mL), filtered through a glass microfiber frit and purified by preparative HPLC
20 [Waters XBridge™ C18 5 μ m OBD™ column, 30 x 100 mm, flow rate 40 mL/minute, 5-100% gradient of acetonitrile in buffer (carbonic acid buffer prepared by sparging carbon dioxide gas bubbles through deionized water for 15 minutes immediately before use)] to give the title compound (16 mg, 0.031 mmol, 48.9% yield). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.83 – 8.71 (m, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.45 (t, *J* = 8.9 Hz, 1H), 7.07 (dd, *J* = 11.4, 2.9 Hz, 1H),
25 7.01 (dd, *J* = 11.5, 2.9 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.79 (d, *J* = 8.9 Hz, 1H), 5.21 – 4.80 (m, 3H), 4.48 (s, 2H), 3.58 – 3.49 (m, 2H), 3.40 – 3.33 (m, 2H), 2.45 – 2.28 (m, 6H). MS (ESI⁺) *m/z* 515 (M+H)⁺.

Example 92: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-*N*-(2-hydroxyethyl)-2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamide (Compound 191)

30 **Example 92A** = *N*-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-*N*-(3-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetamide

- 292 -

The title compound was prepared as described in Example 81, substituting the product of Example 90A for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and the product of Example 76B for 2-(4-chloro-3-fluorophenoxy)acetic acid. MS (ESI⁺) *m/z* 646 (M+H)⁺.

5 *Example 92B N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-N-(2-hydroxyethyl)-2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamide*

The title compound was prepared as described in Example 91, substituting the product of Example 92A for the product of Example 90. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.80 and 8.72 (two s, 1H, amide rotamers), 8.40 – 8.36 (m, 1H), 7.83 – 7.78 (m, 1H), 7.51 – 7.43 (m, 2H),
10 7.05 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.86 – 6.80 (m, 1H), 5.20 – 4.99 (m, 3H), 4.52 – 4.41 (m, 2H), 3.60 – 3.48 (m, 2H), 3.44 – 3.30 (m, 2H), 2.46 – 2.24 (m, 6H). MS (ESI⁺) *m/z* 515 (M+H)⁺.

Example 93: benzyl {3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}carbamate (Compound 192)

Benzyl chloroformate (Aldrich, 50% solution in toluene, 40 mg, 0.12 mmol) was added
15 to a solution of the product of Example 27D (30mg, 0.11 mmol) and Hunig's Base (0.055 mL, 0.32 mmol) in dichloromethane (3.0 mL), and the reaction mixture was stirred at ambient temperature for 1 hour and then concentrated in vacuo. The resulting residue was taken up in methanol (3 mL), filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 μ m OBD™ column, 50 x 100 mm, flow rate 90 mL/minute, 5-100%
20 gradient of acetonitrile in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)] to give the title compound (27 mg, 0.064 mmol, 61% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 7.99 (br s, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.40 – 7.27 (m, 5H), 7.07 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.85 (ddd, *J* = 8.9, 2.8, 1.1 Hz, 1H), 5.00 (s, 2H), 4.47 (s, 2H), 2.18 (br s, 6H). MS (ESI⁺) *m/z* 417 (M-H)⁺.

25 **Example 94: benzyl {4-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[2.1.1]hexan-1-yl}carbamate (Compound 193)**

The title compound was prepared as described in Example 81, substituting 2-(3,4-dichlorophenoxy)acetic acid (commercially available from Aldrich) for 2-(4-chloro-3-fluorophenoxy)acetic acid. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.47 (s, 1H), 7.79 (br s, 1H),
30 7.54 (d, *J* = 8.9 Hz, 1H), 7.40 – 7.29 (m, 5H), 7.25 (d, *J* = 2.9 Hz, 1H), 6.98 (dd, *J* = 9.0, 2.9 Hz, 1H), 4.99 (s, 2H), 4.48 (s, 2H), 2.11 – 2.00 (m, 2H), 1.80 – 1.67 (m, 6H). MS (ESI⁺) *m/z* 447 (M-H)⁺.

- 293 -

Example 95: benzyl {5-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[3.1.1]heptan-1-yl}carbamate (Compound 194)

The title compound was prepared as described in Example 81, substituting benzyl (5-aminobicyclo[3.1.1]heptan-1-yl)carbamate hydrochloride (commercially available from Curpys) for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and 2-(3,4-dichlorophenoxy)acetic acid (commercially available from Aldrich) for 2-(4-chloro-3-fluorophenoxy)acetic acid. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.25 (s, 1H), 7.53 (d, J = 8.9 Hz, 1H), 7.49 (br s, 1H), 7.38 – 7.27 (m, 5H), 7.23 (d, J = 2.9 Hz, 1H), 6.96 (dd, J = 9.0, 2.9 Hz, 1H), 4.97 (s, 2H), 4.45 (s, 2H), 2.24 – 2.13 (m, 2H), 2.06 – 2.01 (m, 2H), 1.82 – 1.67 (m, 6H). MS (ESI⁺) *m/z* 461 (M+H)⁺.

Example 96 2-(3,4-dichlorophenoxy)-N-(4-{2-[(4-fluoro-1H-indazol-6-yl)oxy]acetamido}-bicyclo[2.1.1]hexan-1-yl)acetamide (Compound 195)

Example 96A: N-(4-aminobicyclo[2.1.1]hexan-1-yl)-2-(3,4-dichlorophenoxy)acetamide

The title compound was prepared as described in Example 88C, substituting the product of Example 94 for the product of Example 81 and purified by preparative HPLC [Waters XBridge™ C18 5 μm OBD™ column, 30 x 100 mm, flow rate 40 mL/minute, 5-100% gradient of acetonitrile in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)]. MS (ESI⁺) *m/z* 315 (M+H)⁺.

Example 96B: 2-(3,4-dichlorophenoxy)-N-(4-{2-[(4-fluoro-1H-indazol-6-yl)oxy]acetamido}bicyclo[2.1.1]hexan-1-yl)acetamide

The title compound was prepared as described in Example 81, substituting the product of Example 12B for 2-(4-chloro-3-fluorophenoxy)acetic acid, the product of Example 96A for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and Hunig's base for triethylamine. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.08 (br s, 1H), 8.51 (s, 1H), 8.49 (s, 1H), 8.05 (s, 1H), 7.54 (d, J = 8.9 Hz, 1H), 7.25 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 8.9, 2.9 Hz, 1H), 6.77 (br s, 1H), 6.70 – 6.66 (m, 1H), 4.51 (s, 2H), 4.49 (s, 2H), 2.11 – 2.06 (m, 2H), 1.85 – 1.78 (m, 6H). MS (ESI⁺) *m/z* 507 (M+H)⁺.

Example 97: 2-(3,4-dichlorophenoxy)-N-[4-(2-{[6-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[2.1.1]hexan-1-yl]acetamide (Compound 196)

The title compound was prepared as described in Example 81, substituting the product of Example 96A for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and the product of Example 76B for 2-(4-chloro-3-fluorophenoxy)acetic acid. ¹H NMR (501 MHz,

- 294 -

DMSO- d_6) δ ppm 8.58 (s, 1H), 8.48 (s, 1H), 8.46 (d, J = 2.9 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.58 – 7.55 (m, 1H), 7.54 (d, J = 8.9 Hz, 1H), 7.25 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 9.0, 2.9 Hz, 1H), 4.66 (s, 2H), 4.49 (s, 2H), 2.11 – 2.06 (m, 2H), 1.83 – 1.79 (m, 6H). MS (ESI⁺) m/z 518 (M+H)⁺.

5 **Example 98: *N*-{3-[2-(3-chloro-4-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-2-(3,4-dichlorophenoxy)-*N*-methylacetamide (Compound 197)}**

Example 98A

To a solution of the product of Example 22A (220 mg, 0.55 mmol) in *N,N*-dimethylacetamide (3.5 mL) was added sodium hydride (60% dispersion in mineral oil, 26 mg, 0.66 mmol) in one portion. Tetrahydrofuran (2.0 mL) was then added. After stirring at ambient
10 temperature for 5 minutes, methyl iodide (0.051 mL, 0.82 mmol) was added in one portion. After stirring for another 10 minutes, methanol (2.0 mL) was added, and the resulting solution was concentrated under reduced pressure to about 3 mL, filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 μ m OBD™ column, 50 x 100 mm, flow rate 90 mL/minute, 35-75% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to
15 give the title compound (0.08 g, 0.19 mmol, 35% yield). ¹H NMR (400 MHz, DMSO- d_6 , 120 °C) δ ppm 7.44 (d, J = 8.9 Hz, 1H), 7.14 (d, J = 2.9 Hz, 1H), 6.97 – 6.88 (m, 2H), 4.75 (s, 2H), 2.86 (s, 3H), 2.25 (s, 6H), 1.39 (d, J = 0.6 Hz, 9H). MS (ESI⁺) m/z 415 (M+H)⁺.

*Example 98B: *N*-{3-[2-(3-chloro-4-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-2-(3,4-dichlorophenoxy)-*N*-methylacetamide}*

20

The title compound was prepared as described in Example 83C, substituting the product of Example 98A for the product of Example 9A and 2-(4-chloro-3-fluorophenoxy)acetic acid (commercially available from Aldlab Chemicals) for the product of Example 83B. ¹H NMR (400 MHz, DMSO- d_6 , 120 °C) δ ppm 8.25 (s, 1H), 7.46 – 7.37 (m, 2H), 7.14 (d, J = 2.9 Hz, 1H),
25 6.98 (dd, J = 11.3, 2.8 Hz, 1H), 6.92 (dd, J = 8.9, 2.9 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.3 Hz, 1H), 4.76 (s, 2H), 4.45 (s, 2H), 2.88 (s, 3H), 2.37 (br s, 6H). MS (ESI⁺) m/z 501/503 (M+H)⁺.

Example 99: 2-(3,4-dichlorophenoxy)-*N*-{3-[2-(3,4-dichlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-*N*-methylacetamide (Compound 198)}

The title compound was prepared as described in Example 83C, substituting the product
30 of Example 98A for the product of Example 9A and 2-(3,4-dichlorophenoxy)acetic acid (commercially available from Aldrich) for the product of Example 83B. ¹H NMR (400 MHz, DMSO- d_6 , 120 °C) δ ppm 8.27 (s, 1H), 7.49 – 7.40 (m, 2H), 7.20 (d, J = 2.9 Hz, 1H), 7.15 (d, J =

- 295 -

3.0 Hz, 1H), 6.96 (dd, J = 8.9, 2.9 Hz, 1H), 6.92 (dd, J = 8.9, 2.9 Hz, 1H), 4.77 (s, 2H), 4.46 (s, 2H), 2.88 (s, 3H), 2.37 (br s, 6H). MS (ESI⁺) *m/z* 519/517 (M+H)⁺.

Example 100: *N*-{3-[2-(4-chlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-2-(3,4-dichlorophenoxy)-*N*-methylacetamide (Compound 199)

5 The title compound was prepared as described in Example 83C, substituting the product of Example 98A for the product of Example 9A and 2-(4-chlorophenoxy)acetic acid (commercially available from Aldrich) for the product of Example 83B. ¹H NMR (400 MHz, DMSO-*d*₆, 120 °C) δ ppm 8.21 (s, 1H), 7.44 (d, J = 9.0 Hz, 1H), 7.30 – 7.26 (m, 2H), 7.14 (d, J = 2.9 Hz, 1H), 6.99 – 6.94 (m, 2H), 6.92 (dd, J = 8.9, 2.9 Hz, 1H), 4.76 (s, 2H), 4.41 (s, 2H), 2.88
10 (s, 3H), 2.37 (br s, 6H). MS (ESI⁺) *m/z* 483/485 (M+H)⁺.

Example 101: *N*²-(4-chlorophenyl)-*N*-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}-*N*²-methylglycinamide (Compound 200)

 The title compound was prepared as described in Example 83C, substituting the product of Example 22A for the product of Example 9A and 2-((4-chlorophenyl)(methyl)amino)acetic
15 acid hydrochloride (commercially available from Enamine) for the product of Example 83B. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.53 (s, 1H), 7.54 (d, J = 8.9 Hz, 1H), 7.25 (d, J = 2.9 Hz, 1H), 7.20 – 7.14 (m, 2H), 6.98 (dd, J = 8.9, 2.9 Hz, 1H), 6.62 – 6.56 (m, 2H), 4.47 (s, 2H), 3.85 (s, 2H), 2.94 (s, 3H), 2.21 (br s, 6H). MS (ESI⁺) *m/z* 482/484 (M+H)⁺.

Example 102: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-*N*²-(4-chlorophenyl)-*N*²-methylglycinamide (Compound 201)

 The title compound was prepared as described in Example 81, substituting 2-((4-chlorophenyl)(methyl)amino)acetic acid hydrochloride (commercially available from Enamine)
for 2-(4-chloro-3-fluorophenoxy)acetic acid and the product of Example 9B for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride. ¹H NMR (400 MHz, DMSO-*d*₆, 120
25 °C) δ ppm 8.17 (s, 1H), 8.07 (s, 1H), 7.46 – 7.36 (m, 5H), 6.98 (dd, J = 11.3, 2.8 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.3 Hz, 1H), 4.43 (s, 2H), 3.88 (s, 2H), 2.92 (s, 3H), 2.25 (br s, 6H). MS (ESI⁺) *m/z* 494 (M+H)⁺.

Example 103: *N*²-(4-chlorophenyl)-*N*-{4-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[2.1.1]hexan-1-yl}-*N*²-methylglycinamide (Compound 202)

30 The title compound was prepared as described in Example 81, substituting 2-((4-chlorophenyl)(methyl)amino)acetic acid hydrochloride (commercially available from Enamine) for 2-(4-chloro-3-fluorophenoxy)acetic acid and the product of Example 96A for benzyl (4-

- 296 -

aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride. ^1H NMR (501 MHz, $\text{DMSO}-d_6$) δ ppm 8.43 (s, 1H), 8.29 (s, 1H), 7.52 (d, $J = 8.9$ Hz, 1H), 7.22 (d, $J = 2.9$ Hz, 1H), 7.17 – 7.12 (m, 2H), 6.95 (dd, $J = 8.9, 2.9$ Hz, 1H), 6.61 – 6.56 (m, 2H), 4.46 (s, 2H), 3.83 (s, 2H), 2.93 (s, 3H), 2.04 – 1.99 (m, 2H), 1.77 – 1.71 (m, 6H). MS (ESI^+) m/z 496/498 ($\text{M}+\text{H}$) $^+$.

5 **Example 104: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-*N*²-(4-chlorophenyl)glycinamide (Compound 203)**

The title compound was prepared as described in Example 81, substituting the product of Example 9B for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and 2-((4-chlorophenyl)amino)acetic acid (commercially available for Enamine) for 2-(4-chloro-3-fluorophenoxy)acetic acid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.65 (s, 1H), 8.48 (s, 1H), 7.45 (t, $J = 8.8$ Hz, 1H), 7.09 – 7.00 (m, 3H), 6.81 (ddd, $J = 9.0, 2.9, 1.2$ Hz, 1H), 6.52 – 6.46 (m, 2H), 5.97 (t, $J = 5.9$ Hz, 1H), 4.43 (s, 2H), 3.54 (d, $J = 5.9$ Hz, 2H), 2.19 (br s, 6H). MS (ESI^+) m/z 452 ($\text{M}+\text{H}$) $^+$.

15 **Example 105: 4-chloro-*N*-[2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}amino)-2-oxoethyl]-*N*-methylbenzamide (Compound 204)**

*Example 105A: methyl 2-(4-chloro-*N*-methylbenzamido)acetate*

4-Chlorobenzoic acid (0.617 g, 3.94 mmol), sarcosine methyl ester hydrochloride (Ark Pharm, 0.55 g, 3.94 mmol) and triethylamine (1.65 mL, 11.8 mmol) were combined with *N,N*-dimethylacetamide (8 mL), and the mixture was stirred at ambient temperature. 1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (1.798 g, 4.73 mmol, HATU) was added in one portion. After stirring for 1 hour, dimethyl sulfoxide (2 mL) was added, and the resulting solution was filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 μm OBD™ column, 50 x 100 mm, flow rate 90 mL/minute, 5-45% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to give the title compound (0.30 g, 1.24 mmol, 32% yield). MS (ESI^+) m/z 242 ($\text{M}+\text{H}$) $^+$.

*Example 105B: 2-(4-chloro-*N*-methylbenzamido)acetic acid*

The product of Example 105A (0.46 g, 1.738 mmol) was dissolved in ethanol (30 mL), aqueous sodium hydroxide (2.5 M, 10 mL) was added, and the resulting mixture was stirred at ambient temperature for 20 minutes. The mixture was partitioned between dichloromethane (2 x 100 mL) and aqueous citric acid (10 weight %, 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give the title compound. MS (ESI^-) m/z 226 ($\text{M}-\text{H}$) $^-$.

- 297 -

Example 105C: 4-chloro-N-[2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo-[1.1.1]pentan-1-yl}amino)-2-oxoethyl]-N-methylbenzamide

The title compound was prepared as described in Example 81, substituting the product of Example 9B for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride and the product of Example 105B for 2-(4-chloro-3-fluorophenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆, 120 °C) δ ppm 8.17 (s, 1H), 8.07 (s, 1H), 7.46 – 7.36 (m, 5H), 6.98 (dd, J = 11.3, 2.8 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.3 Hz, 1H), 4.43 (s, 2H), 3.88 (s, 2H), 2.92 (s, 3H), 2.25 (br s, 6H). MS (ESI⁺) *m/z* 494 (M+H)⁺.

Example 106: N²-acetyl-N-[3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo-[1.1.1]pentan-1-yl]-N²-(4-chlorophenyl)glycinamide (Compound 205)

Acetyl chloride (7.9 μL, 0.11 mmol) was added to a solution of the product of Example 104 (25mg, 0.055 mmol) in pyridine (1.0 mL). After stirring at ambient temperature for 1 hour, methanol (1 mL) was added, and the resulting solution was concentrated in vacuo. The residue was taken up in *N,N*-dimethylformamide (2 mL), filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 μm OBD™ column, 50 x 100 mm, flow rate 90 mL/minute, 5-100% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to give the title compound (24 mg, 0.049 mmol, 88% yield). ¹H NMR (400 MHz, DMSO-*d*₆, 120 °C) δ ppm 8.19 (s, 1H), 8.06 (s, 1H), 7.46 - 7.36 (m, 5H), 7.00 (dd, J = 11.3, 2.9 Hz, 1H), 6.85 (ddd, J = 8.9, 2.9, 1.3 Hz, 1H), 4.46 (s, 2H), 4.16 (s, 2H), 2.25 (br s, 6H), 1.86 (s, 3H). MS (ESI⁺) *m/z* 494 (M+H)⁺.

Example 107: 2-(4-chloro-3-fluorophenoxy)-N-(3-[2-[(6-methylpyridin-3-yl)oxy]acetamido]bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 206)

Example 107A: 2-[(6-methylpyridin-3-yl)oxy]acetic acid, 2.5 sodium hydroxide

Ethyl 2-[(6-methylpyridin-3-yl)oxy]acetate (Aldrich-CPR, 1.0 g, 5.12 mmol) was dissolved in ethanol (15 mL) and aqueous sodium hydroxide (2.5 M, 5.12 mL) was added in one portion. The resulting mixture was stirred at ambient temperature for 20 minutes and then concentrated in vacuo to provide the title compound as a sodium salt with 2.5 equivalent sodium hydroxide excipient (1.4 g, 5.12 mmol, quantitative). MS (ESI⁺) *m/z* 168 (M+H)⁺.

Example 107B: 2-(4-chloro-3-fluorophenoxy)-N-(3-[2-[(6-methylpyridin-3-yl)oxy]acetamido]bicyclo[1.1.1]pentan-1-yl)acetamide

N,N-Dimethylformamide (1.0 mL), pyridine (1.0 mL, 12.4 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate

- 298 -

(100 mg, 0.26 mmol, HATU) were added to a mixture of the product of Example 107A (73 mg, 0.241 mmol) and the product of Example 9B (84 mg, 0.21 mmol) in sequential order. The reaction was then stirred at ambient temperature for 18 hours, filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 µm OBD™ column, 30 x 100 mm, flow rate 40 mL/minute, 5-100% gradient of acetonitrile in buffer (0.025 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)] to give the title compound (35 mg, 0.08 mmol, 38% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.71 (s, 2H), 8.16 (d, J = 3.0 Hz, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.29 – 7.24 (m, 1H), 7.20 – 7.15 (m, 1H), 7.07 (dd, J = 11.4, 2.8 Hz, 1H), 6.85 (ddd, J = 9.0, 2.8, 1.2 Hz, 1H), 4.48 (s, 2H), 4.47 (s, 2H), 2.39 (s, 3H), 2.26 (s, 6H). MS (ESI⁺) *m/z* 434 (M+H)⁺.

Example 108: 2-(benzyloxy)-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 207)

The title compound was prepared as described in Example 107B, substituting benzyloxyacetic acid (commercially available from Aldrich) for the product of Example 107A. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.35 (s, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.38 – 7.32 (m, 4H), 7.30 (ddd, J = 7.7, 5.0, 3.8 Hz, 1H), 7.07 (dd, J = 11.3, 2.9 Hz, 1H), 6.85 (ddd, J = 8.9, 2.9, 1.1 Hz, 1H), 4.52 (s, 2H), 4.47 (s, 2H), 3.84 (s, 2H), 2.24 (br s, 6H). MS (ESI⁺) *m/z* 433 (M+H)⁺.

Example 109: 2-(benzyloxy)-N-{3-[2-(4-chlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 208)

Example 109A: tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate

To a solution of *tert*-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (PharmaBlock, 1.1 g, 5.55 mmol) in tetrahydrofuran (40 mL) was added triethylamine (2.32 mL, 16.64 mmol) followed by 4-chlorophenoxyacetyl chloride (Aldrich, 0.866 mL, 5.55 mmol). The mixture was allowed to stir at ambient temperature for 4 hours, and then the resulting solids were isolated via filtration to give the title compound (2.0 g, 5.45 mmol, 98% yield). MS (ESI⁺) *m/z* 384 (M+NH₄)⁺.

Example 109B: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide, trifluoroacetate

To a solution of the product of Example 109A (2.0 g, 5.45 mmol) in dichloromethane (25 mL) at ambient temperature was added trifluoroacetic acid (8.40 mL, 109 mmol). The mixture

- 299 -

was allowed to stir at ambient temperature for 2 hours and was concentrated in vacuo. The resulting residue was treated with ether/heptane to give the title compound as a solid (1.5 g, 3.94 mmol, 72% yield). MS (ESI⁺) *m/z* 302 (M+NH₄)⁺.

Example 109C: 2-(benzyloxy)-N-{3-[2-(4-chlorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide

The title compound was prepared as described in Example 107B, substituting benzyloxyacetic acid (commercially available from Aldrich) for the product of Example 107A and the product of Example 109B for the product of Example 9B. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.67 (s, 1H), 8.34 (s, 1H), 7.40 - 7.27 (m, 7H), 6.99 - 6.93 (m, 2H), 4.52 (s, 2H), 4.42 (s, 2H), 3.84 (s, 2H), 2.24 (br s, 6H). MS (ESI⁺) *m/z* 415 (M+H)⁺.

Example 110: *N,N'*-(bicyclo[3.1.1]heptane-1,5-diyl)bis[2-(3,4-dichlorophenoxy)acetamide (Compound 209)]

Example 110A: benzyl (5-(2-(3,4-dichlorophenoxy)acetamido)bicyclo[3.1.1]heptan-1-yl)carbamate

The title compound was prepared as described in Example 81, substituting 2-(3,4-dichlorophenoxy)acetic acid (commercially available from Aldrich) for 2-(4-chloro-3-fluorophenoxy)acetic acid and benzyl (5-aminobicyclo[3.1.1]heptan-1-yl)carbamate hydrochloride (commercially available from Curpys) for benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.25 (s, 1H), 7.53 (d, *J* = 8.9 Hz, 1H), 7.49 (br s, 1H), 7.38 - 7.27 (m, 5H), 7.23 (d, *J* = 2.9 Hz, 1H), 6.96 (dd, *J* = 9.0, 2.9 Hz, 1H), 4.97 (s, 2H), 4.45 (s, 2H), 2.24 - 2.13 (m, 2H), 2.06 - 2.01 (m, 2H), 1.82 - 1.67 (m, 6H). MS (ESI⁺) *m/z* 480 (M+NH₄)⁺.

*Example 110B: *N,N'*-(bicyclo[3.1.1]heptane-1,5-diyl)bis[2-(3,4-dichlorophenoxy)acetamide]*

The product of Example 110A (25 mg, 0.054 mmol) was stirred in trifluoroacetic acid (0.5 mL, 6.49 mmol) at 75 °C for 2 hours. The reaction mixture was cooled to ambient temperature and then concentrated in vacuo. To the resulting residue was added *N,N*-dimethylformamide (2.0 mL), 2-(3,4-dichlorophenoxy)acetic acid (commercially available from Aldrich, 17.9 mg, 0.081 mmol), triethylamine (38 μL, 0.27 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (30.8 mg, 0.081 mmol, HATU) in sequential order. The reaction mixture was stirred at ambient temperature for 1 hour. The resulting solution was filtered through a glass microfiber frit and purified by preparative HPLC [Waters XBridge™ C18 5 μm OBD™ column, 30 x 100 mm,

- 300 -

flow rate 40 mL/minute, 5-100% gradient of acetonitrile in buffer (0.1% trifluoroacetic acid)] to give the title compound (16 mg, 0.03 mmol, 56% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.26 (s, 2H), 7.54 (d, J = 8.9 Hz, 2H), 7.23 (d, J = 2.9 Hz, 2H), 6.96 (dd, J = 8.9, 2.9 Hz, 2H), 4.46 (s, 4H), 2.21 – 2.12 (m, 4H), 1.86 – 1.69 (m, 6H). MS (ESI⁺) *m/z* 415 (M+H)⁺.

5 **Example 111: 2-(4-chloro-3-fluorophenoxy)-N-{3-[2-(6-methylpyridin-3-yl)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 210)**

The title compound was prepared as described in Example 107B, substituting 2-(6-methylpyridin-3-yl)acetic acid (commercially available from Enamine) for the product of Example 107A. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.68 (s, 1H), 8.27 (d, J = 2.3 Hz, 1H), 7.53 – 7.46 (m, 2H), 7.20 – 7.15 (m, 1H), 7.06 (dd, J = 11.4, 2.8 Hz, 1H), 6.84 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.46 (s, 2H), 3.35 (s, 2H), 2.42 (s, 3H), 2.21 (br s, 6H). MS (ESI⁺) *m/z* 418 (M+H)⁺.

Example 112: 4-[[2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}amino)-2-oxoethoxy]methyl]benzoic acid (Compound 211)

15 *Example 112A: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride*

A mixture of Example 9A (1.20 g, 3.12 mmol) and 4 N HCl (in dioxane, 4.68 mL, 18.71 mmol) in dioxane (10 mL) was stirred overnight. The solids were filtered, washed with ethyl acetate, and vacuum oven-dried to give the title compound (0.985 g, 98%). MS (ESI⁺) *m/z* 284.9 (M+H)⁺.

Example 112B: 2-(4-chloro-3-fluorophenoxy)-N-(3-(2-hydroxyacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide

A mixture of Example 112A (0.475 g, 1.479 mmol), 2-hydroxyacetic acid (0.193 g, 1.775 mmol) 70% in water, 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU, 0.675 g, 1.775 mmol), and triethylamine (0.618 mL, 4.44 mmol) in tetrahydrofuran (8 mL) was stirred overnight. The reaction mixture was then treated with water and brine and extracted with ethyl acetate (2x). The combined organic layers were dried over MgSO₄, filtered, and concentrated. The residue was purified on a 40 g silica gel column using a Biotage® Isolera™ One flash system eluting with heptanes/ethyl acetate (1:9) to ethyl acetate to give the title compound (0.323 g, 64%). MS (ESI⁺) *m/z* 342.9 (M+H)⁺.

Example 112C: methyl 4-((2-((3-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)amino)-2-oxoethoxy)methyl)benzoate

- 301 -

A mixture of Example 112B (100.0 mg, 0.292 mmol) and 60% sodium hydride in mineral oil (12.84 mg, 0.321 mmol) in tetrahydrofuran (3.5 mL) was stirred for 10 minutes. Methyl 4-(bromomethyl)benzoate (73.5 mg, 0.321 mmol) was added. The reaction mixture was stirred overnight. The reaction was quenched with brine and extracted with ethyl acetate (2x).
5 The combined organic layers were dried over MgSO₄, filtered, and concentrated. The residue was purified on a 12 g silica gel column using a Biotage® Isolera™ One flash system eluting with heptanes/ethyl acetate (4:6 to 1:9) to give the title compound (55.1 mg, 39%). MS (APCI⁺) *m/z* 491.1 (M+H)⁺.

Example 112D: 4-([2-([3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]amino)-2-oxoethoxy]methyl]benzoic acid
10

A solution of Example 112C (53.0 mg, 0.108 mmol) in tetrahydrofuran (1.2 mL) and methanol (0.8 mL) was treated with a solution of LiOH (7.76 mg, 0.324 mmol) in water (0.6 mL). The mixture was stirred for 6 hours and concentrated. The residue was purified by reverse-phase HPLC performed on a Zorbax Rx-C18 column (250 x 21.2 mm, 7 μm particle size) using a gradient of 10% to 95% acetonitrile : 0.1% aqueous trifluoroacetic acid over 30 minutes at a flow rate of 18 mL/minute to provide the title compound (22.7 mg, 44%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.39 (s, 1H), 7.97 – 7.85 (m, 2H), 7.54 – 7.39 (m, 3H), 7.05 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.83 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 1H), 4.59 (s, 2H), 4.45 (s, 2H), 3.87 (s, 2H), 2.23 (s, 6H). MS (ESI⁺) *m/z* 476.9 (M+H)⁺.

Example 113: 3-([2-([3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]amino)-2-oxoethoxy]methyl]benzoic acid (Compound 212)
20

Example 113A: methyl 3-((2-((3-(2-(4-chloro-3-fluorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)amino)-2-oxoethoxy)methyl)benzoate

A mixture of Example 112B (100.0 mg, 0.292 mmol) and 60% sodium hydride in mineral oil (12.84 mg, 0.321 mmol) in tetrahydrofuran (4 mL) was stirred for 10 minutes.
25 Methyl 3-(bromomethyl)benzoate (73.5 mg, 0.321 mmol) was added. The reaction mixture was stirred overnight. The reaction was quenched with brine and extracted with ethyl acetate (twice). The combined organic layers were dried over MgSO₄, filtered, concentrated. The residue was purified on a 12 g silica gel column using a Biotage® Isolera™ One flash system eluting with heptanes/ethyl acetate (4:6 to 1:9) to give the title compound (46.1 mg, 32%). MS (APCI⁺) *m/z* 491.1 (M+H)⁺.
30

- 302 -

Example 113B: 3-([2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}amino)-2-oxoethoxy)methyl]benzoic acid

A solution of Example 113A (45.0 mg, 0.092 mmol) in tetrahydrofuran (1.2 mL) and methanol (0.8 mL) was treated with a solution of LiOH (6.59 mg, 0.275 mmol) in water (0.6 mL). The mixture was stirred for 6 hours and then concentrated. The residue was purified by HPLC (see protocol in Example 112D) to provide the title compound (11.8 mg, 27%). ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.39 (s, 1H), 7.91 (d, *J* = 1.9 Hz, 1H), 7.86 (dt, *J* = 7.7, 1.5 Hz, 1H), 7.60 (dt, *J* = 7.7, 1.5 Hz, 1H), 7.53 – 7.42 (m, 2H), 7.05 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.83 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.57 (s, 2H), 4.45 (s, 2H), 3.86 (s, 2H), 2.23 (s, 6H). MS (ESI⁺) *m/z* 476.9 (M+H)⁺.

Example 114: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(5-chloropyridin-2-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 213)

To a mixture of Example 112B (50 mg, 0.146 mmol), and 5-chloro-2-fluoropyridine (0.018 mL, 0.175 mmol) in dimethylformamide (1.5 mL) was added 60% NaH in mineral oil (7.58 mg, 0.190 mmol). The mixture was stirred for 2 hours. The reaction was quenched with water and brine and extracted with ethyl acetate (twice). The combined organic layers were dried over MgSO₄ and concentrated. The residue was purified by HPLC (see protocol in Example 112D) to provide the title compound as a trifluoroacetic acid salt (23.9 mg, 28.8%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.62 (s, 1H), 8.16 (d, *J* = 2.7 Hz, 1H), 7.82 (dd, *J* = 8.8, 2.7 Hz, 1H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.05 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.93 (d, *J* = 8.8 Hz, 1H), 6.83 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 1H), 4.64 (s, 2H), 4.45 (s, 2H), 2.22 (s, 6H). MS (ESI⁺) *m/z* 454.0 (M+H)⁺.

Example 115: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 214)

A mixture of Example 112B (65 mg, 0.190 mmol), 2-fluoro-5-(trifluoromethyl)pyridine (0.027 mL, 0.228 mmol), and 60% NaH in mineral oil (25.03 mg, 0.626 mmol) in dimethylformamide (2 mL) was stirred for 2.5 hours. The reaction was quenched with water and brine and extracted with ethyl acetate (twice). The combined organic layers were dried over MgSO₄ and concentrated. The residue was purified by HPLC (see protocol in Example 112D) to provide the title compound as a trifluoroacetic acid salt (10.3 mg, 9%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.67 (s, 2H), (s, 1H), 8.07 (dd, *J* = 8.8, 2.6 Hz, 1H), 7.45 (t, *J* = 8.9 Hz, 1H),

- 303 -

7.11 – 6.95 (m, 2H), 6.81 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.74 (s, 2H), 4.44 (s, 2H), 2.21 (s, 6H). MS (APCI⁺) *m/z* 487.8 (M+H)⁺.

Example 116: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(5-cyanopyridin-2-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 215)

5 A mixture of Example 112B (80.2 mg, 0.234 mmol), 6-fluoronicotinonitrile (51.4 mg, 0.421 mmol), and cesium carbonate (152 mg, 0.468 mmol) in dimethylformamide (4 mL) was stirred for 5 hours. The reaction was quenched with water and brine and extracted with ethyl acetate (twice). The combined organic layers were dried over MgSO₄, filtered, and concentrated. The residue was purified by HPLC (see protocol in Example 112D) to provide the
10 title compound as a trifluoroacetic acid salt (68.7 mg, 53%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.77 – 8.55 (m, 3H), 8.15 (dd, J = 8.7, 2.3 Hz, 1H), 7.45 (t, J = 8.9 Hz, 1H), 7.04 (ddd, J = 9.7, 6.6, 1.8 Hz, 2H), 6.81 (ddd, J = 8.9, 2.8, 1.2 Hz, 1H), 4.74 (s, 2H), 4.43 (s, 2H), 2.20 (s, 6H). MS (ESI⁺) *m/z* 444.9 (M+H)⁺.

Example 117: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(5-chloro-4-methylpyridin-2-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 216)

A mixture of Example 112B (65 mg, 0.190 mmol), 5-chloro-2-fluoro-4-methylpyridine (0.026 mL, 0.228 mmol), and 60% NaH in mineral oil (25.03 mg, 0.626 mmol) in dimethylformamide (2 mL) was stirred for 1.5 hours. The reaction was quenched with water and brine and extracted with ethyl acetate (twice). The combined organic layers were dried over
20 MgSO₄, filtered, and concentrated. The residue was purified by HPLC (see protocol in Example 112D) to provide the title compound as a trifluoroacetic acid salt (7.0 mg, 6.3%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.68 (s, 1H), 8.60 (s, 1H), 8.09 (s, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.05 (dd, J = 11.4, 2.8 Hz, 1H), 6.91 (s, 1H), 6.83 (dd, J = 9.0, 2.8 Hz, 1H), 4.63 (s, 2H), 4.45 (s, 2H), 2.30 (s, 3H), 2.21 (s, 6H). MS (APCI⁺) *m/z* 468.1 (M+H)⁺.

Example 118: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 217)

Example 118A: methyl [2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}amino)-2-oxoethoxy]acetate

To a mixture of Example 112B (600.0 mg, 1.751 mmol) and methyl 2-bromoacetate
30 (0.282 mL, 2.98 mmol) in tetrahydrofuran (20 mL) was added cesium carbonate (1711 mg, 5.25 mmol). The reaction mixture was stirred overnight. The reaction mixture was treated with brine and extracted with ethyl acetate (twice). The combined organic layers were dried over MgSO₄,

- 304 -

filtered, and concentrated. The residue was purified on a 40 g silica gel column using a Biotage® Isolera™ One flash system eluting with heptanes/ethyl acetate (5:95) to give the title compound (0.310 g, 43%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.66 (s, 1H), 8.34 (s, 1H), 7.46 (t, J = 8.9 Hz, 1H), 7.03 (dd, J = 11.4, 2.8 Hz, 1H), 6.81 (ddd, J = 8.9, 2.8, 1.2 Hz, 1H), 4.44 (s, 2H), 4.16 (s, 2H), 3.88 (s, 2H), 3.63 (s, 3H), 2.21 (s, 6H). MS (ESI⁺) *m/z* 415.0 (M+H)⁺.

Example 118B: [2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}amino)-2-oxoethoxy]acetic acid

A solution of Example 118A (0.345 g, 0.832 mmol) in tetrahydrofuran (4.5 mL) and methanol (3 mL) was treated with a solution of LiOH (0.060 g, 2.495 mmol) in water (2 mL).

The mixture was stirred for 6 hours and concentrated until most solvent was evaporated. The remaining light suspension was treated with 5% citric acid until pH=3. The resulting suspension was filtered. The collected solid was washed with water and vacuum oven-dried to give the title compound. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.43 (s, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.06 (dd, J = 11.4, 2.8 Hz, 1H), 6.84 (ddd, J = 9.0, 2.8, 1.2 Hz, 1H), 4.47 (s, 2H), 4.09 (s, 2H), 3.91 (s, 2H), 2.24 (s, 6H). MS (ESI⁺) *m/z* 401.0 (M+H)⁺.

Example 118C: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide

A mixture of Example 118B (71.5 mg, 0.178 mmol), *N*-hydroxyacetimidamide (15.86 mg, 0.214 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU, 81 mg, 0.214 mmol), and triethylamine (0.037 mL, 0.268 mmol) in acetonitrile (6 mL) was stirred for 6 hours. To the reaction mixture was added 10 mg of 4Å molecular sieves, and the reaction was heated to 81 °C overnight. The reaction mixture was filtered, and the filtrate was concentrated. The concentrate was treated with brine and extracted with ethyl acetate (twice). The combined organic layers were concentrated, and the residue was purified by HPLC (see protocol in Example 112D) to provide the title compound (42.5 mg, 54%). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.72 (s, 1H), 8.51 (s, 1H), 7.50 (t, J = 8.9 Hz, 1H), 7.08 (dd, J = 11.4, 2.8 Hz, 1H), 6.86 (ddd, J = 9.0, 2.9, 1.1 Hz, 1H), 4.85 (s, 2H), 4.48 (s, 2H), 4.01 (s, 2H), 2.36 (s, 3H), 2.25 (s, 6H). MS (ESI⁺) *m/z* 439.0 (M+H)⁺.

Example 119: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 218)

Example 119A: 2-(4-chloro-3-fluorophenoxy)-N-{3-[2-(2-hydrazinyl-2-oxoethoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide

- 305 -

A mixture of Example 118A (0.245 g, 0.591 mmol) and hydrazine monohydrate (0.046 mL, 1.477 mmol) in ethanol was heated at 80 °C for 3 hours. The reaction mixture was concentrated. The concentrate was purified on a 12 g silica gel column using a Biotage® Isolera™ One flash system eluting with methanol/ethyl acetate (1:9) to give the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.32 (s, 1H), 8.70 (s, 1H), 8.59 (s, 1H), 7.48 (t, J = 8.9 Hz, 1H), 7.05 (dd, J = 11.4, 2.8 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.46 (s, 2H), 4.28 (d, J = 4.0 Hz, 2H), 3.93 (s, 2H), 3.85 (s, 2H), 2.26 (s, 6H). MS (ESI⁺) *m/z* 415.0 (M+H)⁺.

Example 119B: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide

A mixture of Example 119A (50.0 mg, 0.121 mmol) and 1,1'-carbonyldiimidazole (23.45 mg, 0.145 mmol) in 1,4-dioxane (1.5 mL) was heated at reflux for 45 minutes. The reaction mixture was concentrated, and the residue was purified by HPLC (see protocol in Example 112D) to provide the title compound (34.2 mg, 64%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.37 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.05 (dd, J = 11.4, 2.9 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.45 (s, 2H), 4.40 (s, 2H), 3.90 (s, 2H), 2.22 (s, 6H). MS (ESI⁺) *m/z* 440.9 (M+H)⁺.

Example 120: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[4-(pentafluoro-λ⁶-sulfanyl)phenoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 219)

A mixture of Example 28A (60.0 mg, 0.166 mmol), 4-(pentafluorothio)phenol (54.9 mg, 0.249 mmol), and potassium carbonate (45.9 mg, 0.332 mmol) in acetone (2 mL) was heated at 120 °C in a Biotage® Initiator microwave reactor for 20 minutes. The reaction mixture was concentrated. The residue was treated with brine and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by HPLC (see protocol in Example 112D) to provide the title compound (54.1 mg, 60%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.75 (s, 1H), 8.70 (s, 1H), 7.82 (d, J = 9.3 Hz, 2H), 7.47 (t, J = 8.9 Hz, 1H), 7.12 – 7.00 (m, 3H), 6.83 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.54 (s, 2H), 4.46 (s, 2H), 2.25 (s, 6H). MS (ESI⁺) *m/z* 544.8 (M+H)⁺.

Example 121: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(2,6-dimethylpyridin-4-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 220)

A mixture of Example 28A (65.0 mg, 0.180 mmol), 2,6-dimethylpyridin-4-ol (33.2 mg, 0.270 mmol), potassium carbonate (49.7 mg, 0.360 mmol), and potassium iodide (2.091 mg, 0.013 mmol) in acetone (2.5 mL) was heated at 140 °C in a Biotage® Initiator microwave

- 306 -

reactor for 40 minutes. The reaction mixture was concentrated. The residue was treated with brine and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by HPLC (see protocol in Example 112D) to provide the title compound as a trifluoroacetic acid salt (53.2 mg, 53%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.88 (s, 1H), 8.72 (s, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.26 (s, 2H), 7.05 (dd, J = 11.4, 2.9 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.79 (s, 2H), 4.46 (s, 2H), 2.57 (s, 6H), 2.25 (s, 6H). MS (ESI⁺) *m/z* 448.1 (M+H)⁺.

Example 122: 2-[(6-*tert*-butylpyridin-3-yl)oxy]-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 221)

A mixture of Example 28A (65.0 mg, 0.180 mmol), 6-(*tert*-butyl)pyridin-3-ol (40.8 mg, 0.270 mmol), and potassium carbonate (49.7 mg, 0.360 mmol) in acetone (2 mL) was heated at 120 °C in a Biotage® Initiator microwave reactor for 30 minutes. The reaction mixture was concentrated. The residue was treated with brine and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by HPLC (see protocol in Example 112D) to provide the title compound as a trifluoroacetic acid salt (49.8 mg, 47%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.72 (d, J = 15.7 Hz, 2H), 8.26 (t, J = 1.8 Hz, 1H), 7.55 – 7.37 (m, 3H), 7.05 (dd, J = 11.3, 2.8 Hz, 1H), 6.83 (ddd, J = 8.9, 3.0, 1.2 Hz, 1H), 4.54 (s, 2H), 4.46 (s, 2H), 2.25 (s, 6H), 1.30 (s, 9H). MS (ESI⁺) *m/z* 476.2 (M+H)⁺.

Example 123: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-[[5-chloro-6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 222)

A mixture of Example 28A (70.0 mg, 0.194 mmol), 5-chloro-6-(trifluoromethyl)pyridin-3-ol (57.4 mg, 0.291 mmol), and potassium carbonate (53.6 mg, 0.388 mmol) in acetone (2.5 mL) was heated at 120 °C in a Biotage® Initiator microwave reactor for 20 minutes. The reaction mixture was concentrated. The residue was treated with brine and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by HPLC (see protocol in Example 112D) to provide the title compound (32.9 mg, 47%). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.80 (s, 1H), 8.71 (s, 1H), 8.39 (d, J = 2.5 Hz, 1H), 7.85 (d, J = 2.4 Hz, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.05 (dd, J = 11.4, 2.9 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.71 (s, 2H), 4.46 (s, 2H), 2.26 (s, 6H). MS (ESI⁺) *m/z* 522.0 (M+H)⁺.

Example 124: methyl 2-chloro-5-[2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]amino)-2-oxoethoxy]benzoate (Compound 223)

Example 124A: 2-(4-chloro-3-(methoxycarbonyl)phenoxy)acetic acid

- 307 -

The title compound was prepared as described in Example 9C and Example 9D, except substituting methyl 2-chloro-5-hydroxybenzoate for 6-hydroxy-1H-indazole. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.43 (d, *J* = 8.9 Hz, 1H), 7.25 (d, *J* = 3.1 Hz, 1H), 7.10 (dd, *J* = 8.9, 3.2 Hz, 1H), 4.71 (s, 2H), 3.81 (s, 3H).

5 **Example 124B: methyl 2-chloro-5-[2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}amino)-2-oxoethoxy]benzoate**

To a mixture of Example 9B (0.16 g, 0.401 mmol), Example 124A (0.123 g, 0.502 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (0.350 mL, 2.006 mmol) in *N,N*-dimethylformamide (5.0 mL), 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.229 g, 0.602 mmol) was added, and the reaction mixture was stirred at ambient temperature for 16 hours. Volatiles were removed under high vacuum, and the residue was purified by HPLC (10~95% acetonitrile in 0.1% trifluoroacetic acid/water on Phenomenex® C18 5 μm column) to give 171 mg of the title compound as a light yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.71 (d, *J* = 11.6 Hz, 2H), 7.52 7.42 (m, 2H), 7.37 (d, *J* = 3.1 Hz, 1H), 7.15 (dd, *J* = 8.9, 3.1 Hz, 1H), 7.05 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.83 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.47 (d, *J* = 6.6 Hz, 4H), 3.84 (s, 3H), 2.25 (s, 6H). MS (ESI+) *m/z* 510.9 (M+H)⁺.

Example 125: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[4-chloro-3-(hydroxymethyl)phenoxy]-acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 224)

20 A mixture of Example 124 (0.13 g, 0.254 mmol) and lithium tetrahydroborate (0.055 g, 2.54 mmol) in tetrahydrofuran (5.0 mL) was stirred at 40 °C for 24 hours. The mixture was concentrated under high vacuum, and the residue was purified by HPLC (10~95% acetonitrile in 0.1% trifluoroacetic acid/water on a Phenomenex® C18 5 μm column) to give 66 mg of the title compound as a light yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.68 (d, *J* = 2.8 Hz, 2H), 7.45 (t, *J* = 8.9 Hz, 1H), 7.26 (d, *J* = 8.7 Hz, 1H), 7.12 (d, *J* = 3.1 Hz, 1H), 7.03 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.85 - 6.77 (m, 2H), 5.40 (t, *J* = 5.6 Hz, 1H), 4.51 - 4.41 (m, 4H), 4.38 (s, 2H), 2.23 (s, 6H). MS (ESI+) *m/z* 482.9 (M+H)⁺.

Example 126: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(6-chloropyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 225)

30 The title compound was prepared as described in Example 124, except substituting 2-((6-chloropyridin-3-yl)oxy)acetic acid for 2-(4-chloro-3-(methoxycarbonyl)phenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.71 (d, *J* = 14.8 Hz, 2H), 8.08 (dd, *J* = 2.8, 0.9 Hz, 1H),

- 308 -

7.49 – 7.36 (m, 3H), 7.03 (dd, $J = 11.4, 2.8$ Hz, 1H), 6.81 (ddd, $J = 9.0, 2.9, 1.2$ Hz, 1H), 4.51 (s, 2H), 4.43 (s, 2H), 2.23 (s, 6H). MS (ESI+) m/z 454.0 (M+H)⁺.

Example 127: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-chloro-5-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 226)

5 A mixture of Example 28A (0.06 g, 0.166 mmol), 6-chloro-5-methylpyridin-3-ol (0.048 g, 0.332 mmol), potassium carbonate (0.046 g, 0.332 mmol) and potassium iodide (1.930 mg, 0.012 mmol) in acetone (2.0 mL) was stirred at 140 °C in a Biotage® Initiator microwave reactor (0-450 W) for 45 minutes. The suspension was filtered, and the filter was washed with methanol. The filtrate was concentrated, and the residue was purified by HPLC (10~85%
10 acetonitrile in 0.1% trifluoroacetic acid/water on a Phenomenex® C18 5 µm column) to give 59 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.70 (s, 1H), 8.68 (s, 1H), 7.93 (d, $J = 3.0$ Hz, 1H), 7.50 7.41 (m, 2H), 7.03 (dd, $J = 11.4, 2.9$ Hz, 1H), 6.81 (ddd, $J = 9.0, 2.9, 1.1$ Hz, 1H), 5.71 (s, 1H), 4.49 (s, 2H), 4.44 (s, 2H), 2.27 (s, 3H), 2.23 (s, 6H). MS (ESI-) m/z 466.0 (M-H)⁻.

15 **Example 128: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-chloro-5-fluoropyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 227)**

The title compound was prepared as described in Example 127, except substituting 6-chloro-5-fluoropyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.73 (s, 1H), 8.68 (s, 1H), 8.03 (d, $J = 2.5$ Hz, 1H), 7.67 (dd, $J = 10.2, 2.6$ Hz, 1H), 7.46 (t, $J = 8.9$ Hz, 1H), 7.03 (dd, $J = 11.3, 2.9$ Hz, 1H), 6.81 (ddd, $J = 9.0, 2.9, 1.1$ Hz, 1H), 4.57 (s,
20 2H), 4.44 (s, 2H), 2.23 (s, 6H). MS (ESI-) m/z 470.0 (M-H)⁻.

Example 129: 2-(3-amino-4-chlorophenoxy)-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 228)

Example 129A: 2-(4-chloro-3-nitrophenoxy)acetic acid

25 To a solution of 4-chloro-3-nitrophenol (2.2 g, 12.68 mmol) in *N,N*-dimethylformamide (25.0 mL) at ambient temperature was added potassium carbonate (3.50 g, 25.4 mmol) and *tert*-butyl bromoacetate (2.138 mL, 14.58 mmol). This mixture was warmed to 65 °C and allowed to stir for 1.5 hours. The mixture was allowed to cool to ambient temperature and was partitioned between ethyl acetate (50 mL) and H₂O (50 mL). The layers were separated, and the aqueous
30 layer was extracted with ethyl acetate (3 x 15 mL). The combined organic layers were dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified via column chromatography (SiO₂, 0~10% ethyl acetate/heptanes) to give

- 309 -

3.8 g of *tert*-butyl 2-(4-chloro-3-nitrophenoxy)acetate. To a mixture of *tert*-butyl 2-(4-chloro-3-nitrophenoxy)acetate (3.65 g, 12.68 mmol) in methanol (30 mL) and water (10 mL) was added NaOH (12.68 mL, 63.4 mmol) (5 M solution in water). This mixture was allowed to stir at ambient temperature for 2 hours, and was concentrated under reduced pressure to give a white solid which was dissolved in water. The pH was adjusted to ~1 with 1 N HCl, and the resulting white solid was isolated via filtration to give the title compound (2.0 g, 8.64 mmol, 68.1% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.64 7.56 (m, 2H), 7.22 (dd, *J* = 9.0, 3.0 Hz, 1H), 4.70 (s, 2H).

Example 129B: 2-(4-chloro-3-fluorophenoxy)-N-(3-(2-(4-chloro-3-nitrophenoxy)-acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide

The title compound was prepared as described in Example 124B, except substituting Example 129A for 2-(4-chloro-3-(methoxycarbonyl)phenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.73 (s, 1H), 8.68 (s, 1H), 7.69 – 7.57 (m, 2H), 7.45 (t, *J* = 8.9 Hz, 1H), 7.27 (dd, *J* = 9.0, 3.0 Hz, 1H), 7.03 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.81 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 4.54 (s, 2H), 4.44 (s, 2H), 2.23 (s, 6H).

Example 129C: 2-(3-amino-4-chlorophenoxy)-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide

To a mixture of Example 129B (0.19 g, 0.381 mmol) in tetrahydrofuran (20 mL) was added Ra-Ni 2800, water slurry (0.4 g, 3.41 mmol) in a 50 mL pressure bottle, and the reaction vessel was shaken under hydrogen (50 psi) and ambient temperature for 5 hours. The suspension was filtered, and the filtrate was concentrated. The residue was purified by HPLC (10~85% acetonitrile in 0.1% trifluoroacetic acid/water on Phenomenex® C18 5 μm column) to give 72 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.67 (s, 1H), 8.60 (s, 1H), 7.46 (t, *J* = 8.8 Hz, 1H), 7.08 - 6.99 (m, 2H), 6.82 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 1H), 6.34 (d, *J* = 2.9 Hz, 1H), 6.12 (dd, *J* = 8.7, 2.9 Hz, 1H), 5.29 (s, 2H), 4.44 (s, 2H), 4.27 (s, 2H), 2.23 (s, 6H). MS (ESI+) *m/z* 467.9 (M+H)⁺.

Example 130: 2-[(2-amino-6-methylpyridin-3-yl)oxy]-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 229)

The title compound was prepared as described in Example 127, except substituting 2-amino-6-methylpyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 14.26 (s, 1H), 8.80 (s, 1H), 8.72 (s, 1H), 8.18 (s, 2H), 7.46 (t, *J* = 8.9 Hz, 1H), 7.37 (d, *J* = 8.1 Hz, 1H), 7.04 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.59 (dd, *J* =

- 310 -

8.1, 1.0 Hz, 1H), 4.54 (s, 2H), 4.45 (s, 2H), 2.32 (s, 3H), 2.28 (s, 6H). MS (ESI+) m/z 449.1 (M+H)⁺.

Example 131: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-{[5-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 230)

5 The title compound was prepared as described in Example 127, except substituting 5-(trifluoromethyl)pyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.78 (s, 1H), 8.71 (s, 1H), 8.58 (dd, J = 15.7, 2.2 Hz, 4H), 7.73 (t, J = 2.3 Hz, 1H), 7.47 (t, J = 8.8 Hz, 1H), 7.05 (dd, J = 11.4, 2.8 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.66 (s, 2H), 4.46 (s, 2H), 2.25 (s, 6H). MS (ESI+) m/z 488.0 (M+H)⁺.

10 **Example 132: 2-chloro-5-[2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl]amino)-2-oxoethoxy]pyridine-3-carboxylic acid (Compound 231)**

The title compound was prepared as described in Example 127, except substituting 2-chloro-5-hydroxynicotinic acid for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.66 (s, 1H), 8.71 (d, J = 19.7 Hz, 2H), 8.11 (d, J = 3.0 Hz, 1H), 7.68 (d, J = 3.0 Hz, 1H), 7.46 (t, J = 8.9 Hz, 1H), 7.04 (dd, J = 11.4, 2.9 Hz, 1H), 6.82 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.66 (s, 2H), 4.44 (s, 2H), 2.22 (s, 6H). MS (ESI+) m/z 497.9 (M+H)⁺.

Example 133: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(2,6-dimethylpyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 232)

20 The title compound was prepared as described in Example 127, except substituting 2,6-dimethylpyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.73 (d, J = 13.7 Hz, 2H), 7.81 (d, J = 8.7 Hz, 1H), 7.57 – 7.44 (m, 2H), 7.05 (dd, J = 11.4, 2.8 Hz, 1H), 6.83 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 4.69 (s, 2H), 4.46 (s, 2H), 2.54 (s, 6H), 2.24 (s, 6H). MS (ESI+) m/z 448.1 (M+H)⁺.

25 **Example 134: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-{[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 233)**

The title compound was prepared as described in Example 127, except substituting 2-(trifluoromethyl)pyridin-4-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.79 (s, 1H), 8.71 (s, 1H), 8.57 (d, J = 5.7 Hz, 1H), 7.52 – 7.40 (m, 2H), 7.24 (dd, J = 5.8, 2.4 Hz, 1H), 7.05 (dd, J = 11.4, 2.9 Hz, 1H), 6.83 (ddd, J = 8.9, 2.8, 1.2 Hz, 1H), 4.67 (s, 2H), 4.46 (s, 2H), 2.25 (s, 6H). MS (ESI+) m/z 488.1 (M+H)⁺.

30 **Example 135: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(5,6-dimethylpyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 234)**

- 311 -

The title compound was prepared as described in Example 127, except substituting 5,6-dimethylpyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.80 (s, 1H), 8.72 (s, 1H), 8.29 (d, *J* = 2.7 Hz, 1H), 7.91 (d, *J* = 2.6 Hz, 1H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.05 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.83 (dd, *J* = 9.0, 2.7 Hz, 1H), 4.65 (s, 2H), 4.46 (s, 2H), 2.52 (s, 3H), 2.35 (s, 3H), 2.25 (s, 6H). MS (ESI+) *m/z* 448.1 (M+H)⁺.

Example 136: 2-[(6-acetylpyridin-3-yl)oxy]-N-[3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 235)

A 2.5 mL microwave vial was charged with Example 28A (35 mg, 1 equivalent, 0.096 mmol), K₂CO₃ (27mg, 0.19 mmol), 1-(5-hydroxypyridin-2-yl)ethanone (27 mg, 0.19 mmol) and potassium iodide (1,2 mg, 0.07 equivalent, 0.05 mmol). To this mixture was added acetone (1.5 mL). The resulting mixture was heated in a Biotage® Initiator microwave for 45 minutes at 140 °C (0-450 W). Upon completion, the mixture was then filtered, and the filtrate was concentrated to dryness. The residue was dissolved in 1:1 dimethyl sulfoxide/methanol and purified by preparative reverse phase HPLC on a Phenomenex® Luna® C8(2) 5 μm 100 Å AXIA™ column (30 mm × 150mm). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/minute (0-0.5 minutes 5% A, 0.5-8.5 minutes linear gradient 5-100% A, 8.7-10.7 minutes 100% A, 10.7 -11.0 minutes linear gradient 100-5% A) to afford the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.39 (d, *J* = 2.9 Hz, 1H), 7.96 (d, *J* = 8.8 Hz, 1H), 7.53 – 7.45 (m, 2H), 7.05 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 1H), 4.64 (s, 2H), 4.46 (s, 2H), 2.58 (s, 3H), 2.28 (s, 6H). MS (APCI) *m/z* 462.3 (M+H)⁺.

Example 137: 2-[(2-amino-6-chloropyridin-3-yl)oxy]-N-[3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 236)

The title compound was prepared as described in Example 136, except substituting 2-amino-6-chloropyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.48 (t, *J* = 8.9 Hz, 1H), 7.12 – 6.99 (m, 2H), 6.86 (ddd, *J* = 8.9, 2.9, 1.1 Hz, 1H), 6.48 (d, *J* = 8.1 Hz, 1H), 4.47 (s, 2H), 4.40 (s, 2H), 2.31 (s, 6H). MS (APCI) *m/z* 469.2 (M+H)⁺.

Example 138: 2-(4-chloro-3-fluorophenoxy)-N-(3-[2-[(2-chloro-6-methylpyridin-3-yl)oxy]acetamido]bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 237)

The title compound was prepared as described in Example 136, except substituting 2-chloro-6-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.48 (t, *J* = 8.9 Hz, 1H), 7.12 – 6.99 (m, 2H), 6.86 (ddd, *J* = 8.9, 2.9, 1.1 Hz,

- 312 -

1H), 6.48 (d, $J = 8.1$ Hz, 1H), 4.47 (s, 2H), 4.40 (s, 2H), 2.31 (s, 6H). MS (APCI) m/z 469.2 (M+H)⁺.

Example 139: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-cyanopyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 238)

The title compound was prepared as described in Example 136, except substituting 5-hydroxypicolonitrile for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.45 (d, $J = 2.9$ Hz, 1H), 7.97 (d, $J = 8.7$ Hz, 1H), 7.56 – 7.45 (m, 2H), 7.05 (dd, $J = 11.3$, 2.8 Hz, 1H), 6.85 (ddd, $J = 9.0$, 2.9, 1.2 Hz, 1H), 4.65 (s, 2H), 4.46 (s, 2H), 2.27 (s, 6H). MS (APCI) m/z 445.2 (M+H)⁺.

Example 140: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(2-ethyl-6-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 239)

The title compound was prepared as described in Example 136, except substituting 2-ethyl-6-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.95 (d, $J = 8.8$ Hz, 1H), 7.64 (d, $J = 8.9$ Hz, 1H), 7.47 (t, $J = 8.9$ Hz, 1H), 7.04 (dd, $J = 11.3$, 2.9 Hz, 1H), 6.85 (ddd, $J = 9.0$, 2.9, 1.2 Hz, 1H), 4.75 (s, 2H), 4.46 (s, 2H), 2.96 (q, $J = 7.5$ Hz, 2H), 2.60 (s, 3H), 2.26 (s, 6H), 1.23 (t, $J = 7.6$ Hz, 3H). MS (APCI) m/z 462.3 (M+H)⁺.

Example 141: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(5-chloro-6-fluoropyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 240)

The title compound was prepared as described in Example 136, except substituting 5-chloro-6-fluoropyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.92 – 7.84 (m, 2H), 7.48 (t, $J = 8.9$ Hz, 1H), 7.05 (dd, $J = 11.3$, 2.8 Hz, 1H), 6.89 – 6.84 (m, 1H), 4.56 (s, 2H), 4.46 (s, 2H), 2.27 (s, 6H). MS (APCI) m/z 472.2 (M+H)⁺.

Example 142 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-methoxypyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 241)

The title compound was prepared as described in Example 136, except substituting 6-methoxypyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.83 (dd, $J = 3.1$, 0.7 Hz, 1H), 7.49 (d, $J = 8.8$ Hz, 1H), 7.45 – 7.41 (m, 1H), 7.05 (dd, $J = 11.3$, 2.8 Hz, 1H), 6.85 (ddd, $J = 9.0$, 2.8, 1.2 Hz, 1H), 6.78 (dd, $J = 9.0$, 0.6 Hz, 1H), 4.46 (s, 2H), 4.42 (s, 2H), 3.78 (s, 3H), 2.27 (s, 6H). MS (APCI) m/z 450.2 (M+H)⁺.

Example 143: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-cyano-5-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 242)

- 313 -

The title compound was prepared as described in Example 136, except substituting 5-hydroxy-3-methylpicolinonitrile for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.28 (d, *J* = 2.7 Hz, 1H), 7.53 – 7.44 (m, 2H), 7.05 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.85 (ddd, *J* = 8.9, 2.8, 1.2 Hz, 1H), 4.62 (s, 2H), 4.46 (s, 2H), 2.46 (s, 3H), 2.27 (s, 6H). MS (APCI) *m/z* 459.1 (M+H)⁺.

Example 144: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(6-chloro-4-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 243)

The title compound was prepared as described in Example 136, except substituting 6-chloro-4-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.88 (s, 1H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.34 (d, *J* = 0.9 Hz, 1H), 7.05 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.88 – 6.80 (m, 1H), 4.58 (s, 2H), 4.46 (s, 2H), 2.27 (s, 6H), 2.23 (d, *J* = 0.8 Hz, 3H). MS (APCI) *m/z* 468.2 (M+H)⁺.

Example 145: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(6-fluoro-5-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 244)

The title compound was prepared as described in Example 136, except substituting 6-fluoro-5-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.68 (s, 1H), 7.55 – 7.43 (m, 2H), 7.05 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.47 (d, *J* = 7.4 Hz, 4H), 2.27 (s, 6H), 2.21 (dt, *J* = 1.4, 0.7 Hz, 3H). MS (APCI) *m/z* 452.2 (M+H)⁺.

Example 146: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(2-fluoro-6-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 245)

The title compound was prepared as described in Example 136, except substituting 2-fluoro-6-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.48 (d, *J* = 8.9 Hz, 1H), 7.45 – 7.37 (m, 1H), 7.10 (d, *J* = 8.1 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.53 (s, 2H), 4.46 (s, 2H), 2.33 (s, 3H), 2.25 (s, 6H). MS (APCI) *m/z* 452.2 (M+H)⁺.

Example 147: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(6-fluoro-5-methoxypyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 246)

The title compound was prepared as described in Example 136, except substituting 6-fluoro-5-methoxypyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.48 (t, *J* = 8.9 Hz, 1H), 7.37 (t, *J* = 2.6 Hz, 1H), 7.30 (dd, *J* = 8.7, 2.6 Hz,

- 314 -

1H), 7.05 (dd, $J = 11.3, 2.8$ Hz, 1H), 6.85 (ddd, $J = 8.9, 2.9, 1.2$ Hz, 1H), 4.51 (s, 2H), 4.46 (s, 2H), 3.86 (s, 3H), 2.28 (s, 6H). MS (APCI) m/z 468.2 (M+H)⁺.

Example 148: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-fluoro-4-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 247)

5 The title compound was prepared as described in Example 136, except substituting 6-fluoro-4-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.66 (d, $J = 1.6$ Hz, 1H), 7.48 (t, $J = 8.9$ Hz, 1H), 7.12 – 6.99 (m, 2H), 6.90 – 6.82 (m, 1H), 4.54 (s, 2H), 4.46 (s, 2H), 2.27 (s, 9H). MS (APCI) m/z 452.2 (M+H)⁺.

Example 149: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-{[6-(propan-2-yl)pyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 248)

10 The title compound was prepared as described in Example 136, except substituting 6-isopropylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.40 (d, $J = 2.9$ Hz, 1H), 7.99 (dd, $J = 9.0, 2.9$ Hz, 1H), 7.79 (d, $J = 9.0$ Hz, 1H), 7.48 (t, $J = 8.9$ Hz, 1H), 7.04 (dd, $J = 11.3, 2.8$ Hz, 1H), 6.85 (ddd, $J = 9.0, 2.9, 1.3$ Hz, 1H), 4.67 (s, 2H), 4.46 (s, 2H), 3.29 – 3.16 (m, 1H), 2.28 (s, 6H), 1.29 (d, $J = 7.0$ Hz, 6H). MS (APCI) m/z 462.3 (M+H)⁺.

Example 150: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-fluoro-2-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 249)

20 The title compound was prepared as described in Example 136, except substituting 6-fluoro-2-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.49 (d, $J = 8.8$ Hz, 1H), 7.46 – 7.38 (m, 1H), 6.98 – 6.90 (m, 1H), 6.85 (ddd, $J = 8.9, 2.8, 1.2$ Hz, 1H), 4.50 (s, 2H), 4.46 (s, 2H), 2.35 (s, 3H), 2.26 (s, 6H). MS (APCI) m/z 452.2 (M+H)⁺.

Example 151: 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 250)

25 The title compound was prepared as described in Example 136, except substituting 6-amino-5-chloropyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.71 (d, $J = 2.6$ Hz, 1H), 7.64 (d, $J = 2.6$ Hz, 1H), 7.48 (t, $J = 8.9$ Hz, 1H), 7.05 (dd, $J = 11.3, 2.9$ Hz, 1H), 6.85 (ddd, $J = 9.0, 2.8, 1.2$ Hz, 1H), 4.46 (s, 2H), 4.40 (s, 2H), 2.27 (s, 6H). MS (APCI) m/z 469.2 (M+H)⁺.

Example 152: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-cyclopropylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 251)

- 315 -

The title compound was prepared as described in Example 136, except substituting 6-cyclopropylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.28 (d, *J* = 2.9 Hz, 1H), 7.82 (dd, *J* = 9.0, 2.9 Hz, 1H), 7.54 – 7.42 (m, 2H), 7.04 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.3 Hz, 1H), 4.61 (s, 2H), 4.46 (s, 2H), 2.27 (s, 6H), 2.26 – 2.18 (m, 1H), 1.22 – 1.15 (m, 2H), 1.04 – 0.94 (m, 2H). MS (APCI) *m/z* 460.3 (M+H)⁺.

Example 153: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-methoxy-2-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 252)

The title compound was prepared as described in Example 136, except substituting 6-methoxy-2-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.47 (t, *J* = 8.8 Hz, 1H), 7.32 (d, *J* = 8.9 Hz, 1H), 7.05 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.8, 1.2 Hz, 1H), 6.63 (dd, *J* = 8.8, 0.8 Hz, 1H), 4.46 (s, 2H), 4.40 (s, 2H), 3.78 (s, 3H), 2.35 (s, 3H), 2.26 (s, 6H). MS (APCI) *m/z* 464.2 (M+H)⁺.

Example 154: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(6-methoxy-5-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 253)

The title compound was prepared as described in Example 136, except substituting 6-methoxy-5-methylpyridin-3-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.64 (dd, *J* = 3.0, 0.8 Hz, 1H), 7.48 (t, *J* = 8.9 Hz, 1H), 7.29 (dd, *J* = 3.0, 0.9 Hz, 1H), 7.05 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.46 (s, 2H), 4.40 (s, 2H), 3.81 (s, 3H), 2.27 (s, 6H), 2.11 (t, *J* = 0.8 Hz, 3H). MS (APCI) *m/z* 464.2 (M+H)⁺.

Example 155: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(1*H*-pyrrolo[3,2-*b*]pyridin-6-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 254)

The title compound was prepared as described in Example 136, except substituting 1*H*-pyrrolo[3,2-*b*]pyridin-6-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.49 (d, *J* = 2.3 Hz, 1H), 8.18 (dd, *J* = 2.3, 0.9 Hz, 1H), 8.02 (d, *J* = 3.3 Hz, 1H), 7.48 (t, *J* = 8.9 Hz, 1H), 7.04 (dt, *J* = 11.4, 3.6 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.76 (dd, *J* = 3.3, 0.9 Hz, 1H), 4.69 (s, 2H), 4.46 (d, *J* = 5.4 Hz, 2H), 2.27 (d, *J* = 12.5 Hz, 6H). MS (APCI) *m/z* 459.2 (M+H)⁺.

Example 156: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(furo[3,2-*b*]pyridin-6-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 255)

The title compound was prepared as described in Example 136, except substituting furo[3,2-*b*]pyridin-6-ol for 1-(5-hydroxypyridin-2-yl)ethanone. ¹H NMR (400 MHz, DMSO-*d*₆)

- 316 -

δ ppm 8.37 (d, J = 2.4 Hz, 1H), 8.17 (d, J = 2.3 Hz, 1H), 7.76 (dd, J = 2.5, 1.0 Hz, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.10 – 7.02 (m, 2H), 6.85 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 4.58 (s, 2H), 4.46 (s, 2H), 2.28 (s, 6H). MS (APCI) m/z 460.2 (M+H)⁺.

Example 157: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-[[6-(trifluoromethyl)pyridazin-3-yl]oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 201)

A mixture of Example 112B (0.06 g, 0.175 mmol) and 3-chloro-6-(trifluoromethyl)pyridazine (0.038 g, 0.210 mmol) in *N,N*-dimethylformamide (1.5 mL) was added sodium hydride (8.75 mg, 0.219 mmol), and the reaction mixture was stirred at room temperature for 1.5 hours. The mixture was then concentrated under high vacuum, and the residue was purified by HPLC (10~85% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 μ m 100 Å AXIA™ column (250 mm \times 21.2 mm)) to give 26.5 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.77 (s, 1H), 8.67 (s, 1H), 8.15 (d, J = 9.3 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.46 (t, J = 8.9 Hz, 1H), 7.03 (dd, J = 11.4, 2.8 Hz, 1H), 6.81 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.94 (s, 2H), 4.44 (s, 2H), 2.22 (s, 6H). MS (ESI+) m/z 488.9 (M+H)⁺.

Example 158: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-[[6-(methanesulfonyl)pyridin-3-yl]oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 257)

A mixture of Example 112B (0.06 g, 0.175 mmol), 5-chloro-2-(methylsulfonyl)pyridine (0.034 g, 0.175 mmol), and cesium carbonate (0.057 g, 0.175 mmol) in *N*-methyl-2-pyrrolidone (0.5 mL) was irradiated in a Biotage® Initiator microwave reactor at 120 °C (0-450 W) for 0.5 hours. The reaction mixture was concentrated under high vacuum, and the residue was purified by HPLC (10~85% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 μ m 100 Å AXIA™ column (250 mm \times 21.2 mm)) to give 28 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.68 (d, J = 7.0 Hz, 2H), 8.60 (d, J = 2.6 Hz, 1H), 8.18 (dd, J = 8.8, 2.6 Hz, 1H), 7.46 (t, J = 8.9 Hz, 1H), 7.12 (m, 2H), 6.99 (m, 2H), 6.81 (ddd, J = 8.9, 2.8, 1.2 Hz, 1H), 4.77 (s, 2H), 4.44 (s, 2H), 3.23 (s, 3H), 2.21 (s, 6H). MS (ESI+) m/z 431.0 (M+H)⁺.

Example 159: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 258)

Example 159A 2,2-difluorobenzo[d][1,3]dioxol-5-ol

To a cold solution of 5-bromo-2,2-difluorobenzo[d][1,3]dioxole (5.75 mL, 42.2 mmol) in tetrahydrofuran (80 mL) was added a 2.0 M solution of isopropylmagnesium chloride in

- 317 -

tetrahydrofuran (28.1 mL, 56.1 mmol) within 5-10 minutes while maintaining the temperature in the range of 10-20 °C. The reaction mixture was stirred at the same temperature for another 15 minutes and then allowed to attain room temperature with continued overnight stirring. The reaction mixture was cooled with an ice bath, triisopropyl borate (12.74 mL, 54.9 mmol) was added dropwise over 2 minutes, and stirring at room temperature was continued for 30 minutes. The reaction mixture was cooled to 10 °C and 10% H₂SO₄ solution (50 mL) was added slowly which resulted in a slight exotherm to 20 °C. After stirring for 15 minutes, the mixture was partitioned between water and ethyl acetate, and the combined organic extracts were washed with saturated NaHCO₃ solution. The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated. The residue was dissolved in 100 mL of *tert*-butyl methyl ether and cooled to 0 °C. 30% Hydrogen peroxide solution in water (5.39 mL, 52.7 mmol) was added slowly, followed by water (60 mL), and the mixture was stirred overnight while warming up to ambient temperature. The reaction mixture was diluted with ethyl acetate and washed twice with sodium thiosulfate solution and brine. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified on silica gel (0~50% ethyl acetate in heptane) to give 6.43 g of the title compound as an amber oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.75 (s, 1H), 7.12 (d, *J* = 8.7 Hz, 1H), 6.75 (d, *J* = 2.4 Hz, 1H), 6.52 (dd, *J* = 8.7, 2.5 Hz, 1H). MS (ESI-) *m/z* 173.1 (M-H)⁻.

Example 159B 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide

The title compound was prepared as described in Example 127, except substituting 2,2-difluorobenzo[d][1,3]dioxol-5-ol (Example 159A) for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.67 (d, *J* = 9.1 Hz, 2H), 7.46 (t, *J* = 8.9 Hz, 1H), 7.29 (d, *J* = 8.9 Hz, 1H), 7.10 (d, *J* = 2.6 Hz, 1H), 7.04 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.44 (s, 2H), 4.41 (s, 2H), 2.24 (s, 6H). MS (ESI+) *m/z* 498.9 (M+H)⁺.

Example 160: 2-[[6-(aminomethyl)pyridin-3-yl]oxy]-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 259)

A mixture of Example 28A (0.038 g, 0.089 mmol), *tert*-butyl ((5-hydroxypyridin-2-yl)methyl)carbamate (0.04 g, 0.178 mmol), potassium carbonate (0.025 g, 0.178 mmol) and potassium iodide (1.036 mg, 6.24 μmol) in acetone (1.5 mL) was stirred at 140 °C (0-450 W) in a Biotage® Initiator microwave reactor for 45 minutes. The reaction mixture was concentrated.

- 318 -

A mixture of the residue, 4 N HCl in dioxane (1.1 mL), and dichloromethane (5 mL) was stirred at ambient temperature overnight. After concentration, the residue was purified by HPLC (10~85% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 µm 100 Å AXIA™ column (250 mm × 21.2 mm)) to give 48 mg of the title compound as a solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.80 (s, 1H), 8.75 (s, 1H), 8.34 (dd, *J* = 2.7, 0.8 Hz, 1H), 8.31 - 8.16 (m, 3H), 7.54 - 7.40 (m, 3H), 7.08 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.86 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.58 (s, 2H), 4.48 (s, 2H), 4.12 (q, *J* = 5.8 Hz, 2H), 2.27 (s, 6H). MS (ESI+) *m/z* 449.1 (M+H)⁺.

Example 161: 2-(4-chloro-3-fluorophenoxy)-*N*-{3-[2-(4-chloro-3-iodophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 260)

Example 161A: 2-(4-chloro-3-iodophenoxy)acetic acid

The title compound was prepared as described in Example 129A, except substituting methyl 4-chloro-3-iodophenol for 4-chloro-3-nitrophenol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.97 (s, 1H), 7.46 7.38 (m, 2H), 6.95 (dd, *J* = 8.9, 3.0 Hz, 1H), 4.68 (s, 2H).

*Example 161B: 2-(4-chloro-3-fluorophenoxy)-*N*-{3-[2-(4-chloro-3-iodophenoxy)acetamido]bicyclo-[1.1.1]pentan-1-yl}acetamide*

The title compound was prepared as described in Example 124B, except substituting Example 161A for 2-(4-chloro-3-(methoxycarbonyl)phenoxy)acetic acid. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.73 (d, *J* = 6.2 Hz, 2H), 7.56 7.46 (m, 3H), 7.08 (dd, *J* = 11.4, 2.9 Hz, 1H), 7.02 (dd, *J* = 8.9, 3.0 Hz, 1H), 6.86 (ddd, *J* = 9.0, 2.9, 1.1 Hz, 1H), 4.48 (d, *J* = 11.4 Hz, 4H), 2.28 (s, 6H). MS (ESI+) *m/z* 578.8 (M+H)⁺.

Example 162: 2-[4-chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenoxy]-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 261)

A mixture of Example 161B (0.1 g, 0.173 mmol), (3,5-dimethylisoxazol-4-yl)boronic acid (0.036 g, 0.259 mmol), and sodium carbonate (0.173 mL, 0.345 mmol) in *N,N*-dimethylformamide (1.5 mL) was degassed and purged with argon. Then bis(triphenylphosphine)palladium(II) chloride (0.012 g, 0.017 mmol) was added, and the mixture was sparged with argon for 5 minutes. The vessel was sealed and then heated in a Biotage® Initiator microwave reactor at 145 °C (0-450 W) for 60 minutes. The suspension was cooled and filtered, and the filtrate was concentrated under vacuum. The residue was purified by HPLC (15~95% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 µm 100 Å AXIA™ column (250 mm × 21.2 mm)) to give 62 mg of the title

- 319 -

compound as an off-white solid. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ ppm 8.73 (s, 1H), 8.72 (s, 1H), 7.56 - 7.46 (m, 2H), 7.11 - 7.04 (m, 2H), 6.98 (d, $J = 3.0$ Hz, 1H), 6.90 - 6.83 (m, 1H), 4.50 (s, 2H), 4.49 (s, 2H), 2.28 (s, 3H), 2.27 (s, 6H), 2.10 (s, 3H). MS (ESI+) m/z 548.0 ($\text{M}+\text{H}$) $^+$.

Example 163: 2-[4-chloro-3-(cyanomethyl)phenoxy]-N-[3-[2-(4-chloro-3-

5 fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 262)

The title compound was obtained as a byproduct in the procedure described in Example 162. ^1H NMR (501 MHz, $\text{DMSO}-d_6$) δ ppm 8.71 (d, $J = 15.1$ Hz, 2H), 7.51 - 7.40 (m, 2H), 7.15 (d, $J = 3.0$ Hz, 1H), 7.05 (dd, $J = 11.4, 2.9$ Hz, 1H), 6.96 (dd, $J = 8.9, 3.1$ Hz, 1H), 6.83 (ddd, $J = 8.9, 2.9, 1.2$ Hz, 1H), 4.45 (d, $J = 7.8$ Hz, 4H), 4.03 (s, 2H), 2.25 (s, 6H). MS (ESI+) m/z 492.0 ($\text{M}+\text{H}$) $^+$.

Example 164: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-[[6-(1-hydroxyethyl)pyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 263)

A mixture of Example 28A (0.1 g, 0.235 mmol), 1-(5-hydroxypyridin-2-yl)ethanone (0.065 g, 0.471 mmol), potassium carbonate (0.065 g, 0.471 mmol) and potassium iodide (2.73 mg, 0.016 mmol) in acetone (2.0 mL) was stirred at 140 °C (0-450 W) in a Biotage® Initiator microwave reactor for 45 minutes. The suspension was filtered, and the filtrate was concentrated. This residue and NaBH_4 (0.089 g, 2.35 mmol) in methanol was stirred at ambient temperature overnight. The reaction mixture was concentrated, and the residue was purified by HPLC (10~85% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 μm 100 Å AXIA™ column (250 mm \times 21.2 mm)) to give 59 mg of the title compound as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.74 (d, $J = 26.6$ Hz, 2H), 8.30 (d, $J = 2.8$ Hz, 1H), 7.81 - 7.60 (m, 2H), 7.47 (t, $J = 8.9$ Hz, 1H), 7.05 (dd, $J = 11.4, 2.8$ Hz, 1H), 6.83 (ddd, $J = 9.0, 2.9, 1.2$ Hz, 1H), 4.85 (q, $J = 6.5$ Hz, 1H), 4.61 (s, 2H), 4.46 (s, 2H), 2.25 (s, 6H), 1.37 (d, $J = 6.5$ Hz, 3H). MS (ESI+) m/z 464.0 ($\text{M}+\text{H}$) $^+$.

Example 165: methyl 5-[2-((3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]amino)-2-oxoethoxy]pyridine-2-carboxylate (Compound 264)

The title compound was prepared as described in Example 127, except substituting methyl 5-hydroxypicolinate for 6-chloro-5-methylpyridin-3-ol. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.80 (s, 1H), 8.69 (s, 1H), 8.53 (d, $J = 5.7$ Hz, 1H), 7.62 (d, $J = 2.6$ Hz, 1H), 7.46 (t, $J = 8.9$ Hz, 1H), 7.23 (dd, $J = 5.8, 2.6$ Hz, 1H), 7.04 (dd, $J = 11.4, 2.9$ Hz, 1H), 6.82 (ddd, $J = 9.0, 2.8, 1.2$ Hz, 1H), 4.64 (s, 2H), 4.45 (s, 2H), 3.86 (s, 3H), 2.24 (s, 6H). MS (ESI+) m/z 431.0 ($\text{M}+\text{H}$) $^+$.

- 320 -

Example 166: 2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]-N-[3-(2-{[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 265)

Example 166A: 2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)acetic acid

5 The title compound was prepared as described in Example 129A, except substituting Example 159A for 4-chloro-3-nitrophenol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (s, 1H), 7.30 (d, *J* = 8.9 Hz, 1H), 7.13 (d, *J* = 2.6 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.69 (s, 2H).

Example 166B: N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)acetamide hydrochloride

15 The title compound was prepared as described in Example 9A and Example 9B, except substituting 2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)acetic acid (Example 166A) for 2-(4-chloro-3-fluorophenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.01 (s, 3H), 8.88 (s, 1H), 7.29 (d, *J* = 8.9 Hz, 1H), 7.11 (d, *J* = 2.5 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.44 (s, 2H), 2.21 (s, 6H).

Example 166C: 2-chloro-N-(3-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide

20 The title compound was prepared as described in Example 28A, except substituting Example 166B for Example 27D. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.81 (s, 1H), 8.68 (s, 1H), 7.30 (d, *J* = 8.9 Hz, 1H), 7.12 (d, *J* = 2.6 Hz, 1H), 6.75 (dd, *J* = 8.8, 2.6 Hz, 1H), 4.42 (s, 2H), 3.97 (s, 2H), 2.23 (s, 6H). MS (ESI+) *m/z* 388.9 (M+H)⁺.

Example 166D: 2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]-N-[3-(2-{[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide

25 The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 2-(trifluoromethyl)pyridin-4-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.79 (s, 1H), 8.68 (s, 1H), 8.57 (d, *J* = 5.7 Hz, 1H), 7.43 (d, *J* = 2.4 Hz, 1H), 7.30 (d, *J* = 8.9 Hz, 1H), 7.24 (dd, *J* = 5.7, 2.5 Hz, 1H), 7.12 (d, *J* = 2.5 Hz, 1H), 6.75 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.67 (s, 2H), 4.42 (s, 2H), 2.25 (s, 6H). MS (ESI+) *m/z* 516.0 (M+H)⁺.

30 **Example 167: 2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]-N-[3-(2-{[6-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 266)**

- 321 -

The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 6-(trifluoromethyl)pyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.77 (s, 1H), 8.66 (s, 1H), 8.43 (d, *J* = 2.9 Hz, 1H), 7.83 (d, *J* = 8.8 Hz, 1H), 7.53 (dd, *J* = 8.7, 2.9 Hz, 1H), 7.28 (d, *J* = 8.9 Hz, 1H), 7.10 (d, *J* = 2.6 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.63 (s, 2H), 4.40 (s, 2H), 2.24 (s, 6H). MS (ESI+) *m/z* 516.0 (M+H)⁺.

Example 168: 2-[(6-cyanopyridin-3-yl)oxy]-N-(3-{2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 267)

The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 5-hydroxypicolinonitrile for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.77 (s, 1H), 8.66 (s, 1H), 8.43 (d, *J* = 2.9 Hz, 1H), 7.97 (d, *J* = 8.7 Hz, 1H), 7.51 (dd, *J* = 8.7, 2.9 Hz, 1H), 7.28 (d, *J* = 8.9 Hz, 1H), 7.10 (d, *J* = 2.6 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.64 (s, 2H), 4.40 (s, 2H), 2.23 (s, 6H). MS (ESI-) *m/z* 470.9 (M-H)⁻.

Example 169: 2-[(6-cyclopropylpyridin-3-yl)oxy]-N-(3-{2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 268)

The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 6-cyclopropylpyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.69 (d, *J* = 20.8 Hz, 2H), 8.21 (d, *J* = 2.9 Hz, 1H), 7.53 (dd, *J* = 8.9, 2.9 Hz, 1H), 7.30 (dd, *J* = 15.3, 8.9 Hz, 2H), 7.10 (d, *J* = 2.6 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.52 (s, 2H), 4.40 (s, 2H), 2.23 (s, 6H), 2.10 (tt, *J* = 8.2, 4.9 Hz, 1H), 1.04 0.92 (m, 2H), 0.88 (dt, *J* = 4.8, 3.1 Hz, 2H). MS (ESI+) *m/z* 488.1 (M+H)⁺.

Example 170: 2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]-N-[3-(2-{[5-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 269)

The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 5-(trifluoromethyl)pyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (s, 1H), 8.66 (s, 1H), 8.56 (dd, *J* = 15.2, 2.2 Hz, 2H), 7.71 (t, *J* = 2.3 Hz, 1H), 7.29 (d, *J* = 8.9 Hz, 1H), 7.10 (d, *J* = 2.5 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.64 (s, 2H), 4.41 (s, 2H), 2.24 (s, 6H). MS (ESI+) *m/z* 516.0 (M+H)⁺.

- 322 -

Example 171: 2-[(2-cyanopyridin-4-yl)oxy]-N-(3-{2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 270)

The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 4-hydroxypicolonitrile for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (s, 1H), 8.66 (s, 1H), 8.52 (d, *J* = 5.8 Hz, 1H), 7.65 (d, *J* = 2.5 Hz, 1H), 7.33 7.21 (m, 2H), 7.10 (d, *J* = 2.5 Hz, 1H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 1H), 4.64 (s, 2H), 4.40 (s, 2H), 2.23 (s, 6H). MS (ESI+) *m/z* 473.0 (M+H)⁺.

Example 172: 2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]-N-(3-{2-[(6-methoxypyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 271)

The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 6-methoxypyridin-3-ol for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.65 (d, *J* = 1.6 Hz, 2H), 7.81 (d, *J* = 3.0 Hz, 1H), 7.38 (dd, *J* = 8.9, 3.1 Hz, 1H), 7.29 (d, *J* = 8.9 Hz, 1H), 7.10 (d, *J* = 2.6 Hz, 1H), 6.78 6.69 (m, 2H), 4.40 (d, *J* = 3.2 Hz, 4H), 3.75 (s, 3H), 2.24 (s, 6H). MS (ESI+) *m/z* 478.1 (M+H)⁺.

Example 173: N,N'-(2-oxobicyclo[2.2.2]octane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 272)

Example 173A: ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate

A mixture of ethyl 4-oxocyclohexanecarboxylate (11.70 mL, 73.4 mmol), ethane-1,2-diol (12.29 mL, 220 mmol), and *p*-toluenesulfonic acid monohydrate (1.397 g, 7.34 mmol) in toluene (200) was stirred at 120 °C with Dean-Stark trap apparatus for 180 minutes. The reaction mixture was neutralized with *N*-ethyl-*N*-isopropylpropan-2-amine and concentrated. The residue was purified on silica gel (0~30% ethyl acetate in heptane) to give 12.77 g of the title compound as a clear oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 4.01 (q, *J* = 7.1 Hz, 2H), 3.81 (s, 4H), 2.32 (tt, *J* = 10.4, 3.8 Hz, 1H), 1.83 1.71 (m, 2H), 1.66 1.57 (m, 1H), 1.62 1.38 (m, 5H), 1.13 (t, *J* = 7.1 Hz, 3H).

Example 173B: ethyl 8-acetyl-1,4-dioxaspiro[4.5]decane-8-carboxylate

To a solution of diisopropylamine (5.19 mL, 36.4 mmol) in 25 mL of tetrahydrofuran at 0 °C was added *n*-butyllithium (14.56 mL, 2.5 M in hexane) slowly below 5 °C. After stirring for 30 minutes, the solution was cooled to -78 °C under nitrogen, a solution of ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate (6.0 g, 28.0 mmol) in tetrahydrofuran (3 mL) was added slowly, and the mixture was stirred for 30 minutes at the same temperature. Then acetyl chloride (2.59 mL, 36.4 mmol) was added slowly to maintain the temperature below -60 °C, and the

- 323 -

mixture was stirred at -70 °C for 2 hours. The reaction was quenched with saturated aqueous NH₄Cl solution, and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified on silica gel (0~70% ethyl acetate in heptane) to give 6.78 g of the title compound. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 4.19 4.11 (m, 2H), 3.85 (s, 4H), 2.13 (s, 3H), 2.10 2.01 (m, 2H), 1.90 (ddd, *J* = 13.9, 9.6, 4.6 Hz, 2H), 1.54 (th, *J* = 13.6, 4.7 Hz, 4H), 1.18 (dd, *J* = 7.6, 6.5 Hz, 3H).

Example 173C: ethyl 1-acetyl-4-oxocyclohexanecarboxylate

A mixture of Example 173B (6.5 g, 25.4 mmol) and HCl (21.13 mL, 127 mmol) in acetone (60 mL) was stirred at ambient temperature overnight. The mixture was concentrated, and the residue was taken up in dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to give 5.46 g of the title compound that was used without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 4.16 (q, *J* = 7.1 Hz, 2H), 2.17 (s, 3H), 2.35 2.07 (m, 8H), 1.17 (t, *J* = 7.1 Hz, 3H).

Example 173D: ethyl 4-(benzylamino)-2-oxobicyclo[2.2.2]octane-1-carboxylate

A mixture of ethyl 1-acetyl-4-oxocyclohexanecarboxylate (Example 173C, 9.7 g, 45.7 mmol), benzylamine (14.98 mL, 137 mmol), and *p*-toluenesulfonic acid monohydrate (0.087 g, 0.457 mmol) in toluene (100 mL) was stirred at 130 °C in a Dean-Stark trap apparatus overnight. The mixture was concentrated, and the residue was stirred with a mixture of 50 mL of ethyl acetate and 100 mL of 3 N aqueous HCl for 30 minutes. The precipitate was collected by filtration, washed with a mixture of ethyl acetate/heptane, and air-dried to give 11.3 g of the title compound as a hydrochloride salt. The filtrate was neutralized with 6 N aqueous NaOH and extracted with ethyl acetate (100 mL x 2). The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified on silica gel (0~70% ethyl acetate in heptane) to give another 0.77 g of the title compound as yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.73 (t, *J* = 6.2 Hz, 2H), 7.87 7.12 (m, 5H), 4.09 (m, 4H), 2.88 (s, 2H), 2.08 (dt, *J* = 20.7, 13.4 Hz, 6H), 1.16 (t, *J* = 7.1 Hz, 3H). MS (ESI+) *m/z* 302.1 (M+H)⁺.

Example 173E: ethyl 4-amino-2-oxobicyclo[2.2.2]octane-1-carboxylate hydrochloride

To a mixture of ethyl 4-(benzylamino)-2-oxobicyclo[2.2.2]octane-1-carboxylate hydrochloride (Example 173D, 11.2 g, 33.2 mmol) in tetrahydrofuran (110 mL) in a 50 mL pressure bottle was added 20% Pd(OH)₂/C, wet (2.2 g, 1.598 mmol), and the reaction mixture

- 324 -

was shaken at 50 °C under 50 psi of hydrogen for 22 hours. The reaction mixture was cooled to ambient temperature and filtered washing the solids with 1000 mL of methanol. The filtrate was concentrated to give 7.9 g of the title compound as a light yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.46 (s, 3H), 4.07 (q, *J* = 7.1 Hz, 2H), 2.62 (s, 2H), 2.17 2.05 (m, 2H), 2.04 1.78 (m, 6H), 1.14 (t, *J* = 7.1 Hz, 3H).

Example 173F: ethyl 4-(2-(4-chloro-3-fluorophenoxy)acetamido)-2-oxobicyclo[2.2.2]octane-1-carboxylate

To a suspension of Example 173E (7.8 g, 31.5 mmol), *N*-ethyl-*N*-isopropylpropan-2-amine (22.00 mL, 126 mmol) and 2-(4-chloro-3-fluorophenoxy)acetic acid (7.41 g, 36.2 mmol) in *N,N*-dimethylformamide (200 mL), 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (14.97 g, 39.4 mmol) was added, and the resulting brown solution was stirred at ambient temperature for 16 hours. Water was added, and the mixture was stirred for 15 minutes. The precipitate was collected by filtration, washed with water, and air-dried to give 12.1 g of the title compound as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.87 (s, 1H), 7.45 (t, *J* = 8.9 Hz, 1H), 7.00 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.79 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 4.45 (s, 2H), 4.06 (q, *J* = 7.1 Hz, 2H), 2.73 (s, 2H), 2.07 (m, 1H), 2.01 - 1.84 (m, 6H), 1.14 (t, *J* = 7.1 Hz, 3H). MS (ESI+) *m/z* 398.0 (M+H)⁺.

Example 173G: 4-(2-(4-chloro-3-fluorophenoxy)acetamido)-2-oxobicyclo[2.2.2]octane-1-carboxylic acid

A suspension of Example 173F (11.37 g, 28.6 mmol) and sodium hydroxide (7.15 mL, 57.2 mmol) (8 M solution) in methanol (100 mL) was stirred at ambient temperature for 16 hours. The reaction mixture was concentrated, and the residue was acidified with 1 N aqueous HCl. The precipitate was collected by filtration and dried in vacuum oven to give 9.9 g of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.49 (s, 1H), 7.86 (s, 1H), 7.45 (t, *J* = 8.9 Hz, 1H), 7.00 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.83 - 6.74 (m, 1H), 4.45 (s, 2H), 2.71 (s, 2H), 2.01 - 1.81 (m, 7H). MS (ESI-) *m/z* 368.1 (M-H)⁻.

Example 173H: tert-butyl (4-(2-(4-chloro-3-fluorophenoxy)acetamido)-2-oxobicyclo[2.2.2]octan-1-yl)carbamate

A mixture of Example 173G (0.33 g, 0.892 mmol) diphenylphosphoryl azide (0.193 mL, 0.892 mmol) and triethylamine (0.124 mL, 0.892 mmol) in toluene (3 mL) was heated at 110 °C for about 45 minutes. To the resulting yellow solution, *tert*-butanol (0.427 mL, 4.46 mmol) was added, and the reaction mixture was heated at about 110 °C for about 16 hours. The mixture was

- 325 -

concentrated, and the residue was partitioned between saturated NaHCO₃ and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified on silica gel (10~100% ethyl acetate in heptane) to give 106 mg of the title compound as a white solid.

5 **Example 173I: *N,N'*-(2-oxobicyclo[2.2.2]octane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide]**

A mixture of Example 173H (0.1 g, 0.227 mmol) and 4 N hydrogen chloride in dioxane (4.0 mL, 16.00 mmol) was stirred ambient temperature for about 45 minutes. The mixture was then concentrated, and the residue was used without further purification. A mixture of this
 10 residue, 2-(4-chloro-3-fluorophenoxy)acetic acid (0.058 g, 0.284 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (0.198 mL, 1.134 mmol) in *N,N*-dimethylformamide (2.000 mL) was treated with 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.129 g, 0.340 mmol), and the reaction mixture was stirred at ambient temperature overnight. The mixture was concentrated under high vacuum, and the residue was
 15 purified by HPLC (20~95% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 μm 100 Å AXIA™ column (250 mm × 21.2 mm)) to give 96 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.88 (s, 1H), 7.67 (s, 1H), 7.45 (td, *J* = 8.9, 2.4 Hz, 2H), 7.03 (ddd, *J* = 15.1, 11.4, 2.8 Hz, 2H), 6.80 (dddd, *J* = 10.3, 9.0, 2.9, 1.2 Hz, 2H), 4.53 (s, 2H), 4.45 (s, 2H), 2.83 (s, 2H), 2.45 2.33 (m, 2H), 2.08 1.91
 20 (m, 2H), 2.01 (s, 2H), 1.80 (td, *J* = 11.8, 4.5 Hz, 2H). MS (ESI+) *m/z* 527.0 (M+H)⁺.

Example 174: *N,N'*-(2-hydroxybicyclo[2.2.2]octane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 273)

A mixture of Example 173 (65 mg, 0.123 mmol) and sodium tetrahydroborate (23.32 mg, 0.616 mmol) in a mixture of methanol/dichloromethane (1.0 mL, 1:1) was stirred at ambient
 25 temperature for 1 hour. The mixture was concentrated, and the residue was purified by HPLC (20~95% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 μm 100 Å AXIA™ column (250 mm × 21.2 mm)) to give 54 mg of the title compound as a light brown solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.49 7.39 (m, 3H), 7.22 (s, 1H), 7.00 (ddd, *J* = 12.5, 11.4, 2.9 Hz, 2H), 6.78 (dddd, *J* = 9.0, 7.9, 2.9, 1.2 Hz, 2H),
 30 5.04 (d, *J* = 4.4 Hz, 1H), 4.43 (s, 2H), 4.40 (s, 2H), 4.00 (dt, *J* = 8.7, 3.7 Hz, 1H), 2.23 (ddd, *J* = 12.2, 9.5, 2.3 Hz, 1H), 2.03 (ddd, *J* = 12.3, 10.5, 4.7 Hz, 1H), 1.88 (t, *J* = 12.9 Hz, 2H), 1.86 1.78 (m, 1H), 1.75 (ddd, *J* = 12.9, 7.8, 2.4 Hz, 4H). MS (ESI+) *m/z* 528.9 (M+H)⁺.

- 326 -

Example 175: *N,N'*-(bicyclo[1.1.1]pentane-1,3-diyl)bis{2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetamide} (Compound 274)

The title compound was prepared as described in Example 124B, except substituting Example 166B for Example 9B and Example 166A for 2-(4-chloro-3-

5 (methoxycarbonyl)phenoxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.65 (s, 2H), 7.28 (d, *J* = 8.8 Hz, 2H), 7.10 (d, *J* = 2.6 Hz, 2H), 6.73 (dd, *J* = 8.9, 2.6 Hz, 2H), 4.41 (s, 4H), 2.24 (s, 6H). MS (ESI+) *m/z* 526.8 (M+H)⁺.

Example 176: methyl 2-chloro-5-{2-[(3-{2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)amino]-2-oxoethoxy}benzoate (Compound 275)

10 The title compound was prepared as described in Example 124B, except substituting Example 166B for Example 9B. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.73 (s, 1H), 8.67 (s, 1H), 7.47 (d, *J* = 8.8 Hz, 1H), 7.37 (d, *J* = 3.0 Hz, 1H), 7.30 (d, *J* = 8.8 Hz, 1H), 7.19 7.09 (m, 2H), 6.75 (dd, *J* = 8.9, 2.5 Hz, 1H), 4.48 (s, 2H), 4.42 (s, 2H), 3.84 (s, 3H), 2.26 (s, 6H). MS (ESI-) *m/z* 536.8 (M-H)⁻.

Example 177: 2-[4-chloro-3-(hydroxymethyl)phenoxy]-*N*-(3-{2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 276)

A mixture of Example 176 (0.07, 0.130 mmol) and lithium tetrahydroborate (0.028 g, 1.299 mmol) in tetrahydrofuran (2.0 mL) was stirred at 40 °C for 24 hours. The reaction mixture was concentrated under high vacuum, and the residue was purified by HPLC (10~95%
20 acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® Luna® C18 5 μm 100 Å AXIA™ column (250 mm × 21.2 mm)) to give 23 mg of the title compound as a light yellow solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.70 (d, *J* = 16.9 Hz, 2H), 7.31 (dd, *J* = 10.7, 8.8 Hz, 2H), 7.15 (dd, *J* = 14.7, 2.9 Hz, 2H), 6.84 (dd, *J* = 8.7, 3.2 Hz, 1H), 6.77 (dd, *J* = 8.8, 2.6 Hz, 1H), 5.41 (s, 1H), 4.51 (s, 2H), 4.43 (d, *J* = 8.4 Hz, 4H), 2.27 (s, 6H). MS (ESI-) *m/z* 509.0 (M-H)⁻.
25

Example 178: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(2-cyanopyridin-4-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 277)

The title compound was prepared as described in Example 127, except substituting 4-hydroxypicolinonitrile for 6-chloro-5-methylpyridin-3-ol. ¹H NMR (400 MHz, DMSO-*d*₆) δ
30 ppm 8.76 (s, 1H), 8.68 (s, 1H), 8.56 8.49 (m, 1H), 7.68 7.63 (m, 1H), 7.46 (t, *J* = 8.9 Hz, 1H), 7.25 (dd, *J* = 5.8, 2.6 Hz, 1H), 7.04 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.64 (s, 2H), 4.44 (s, 2H), 2.23 (s, 6H). MS (ESI+) *m/z* 445.0 (M+H)⁺.

- 327 -

Example 179: 2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]-N-(3-{2-[4-(pentafluoro- λ^6 -sulfanyl)phenoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 278)

The title compound was prepared as described in Example 127, except substituting Example 166C for Example 28A and 4-(pentafluorothiol)phenol for 6-chloro-5-methylpyridin-3-ol. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 8.73 (s, 1H), 8.65 (s, 1H), 7.85 - 7.76 (m, 2H), 7.29 (d, J = 8.9 Hz, 1H), 7.13 - 7.04 (m, 3H), 6.73 (dd, J = 8.9, 2.6 Hz, 1H), 4.53 (s, 2H), 4.40 (s, 2H), 2.24 (s, 6H). MS (ESI+) m/z 572.9 (M+H) $^+$.

Example 180: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-{[6-(difluoromethoxy)pyridin-3-yl]methoxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 279)

A 2.5 mL microwave vial was charged with Example 112B (35 mg, 1 equivalent, 0.102 mmol), Cs₂CO₃ (66 mg, 0.2 mmol), 5-(chloromethyl)-2-(difluoromethoxy)pyridine (39 mg, 0.2 mmol) and potassium iodide (1.2 mg, 0.07 equivalent, 0.07 mmol). Acetone (1.5 mL) was added. The resulting mixture was heated in a Biotage® Initiator microwave reactor for 45 minutes at 140 °C (0-450 W). Upon completion, the mixture was then filtered and concentrated to dryness. The residue was dissolved in 1:1 dimethyl sulfoxide/methanol and purified by preparative reverse phase HPLC on a Phenomenex® Luna® C8(2) 5 μm 100 Å AXIA™ column (30 mm \times 150mm). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/minute (0-0.5 minutes 5% A, 0.5-8.5 minutes linear gradient 5-100% A, 8.7-10.7 minutes 100% A, 10.7 -11.0 minutes linear gradient 100-5% A) to afford the title compound. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 8.32 – 8.21 (m, 1H), 7.93 (dd, J = 8.5, 2.4 Hz, 1H), 7.66 (s, 1H), 7.54 – 7.43 (m, 1H), 7.11 – 6.99 (m, 2H), 6.84 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.53 (s, 2H), 4.45 (s, 2H), 3.86 (s, 2H), 2.24 (s, 6H). MS (APCI) m/z 500.1 (M+H) $^+$.

Example 181: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-{[6-(1H-pyrazol-1-yl)pyridin-3-yl]methoxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 280)

The title compound was prepared as described in Example 180, except substituting 5-(chloromethyl)-2-(1H-pyrazol-1-yl)pyridine for 5-(chloromethyl)-2-(difluoromethoxy)pyridine. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 8.60 (dd, J = 2.6, 0.7 Hz, 1H), 8.51 – 8.45 (m, 1H), 8.00 (dd, J = 8.4, 2.3 Hz, 1H), 7.91 (dd, J = 8.4, 0.8 Hz, 1H), 7.82 (dd, J = 1.7, 0.7 Hz, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.04 (dd, J = 11.3, 2.9 Hz, 1H), 6.89 – 6.83 (m, 1H), 6.58 (dd, J = 2.6, 1.7 Hz, 1H), 4.59 (s, 2H), 4.45 (s, 1H), 3.90 (s, 2H), 2.25 (s, 6H). MS (APCI) m/z 500.2 (M+H) $^+$.

Example 182: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[6-methoxypyridin-3-yl]methoxy}acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 281)

- 328 -

The title compound was prepared as described in Example 180, except substituting 5-(chloromethyl)-2-methoxypyridine for 5-(chloromethyl)-2-(difluoromethoxy)pyridine. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.13 (dd, *J* = 2.4, 0.7 Hz, 1H), 7.73 (dd, *J* = 8.5, 2.4 Hz, 1H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.04 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.87 – 6.79 (m, 2H), 4.46 (d, 4H), 3.84 (s, 3H), 3.82 (s, 2H), 2.23 (s, 6H). MS (APCI) *m/z* 464.2 (M+H)⁺.

Example 183: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(2,6-dimethylpyridin-4-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 282)

The title compound was prepared as described in Example 180, except substituting 4-(chloromethyl)-2,6-dimethylpyridine for 5-(chloromethyl)-2-(difluoromethoxy)pyridine. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.66 (s, 2H), 7.48 (t, *J* = 8.9 Hz, 1H), 7.04 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.85 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.76 (s, 2H), 4.46 (s, 2H), 4.00 (s, 2H), 2.66 (s, 6H), 2.27 (s, 6H). MS (APCI) *m/z* 462.2 (M+H)⁺.

Example 184: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{2-[(6-cyanopyridin-3-yl)methoxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 283)

The title compound was prepared as described in Example 180, except substituting 5-(chloromethyl)picolinonitrile hydrochloride for 5-(chloromethyl)-2-(difluoromethoxy)pyridine. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.82 – 8.74 (m, 1H), 8.02 (qd, *J* = 8.0, 1.5 Hz, 1H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.04 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.89 – 6.81 (m, 1H), 4.67 (s, 2H), 4.45 (s, 2H), 3.93 (s, 2H), 2.25 (s, 6H). MS (APCI) *m/z* 459.1 (M+H)⁺.

Example 185: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-(2-[[6-(trifluoromethyl)pyridin-3-yl]methoxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 284)

The title compound was prepared as described in Example 180, except substituting 5-(chloromethyl)-2-(trifluoromethyl)pyridine for 5-(chloromethyl)-2-(difluoromethoxy)pyridine. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (d, *J* = 1.9 Hz, 1H), 8.08 (ddd, *J* = 8.1, 2.0, 0.9 Hz, 1H), 7.90 (dd, *J* = 8.1, 0.9 Hz, 1H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.04 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.85 (ddd, *J* = 8.9, 2.8, 1.2 Hz, 1H), 4.68 (s, 2H), 4.46 (s, 2H), 3.94 (s, 2H), 2.25 (s, 6H). MS (APCI) *m/z* 502.1 (M+H)⁺.

Example 186: 2-[(5-cyclopropylpyrazin-2-yl)oxy]-*N*-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 285)

Example 186A: ethyl 2-((5-cyclopropylpyrazin-2-yl)oxy)acetate

To ethyl 2-hydroxyacetate (1.475 g, 14 mmol) in tetrahydrofuran (40 mL) at room temperature was added potassium *tert*-butoxide (20 mL, 1 M in tetrahydrofuran, 20 mmol).

- 329 -

After 5 minutes, 2-bromo-5-cyclopropylpyrazine (1.752 g, 8.8 mmol) in tetrahydrofuran (5 mL) was added. The mixture was stirred at room temperature for 2 days. The reaction was quenched by addition of water (20 mL), and then extracted with ethyl acetate (100 mL). The organic phase was concentrated to give 1.97 g of ethyl 2-((5-cyclopropylpyrazin-2-yl)oxy)acetate as a solid.

5 LC/MS (ESI+) m/z 223 (M+H)⁺.

Example 186B: 2-((5-cyclopropylpyrazin-2-yl)oxy)acetic acid

To a solution of ethyl 2-((5-cyclopropylpyrazin-2-yl)oxy)acetate (1.96 g, 8.8 mmol) in methanol (8 mL) was added 2 M aqueous potassium hydroxide solution (11 mL). The mixture was stirred at room temperature for 2 hours and was concentrated. The aqueous mixture was
10 then extracted with ethyl acetate (80 mL). Then aqueous phase was acidified with 2 N aqueous HCl solution to pH ~ 3, and then extracted with ethyl acetate (100 mL x 2). The combined organic phase was dried over Na₂SO₄. The organic phase was filtered and concentrated to give 0.6 g of the title compound as a solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.22 (s, 1H), 8.12 (s, 1H), 4.83 (s, 2H), 2.13 (m, 1H), 0.96 (m, 2H), 0.80 (m, 2H). MS (ESI+) m/z 195 (M+H)⁺.

15 *Example 186C: 2-[(5-cyclopropylpyrazin-2-yl)oxy]-N-{3-[2-(3,4-dichlorophenoxy)acetamido]-bicyclo[1.1.1]pentan-1-yl}acetamide*

To a mixture of *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide hydrochloride (0.169 g, 0.5 mmol, Example 6C) and 2-((5-cyclopropylpyrazin-2-yl)oxy)acetic acid (Example 186B, 0.097 g, 0.5 mmol) in *N,N*-
20 dimethylformamide (2 mL) was added *N,N*-diisopropylethylamine (0.194 g, 1.5 mmol), followed by 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.209 g, 0.55 mmol, HATU). The mixture was stirred at room temperature for 3 hours, and then diluted with dichloromethane (60 mL). The mixture was washed with water (50 mL x 2) and 0.02 M aqueous Na₂CO₃ solution (50 mL x 2), dried over
25 Na₂SO₄, filtered and concentrated to give 0.24 g of a solid residue. The solid was dissolved in ethyl acetate/methanol (1:1, 3 mL), and purified by flash column chromatography on silica gel (80 g) eluted with heptane and ethyl acetate (10 to 60%) to give 81 mg of the title compound (34% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.72 (s, 1H), 8.63 (s, 1H), 8.20 (s, 1H), 8.16 (s, 1H), 7.55 (d, *J* = 8, 1H), 7.24 (d, *J* = 2, 1H), 6.98 (dd, *J* = 8, 2, 1H), 4.68 (s,
30 2H), 4.48 (s, 2H), 2.23 (s, 6H), 2.13 (m, 1H), 0.96 (m, 2H), 0.82 (m, 2H). MS (ESI+) m/z 477 (M+H)⁺.

- 330 -

Example 187: 2-(4-chloro-3-fluorophenoxy)-N-(3-{[2-(3,4-dichlorophenyl)-2-oxoethyl]amino}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 286)

A mixture of *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride (Example 112A, 0.096 g, 0.3 mmol), 2-bromo-1-(3,4-dichlorophenyl)ethanone (0.096 g, 0.36 mmol) and *N,N*-diisopropylethylamine (0.116 g, 0.9 mmol) in *N,N*-dimethylformamide (0.6 mL) was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate (40 mL) and washed with 0.1 M aqueous Na₂HPO₃ solution (60 mL x3). The organic phase was dried over Na₂SO₄, filtered and concentrated to give 0.16 g of solid residue. The solid was dissolved in ethyl acetate (1.5 mL) and was purified by flash column chromatography on silica gel (80 g) eluting with heptane and ethyl acetate (70 to 100%) to give 40 mg of the title compound (28% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.60 (s, 1H), 8.18 (d, J = 2, 1H), 7.94 (dd, J = 8, 2, 1H), 7.82 (d, J = 8, 1H), 7.48 (t, J = 8, 1H), 7.07 (dd, J = 8, 2, 1H), 6.85 (dd, J = 8, 2, 1H), 4.47 (s, 2H), 4.07 (s, 2H), 1.97 (s, 6H). MS (ESI+) *m/z* 471 (M+H)⁺.

Example 188: N-(3-{[2-(4-chlorophenyl)-2-oxoethyl]amino}bicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide (Compound 287)

To *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide hydrochloride (0.338 g, 1 mmol, Example 6C), and *N,N*-diisopropylethylamine (0.45 g, 3.5 mmol) in *N,N*-dimethylformamide (1 mL) was added 2-chloro-1-(4-chlorophenyl)ethanone (0.208 g, 1.1 mmol) in *N,N*-dimethylformamide (0.5 mL). The mixture was stirred at 45 °C for 2 hours. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with 0.1 M aqueous Na₂HPO₃ solution (80 mL x 3). The organic phase was dried over Na₂SO₄, filtered and concentrated to give 0.46 g of a residue. The residue was dissolved in ethyl acetate (2 mL) and purified by flash column chromatography on silica gel (80 g) eluted with heptane and ethyl acetate (70 to 100%) to give 286 mg the title compound (63% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.60 (s, 1H), 8.00 (d, J = 8, 2H), 7.60 (d, J = 8, 2H), 7.54 (d, J = 8, 1H), 7.25 (d, J = 2, 1H), 6.98 (dd, J = 8, 2, 1H), 4.47 (s, 2H), 4.04 (s, 2H), 2.84 (m, 1H), 1.96 (s, 6H). MS (ESI+) *m/z* 453 (M+H)⁺.

Example 189: N-(3-{[2-(4-chlorophenyl)-2-hydroxyethyl]amino}bicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide (Compound 288)

A mixture of *N*-(3-{[2-(4-chlorophenyl)-2-oxoethyl]amino}bicyclo[1.1.1]pentan-1-yl)-2-(3,4-dichlorophenoxy)acetamide (Example 188, 0.254 g, 0.56 mmol) and sodium borohydride

- 331 -

(0.085 g, 2.24 mmol) in methanol (2 mL) was stirred at room temperature overnight. 1 N aqueous HCl (1.5 mL) was added. The mixture was stirred at room temperature for 1 hour and was basified with 2 M aqueous sodium carbonate solution to pH ~ 10. The mixture was extracted with ethyl acetate (25 mL x 3). The organic phase was dried over Na₂SO₄, filtered and concentrated to give 0.26 g of a residue. The residue was dissolved in ethyl acetate (2 mL) and purified by flash column chromatography on silica gel (40 g) eluted with ethyl acetate and methanol (0 to 8%) to give 182 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.60 (s, 1H), 7.54 (d, J = 8, 1H), 7.36 (m, 4H), 7.25 (t, J = 2, 1H), 6.98 (dd, J = 8, 2, 1H), 5.35 (d, J = 5, 1H), 4.57 (m, 1H), 4.46 (s, 2H), 2.58 (d, J = 8, 2H), 2.36 (m, 1H), 1.95 (m, 6H). MS (ESI+) *m/z* 455 (M+H)⁺.

Example 190: 2-(4-chloro-3-fluorophenoxy)-N-(3-([2-(4-chlorophenyl)-2-oxoethyl]amino)bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 289)

To *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride (Example 112A, 0.642 g, 2 mmol), and *N,N*-diisopropylethylamine (0.9 g, 7 mmol) in *N,N*-dimethylformamide (2 mL) was added 2-chloro-1-(4-chlorophenyl)ethanone (0.416 g, 2.2 mmol) in *N,N*-dimethylformamide (1 mL). The mixture was stirred at 45 °C for 1.5 hours. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with 0.1 M aqueous Na₂HPO₃ solution (80 mL x 3). The organic phase was dried over Na₂SO₄, filtered and concentrated to give 0.88 g of a residue. The residue was dissolved in ethyl acetate (2 mL) and purified by flash column chromatography on silica gel (80 g) eluted with heptane and ethyl acetate (70 to 100%) to give 359 mg of the title compound (41% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.60 (s, 1H), 8.00 (d, J = 8, 2H), 7.60 (d, J = 8, 2H), 7.49 (d, t = 8, 1H), 7.06 (dd, J = 8, 2, 1H), 6.84 (m, 1H), 4.46 (s, 2H), 4.05 (s, 2H), 2.84 (m, 1H), 1.96 (s, 6H). MS (ESI+) *m/z* 437 (M+H)⁺.

Example 191: 2-(4-chloro-3-fluorophenoxy)-N-(3-([2-(4-chlorophenyl)-2-hydroxyethyl]amino)bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 290)

A mixture of 2-(4-chloro-3-fluorophenoxy)-*N*-(3-([2-(4-chlorophenyl)-2-oxoethyl]amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.341 g, 0.78 mmol, Example 190) and sodium borohydride (0.118 g, 3.12 mmol) in methanol (5 mL) was stirred at room temperature overnight. 1 N aqueous HCl (1.5 mL) was added. The mixture was stirred at room temperature for 1 hour and was basified with 2 M aqueous sodium carbonate to pH ~ 10. The mixture was extracted with ethyl acetate (50 mL x 2). The organic phase was dried over Na₂SO₄, filtered and

- 332 -

concentrated to give 0.36 g of a residue. The residue was dissolved in ethyl acetate (2 mL) and purified by flash column chromatography on silica gel (40 g) eluting with ethyl acetate and methanol (0 to 9%) to give 310 mg of the title compound (90% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.60 (s, 1H), 7.48 (t, J = 8, 1H), 7.36 (m, 4H), 7.06 (dd, J = 8, 2, 1H), 6.84 (m, 1H), 5.36 (d, J = 5, 1H), 4.58 (m, 1H), 4.45 (s, 2H), 2.59 (d, J = 8, 2H), 2.35 (m, 1H), 1.95 (m, 6H). MS (ESI+) *m/z* 439 (M+H)⁺.

Example 192: 2-(4-chloro-3-fluorophenoxy)-N-(3-{[2-(4-chloro-3-fluorophenyl)-2-oxoethyl]amino}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 291)

To *N*-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride (Example 112A, 0.321 g, 1. mmol), and *N,N*-diisopropylethylamine (0.45 g, 3.5 mmol) in *N,N*-dimethylformamide (1 mL) was added 2-chloro-1-(4-chloro-3-fluorophenyl)ethanone (0.23 g, 1.1 mmol) in *N,N*-dimethylformamide (0.5 mL). The mixture was stirred at room temperature for 5 hours. The reaction mixture was diluted with ethyl acetate (80 mL) and then washed with 2 M aqueous sodium carbonate solution (50 mL x 3). The organic phase was dried over Na₂SO₄, filtered and concentrated to give 0.46 g of a residue. The residue was dissolved in ethyl acetate (2 mL) and purified by flash column chromatography on silica gel (80 g) eluting with heptane and ethyl acetate (70 to 100%) to give 164 mg of the title compound (36% yield) as a white solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.60 (s, 1H), 7.97 (dd, J = 8, 2, 1H), 7.83 (dd, J = 8, 2, 1H), 7.76 (d, t = 8, 1H), 7.47 (d, t = 8, 1H), 7.04 (dd, J = 8, 2, 1H), 6.83 (m, 1H), 4.44 (s, 2H), 4.05 (s, 2H), 2.85 (m, 1H), 1.95 (s, 6H). MS (ESI+) *m/z* 455 (M+H)⁺.

Example 193: 2-(4-chloro-3-fluorophenoxy)-N-(3-{[2-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]amino}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 292)

A mixture of 2-(4-chloro-3-fluorophenoxy)-*N*-(3-{[2-(4-chloro-3-fluorophenyl)-2-oxoethyl]amino}bicyclo[1.1.1]pentan-1-yl)acetamide (Example 192, 0.15 g, 0.33 mmol) and sodium borohydride (0.050 g, 1.32 mmol) in methanol (5 mL) was stirred at room temperature overnight. 1 N aqueous HCl (1 mL) was added. The mixture was stirred at room temperature for 1 hour and then was basified with 2 M aqueous sodium carbonate solution to pH ~ 10. The mixture was extracted with ethyl acetate (50 mL x 2). The organic phase was dried over Na₂SO₄, filtered and concentrated to give 0.36 g of a residue. The residue was dissolved in ethyl acetate (2 mL), and purified by flash column chromatography on silica gel (40 g) eluting with ethyl acetate and methanol (0 to 9%) to give 127 mg of the title compound (84% yield) as a

- 333 -

white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.60 (s, 1H), 7.50 (m, 2H), 7.35 (dd, $J=8, 1$, 1H), 7.21 (dd, $J=7, 1$, 1H), 7.06 (dd, $J=8, 2$, 1H), 6.85 (m, 1H), 5.48 (d, $J=5$, 1H), 4.58 (m, 1H), 4.45 (s, 2H), 2.61 (d, $J=8$, 2H), 2.43 (m, 1H), 1.95 (m, 6H). MS (ESI+) m/z 457 ($\text{M}+\text{H}$) $^+$.

Example 194: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(4-chlorophenyl)-3-oxopropanamide (Compound 293)

Example 194A: 3-(4-chlorophenyl)-3-oxopropanoic acid

A 100 mL round bottom flask equipped with a magnetic stir bar was charged with KOH (1.35 g, 24.1 mmol). Water (28.2 mL) was added, and as the solution was stirred at ambient temperature, methyl-3-(4-chlorophenyl)-3-oxopropanoate (3 g, 14.11 mmol) was added. The reaction mixture was stirred at ambient temperature for 44 hours. The basic aqueous reaction mixture was washed twice with methyl *tert*-butyl ether (2×10 mL), then was chilled in an ice bath and treated slowly with 1 N aqueous HCl. The resulting white precipitate was collected by filtration and rinsed with water to give the title compound (209 mg, 1.05 mmol, 7.4% yield.). ^1H NMR (501 MHz, $\text{DMSO}-d_6$) δ ppm 12.72 (s, 1H), 7.96 (d, $J=8.7$ Hz, 2H), 7.60 (d, $J=8.7$ Hz, 2H), 4.04 (s, 2H).

*Example 194B: *N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(4-chlorophenyl)-3-oxopropanamide*

A 4 mL vial, equipped with a magnetic stir bar, was charged with the product of Example 194A (87 mg, 0.44 mmol), the product of Example 112A (128 mg, 0.40 mmol), and (1-cyano-2-ethoxy-2-oxoethylidenaminoxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU, 206 mg, 0.48 mmol). The vial was sealed with a septum screw cap and the contents were placed under a dry nitrogen atmosphere. *N,N*-Dimethylformamide (DMF) (2 mL) was introduced via syringe to give a solution that was stirred at ambient temperature as *N,N*-diisopropylethylamine (0.21 mL, 1.20 mmol) was added dropwise via syringe. When the addition was complete, the reaction mixture was stirred at ambient temperature for 20.5 hours. The reaction mixture was partitioned between dilute aqueous citric acid (5 mL) and ethyl acetate (5 mL). The organic layer was washed twice with brine (2×5 mL), then dried over anhydrous MgSO_4 and filtered. The filtrate was concentrated under reduced pressure to give a yellow oil which was stirred with hot water. The water was decanted away, and the residue was treated with methyl *tert*-butyl ether to give a pale yellow solid which was isolated by filtration and combined with additional material as described below. The filtrate was dried over anhydrous MgSO_4 , filtered and concentrated. The residue was purified by preparative HPLC

- 334 -

(Phenomenex® Luna® C8(2) 5 μ m 100Å AXIA™ column (30 mm \times 75 mm); a gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/minute (0-1.0 minute 5% A, 1.0-8.5 minutes linear gradient 5-100% A, 8.5-11.5 minutes 100% A, 11.5-12.0 minutes linear gradient 95-5% A) to give additional solids. Solids were combined to give the title compound (136 mg, 0.29 mmol; 73% yield). ^1H NMR (400 MHz, CDCl_3) δ ppm 7.93 (d, J = 8.6 Hz, 2H), 7.48 (d, J = 8.6 Hz, 2H), 7.32 (t, J = 8.6 Hz, 1H), 6.83 (s, 1H), 6.76 (dd, J = 10.3, 3.0 Hz, 1H), 6.67 (ddd, J = 8.8, 2.9, 1.3 Hz, 1H), 4.39 (s, 2H), 3.89 (s, 2H), 2.48 (s, 6H); MS (ESI^+) m/z 465 ($\text{M}+\text{H}$) $^+$.

Example 195: (2E)-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(4-chlorophenyl)prop-2-enamide (Compound 294)

The title compound was prepared using the methodologies described above. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.74 (s, 1H), 8.73 (s, 1H), 7.57 (d, J = 8.6 Hz, 2H), 7.53 – 7.45 (m, 3H), 7.39 (d, J = 15.8 Hz, 1H), 7.08 (dd, J = 11.4, 2.8 Hz, 1H), 6.86 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 6.54 (d, J = 15.9 Hz, 1H), 4.49 (s, 2H), 2.29 (s, 6H); MS (ESI^+) m/z 449 ($\text{M}+\text{H}$) $^+$.

Example 196: 2-(3,4-dichlorophenoxy)-N-(3-{2-[(6-methylpyridin-3-yl)oxy]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 295)

The reaction and purification conditions described in Example 107B substituting the product of Example 6C for the product of Example 9B gave the title compound. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.71 (br s, 2H), 8.16 (d, J = 3.0 Hz, 1H), 7.55 (d, J = 8.9 Hz, 1H), 7.29 – 7.23 (m, 2H), 7.19 – 7.14 (m, 1H), 6.99 (dd, J = 8.9, 2.9 Hz, 1H), 4.49 (s, 2H), 4.47 (s, 2H), 2.39 (s, 3H), 2.26 (br s, 6H); MS (ESI^+) m/z 450 ($\text{M}+\text{H}$) $^+$.

Example 197: 2-[[2,6-bis(trifluoromethyl)pyridin-4-yl]oxy]-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}acetamide (Compound 296)

A mixture of Example 28A (60.0 mg, 0.166 mmol), 2,6-bis(trifluoromethyl)pyridin-4-ol (57.6 mg, 0.25 mmol), and potassium carbonate (45.9 mg, 0.33 mmol) in acetone (2.5 mL) was heated at 130 °C in a Biotage® Initiator microwave reactor for 20 minutes. The reaction mixture was concentrated under reduced pressure. The residue was treated with brine and extracted with ethyl acetate (2 \times). The combined organic layers were concentrated under reduced pressure, and the residue was purified by reverse-phase HPLC (see protocol in Example 112D) to provide the title compound (35 mg, 0.063 mmol, 38% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.82 (s, 1H), 8.71 (s, 1H), 7.78 (s, 2H), 7.48 (t, J = 8.9 Hz, 1H), 7.05 (dd, J = 11.4, 2.8 Hz, 1H), 6.83

- 335 -

(ddd, $J = 9.0, 2.9, 1.2$ Hz, 1H), 4.84 (s, 2H), 4.46 (s, 2H), 2.26 (s, 6H); MS (ESI⁺) m/z 556.0 (M+H)⁺.

Example 198: *N,N'*-[(2*S*)-2-hydroxybicyclo[2.2.2]octane-1,4-diyl]bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 297)

5 *Example 198A: ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate*

A mixture of ethyl 4-oxocyclohexanecarboxylate (11.70 mL, 73.4 mmol), ethane-1,2-diol (12.29 mL, 220 mmol), and *p*-toluenesulfonic acid monohydrate (1.397 g, 7.34 mmol) in toluene (200 mL) was stirred at 120 °C with a Dean-Stark trap apparatus for 180 minutes. The reaction mixture was neutralized with *N*-ethyl-*N*-isopropylpropan-2-amine and then concentrated. The residue was purified on silica gel (0-30% ethyl acetate in heptane) to give 12.77 g of the title compound as a clear oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 4.01 (q, $J = 7.1$ Hz, 2H), 3.81 (s, 4H), 2.32 (tt, $J = 10.4, 3.8$ Hz, 1H), 1.83 – 1.71 (m, 2H), 1.66 – 1.57 (m, 1H), 1.62 – 1.38 (m, 5H), 1.13 (t, $J = 7.1$ Hz, 3H).

Example 198B: ethyl 8-acetyl-1,4-dioxaspiro[4.5]decane-8-carboxylate

15 To a solution of diisopropylamine (5.19 mL, 36.4 mmol) in tetrahydrofuran (25 mL) at 0 °C was added *n*-butyllithium slowly below 5 °C. After stirring for 30 minutes, the solution was cooled to -78 °C under nitrogen, and a solution of Example 198A (6.0 g, 28.0 mmol) in tetrahydrofuran (3 mL) was added slowly, and the resultant mixture was stirred for 30 minutes at the same temperature. Then acetyl chloride (2.59 mL, 36.4 mmol) was added slowly to maintain the temperature below -60 °C, and the mixture was stirred at -70 °C for 2 hours. The reaction was quenched with saturated NH₄Cl solution, and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified on silica gel (0-70% ethyl acetate in heptane) to give 6.78 g of the title compound as a clear oil. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 4.19 – 4.11 (m, 2H), 3.85 (s, 4H), 2.13 (s, 3H), 2.10 – 2.01 (m, 2H), 1.90 (ddd, $J = 13.9, 9.6, 4.6$ Hz, 2H), 1.54 (th, $J = 13.6, 4.7$ Hz, 4H), 1.18 (dd, $J = 7.6, 6.5$ Hz, 3H).

Example 198C: ethyl 1-acetyl-4-oxocyclohexane-1-carboxylate

A mixture of Example 198B (6.5 g, 25.4 mmol) and HCl (21.13 mL, 127 mmol) in acetone (60 mL) was stirred at ambient temperature overnight. Volatiles were removed under reduced pressure, and the residue was partitioned between water and dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to give 5.46 g of the title compound as a clear oil, used without further purification.

- 336 -

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 4.16 (q, *J* = 7.1 Hz, 2H), 2.17 (s, 3H), 2.35 2.07 (m, 8H), 1.17 (t, *J* = 7.1 Hz, 3H).

Example 198D: ethyl 4-(benzylamino)-2-oxobicyclo[2.2.2]octane-1-carboxylate

A mixture of Example 198C (9.7 g, 45.7 mmol), benzylamine (14.98 mL, 137 mmol),
5 and *p*-toluenesulfonic acid monohydrate (0.087 g, 0.457 mmol) in toluene (100 mL) was stirred
at 130 °C with Dean-Stark trap apparatus overnight. The mixture was concentrated, and the
residue was stirred with a mixture of ethyl acetate (50 mL) and 3 N HCl (100 mL) for 30
minutes. The precipitate was collected by filtration, washed with mixture of ethyl
acetate/heptane, air-dried to give 11.3 g of title compound as a HCl salt. The filtrate was
10 neutralized with 6 N NaOH and extracted with ethyl acetate (100 mL × 2). The organic layer
was washed with brine, dried over magnesium sulfate and filtered. The residue was purified on
silica gel (0-70% ethyl acetate in heptane) to give another 0.77 g of the title compound as yellow
solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.73 (t, *J* = 6.2 Hz, 2H), 7.87 – 7.12 (m, 5H), 4.09
(m, 4H), 2.88 (s, 2H), 2.08 (dt, *J* = 20.7, 13.4 Hz, 6H), 1.16 (t, *J* = 7.1 Hz, 3H); MS (ESI⁺) *m/z*
15 302.1 (M+H)⁺.

Example 198E: ethyl 4-amino-2-oxobicyclo[2.2.2]octane-1-carboxylate, hydrochloric acid

To a mixture of Example 198D (11.2 g, 33.2 mmol) in tetrahydrofuran (110 mL) in a 50
mL pressure bottle was added 20% Pd(OH)₂/C, wet (2.2 g, 1.598 mmol), and the reaction was
shaken at 50 °C under 50 psi of hydrogen for 22 hours. The reaction mixture was cooled to
20 ambient temperature, solids were removed by filtration and washed with methanol (1 L). The
filtrate and wash were concentrated to give 7.9 g of the title compound as a light yellow solid.
¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.46 (s, 3H), 4.07 (q, *J* = 7.1 Hz, 2H), 2.62 (s, 2H), 2.17
– 2.05 (m, 2H), 2.04 – 1.78 (m, 6H), 1.14 (t, *J* = 7.1 Hz, 3H).

Example 198F: ethyl 4-[2-(4-chloro-3-fluorophenoxy)acetamido]-2-oxobicyclo[2.2.2]octane-1-
25 *carboxylate*

To a suspension of Example 198E (7.8 g, 31.5 mmol), *N*-ethyl-*N*-isopropylpropan-2-
amine (22.00 mL, 126 mmol) and 2-(4-chloro-3-fluorophenoxy)acetic acid (7.41 g, 36.2 mmol)
in *N,N*-dimethylformamide (200 mL), 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-
tetramethylisouronium hexafluorophosphate(V) (14.97 g, 39.4 mmol) was added, and the
30 resulting brown solution was stirred at ambient temperature for 16 hours. Water was added, and
the mixture was stirred for 15 minutes. The precipitate was collected by filtration, washed with
water, and air-dried to give 12.1 g of the title compound as an off-white solid. ¹H NMR (400

- 337 -

MHz, DMSO- d_6) δ ppm 7.87 (s, 1H), 7.45 (t, J = 8.9 Hz, 1H), 7.00 (dd, J = 11.4, 2.9 Hz, 1H), 6.79 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 4.45 (s, 2H), 4.06 (q, J = 7.1 Hz, 2H), 2.73 (s, 2H), 2.07 (m, 1H), 2.01 – 1.84 (m, 6H), 1.14 (t, J = 7.1 Hz, 3H); MS (ESI⁺) m/z 398.0 (M+H)⁺.

Example 198G: 4-[2-(4-chloro-3-fluorophenoxy)acetamido]-2-oxobicyclo[2.2.2]octane-1-carboxylic acid

A suspension of Example 198F (11.37 g, 28.6 mmol) and sodium hydroxide (7.15 mL, 57.2 mmol, 8 M solution) in methanol (100 mL) was stirred at ambient temperature for 16 hours. Volatiles were removed, and the residue was acidified with 1 N HCl. The precipitate was collected by filtration and dried in vacuum oven to give 9.9 g of the title compound as a white solid. ¹H NMR (400 MHz, DMSO- d_6) δ ppm 12.49 (s, 1H), 7.86 (s, 1H), 7.45 (t, J = 8.9 Hz, 1H), 7.00 (dd, J = 11.4, 2.9 Hz, 1H), 6.83 – 6.74 (m, 1H), 4.45 (s, 2H), 2.71 (s, 2H), 2.01 – 1.81 (m, 7H); MS (ESI⁻) m/z 368.1 (M-H)⁻.

Example 198H: N-(4-amino-3-oxobicyclo[2.2.2]octan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide

A mixture of Example 198G (3.24 g, 8.76 mmol), diphenylphosphoryl azide (2.84 mL, 13.14 mmol), and triethylamine (3.66 mL, 26.3 mmol) in toluene (100 mL) was heated at 110 °C for 2 hours. The solution was cooled to ambient temperature and poured into 150 mL of 3 N HCl solution. The mixture was stirred for 16 hours to give a suspension. The precipitate was filtered, washed with ethyl acetate, and air-dried to give the title compound (1.63 g) as an HCl salt as a white solid. The filtrate was then basified with solid sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified on silica gel (0-10% methanol/dichloromethane) to give the title compound (0.6 g) as the free base. ¹H NMR (400 MHz, DMSO- d_6) δ ppm 8.49 (s, 3H), 8.08 (s, 1H), 7.45 (t, J = 8.9 Hz, 1H), 7.01 (dd, J = 11.4, 2.8 Hz, 1H), 6.79 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.48 (s, 2H), 2.90 (s, 2H), 2.12 – 1.79 (m, 8H).

Example 198I: N-(4-amino-3-hydroxybicyclo[2.2.2]octan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide hydrochloride

A mixture of Example 198H (2.5 g, 6.63 mmol) and sodium borohydride (1.254 g, 33.1 mmol) in a 1:1 mixture of methanol/dichloromethane (50 mL) was stirred for 24 hours. Volatiles were removed, and the residue was partitioned between water and dichloromethane. The organic fraction was separated, dried (MgSO₄), and concentrated. The residue was then treated with 4 N HCl in dioxane. The suspension was sonicated and concentrated. The residue

- 338 -

was dried under vacuum to give 2.82 g of the title compound as a light yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 7.97 (s, 3H), 7.72 (s, 1H), 7.40 (t, $J = 8.9$ Hz, 1H), 6.95 (dd, $J = 11.4, 2.8$ Hz, 1H), 6.74 (ddd, $J = 9.0, 2.9, 1.1$ Hz, 1H), 5.64 (s, 1H), 4.41 (s, 2H), 3.83 (d, $J = 9.1$ Hz, 1H), 2.24 (td, $J = 10.8, 9.9, 5.3$ Hz, 1H), 1.96 – 1.51 (m, 9H); MS (ESI^+) m/z 343.0 ($\text{M}+\text{H}$) $^+$.

5 *Example 198J: N,N'-(2-oxobicyclo[2.2.2]octane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide]*

A mixture of Example 198H (0.5 g, 1.325 mmol), 2-(4-chloro-3-fluorophenoxy)acetic acid (0.339 g, 1.657 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (1.157 mL, 6.63 mmol) in *N,N*-dimethylformamide (20 mL) was treated with 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.756 g, 1.988 mmol), and the reaction mixture was stirred at ambient temperature for 30 minutes to see a complete conversion. Water was added, and the resultant mixture was stirred for 15 minutes. The precipitate was collected by filtration, washed with water, and dried in vacuum oven at 50 °C for 2 hours to give 0.64 g of the title compound as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 7.88 (s, 1H), 7.67 (s, 1H), 7.45 (td, $J = 8.9, 2.4$ Hz, 2H), 7.03 (ddd, $J = 15.0, 11.4, 2.8$ Hz, 2H), 6.80 (dddd, $J = 10.3, 8.9, 2.9, 1.2$ Hz, 2H), 4.53 (s, 2H), 4.45 (s, 2H), 2.83 (s, 2H), 2.45 – 2.33 (m, 2H), 2.10 – 1.90 (m, 4H), 1.81 (td, $J = 11.6, 6.3$ Hz, 2H); MS (ESI^+) m/z 527.0 ($\text{M}+\text{H}$) $^+$.

Example 198K: N,N'-(2-hydroxybicyclo[2.2.2]octane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide]

20 To a solution of Example 198J (0.63 g, 1.195 mmol) in dichloromethane (10 mL) and methanol (10 mL), sodium borohydride (0.226 g, 5.97 mmol) was added portionwise, and the mixture was stirred at ambient temperature for 4 hours. Volatiles were removed, and the residue was triturated with dichloromethane/methanol to give 0.32 g of the title compound as a white solid. The filtrate was concentrated, and the residue was purified on silica gel (10-100% ethyl acetate in heptane) to give 0.21 g of the title compound. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 7.49 – 7.39 (m, 3H), 7.22 (s, 1H), 7.00 (ddd, $J = 12.4, 11.4, 2.8$ Hz, 2H), 6.78 (tdd, $J = 9.1, 2.9, 1.2$ Hz, 2H), 5.04 (s, 1H), 4.41 (d, $J = 13.3$ Hz, 4H), 4.00 (dd, $J = 9.6, 3.1$ Hz, 1H), 2.23 (ddd, $J = 12.1, 9.4, 2.2$ Hz, 1H), 2.09 – 1.97 (m, 1H), 1.93 – 1.80 (m, 2H), 1.84 – 1.68 (m, 6H); MS (ESI^+) m/z 529.1 ($\text{M}+\text{H}$) $^+$.

30 *Example 198L: N,N'-[(2*S*)-2-hydroxybicyclo[2.2.2]octane-1,4-diyl]bis[2-(4-chloro-3-fluorophenoxy)acetamide]*

- 339 -

The title compound was isolated by chiral preparative SFC (Supercritical Fluid Chromatography) of Example 198K as the second peak eluted off the column. Preparative SFC was performed on a THAR/Waters SFC 80 system running under SuperChrom™ software control. The preparative SFC system was equipped with an 8-way preparative column switcher, CO₂ pump, modifier pump, automated back pressure regulator (ABPR), UV detector, and 6-position fraction collector. The mobile phase was comprised of supercritical CO₂ supplied by a Dewar of bone-dry non-certified CO₂ pressurized to 350 psi with a modifier of methanol at a flow rate of 70 g/minute. The column was at ambient temperature, and the backpressure regulator was set to maintain 100 bar. The sample was dissolved in a mixture of methanol/dichloromethane (1:1) at a concentration of 10 mg/mL. The sample was loaded into the modifier stream in 1 mL (10 mg) injections. The mobile phase was held isocratically at 30% methanol:CO₂. Fraction collection was time triggered. The instrument was fitted with a Chiralpak® AD-H column with dimensions 21 mm i.d. × 250 mm length with 5 μm particles. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.49 – 7.39 (m, 3H), 7.23 (s, 1H), 7.00 (ddd, *J* = 12.4, 11.4, 2.9 Hz, 2H), 6.78 (dddd, *J* = 9.0, 8.0, 2.9, 1.2 Hz, 2H), 5.05 (s, 1H), 4.41 (d, *J* = 13.5 Hz, 4H), 4.00 (dd, *J* = 9.4, 3.0 Hz, 1H), 2.23 (ddd, *J* = 12.3, 9.4, 2.3 Hz, 1H), 2.03 (ddd, *J* = 12.3, 10.5, 4.7 Hz, 1H), 1.89 (d, *J* = 10.7 Hz, 2H), 1.87 – 1.76 (m, 1H), 1.74 (ddd, *J* = 12.6, 6.7, 2.4 Hz, 5H); MS (ESI⁺) *m/z* 529.1 (M+H)⁺.

Example 199: *N,N'*-(2*R*)-2-hydroxybicyclo[2.2.2]octane-1,4-diyl]bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 298)

The title compound was isolated using the chiral preparative SFC described in Example 198 as the first peak eluted off the column. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.53 – 7.43 (m, 3H), 7.28 (s, 1H), 7.04 (ddd, *J* = 12.3, 11.5, 2.9 Hz, 2H), 6.82 (tdd, *J* = 9.0, 2.9, 1.2 Hz, 2H), 5.10 (s, 1H), 4.45 (d, *J* = 13.5 Hz, 4H), 4.04 (dd, *J* = 9.6, 3.1 Hz, 1H), 2.27 (ddd, *J* = 12.2, 9.4, 2.2 Hz, 1H), 2.07 (ddd, *J* = 12.2, 10.4, 4.7 Hz, 1H), 1.96 – 1.72 (m, 8H); MS (ESI⁺) *m/z* 529.1 (M+H)⁺.

Example 200: *N,N'*-(2-methoxybicyclo[2.2.2]octane-1,4-diyl]bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 299)

To a suspension of Example 198K (0.05 g, 0.094 mmol) and potassium hydroxide (6.62 mg, 0.118 mmol) in dimethyl sulfoxide (1.0 mL) at 0 °C was added iodomethane (7.38 μL, 0.118 mmol), and the mixture was stirred at ambient temperature for 30 minutes. Water was added, and the mixture was extracted with dichloromethane. The organic layer was dried over

- 340 -

magnesium sulfate and concentrated. The residue was purified by HPLC (performed on a Phenomenex® Luna® C18(2) 5 µm 100Å AXIA™ column (250 mm × 21.2 mm) or Phenomenex® Luna® C18(2) 10 µm 100Å AXIA™ column (250 mm × 50 mm). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 25 mL/minute. A linear gradient was used from about 5% of A to about 95% of A over about 10 minutes. Detection method was UV at wave lengths of 218 nm and 254 nm) to give 18 mg of the title compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.32 (td, J = 8.6, 3.7 Hz, 2H), 6.78 – 6.70 (m, 2H), 6.75 – 6.61 (m, 3H), 6.14 (s, 1H), 4.35 (d, J = 5.7 Hz, 4H), 3.73 (ddd, J = 9.2, 3.8, 1.6 Hz, 1H), 3.34 (s, 3H), 2.65 – 2.45 (m, 3H), 2.17 – 1.81 (m, 7H); MS (ESI⁺) *m/z* 541.2 (M-H)⁺.

Example 201: *N,N'*-[2-(dimethylamino)bicyclo[2.2.2]octane-1,4-diyl]bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 300)

A mixture of Example 198J (100 mg, 0.190 mmol), dimethylamine (0.119 mL, 0.237 mmol) and tetraisopropoxytitanium(IV) (0.167 mL, 0.569 mmol) in dichloroethane (2.0 mL) was stirred at 85 °C in a microwave vial for 8 hours. The vial was cooled to ambient temperature and sodium triacetoxyborohydride (201 mg, 0.948 mmol) was added, and the mixture was stirred at 85 °C for 16 hours. Volatiles were removed, and the residue was purified by HPLC (10-95% acetonitrile in 0.1% trifluoroacetic acid/water over 15 minutes at 25 mL/minute on a Phenomenex® C18 5 µm (250 mm × 21.2 mm) column) to give 6 mg of the titled compound as a solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.95 (s, 1H), 7.98 (s, 1H), 7.86 (s, 1H), 7.54 (td, J = 8.9, 4.6 Hz, 2H), 7.10 (td, J = 11.3, 2.8 Hz, 2H), 6.88 (td, J = 8.6, 2.7 Hz, 2H), 4.66 – 4.50 (m, 4H), 4.34 (d, J = 9.4 Hz, 1H), 2.84 (dd, J = 21.6, 4.7 Hz, 6H), 2.37 (td, J = 11.9, 10.4, 2.8 Hz, 1H), 2.32 – 2.08 (m, 4H), 2.12 – 2.00 (m, 1H), 1.97 – 1.74 (m, 3H), 1.52 (ddd, J = 22.1, 14.1, 8.1 Hz, 1H); MS (ESI⁺) *m/z* 556.1 (M+H)⁺.

Example 202: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-hydroxy-4-(2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 301)

A mixture of Example 198I (0.1 g, 0.219 mmol), 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid (0.073 g, 0.328 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (0.153 mL, 0.876 mmol) in *N,N*-dimethylformamide (2.0 mL) was treated with 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.125 g, 0.328 mmol), and the reaction mixture was stirred at ambient temperature overnight. Volatiles were removed

- 341 -

under high vacuum, and the residue was purified by HPLC (10-95% acetonitrile in 0.1% trifluoroacetic acid/water over 15 minutes at 25 mL/minute on a Phenomenex® C18 5 µm (250 mm × 21.2 mm) column) to give 47 mg of the title compound as a solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.40 (d, J = 2.9 Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.55 – 7.40 (m, 3H), 7.36 (s, 1H), 6.99 (dd, J = 11.4, 2.8 Hz, 1H), 6.77 (ddd, J = 9.0, 3.0, 1.2 Hz, 1H), 5.00 (s, 1H), 4.61 (s, 2H), 4.40 (s, 2H), 4.05 (d, J = 9.3 Hz, 1H), 2.23 (dd, J = 13.2, 9.5 Hz, 1H), 2.04 – 1.85 (m, 4H), 1.81 – 1.68 (m, 5H); MS (ESI⁺) *m/z* 546.0 (M+H)⁺.

Example 203: 2-(4-chloro-3-fluorophenoxy)-*N*-[(3*S*)-3-hydroxy-4-(2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide

(Compound 302)

The title compound was isolated by chiral preparative SFC of Example 202 as the second peak eluted off the column using the methodologies described in Example 198. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.40 (d, J = 2.9 Hz, 1H), 7.81 (d, J = 8.7 Hz, 1H), 7.55 – 7.40 (m, 3H), 7.36 (s, 1H), 6.99 (dd, J = 11.4, 2.9 Hz, 1H), 6.77 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 5.00 (d, J = 4.3 Hz, 1H), 4.61 (s, 2H), 4.40 (s, 2H), 4.04 (dt, J = 8.1, 3.2 Hz, 1H), 2.23 (dd, J = 13.1, 9.6 Hz, 1H), 2.04 – 1.81 (m, 4H), 1.86 1.68 (m, 5H); MS (ESI⁺) *m/z* 545.9 (M+H)⁺.

Example 204: 2-(4-chloro-3-fluorophenoxy)-*N*-[(3*R*)-3-hydroxy-4-(2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide

(Compound 303)

The title compound was isolated by chiral preparative SFC of Example 202 as the first peak eluted off the column using the methodologies described in Example 198. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.40 (d, J = 2.9 Hz, 1H), 7.81 (d, J = 8.7 Hz, 1H), 7.55 7.36 (m, 4H), 6.98 (dd, J = 11.4, 2.8 Hz, 1H), 6.77 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 5.03 (s, 1H), 4.61 (s, 2H), 4.40 (s, 2H), 4.04 (d, J = 9.0 Hz, 1H), 2.23 (dd, J = 13.2, 9.6 Hz, 1H), 2.04 – 1.81 (m, 4H), 1.83 – 1.68 (m, 5H); MS (ESI⁺) *m/z* 546.0 (M+H)⁺.

Example 205: benzyl [2-({3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}amino)-2-oxoethyl]carbamate (Compound 304)

The reaction and purification conditions described in Example 107B substituting ((benzyloxy)carbonyl)glycine (Aldrich) for the product of Example 107A gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.47 (s, 1H), 7.49 (t, J = 8.9 Hz, 1H), 7.40 – 7.27 (m, 6H), 7.07 (dd, J = 11.4, 2.9 Hz, 1H), 6.85 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 5.03 (s, 2H), 4.47 (s, 2H), 3.55 (d, J = 6.2 Hz, 2H), 2.22 (br s, 6H); MS (ESI⁺) *m/z* 476 (M+H)⁺.

- 342 -

Example 206: 2-(4-chloro-3-fluorophenoxy)-N-(4-{2-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)oxy]acetamido}-3-hydroxybicyclo[2.2.2]octan-1-yl)acetamide (Compound 305)

Example 206A: 2,2-difluoro-2H-1,3-benzodioxol-5-ol

To a cold solution of 5-bromo-2,2-difluorobenzo[d][1,3]dioxole (5.75 mL, 42.2 mmol) in tetrahydrofuran (80 mL) was added a 2.0 M solution of isopropylmagnesium chloride in tetrahydrofuran (28.1 mL, 56.1 mmol) within 5-7 minutes by keeping the temperature around 10-20 °C. The reaction mixture was stirred at the same temperature for 15 minutes and then was allowed to attain ambient temperature for overnight. The reaction mixture was cooled with an ice bath, and triisopropyl borate (12.74 mL, 54.9 mmol) was added dropwise over 2 minutes. The reaction mixture was stirred at ambient temperature for 30 minutes. Then the reaction mixture was cooled to 10 °C, and 10% sulfuric acid solution (50 mL) was added slowly to the reaction mixture resulting in a slight exotherm up to 20 °C. The reaction mixture was stirred at ambient temperature for 15 minutes and transferred to separating funnel. Some water was added to dissolve salts. The aqueous layer was separated and washed with ethyl acetate. The combined organic fractions were washed with a saturated aqueous solution of sodium bicarbonate. The organic extract was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was then dissolved in *tert*-butyl methyl ether (100 mL), cooled to 0 °C and 30% hydrogen peroxide solution in water (5.39 mL, 52.7 mmol) was added slowly to the reaction mixture followed by water (60 mL). The mixture was stirred overnight while warming up to ambient temperature. The reaction mixture was diluted with ethyl acetate and washed twice with 10% sodium thiosulfate solution and brine. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified on silica gel (0-50% ethyl acetate in heptane) to give 6.43 g of the title compound as an amber oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.79 (s, 1H), 7.16 (d, *J* = 8.7 Hz, 1H), 6.79 (d, *J* = 2.4 Hz, 1H), 6.56 (dd, *J* = 8.7, 2.5 Hz, 1H).

Example 206B: 2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)acetic acid

To a solution of Example 206A in *N,N*-dimethylformamide (30 mL) at ambient temperature was added potassium carbonate (4.76 g, 34.5 mmol) and *tert*-butyl bromoacetate (2.91 mL, 19.82 mmol). This mixture was warmed to 65 °C and was allowed to stir for 1.5 hours. The mixture was allowed to cool to ambient temperature and was diluted with ethyl acetate (50 mL) and water (50 mL). The layers were separated, and the aqueous layer was extracted with ethyl acetate (3 × 15 mL). The combined organic extracts were dried over

- 343 -

anhydrous Na₂SO₄, filtered, concentrated under reduced pressure to give *tert*-butyl [(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetate which was used without further purification. This crude was dissolved in methanol (60 mL) and water (20.00 mL) and treated with 5 M sodium hydroxide solution (17.35 mL, 87 mmol). This reaction mixture was allowed to stir at ambient temperature for 2 hours. Volatiles were removed under reduced pressure, and the residue was acidified with 1 N HCl solution. The resulting precipitate was collected by filtration, air-dried to give the title compound (3.28 g, 14.13 mmol, 81 % yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (s, 1H), 7.30 (d, J = 8.9 Hz, 1H), 7.13 (d, J = 2.6 Hz, 1H), 6.73 (dd, J = 8.9, 2.6 Hz, 1H), 4.69 (s, 2H); MS (ESI⁻) *m/z* 231.0 (M-H)⁻.

10 **Example 206C:** 2-(4-chloro-3-fluorophenoxy)-*N*-(4-{2-[(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)oxy]acetamido}-3-hydroxybicyclo[2.2.2]octan-1-yl)acetamide

The title compound was prepared using the methodologies described in Example 202 substituting Example 206B for 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 7.49 – 7.40 (m, 2H), 7.28 (d, J = 8.9 Hz, 1H), 7.19 (s, 1H), 7.09 (d, J = 2.6 Hz, 1H), 6.99 (dd, J = 11.4, 2.8 Hz, 1H), 6.81 – 6.67 (m, 2H), 4.39 (d, J = 2.6 Hz, 4H), 3.99 (dd, J = 9.7, 3.1 Hz, 1H), 2.24 (ddd, J = 12.4, 9.5, 2.4 Hz, 1H), 2.12 – 2.00 (m, 1H), 1.96 – 1.69 (m, 8H); MS (ESI⁺) *m/z* 557.0 (M+H)⁺.

Example 207: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-hydroxy-4-(2-[[5-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide
20 **(Compound 306)**

Example 207A: 2-chloro-*N*-{4-[2-(4-chloro-3-fluorophenoxy)acetamido]-2-oxobicyclo[2.2.2]octan-1-yl}acetamide

To a mixture of Example 198H (0.6 g, 1.591 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (1.389 mL, 7.95 mmol) in tetrahydrofuran (10.0 mL), 2-chloroacetyl chloride (0.198 g, 1.750 mmol) was added dropwise, and the mixture was stirred at ambient temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified on silica gel (0-75%ethyl acetate in heptane) to afford 0.43 g of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.86 (d, J = 13.7 Hz, 2H), 7.45 (t, J = 8.9 Hz, 1H), 7.01 (dd, J = 11.4, 2.9 Hz, 1H), 6.79 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.45 (s, 2H), 4.09 (s, 2H), 2.82 (s, 2H), 2.37 - 1.75 (m, 8H); MS (ESI⁺) *m/z* 417.0 (M+H)⁺.

- 344 -

Example 207B: 2-(4-chloro-3-fluorophenoxy)-N-[3-hydroxy-4-(2-{[5-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide

A mixture of Example 207A (0.043 g, 0.103 mmol), 5-(trifluoromethyl)pyridin-3-ol (0.034 g, 0.206 mmol), potassium carbonate (0.028 g, 0.206 mmol) and potassium iodide (1.198 mg, 7.21 μ mol) in acetone (1.0 mL) was stirred at 140 °C in a 2 mL microwave via for 45 minutes. The cooled suspension was filtered, and the crude material was purified by HPLC (10-85% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on Phenomenex® C18 5 μ m column) to give 44 mg of 2-(4-chloro-3-fluorophenoxy)-N-[3-oxo-4-(2-{[5-(trifluoromethyl)pyridin-3-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide as a light yellow solid. The solid was dissolved in a mixture of methanol/dichloromethane (1:1, 2 mL) and treated with sodium borohydride (0.019 g, 0.515 mmol). The reaction mixture was stirred at ambient temperature for 1 hour. Water was added, and the mixture was extracted with dichloromethane. The organic layer was separated, dried (MgSO₄), and concentrated to give 32 mg of the title compound as a light brown solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.58 – 8.50 (m, 2H), 7.68 (s, 1H), 7.49 – 7.39 (m, 2H), 7.35 (s, 1H), 6.98 (dd, J = 11.4, 2.8 Hz, 1H), 6.77 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 5.02 (s, 1H), 4.63 (s, 2H), 4.40 (s, 2H), 4.03 (dd, J = 9.8, 3.1 Hz, 1H), 2.29 – 2.18 (m, 1H), 2.04 – 1.76 (m, 4H), 1.80 – 1.68 (m, 5H); MS (ESI⁺) *m/z* 546.1 (M+H)⁺.

Example 208: (2*S*)-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-2-(4-chlorophenyl)-2-hydroxyacetamide (Compound 307)

The title compound was prepared using the methodologies described above. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.35 (s, 4H), 7.32 (t, J = 8.6 Hz, 1H), 6.85 (s, 1H), 6.77 – 6.71 (m, 2H), 6.66 (ddd, J = 8.9, 2.9, 1.3 Hz, 1H), 5.00 (d, J = 3.2 Hz, 1H), 4.37 (s, 2H), 3.54 (d, J = 3.6 Hz, 1H), 2.45 (s, 6H); MS (ESI⁺) *m/z* 453 (M+H)⁺.

Example 209: 2-(4-chloro-3-fluorophenoxy)-N-[3-hydroxy-4-(2-{[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 308)

The title compound was prepared using the methodologies described in Example 207 substituting 2-(trifluoromethyl)pyridin-4-ol for 5-(trifluoromethyl)pyridin-3-ol. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.53 (d, J = 5.7 Hz, 1H), 7.49 – 7.39 (m, 2H), 7.43 – 7.34 (m, 2H), 7.19 (dd, J = 5.8, 2.5 Hz, 1H), 6.98 (dd, J = 11.4, 2.8 Hz, 1H), 6.77 (dt, J = 8.7, 1.8 Hz, 1H), 4.64 (s,

- 345 -

2H), 4.40 (s, 2H), 4.05 (dd, J = 9.5, 3.0 Hz, 1H), 2.23 (dd, J = 13.2, 9.3 Hz, 1H), 2.02 – 1.74 (m, 9H); MS (ESI⁺) *m/z* 546.2 (M+H)⁺.

Example 210: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-[[3-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydropyridazin-4-yl]oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 309)

Examples 210A and B: tert-butyl {[5-chloro-3-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydropyridazin-4-yl]oxy}acetate (A) and tert-butyl {[5-chloro-6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl]oxy}acetate (B)

A 100 mL round bottom flask, equipped with a magnetic stir bar, was charged with *tert*-butyl 2-hydroxyacetate (1.07 g, 8.10 mmol) and 4,5-dichloro-2-(2,2,2-trifluoroethyl)pyridazin-3(2H)-one (FCH Group; CAS: 97137-16-1; 2 g, 8.10 mmol). The flask contents were placed under a dry nitrogen atmosphere and tetrahydrofuran (THF) (16 mL) was introduced via syringe. The resulting solution was stirred at ambient temperature as lithium bis(trimethylsilyl)amide (1.0 M in THF; 8.10 mL, 8.10 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 65 hours. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with dilute aqueous citric acid (2 × 10 mL) and with brine (1 × 10 mL). The organic layer was dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure to give a crude mixture that was purified via column chromatography (SiO₂, 10-35% ethyl acetate/heptanes) to give the earlier eluting title compound A (577 mg, 1.7 mmol, 21% yield) and the later eluting title compound B (768 mg, 2.2 mmol, 28% yield). Title compound A: ¹H NMR (400 MHz, CDCl₃) δ ppm 7.77 (s, 1H), 5.21 (s, 2H), 4.71 (q, J = 8.3 Hz, 2H), 1.45 (s, 9H); MS (ESI⁺) *m/z* 343 (M+H)⁺. Title Compound B: ¹H NMR (400 MHz, CDCl₃) δ ppm 7.68 (s, 1H), 4.80 (q, 8.3 Hz, 2H), 4.80 (s, 2H), 1.50 (s, 9H); MS (ESI⁺) *m/z* 343 (M+H)⁺.

Example 210C: tert-butyl {[3-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydropyridazin-4-yl]oxy}acetate

The product of Example 210A (575 mg, 1.7 mmol) and tetrahydrofuran (THF) (14 mL) were added to 5% Pd/C (wet, 131 mg, 0.55 mmol) and triethylamine (0.47 mL, 3.4 mmol) in a 20 mL vessel. The mixture was stirred for 22 hours at 50 psi hydrogen and 25 °C. The mixture was then filtered and concentrated under reduced pressure to give the title compound (397 mg, 1.3 mmol, 77% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm 7.70 (d, J = 4.8 Hz, 1H), 6.36 (d, J = 4.8 Hz, 1H), 4.80 (q, J = 8.4 Hz, 2H), 4.69 (s, 2H), 1.48 (s, 9H); MS (ESI⁺) *m/z* 326 (M+NH₄)⁺.

Example 210D: {[3-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydropyridazin-4-yl]oxy}acetic acid

- 346 -

A 100 mL round bottom flask, equipped with a magnetic stir bar, was charged with the product of Example 210C (360 mg, 1.17 mmol) and 1,2-dichloroethane (40 mL). The resulting solution was stirred at ambient temperature as trifluoroacetic acid (0.41 mL, 5.32 mmol) was added. The reaction mixture was then stirred at 75 °C for 40 minutes, then the heat was removed, and the mixture was allowed to stir at ambient temperature for 16 hours. Some starting material remained, so additional trifluoroacetic acid (0.41 mL, 5.32 mmol) was added, and the reaction mixture was stirred at 70 °C for 7.5 hours. The mixture was concentrated under reduced pressure to give the title compound (268 mg, 1.06 mmol, 91% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.30 (s, 1H), 7.87 (d, J = 4.9 Hz, 1H), 6.78 (d, J = 5.0 Hz, 1H), 4.94 (q, J = 9.1 Hz, 2H), 4.84 (s, 2H); MS (ESI⁺) *m/z* 270 (M+NH₄)⁺.

Example 210E: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-[[3-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydropyridazin-4-yl]oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide

A 4 mL vial, equipped with a magnetic stir bar, was charged with the product of Example 210D (43.2 mg, 0.17 mmol). The vial was sealed with a septum screw cap and the contents were placed under a dry nitrogen atmosphere. Dichloromethane (1.0 mL) was introduced via syringe, and the resulting solution was stirred at ambient temperature as oxalyl chloride (0.027 mL, 0.31 mmol) was added via syringe followed by one drop of *N,N*-dimethylformamide (~0.05 mL). The reaction mixture was stirred at ambient temperature for 30 minutes, then volatiles were removed under reduced pressure. The residue was treated with the product of Example 112A (50 mg, 0.16 mmol), and the vial was resealed. The contents were again placed under a dry nitrogen atmosphere, and dichloromethane (3 mL) was added via syringe. This suspension was stirred at ambient temperature while triethylamine (0.065 mL, 0.47 mmol) was added dropwise. When the addition was complete, the reaction mixture was stirred at ambient temperature for 2.25 hours. Volatiles were removed under reduced pressure, and the residue was partitioned between dilute aqueous citric acid (10 mL) and ethyl acetate (10 mL). The organic layer was washed with saturated aqueous sodium bicarbonate (10 mL), then dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The crude residue was purified via column chromatography (SiO₂, 100% CH₂Cl₂ to 3% CH₃OH in CH₂Cl₂) to give the title compound. ¹H NMR (501 MHz, CDCl₃) δ ppm 7.77 (d, J = 4.8 Hz, 1H), 7.45 (s, 1H), 7.33 (t, J = 8.6 Hz, 1H), 6.85 (s, 1H), 6.76 (dd, J = 10.3, 2.9 Hz, 1H), 6.68 (ddd, J = 8.9, 2.9, 1.3 Hz, 1H), 6.48 (d, J = 4.9 Hz, 1H), 4.81 (q, J = 8.3 Hz, 2H), 4.44 (s, 2H), 4.40 (s, 2H), 2.52 (s, 6H); MS (ESI⁺) *m/z* 519 (M+H)⁺.

- 347 -

Example 211: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-[[6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 310)

Example 211A: tert-butyl {[6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl]oxy}acetate

The product of Example 210B was processed as described in Example 210C to give the title compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.70 (d, J = 2.9 Hz, 1H), 6.03 (d, J = 2.9 Hz, 1H), 4.72 (q, J = 8.4 Hz, 2H), 4.49 (s, 2H), 1.51 (s, 9H); MS (ESI⁺) *m/z* 309 (M+H)⁺.

Example 211B: {[6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl]oxy}acetic acid

The product of Example 211A was processed as described for Example 210D to give the title compound (415 mg, 1.65 mmol, 93% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.33 (s, 1H), 7.96 (d, J = 2.8 Hz, 1H), 6.37 (d, J = 2.8 Hz, 1H), 4.89 (q, J = 9.1 Hz, 2H), 4.84 (s, 2H); MS (ESI⁺) *m/z* 270 (M+NH₄)⁺.

Example 211C: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-[[6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl]oxy}acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide

The product of Example 211B was processed as described for Example 210E to give the title compound (48.5 mg, 0.093 mmol, 60% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm 7.72 (d, J = 2.9 Hz, 1H), 7.33 (t, J = 8.6 Hz, 1H), 6.87 (s, 1H), 6.76 (dd, J = 10.2, 2.9 Hz, 1H), 6.69 (s, 1H), 6.68 (ddd, J = 10.2, 2.9, 1.3 Hz, 1H), 6.17 (d, J = 2.9 Hz, 1H), 4.73 (q, J = 8.4 Hz, 2H), 4.42 (s, 2H), 4.41 (s, 2H), 2.54 (s, 6H); MS (ESI⁺) *m/z* 519 (M+H)⁺.

Example 212: 2-(4-chloro-3-fluorophenoxy)-N-(4-{2-[(6-cyclopropylpyridin-3-yl)oxy]acetamido}-3-hydroxybicyclo[2.2.2]octan-1-yl)acetamide (Compound 311)

The title compound was prepared using the methodologies described in Example 207 substituting 6-cyclopropylpyridin-3-ol for 5-(trifluoromethyl)pyridin-3-ol. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.27 (s, 1H), 8.19 (d, J = 2.9 Hz, 1H), 7.62 (dd, J = 8.9, 2.9 Hz, 1H), 7.51 (s, 1H), 7.46 – 7.30 (m, 3H), 6.95 (dd, J = 11.4, 2.9 Hz, 1H), 6.76 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.52 (s, 2H), 4.37 (s, 2H), 4.03 (dd, J = 9.5, 3.1 Hz, 1H), 2.28 – 2.06 (m, 2H), 1.96 (ddt, J = 17.8, 10.6, 5.6 Hz, 1H), 1.88 (s, 2H), 1.88 – 1.73 (m, 2H), 1.77 – 1.66 (m, 4H), 1.04 (dt, J = 8.4, 3.3 Hz, 2H), 0.94 – 0.85 (m, 2H); MS (ESI⁺) *m/z* 518.2 (M+H)⁺.

Example 213: N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-3-(4-chlorophenyl)-2-oxopropanamide (Compound 312)

- 348 -

The title compound was prepared using the methodologies described above. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.37 – 7.28 (m, 4H), 7.17 (d, J = 8.4 Hz, 2H), 6.86 (s, 1H), 6.76 (dd, J = 10.3, 2.9 Hz, 1H), 6.68 (ddd, J = 8.9, 2.9, 1.3 Hz, 1H), 4.40 (s, 2H), 4.16 (s, 2H), 2.52 (s, 6H); MS (ESI⁺) *m/z* 465 (M+H)⁺.

5 **Example 214: 2-(4-chloro-3-fluorophenoxy)-N-[2-hydroxy-4-(2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 313)**

Example 214A: ethyl 4-[[[(4-methoxyphenyl)methyl]amino]-2-oxobicyclo[2.2.2]octane-1-carboxylate

10 The title compound was prepared using the methodologies described in Example 198D substituting 4-methoxybenzylamine for benzylamine. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.67 (s, 2H), 7.56 – 7.47 (m, 2H), 6.98 – 6.90 (m, 2H), 4.13 – 3.96 (m, 4H), 3.73 (s, 3H), 2.87 (s, 2H), 2.16 – 1.93 (m, 8H), 1.15 (t, J = 7.1 Hz, 3H).

Example 214B: 4-[[[(4-methoxyphenyl)methyl]amino]-2-oxobicyclo[2.2.2]octane-1-carboxylic acid

15

The title compound was prepared using the methodologies described in Example 198G substituting 214A for 198F. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.65 (s, 1H), 7.53 – 7.46 (m, 2H), 6.98 – 6.90 (m, 2H), 4.00 (s, 2H), 2.82 (s, 2H), 2.13 – 1.94 (m, 8H); MS (ESI⁺) *m/z* 303.8 (M+H)⁺.

20 *Example 214C: 1-amino-4-[[[(4-methoxyphenyl)methyl]amino]bicyclo[2.2.2]octan-2-one*

The title compound was prepared using the methodologies described in Example 198H substituting 214B for 198G. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.25 (s, 2H), 8.55 – 8.50 (m, 3H), 7.44 – 7.35 (m, 2H), 7.02 – 6.93 (m, 2H), 4.05 (s, 1H), 3.73 (s, 2H), 2.94 (s, 2H), 2.19 – 2.03 (m, 6H), 1.91 (t, J = 10.2 Hz, 2H).

25 *Example 214D: 2-(4-chloro-3-fluorophenoxy)-N-(4-[[[(4-methoxyphenyl)methyl]amino]-2-oxobicyclo[2.2.2]octan-1-yl]acetamide*

The title compound was prepared using the methodologies described in Example 198F substituting 214C for 198E. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.64 (s, 1H), 7.46 (t, J = 8.9 Hz, 1H), 7.24 – 7.16 (m, 2H), 7.05 (dd, J = 11.4, 2.8 Hz, 1H), 6.86 – 6.78 (m, 3H), 4.52 (s, 2H), 3.68 (s, 3H), 3.55 (s, 2H), 2.43 (s, 2H), 2.43 – 2.32 (m, 2H), 1.82 – 1.65 (m, 4H); MS (ESI⁺) *m/z* 460.9 (M+H)⁺.

30

- 349 -

Example 214E: N-(4-amino-2-oxobicyclo[2.2.2]octan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide

A mixture of Example 214D (1.24 g, 2.69 mmol), ceric ammonium nitrate (6.64 g, 12.11 mmol) and 2,2,2-trifluoroacetic acid (15.0 mL, 195 mmol) in water (15.0 mL) and acetonitrile (2.0 mL) was stirred at 0 °C for 1 hour and then warmed up to room temperature and stirred for another 3 hours. The reaction mixture was diluted with water and washed with ethyl acetate. The aqueous phase was partitioned between ammonium hydroxide and ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated, and the residue was purified by HPLC (10-80% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® C18 5 µm column (250 mm × 21.2 mm)) to give 1.14 g of the titled compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.24 (s, 3H), 7.76 (s, 1H), 7.45 (t, J = 8.9 Hz, 1H), 7.03 (dd, J = 11.3, 2.9 Hz, 1H), 6.81 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.54 (s, 2H), 2.65 (s, 2H), 2.35 (dd, J = 13.4, 9.8 Hz, 2H), 2.04 – 1.78 (m, 6H); MS (ESI⁺) *m/z* 341.2 (M+H)⁺.

Example 214F: N-(4-amino-2-hydroxybicyclo[2.2.2]octan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide, trifluoroacetate

The title compound was prepared using the methodologies described in Example 198I substituting 214E for 198H. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.91 (s, 3H), 7.48 (t, J = 8.9 Hz, 1H), 7.38 (s, 1H), 7.05 (dd, J = 11.4, 2.9 Hz, 1H), 6.87 – 6.74 (m, 1H), 4.48 (s, 2H), 4.14 (dd, J = 9.7, 2.6 Hz, 1H), 2.21 – 1.52 (m, 10H); MS (ESI⁺) *m/z* 343.1 (M+H)⁺.

Example 214G: 2-(4-chloro-3-fluorophenoxy)-N-[2-hydroxy-4-(2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide

To a mixture of Example 214F (0.055 g, 0.121 mmol), 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid (0.031 g, 0.139 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (0.053 mL, 0.302 mmol) in *N,N*-dimethylformamide (1.5 mL), 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.069 g, 0.181 mmol) was added. The mixture was stirred at ambient temperature for 1 hour. Volatiles were removed, and the residue was purified by HPLC (10-95% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® C18 5 µm column (250 mm × 21.2 mm)) to give 36 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.39 (d, J = 2.8 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.61 (s, 1H), 7.51 – 7.40 (m, 2H), 7.22 (s, 1H), 7.02 (dd, J = 11.4, 2.9 Hz, 1H), 6.79 (ddd, J = 8.9, 2.8, 1.2 Hz, 1H), 5.04 (s, 1H), 4.58 (s, 2H), 4.43 (s, 2H), 4.01 (d, J =

- 350 -

9.0 Hz, 1H), 2.24 (ddd, J = 12.1, 9.3, 2.1 Hz, 1H), 2.03 (ddd, J = 12.4, 10.6, 4.6 Hz, 1H), 1.91 – 1.69 (m, 8H); MS (ESI⁺) *m/z* 546.1 (M+H)⁺.

Example 215: 2-(4-chloro-3-fluorophenoxy)-N-(2-hydroxy-4-[(4-methoxyphenyl)methyl]amino)bicyclo[2.2.2]octan-1-yl)acetamide (Compound 314)

5 A mixture of Example 214D (0.042 g, 0.091 mmol) and sodium borohydride (0.017 g, 0.456 mmol) in a mixture of methanol/dichloromethane was stirred for 1 hour. Volatiles were removed, and the residue was purified by HPLC (10-85% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® C18 5 µm column (250 mm × 21.2 mm)) to give 39 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.63 (s, 2H), 7.50 – 7.32 (m, 4H), 7.07 6.92 (m, 3H), 6.80 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 5.32 (d, J = 4.3 Hz, 1H), 4.45 (s, 2H), 4.20 – 4.11 (m, 1H), 3.95 (brs, 2H), 3.73 (s, 3H), 2.30 – 1.64 (m, 10H); MS (ESI⁺) *m/z* 463.0 (M+H)⁺.

Example 216: (2R)-N-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl]-2-(4-chlorophenyl)-2-hydroxyacetamide (Compound 315)

15 The title compound was prepared using the methodologies described above. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.34 (s, 4H), 7.30 (t, J = 8.5 Hz, 1H), 6.87 (s, 1H), 6.84 (s, 1H), 6.74 (dd, J = 10.2, 2.9 Hz, 1H), 6.65 (ddd, J = 8.9, 2.9, 1.3 Hz, 1H), 4.98 (d, J = 3.6 Hz, 1H), 4.35 (s, 2H), 3.74 (t, J = 3.4 Hz, 1H), 2.44 (s, 6H); MS (ESI⁺) *m/z* 453 (M+H)⁺.

Example 217: 2-(4-chloro-3-fluorophenoxy)-N-[3-oxo-4-(2-{[3-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydropyridazin-4-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 316)

A mixture of Example 198H (0.090 g, 0.239 mmol), Example 210D (0.066 g, 0.262 mmol), *N*-[(dimethylamino)-1*H*-1,2,3-triazolo-[4,5-*p*]pyridin-1-ylmethylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide (HATU, 0.109 g, 0.286 mmol), and triethylamine (0.133 mL, 0.954 mmol) in tetrahydrofuran (4 mL) was stirred for 16 hours. The reaction mixture was treated with saturated, aqueous NaHCO₃ and brine and extracted with ethyl acetate (2×). The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified on a 12 g silica gel column using a Biotage® Isolera™ One flash system eluting with 100% ethyl acetate to provide the title compound (0.10 g, 0.17 mmol, 74% yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.95 – 7.85 (m, 2H), 7.82 (s, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.02 (dd, J = 11.4, 2.9 Hz, 1H), 6.80 (ddd, J = 9.1, 2.9, 1.2 Hz, 1H), 6.73 (d, J = 5.0 Hz, 1H), 4.93 (q, J = 9.0 Hz, 2H), 4.64 (s, 2H), 4.47 (s, 2H),

- 351 -

2.85 (s, 2H), 2.47 – 2.35 (m, 2H), 2.13 – 1.92 (m, 4H), 1.83 (dt, J = 13.5, 6.8 Hz, 2H); MS (ESI⁺) *m/z* 575.0 (M+H)⁺.

Example 218: 2-(4-chloro-3-fluorophenoxy)-N-[3-oxo-4-(2-[[6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 317)

The reaction described in Example 217 substituting Example 211B for Example 210D gave the title compound. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.95 – 7.87 (m, 2H), 7.82 (s, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.02 (dd, J = 11.4, 2.8 Hz, 1H), 6.80 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 6.28 (d, J = 2.8 Hz, 1H), 4.85 (q, J = 9.1 Hz, 2H), 4.65 (s, 2H), 4.47 (s, 2H), 2.83 (d, J = 1.4 Hz, 2H), 2.37 – 2.22 (m, 2H), 2.11 – 1.94 (m, 4H), 1.90 (dd, J = 11.7, 4.3 Hz, 2H); MS (ESI⁺) *m/z* 575.4 (M+H)⁺.

Example 219: 2-(4-chloro-3-fluorophenoxy)-N-[(3R)-3-hydroxy-4-(2-[[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 318)

The title compound was isolated by chiral preparative HPLC of Example 209 as the first peak eluted off the column. The gradient was 25-36% B in 19 minute then step to and hold at 50% B for 5 minute (20 mL/minute flow rate). Mobile phase B was HPLC grade ethanol and mobile phase A was HPLC grade heptane with 0.2% diethylamine added. The chromatography used a Daicel Chiralpak® IC column, 21 × 250 mm column (5 μm particles). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.53 (d, J = 5.7 Hz, 1H), 7.50 – 7.39 (m, 2H), 7.38 (s, 2H), 7.19 (dd, J = 5.8, 2.5 Hz, 1H), 6.98 (dd, J = 11.4, 2.8 Hz, 1H), 6.81 – 6.73 (m, 1H), 4.64 (s, 2H), 4.39 (s, 2H), 4.05 (dd, J = 9.5, 3.0 Hz, 1H), 2.23 (dd, J = 13.4, 9.5 Hz, 1H), 2.07 – 1.86 (m, 4H), 1.75 (tdd, J = 11.6, 7.3, 2.9 Hz, 5H); MS (ESI⁺) *m/z* 546.1 (M+H)⁺. X-ray crystallography confirmed the assigned stereochemistry.

Example 220: 2-(4-chloro-3-fluorophenoxy)-N-[(3S)-3-hydroxy-4-(2-[[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 319)

The title compound was isolated by chiral preparative HPLC of Example 209 as the second peak eluted off the column using methodologies described in Example 219. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.53 (d, J = 5.7 Hz, 1H), 7.50 – 7.35 (m, 4H), 7.19 (dd, J = 5.8, 2.5 Hz, 1H), 6.98 (dd, J = 11.4, 2.8 Hz, 1H), 6.77 (dd, J = 9.1, 2.6 Hz, 1H), 4.64 (s, 2H), 4.39 (s,

- 352 -

2H), 4.05 (dd, $J = 9.6, 3.0$ Hz, 1H), 2.22 (dd, $J = 13.2, 9.5$ Hz, 1H), 2.01 – 1.66 (m, 9H); MS (ESI⁺) m/z 546.1 (M+H)⁺.

Example 221: 2-(4-chloro-3-fluorophenoxy)-N-(4-{2-[4-(dimethylamino)phenyl]acetamido}-3-hydroxybicyclo[2.2.2]octan-1-yl)acetamide

5 (Compound 320)

A 4 mL vial was charged with a stir bar, a 500 μ L solution of Example 198I (47.74 mg, 0.13 mmol) in *N,N*-dimethylacetamide, a 395.7 μ L of a 0.35 mmol pre-weighed vial with a solution of 2-(4-(dimethylamino)phenyl)acetic acid (25.2 mg, 0.14 mmol) in 1000 μ L of *N,N*-dimethylacetamide, a 500 μ L solution of 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (57.4 mg, 0.15 mmol) in *N,N*-dimethylacetamide, and triethylamine (53.01 μ L, 0.38 mmol). This was capped and placed to stir at room temperature for 1 hour. Upon completion the mixture was concentrated to dryness, and the residue was purified by reverse phase HPLC (Phenomenex® Luna® C8(2) 5 μ m 100Å AXIA™ column (50 mm \times 30 mm). A gradient of acetonitrile (A) and 0.1% CF₃CO₂H in H₂O (B) was used at a flow rate of 40 mL/minute (0-0.5 minute 5% A, 0.5-6.5 minutes linear gradient 5-100% A, 6.5-8.5 minutes 100% A, 8.5-9.0 minutes linear gradient 100-5% A, 9.0-10.0 minutes 5% A). Detection methods are diode array (DAD) under positive APCI ionization conditions.) to yield the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.47 (td, $J = 8.9, 1.1$ Hz, 1H), 7.43 – 7.32 (m, 3H), 7.36 – 7.26 (m, 1H), 7.00 (dd, $J = 11.4, 2.9$ Hz, 1H), 6.81 (ddd, $J = 9.0, 3.0, 1.3$ Hz, 1H), 4.43 (d, $J = 6.5$ Hz, 2H), 4.06 (dd, $J = 8.6, 1.9$ Hz, 1H), 3.50 – 3.34 (m, 2H), 3.10 (d, $J = 5.9$ Hz, 6H), 2.26 (ddd, $J = 12.4, 9.2, 2.6$ Hz, 1H), 2.01 – 1.71 (m, 9H); MS (ESI⁺) m/z 504.1 (M+H)⁺.

Example 222: 2-(4-chloro-3-fluorophenoxy)-N-(3-hydroxy-4-{2-[3-(trifluoromethyl)phenyl]acetamido}bicyclo[2.2.2]octan-1-yl)acetamide (Compound 321)

25 The title compound was prepared using the methodologies described in Example 221 substituting 2-(3-(trifluoromethyl)phenyl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.64 – 7.51 (m, 4H), 7.47 (t, $J = 8.9$ Hz, 1H), 7.00 (dd, $J = 11.4, 2.8$ Hz, 1H), 6.81 (ddd, $J = 9.0, 2.9, 1.2$ Hz, 1H), 4.42 (s, 2H), 4.13 – 4.05 (m, 1H), 3.52 (d, $J = 4.0$ Hz, 2H), 2.26 (ddd, $J = 13.2, 9.3, 2.7$ Hz, 1H), 2.04 – 1.87 (m, 3H), 1.88 – 1.74 (m, 2H), 1.74 (s, 3H), 1.76 – 1.64 (m, 3H); MS (ESI⁺) m/z 529.1 (M+H)⁺.

Example 223: 2-(4-chloro-3-fluorophenoxy)-N-(3-hydroxy-4-{2-[4-(trifluoromethyl)phenyl]acetamido}bicyclo[2.2.2]octan-1-yl)acetamide (Compound 322)

- 353 -

The title compound was prepared using the methodologies described in Example 221 substituting 2-(4-(trifluoromethyl)phenyl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.69 – 7.54 (m, 2H), 7.52 – 7.41 (m, 3H), 7.00 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.42 (s, 2H), 4.09 (d, *J* = 8.4 Hz, 1H), 3.55 – 3.41 (m, 2H), 2.26 (ddd, *J* = 12.6, 9.2, 2.6 Hz, 1H), 2.08 – 1.89 (m, 2H), 1.94 – 1.81 (m, 1H), 1.84 – 1.76 (m, 1H), 1.80 – 1.64 (m, 5H); MS (ESI⁺) *m/z* 529.1 (M+H)⁺.

Example 224: 2-(2*H*-1,3-benzodioxol-5-yl)-*N*-{4-[2-(4-chloro-3-fluorophenoxy)acetamido]-2-hydroxybicyclo[2.2.2]octan-1-yl}acetamide (Compound 323)

The title compound was prepared using the methodologies described in Example 221 substituting 2-(benzo[*d*][1,3]dioxol-5-yl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.47 (t, *J* = 8.9 Hz, 1H), 7.00 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.85 – 6.77 (m, 3H), 6.70 (dd, *J* = 7.9, 1.8 Hz, 1H), 5.96 (s, 2H), 4.42 (s, 2H), 4.07 – 4.00 (m, 1H), 3.37 – 3.21 (m, 2H), 2.26 (ddd, *J* = 13.2, 9.1, 2.5 Hz, 1H), 2.03 – 1.88 (m, 2H), 1.87 – 1.70 (m, 7H); MS (ESI⁺) *m/z* 505.1 (M+H)⁺.

Example 225: 2-(4-chloro-3-fluorophenoxy)-*N*-{3-hydroxy-4-[2-(pyridin-3-yl)acetamido]bicyclo[2.2.2]octan-1-yl}acetamide (Compound 324)

The title compound was prepared using the methodologies described in Example 221 substituting 2-(pyridin-3-yl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.78 – 8.66 (m, 2H), 8.39 (dt, *J* = 8.1, 1.7 Hz, 1H), 8.01 – 7.91 (m, 1H), 7.47 (td, *J* = 8.9, 1.4 Hz, 1H), 7.04 – 6.96 (m, 1H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.43 (d, *J* = 7.0 Hz, 2H), 4.15 (d, *J* = 8.4 Hz, 1H), 3.70 (s, 2H), 2.27 (ddd, *J* = 12.8, 9.4, 2.8 Hz, 1H), 2.04 (d, *J* = 16.5 Hz, 1H), 2.01 – 1.76 (m, 6H), 1.71 (ddt, *J* = 15.4, 12.0, 6.1 Hz, 2H); MS (ESI⁺) *m/z* 462.1 (M+H)⁺.

Example 226: 2-(4-chloro-3-fluorophenoxy)-*N*-(3-hydroxy-4-{2-[4-

(methanesulfonyl)phenyl]acetamido}bicyclo[2.2.2]octan-1-yl)acetamide (Compound 325)

The title compound was prepared using the methodologies described in Example 221 substituting 2-(4-(methanesulfonyl)phenyl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.89 – 7.78 (m, 2H), 7.59 – 7.42 (m, 3H), 7.00 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.81 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 4.42 (s, 2H), 4.10 (dt, *J* = 9.0, 2.2 Hz, 1H), 3.57 – 3.48 (m, 2H), 3.18 (s, 3H), 2.26 (ddd, *J* = 13.1, 9.3, 2.6 Hz, 1H), 2.04 – 1.78 (m, 4H), 1.81 – 1.64 (m, 5H); MS (ESI⁺) *m/z* 539.1 (M+H)⁺.

- 354 -

Example 227: 2-(4-chloro-3-fluorophenoxy)-N-(3-hydroxy-4-{2-[4-(trifluoromethoxy)phenyl]acetamido}bicyclo[2.2.2]octan-1-yl)acetamide (Compound 326)

The title compound was prepared using the methodologies described in Example 221 substituting 2-(4-(trifluoromethoxy)phenyl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.47 (t, *J* = 8.9 Hz, 1H), 7.40 – 7.33 (m, 2H), 7.37 – 7.24 (m, 2H), 7.00 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.42 (s, 2H), 4.08 (dt, *J* = 8.8, 2.1 Hz, 1H), 3.51 – 3.38 (m, 2H), 2.26 (ddd, *J* = 13.1, 9.2, 2.7 Hz, 1H), 2.08 – 1.89 (m, 2H), 1.93 – 1.73 (m, 2H), 1.76 – 1.64 (m, 5H); MS (ESI⁺) *m/z* 545.1 (M+H)⁺.

Example 228: 2-(4-chloro-3-fluorophenoxy)-N-(3-hydroxy-4-{2-[3-(trifluoromethoxy)phenyl]acetamido}bicyclo[2.2.2]octan-1-yl)acetamide (Compound 327)

The title compound was prepared using the methodologies described in Example 221 substituting 2-(3-(trifluoromethoxy)phenyl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.58 (d, *J* = 12.2 Hz, 1H), 7.52 – 7.38 (m, 2H), 7.31 – 7.17 (m, 3H), 7.00 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.42 (s, 2H), 4.08 (d, *J* = 8.7 Hz, 1H), 3.54 – 3.40 (m, 2H), 2.26 (ddd, *J* = 12.4, 9.2, 2.7 Hz, 1H), 2.06 – 1.66 (m, 9H); MS (ESI⁺) *m/z* 545.1 (M+H)⁺.

Example 229: 2-(4-chloro-3-fluorophenoxy)-N-{3-hydroxy-4-[2-(pyridin-4-yl)acetamido]bicyclo[2.2.2]octan-1-yl}acetamide (Compound 328)

The title compound was prepared using the methodologies described in Example 221 substituting 2-(pyridin-4-yl)acetic acid for 2-(4-(dimethylamino)phenyl)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (d, *J* = 6.0 Hz, 2H), 7.92 – 7.85 (m, 2H), 7.47 (t, *J* = 8.9 Hz, 1H), 7.00 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.81 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 4.42 (s, 2H), 4.15 (d, *J* = 8.7 Hz, 1H), 3.77 (s, 2H), 2.28 (ddd, *J* = 12.5, 9.4, 2.7 Hz, 1H), 1.97 (q, *J* = 10.9, 10.5 Hz, 2H), 1.81 (td, *J* = 19.2, 16.3, 11.6 Hz, 5H), 1.77 – 1.65 (m, 2H); MS (ESI⁺) *m/z* 462.1 (M+H)⁺.

Example 230: 2-(4-chloro-3-fluorophenoxy)-N-{4-[2-(3,4-difluorophenoxy)acetamido]-2-hydroxybicyclo[2.2.2]octan-1-yl}acetamide (Compound 329)

The title compound was prepared using the methodologies described in Example 214 substituting 2-(3,4-difluorophenoxy)acetic acid for 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.39 (m, 2H), 7.31 (dt, *J* = 10.5, 9.3 Hz, 1H), 7.23 (s, 1H), 7.05 – 6.94 (m, 2H), 6.83 – 6.66 (m, 2H), 5.06 (d, *J* = 4.4 Hz, 1H), 4.42 (s, 2H), 4.35 (s, 2H), 4.06 (m, 1H), 2.23 (ddd, *J* = 12.4, 9.6, 2.2 Hz, 1H), 2.08 1.96 (m, 1H), 1.89 (d, *J* = 10.9 Hz, 2H), 1.87 – 1.68 (m, 6H); MS (ESI⁺) *m/z* 5131 (M+H)⁺.

- 355 -

Example 231: 2-(4-chloro-3-fluorophenoxy)-N-{4-[2-(4-fluorophenoxy)acetamido]-2-hydroxybicyclo[2.2.2]octan-1-yl}acetamide (Compound 330)

The title compound was prepared using the methodologies described in Example 214 substituting 2-(4-fluorophenoxy)acetic acid for 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.49 – 7.36 (m, 2H), 7.23 (s, 1H), 7.14 – 6.97 (m, 3H), 6.93 – 6.85 (m, 2H), 6.79 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 5.04 (d, J = 4.4 Hz, 1H), 4.43 (s, 2H), 4.32 (s, 2H), 4.10 – 3.95 (m, 1H), 2.24 (ddd, J = 12.1, 9.4, 2.2 Hz, 1H), 2.09 – 1.97 (m, 1H), 1.93 – 1.69 (m, 8H); MS (ESI⁺) *m/z* 495.0 (M+H)⁺.

Example 232: 2-(4-chloro-3-fluorophenoxy)-N-(4-[[2-(4-fluorophenoxy)ethyl]amino]-3-hydroxybicyclo[2.2.2]octan-1-yl)acetamide (Compound 331)

To a mixture of Example 198I (0.05 g, 0.146 mmol) and 2-(4-fluorophenoxy)acetaldehyde (0.027 g, 0.175 mmol) in buffer (1.5 mL, pH = 4)), sodium cyanoborohydride (0.014 g, 0.219 mmol) was added, and the mixture was stirred at ambient temperature for 16 hours. Solvent was removed under high vacuum, and the residue was purified by HPLC (10-95% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® C18 5 μm column (250 mm × 21.2 mm)) to give 37 mg of the title compound as a white solid. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 8.45 (m, 2H), 7.68 (s, 1H), 7.46 (t, J = 8.9 Hz, 1H), 7.14 (t, J = 8.8 Hz, 2H), 7.03 – 6.93 (m, 3H), 6.79 (dd, J = 9.0, 2.7 Hz, 1H), 5.74 (s, 1H), 4.44 (s, 2H), 4.16 (s, 1H), 4.08 – 4.02 (m, 1H), 3.26 (tt, J = 8.7, 5.0 Hz, 2H), 2.34 (td, J = 9.8, 4.8 Hz, 1H), 2.12 – 1.94 (m, 2H), 1.89 – 1.78 (m, 5H), 1.80 – 1.66 (m, 2H); MS (ESI⁺) *m/z* 481.2 (M+H)⁺.

Example 233: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-[[6-(pentafluoro-λ⁶-sulfanyl)pyridin-3-yl]oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide (Compound 332)

Example 233A: [6-(pentafluoro-λ⁶-sulfanyl)pyridin-3-yl]boronic acid

To a stirred solution of 5-bromo-2-(pentafluoro-λ⁶-sulfanyl)pyridine (500 mg, 1.67 mmol) and triisopropyl borate (157 mg, 8.36 mmol) in tetrahydrofuran (20 mL) in a perfluoroalkoxy (PFA) tube was added 2.5 M *n*-butyllithium (1.0 mL, 2.51 mmol) dropwise at -78 °C under N₂. The mixture was stirred for 30 minutes at -78 °C. The mixture was quenched with saturated aqueous NH₄Cl solution at -78 °C. The mixture was extracted with ethyl acetate (2×). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was treated with dichloromethane and the resultant solids were collected by filtration. The filter cake was dried

- 356 -

under high vacuum to provide the title compound (272 mg, 1.09 mmol, 65% yield). MS (ESI⁺) *m/z* 250 (M+H)⁺.

Example 233B: 6-(pentafluoro-λ⁶-sulfanyl)pyridin-3-ol

To a stirred solution of Example 233A (1.2 g, 4.58 mmol) and triethylamine (6.38 mL, 45.8 mmol) in ethanol (100 mL) and water (10 mL, 555 mmol) was added iodosobenzene diacetate (7.37 g, 22.89 mmol) at 20 °C, and the mixture was allowed to stir for 12 hours at 20 °C. The mixture was concentrated under reduced pressure. The residue was diluted with water (250 mL) and extracted with dichloromethane (3 × 100 mL). The combined organic layers were concentrated under reduced pressure, and the residue was purified by preparative HPLC performed on a Phenomenex® Luna® C18 column (500 × 50 mm, 10 μm particle size) using a gradient of 25% to 55% acetonitrile/0.09% aqueous trifluoroacetic acid over 20 minutes at a flow rate of 80 mL/minute. The desired HPLC fractions were extracted with dichloromethane (3 × 100 mL), and the combined organic layers were concentrated under reduced pressure to provide the title compound (820 mg, 3.7 mmol, yield, 80% yield). MS (ESI⁺) *m/z* 222 (M+H)⁺.

Example 233C: 2-(4-chloro-3-fluorophenoxy)-N-[3-(2-[[6-(pentafluoro-λ⁶-sulfanyl)pyridin-3-yl]oxy]acetamido)bicyclo[1.1.1]pentan-1-yl]acetamide

A mixture of the product of Example 28A (80.0 mg, 0.221 mmol), Example 233B (73.5 mg, 0.332 mmol), KI (1.84 mg, 0.011 mmol), and potassium carbonate (61.2 mg, 0.44 mmol) in acetone (3 mL) was heated at 140 °C in a Biotage® Initiator microwave reactor for 30 minutes. The reaction mixture was filtered. The filtrate was concentrated, and the residue was purified by reverse-phase HPLC (see protocol in Example 112D) to provide the title compound (59.6 mg, 0.11 mmol, 49% yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.80 (s, 1H), 8.70 (s, 1H), 8.29 (d, J = 3.0 Hz, 1H), 7.97 (d, J = 9.1 Hz, 1H), 7.63 (dd, J = 9.2, 2.9 Hz, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.05 (dd, J = 11.3, 2.8 Hz, 1H), 6.83 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 4.68 (s, 2H), 4.46 (s, 2H), 2.25 (s, 6H); MS (ESI⁺) *m/z* 546.0 (M+H)⁺.

Example 234: 2-(4-chloro-3-fluorophenoxy)-N-[3-hydroxy-4-(2-[[3-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydropyridazin-4-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 333)

To a solution of Example 217 (88.0 mg, 0.153 mmol) in CH₂Cl₂ (1.5 mL) and methanol (1.5 mL) was added sodium borohydride (6.95 mg, 0.184 mmol). The reaction mixture was stirred for 1.5 hours. The solution was treated with brine and saturated aqueous NaHCO₃ and extracted with CH₂Cl₂ (2×). The combined organic fractions were concentrated under reduced

- 357 -

pressure, and the residue was purified by reverse-phase HPLC (see protocol in Example 112D) to provide the title compound (54.5 mg, 0.094 mmol, 62% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.87 (d, *J* = 4.9 Hz, 1H), 7.57 – 7.42 (m, 2H), 7.39 (s, 1H), 7.02 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.81 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 6.71 (d, *J* = 5.0 Hz, 1H), 4.94 (q, *J* = 9.1 Hz, 2H), 4.56 (s, 2H), 4.43 (s, 2H), 4.08 (dd, *J* = 9.6, 3.0 Hz, 1H), 2.33 – 2.18 (m, 1H). 2.05 – 1.69 (m, 10H); MS (ESI⁺) *m/z* 577.0 (M+H)⁺.

Example 235: 2-(4-chloro-3-fluorophenoxy)-*N*-[3-hydroxy-4-(2-[[6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl]oxy}acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 334)

The reaction described in Example 234 substituting Example 218 for Example 217 gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.93 (d, *J* = 2.8 Hz, 1H), 7.54 – 7.44 (m, 3H), 7.41 (s, 1H), 7.02 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.29 (d, *J* = 2.8 Hz, 1H), 4.87 (q, *J* = 9.1 Hz, 2H), 4.56 (s, 2H), 4.43 (s, 2H), 4.11 (dd, *J* = 9.5, 2.9 Hz, 1H), 2.26 (ddd, *J* = 12.4, 9.5, 2.3 Hz, 1H), 2.04 – 1.68 (m, 10H); MS (ESI⁺) *m/z* 577.1 (M+H)⁺.

Example 236: 2-(4-chloro-3-fluorophenoxy)-*N*-(4-[[2-(3,4-dichlorophenoxy)ethyl]amino]-3-hydroxybicyclo[2.2.2]octan-1-yl]acetamide (Compound 335)

The title compound was prepared using the methodologies described in Example 232 substituting 2-(3,4-dichlorophenoxy)acetaldehyde for 2-(4-fluorophenoxy)acetaldehyde. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.53 (s, 1H), 8.47 (s, 1H), 7.67 (s, 1H), 7.54 (d, *J* = 8.9 Hz, 1H), 7.45 (t, *J* = 8.9 Hz, 1H), 7.24 (d, *J* = 2.9 Hz, 1H), 6.98 (dq, *J* = 8.9, 3.0 Hz, 2H), 6.77 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 5.73 (d, *J* = 4.7 Hz, 1H), 4.42 (s, 2H), 4.21 (t, *J* = 5.1 Hz, 2H), 4.03 (d, *J* = 9.3 Hz, 1H), 3.24 (m, 2H), 2.33 (ddd, *J* = 13.0, 9.6, 2.9 Hz, 1H), 2.11 – 1.91 (m, 2H), 1.89 – 1.73 (m, 6H), 1.77 – 1.63 (m, 1H); MS (ESI⁺) *m/z* 531.2 (M+H)⁺.

Example 237: 2-(4-chloro-3-fluorophenoxy)-*N*-(4-[[2-(4-chlorophenoxy)ethyl]amino]-3-hydroxybicyclo[2.2.2]octan-1-yl]acetamide (Compound 336)

The title compound was prepared using the methodologies described in Example 232 substituting 2-(4-chlorophenoxy)acetaldehyde for 2-(4-fluorophenoxy)acetaldehyde. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.62 – 8.47 (m, 2H), 7.70 (s, 1H), 7.48 (t, *J* = 8.9 Hz, 1H), 7.38 (d, *J* = 6.7 Hz, 1H), 7.39 – 7.25 (m, 1H), 7.07 – 6.89 (m, 3H), 6.81 (dt, *J* = 8.9, 2.0 Hz, 1H), 5.76 (s, 1H), 4.46 (s, 2H), 4.20 (t, *J* = 5.2 Hz, 2H), 4.07 (d, *J* = 8.9 Hz, 1H), 3.32 – 3.25 (m, 2H), 2.36 (ddd, *J* = 12.8, 9.4, 2.8 Hz, 1H), 2.09 (td, *J* = 11.7, 9.9, 5.0 Hz, 1H), 2.06 – 1.94 (m, 1H), 1.95 –

- 358 -

1.83 (m, 4H), 1.81 (dd, $J = 14.5, 6.2$ Hz, 2H), 1.80 – 1.67 (m, 1H); MS (ESI⁺) m/z 597.2 (M+H)⁺.

Example 238: 2-(4-chloro-3-fluorophenoxy)-N-(4-[[2-(3,4-dichlorophenoxy)ethyl]amino]-2-hydroxybicyclo[2.2.2]octan-1-yl)acetamide (Compound 337)

5 The title compound was prepared using the methodologies described in Example 232 substituting the product of Example 214F for the product of Example 198I and substituting 2-(3,4-dichlorophenoxy)acetaldehyde for 2-(4-fluorophenoxy)acetaldehyde. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.79 (t, $J = 6.1$ Hz, 2H), 7.58 (d, $J = 8.9$ Hz, 1H), 7.55 – 7.40 (m, 2H), 7.31 – 7.20 (m, 1H), 7.04 (ddd, $J = 11.9, 10.2, 2.9$ Hz, 2H), 6.83 (dt, $J = 9.0, 2.0$ Hz, 1H), 5.36 (s, 1H),
10 4.49 (s, 2H), 4.20 (dt, $J = 22.4, 3.8$ Hz, 3H), 3.28 (t, $J = 6.0$ Hz, 2H), 2.27 (ddd, $J = 12.3, 9.3, 2.4$ Hz, 1H), 2.14 – 2.00 (m, 1H), 1.99 (td, $J = 8.7, 3.0$ Hz, 1H), 1.85 (dq, $J = 15.2, 9.2, 7.2$ Hz, 4H), 1.82 – 1.70 (m, 1H), 1.65 (dt, $J = 12.9, 3.0$ Hz, 1H); MS (ESI⁺) m/z 531.2 (M+H)⁺.

Example 239: 2-(4-chloro-3-fluorophenoxy)-N-[3-hydroxy-3-methyl-4-(2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide (Compound 338)

Example 239A: tert-butyl {4-[2-(4-chloro-3-fluorophenoxy)acetamido]-2-hydroxy-2-methylbicyclo[2.2.2]octan-1-yl}carbamate

To a solution of the product of Example 173H (300.0 mg, 0.680 mmol) in tetrahydrofuran (15 mL) at -78 °C was added 1.5 M methyllithium lithium bromide complex in
20 diethyl ether (2.3 mL). The reaction mixture was stirred at -78 °C for 1 hour and then was quenched with brine. The mixture was extracted with ethyl acetate (2×). The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified on a 25 g silica gel column using a Biotage® Isolera™ One flash system eluting with heptanes/ethyl acetate (1:1) to provide the title compound (0.23 g, 0.50
25 mmol, 75% yield). MS (ESI⁺) m/z 455.0 (M+H)⁺.

Example 239B: N-(4-amino-3-hydroxy-3-methylbicyclo[2.2.2]octan-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide, hydrochloric acid

A mixture of the product of Example 239A (0.225 g, 0.49 mmol) and trifluoroacetic acid (0.379 mL, 4.92 mmol) in CH₂Cl₂ (5 mL) was stirred for 5 hours. The reaction mixture was
30 concentrated under reduced pressure, and the residue was dissolved in methanol (2 mL). The solution was treated with 2 M HCl (2 mL) in ether, and the mixture was stirred for 15 minutes.

- 359 -

The solution was concentrated under reduced pressure to give the title compound (0.161 g, 0.41 mmol, 83% yield). MS (ESI⁺) *m/z* 357.1 (M+H)⁺.

Example 239C: 2-(4-chloro-3-fluorophenoxy)-N-[3-hydroxy-3-methyl-4-(2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]acetamido)bicyclo[2.2.2]octan-1-yl]acetamide

- 5 A mixture of the product of Example 239B (78.0 mg, 0.20 mmol), Example 301B (48.2 mg, 0.22 mmol), *N*-[(dimethylamino)-1*H*-1,2,3-triazolo-[4,5-*b*]pyridin-1-ylmethylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide (HATU, 90 mg, 0.24 mmol), and triethylamine (0.11 mL, 0.79 mmol) in tetrahydrofuran (3 mL) was stirred for 2 hours. The reaction mixture was treated with saturated aqueous NaHCO₃ and brine and extracted with ethyl
- 10 acetate (2×). The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (see protocol in Example 112D) to provide the title compound (46.4 mg, 0.083 mmol, 42% yield).
- ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.44 (d, *J* = 2.9 Hz, 1H), 7.87 (d, *J* = 8.7 Hz, 1H), 7.65 – 7.41 (m, 4H), 7.02 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.80 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 5.53 (s, brd, 1H), 4.76 (s, 2H), 4.43 (s, 2H), 2.23 (tt, *J* = 11.5, 3.1 Hz, 1H), 2.04 (dddt, *J* = 13.6, 11.2, 5.9, 2.6 Hz, 2H), 1.97 – 1.69 (m, 6H), 1.62 (td, *J* = 11.5, 6.0 Hz, 1H), 1.10 (s, 3H); MS (ESI⁺) *m/z* 557.9 (M+H)⁺.
- 15

Example 240: *N,N'*-(2-hydroxy-2-methylbicyclo[2.2.2]octane-1,4-diyl)bis[2-(4-chloro-3-fluorophenoxy)acetamide] (Compound 339)

- 20 The reaction described in Example 239C substituting 2-(4-chloro-3-fluorophenoxy)acetic acid for Example 301B gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.58 – 7.41 (m, 6H), 7.03 (td, *J* = 11.7, 2.8 Hz, 2H), 6.81 (dddd, *J* = 9.0, 7.9, 2.8, 1.2 Hz, 2H), 5.57 (s, 1H), 4.58 (s, 2H), 4.43 (s, 2H), 2.21 (dd, *J* = 13.2, 9.9 Hz, 1H), 2.15 – 1.97 (m, 2H), 1.97 – 1.69 (m, 6H), 1.62 (td, *J* = 11.5, 5.8 Hz, 1H), 1.09 (s, 3H); MS (ESI⁺) *m/z* 540.9 (M+H)⁺.

- 25 **Example 241: 2-(4-chloro-3-fluorophenoxy)-*N*-(2-hydroxy-4-{2-[4-(trifluoromethoxy)phenyl]acetamido}bicyclo[2.2.2]octan-1-yl)acetamide (Compound 340)**

- The title compound was prepared using the methodologies described in Example 214 substituting 2-(4-(trifluoromethoxy)phenyl)acetic acid for 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.68 (s, 1H), 7.48 (t, *J* = 8.9 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.31 – 7.22 (m, 3H), 7.05 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.46 (s, 2H), 4.06 – 3.97 (m, 1H), 2.24 (ddd, *J* = 12.4, 9.5, 2.4 Hz, 1H), 2.05 (ddd, *J*
- 30

- 360 -

= 12.3, 10.3, 5.1 Hz, 1H), 1.94 – 1.83 (m, 2H), 1.87 – 1.68 (m, 6H); MS (ESI⁺) *m/z* 545.0 (M+H)⁺.

Example 242: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[4-(trifluoromethyl)phenyl]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 341)

5 A mixture of the product of Example 112A (70.0 mg, 0.22 mmol), 2-(4-(trifluoromethyl)phenyl)acetic acid (48.9 mg, 0.24 mmol), *N*-[(dimethylamino)-1*H*-1,2,3-triazolo-[4,5-*b*]pyridin-1-yl)methylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide (HATU, 99 mg, 0.262 mmol), and triethylamine (0.122 mL, 0.872 mmol) in tetrahydrofuran (2 mL) was stirred for 2 hours. The reaction mixture was treated with saturated aqueous NaHCO₃ and brine and extracted with ethyl acetate (2×). The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (see protocol in Example 112D) to provide the title compound (57.6 mg, 0.122 mmol, 56% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.71 (s, 1H), 8.67 (s, 1H), 7.62 (d, *J* = 7.9 Hz, 2H), 7.53 – 7.35 (m, 3H), 7.03 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.43 (s, 2H), 3.45 (s, 2H), 2.18 (s, 6H); MS (ESI⁺) *m/z* 471.0 (M+H)⁺.

Example 243: 2-(4-chloro-3-fluorophenoxy)-N-(3-{2-[6-(trifluoromethyl)pyridin-3-yl]acetamido}bicyclo[1.1.1]pentan-1-yl)acetamide (Compound 342)

The reaction described in Example 242 substituting 2-(6-(trifluoromethyl)pyridin-3-yl)acetic acid for 2-(4-(trifluoromethyl)phenyl)acetic acid gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.78 (s, 1H), 8.67 (s, 1H), 8.57 (d, *J* = 2.0 Hz, 1H), 7.94 – 7.86 (m, 1H), 7.81 (dd, *J* = 8.1, 0.9 Hz, 1H), 7.45 (t, *J* = 8.9 Hz, 1H), 7.02 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.43 (s, 2H), 3.53 (s, 2H), 2.19 (s, 6H); MS (ESI⁺) *m/z* 472.2 (M+H)⁺.

Example 244: 2-(4-chloro-3-fluorophenoxy)-N-(4-[[4-(4-cyanophenyl)methyl]amino]-3-hydroxybicyclo[2.2.2]octan-1-yl)acetamide (Compound 343)

The title compound was prepared using the methodologies described in Example 232 substituting 2-(4-cyanophenyl)acetaldehyde for 2-(4-fluorophenoxy)acetaldehyde. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.90 (s, 2H), 8.85 (d, *J* = 2.0 Hz, 1H), 8.77 (d, *J* = 10.0 Hz, 1H), 8.20 (dd, *J* = 8.1, 2.0 Hz, 1H), 8.03 (d, *J* = 8.1 Hz, 1H), 7.72 (s, 1H), 7.49 (t, *J* = 8.9 Hz, 1H), 7.03 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.82 (ddd, *J* = 8.9, 2.9, 1.2 Hz, 1H), 5.85 (s, 1H), 4.47 (s, 2H), 4.25 (s, 2H), 4.15 (d, *J* = 9.2 Hz, 1H), 2.40 (td, *J* = 10.4, 9.5, 5.3 Hz, 1H), 2.13 (td, *J* = 11.5, 4.5 Hz, 1H), 2.08 – 1.97 (m, 1H), 1.92 (s, 6H), 1.76 – 1.65 (m, 1H); MS (ESI⁺) *m/z* 458.2 (M+H)⁺.

- 361 -

Example 245: 1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl methanesulfonate (Compound 344)

To a solution of Example 198K (0.32 g, 0.605 mmol) in dichloromethane (4.0 mL) was added triethylamine (0.169 mL, 1.209 mmol) followed by methanesulfonyl chloride (0.061 mL, 0.786 mmol). The mixture was allowed to stir at ambient temperature for 16 hours. The mixture was concentrated under reduced pressure and stirred with water for 30 minutes. The precipitate was collected and air-dried to give 186 mg of the title compound as a white solid. The aqueous filtrate was extracted with dichloromethane, and the organic fraction was dried (MgSO₄) and concentrated. The residue was purified by HPLC (10-95% acetonitrile in 0.1% trifluoroacetic acid/water at 25 mL/minute on a Phenomenex® C18 5 µm column (21.2 × 250 mm)) to give 120 mg of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.70 (d, *J* = 3.9 Hz, 2H), 7.47 (td, *J* = 8.9, 4.0 Hz, 2H), 7.03 (dd, *J* = 11.4, 2.9 Hz, 2H), 6.82 (ddt, *J* = 8.9, 2.7, 1.3 Hz, 2H), 5.41 – 5.33 (m, 1H), 4.54 – 4.41 (m, 4H), 3.11 (s, 3H), 2.19 (dt, *J* = 14.6, 2.3 Hz, 1H), 2.10 – 1.97 (m, 1H), 1.98 – 1.68 (m, 8H); MS (ESI⁺) *m/z* 623.8 [M+NH₄]⁺.

Example 246: 2-(4-chloro-3-fluorophenoxy)-*N*-{4-[2-(4-fluorophenoxy)acetamido]-3-hydroxybicyclo[2.2.2]octan-1-yl}acetamide (Compound 345)

The title compound was prepared using the methodologies described in Example 202 substituting 2-(4-fluorophenoxy)acetic acid for 2-((6-(trifluoromethyl)pyridin-3-yl)oxy)acetic acid. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 7.49 (dd, *J* = 17.3, 8.4 Hz, 2H), 7.21 (s, 1H), 7.18 – 7.07 (m, 2H), 7.02 (dd, *J* = 11.4, 2.9 Hz, 1H), 7.00 – 6.90 (m, 2H), 6.81 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 5.15 (d, *J* = 4.5 Hz, 1H), 4.41 (d, *J* = 17.4 Hz, 4H), 4.05 – 3.96 (m, 1H), 2.28 (ddd, *J* = 12.5, 9.5, 2.4 Hz, 1H), 2.14 (td, *J* = 10.0, 9.2, 5.7 Hz, 1H), 1.93 (s, 1H), 1.93 – 1.73 (m, 8H); MS (ESI⁺) *m/z* 495.1 (M+H)⁺.

Example 247: (2*E*)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-[4-(trifluoromethyl)phenyl]prop-2-enamide (Compound 346)

The reaction described in Example 242 substituting (*E*)-3-(4-(trifluoromethyl)phenyl)acrylic acid for 2-(4-(trifluoromethyl)phenyl)acetic acid gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.80 (s, 1H), 8.71 (s, 1H), 7.73 (s, 4H), 7.54 – 7.36 (m, 2H), 7.04 (dd, *J* = 11.4, 2.8 Hz, 1H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.63 (d, *J* = 15.9 Hz, 1H), 4.45 (s, 2H), 2.26 (s, 6H); MS (ESI⁺) *m/z* 483.1 (M+H)⁺.

Example 248: (2*E*)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(4-methoxyphenyl)prop-2-enamide (Compound 347)

- 362 -

The reaction described in Example 242 substituting (*E*)-3-(4-methoxyphenyl)acrylic acid for 2-(4-(trifluoromethyl)phenyl)acetic acid gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.69 (s, 1H), 8.59 (s, 1H), 7.53 – 7.40 (m, 3H), 7.31 (d, *J* = 15.7 Hz, 1H), 7.04 (dd, *J* = 11.3, 2.9 Hz, 1H), 6.98 – 6.89 (m, 2H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.36 (d, *J* = 15.8 Hz, 1H), 4.45 (s, 2H), 3.75 (s, 3H), 2.24 (s, 6H); MS (ESI⁺) *m/z* 445.1 (M+H)⁺.

Example 249: (2*E*)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(3,4-dichlorophenyl)prop-2-enamide (Compound 348)

The reaction described in Example 242 substituting (*E*)-3-(3,4-dichlorophenyl)acrylic acid for 2-(4-(trifluoromethyl)phenyl)acetic acid gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.72 (d, *J* = 9.4 Hz, 2H), 7.79 (d, *J* = 2.0 Hz, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.55 – 7.41 (m, 2H), 7.34 (d, *J* = 15.8 Hz, 1H), 7.04 (dd, *J* = 11.4, 2.9 Hz, 1H), 6.82 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 6.56 (d, *J* = 15.8 Hz, 1H), 4.45 (s, 2H), 2.25 (s, 6H); MS (ESI⁺) *m/z* 483.0 (M+H)⁺.

Example 250: (2*E*)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(pyridin-2-yl)prop-2-enamide (Compound 349)

A mixture of Example 112A (65.0 mg, 0.20 mmol), (*E*)-3-(pyridin-2-yl)acrylic acid (30.2 mg, 0.20 mmol), *N*-[(dimethylamino)-1*H*-1,2,3-triazolo-[4,5-*b*]pyridin-1-ylmethylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide (HATU, 92 mg, 0.24 mmol), and triethylamine (0.11 mL, 0.81 mmol) in tetrahydrofuran (2 mL) was stirred for 5 hours. Water (10 mL) was added to the suspension, and the mixture was stirred for 30 minutes. The resulting solids were collected by filtration, washed with water (10 mL) and ether (10 mL), and vacuum oven-dried to provide the title compound (68.8 mg, 0.165 mmol, 82% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.85 (s, 1H), 8.72 (s, 1H), 8.62 – 8.54 (m, 1H), 7.81 (td, *J* = 7.7, 1.8 Hz, 1H), 7.59 – 7.36 (m, 3H), 7.34 (ddd, *J* = 7.6, 4.7, 1.1 Hz, 1H), 7.06 (dd, *J* = 11.3, 2.8 Hz, 1H), 6.96 (d, *J* = 15.4 Hz, 1H), 6.84 (ddd, *J* = 9.0, 2.9, 1.2 Hz, 1H), 4.47 (s, 2H), 2.28 (s, 6H); MS (ESI⁺) *m/z* 416.2 (M+H)⁺.

Example 251: (2*E*)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(3-chlorophenyl)prop-2-enamide (Compound 350)

The reaction described in Example 242 substituting (*E*)-3-(3-chlorophenyl)acrylic acid for 2-(4-(trifluoromethyl)phenyl)acetic acid gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.72 (d, *J* = 2.7 Hz, 2H), 7.59 (q, *J* = 1.4 Hz, 1H), 7.54 – 7.28 (m, 5H), 7.06

- 363 -

(dd, J = 11.4, 2.9 Hz, 1H), 6.84 (ddd, J = 8.9, 2.9, 1.2 Hz, 1H), 6.57 (d, J = 15.8 Hz, 1H), 4.47 (s, 2H), 2.27 (s, 6H); MS (ESI⁺) *m/z* 449.1 (M+H)⁺.

Example 252: (2*E*)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-[6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide (Compound 351)

5 The reaction described in Example 242 substituting (*E*)-3-(6-(trifluoromethyl)pyridin-3-yl)acrylic acid for 2-(4-(trifluoromethyl)phenyl)acetic acid gave the title compound. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.98 – 8.84 (m, 2H), 8.73 (s, 1H), 8.21 (dd, J = 8.2, 2.1 Hz, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.58 – 7.37 (m, 2H), 7.06 (dd, J = 11.4, 2.8 Hz, 1H), 6.84 (ddd, J = 8.9, 2.8, 1.2 Hz, 1H), 6.75 (d, J = 15.9 Hz, 1H), 4.47 (s, 2H), 2.28 (s, 6H); MS (ESI⁺) *m/z* 484.1
10 (M+H)⁺.

Example 253: (2*E*)-*N*-{3-[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[1.1.1]pentan-1-yl}-3-(pyridin-3-yl)prop-2-enamide (Compound 352)

 The reaction described in Example 242 substituting (*E*)-3-(pyridin-3-yl)acrylic acid for 2-(4-(trifluoromethyl)phenyl)acetic acid gave the title compound as a trifluoroacetic acid salt. ¹H
15 NMR (500 MHz, DMSO-*d*₆) δ ppm 8.86 (d, J = 5.6 Hz, 2H), 8.74 (s, 1H), 8.65 (dd, J = 5.0, 1.5 Hz, 1H), 8.20 (dt, J = 8.0, 1.9 Hz, 1H), 7.65 (dd, J = 8.0, 5.0 Hz, 1H), 7.54 – 7.40 (m, 2H), 7.07 (dd, J = 11.3, 2.8 Hz, 1H), 6.85 (dt, J = 8.8, 1.8 Hz, 1H), 6.70 (d, J = 15.9 Hz, 1H), 4.48 (s, 2H), 2.29 (s, 6H); MS (ESI⁺) *m/z* 416.1 (M+H)⁺.

Example 254: 2-(4-chloro-3-fluorophenoxy)-*N*-{(3*R*)-4-[2-(4-fluorophenoxy)acetamido]-3-hydroxybicyclo[2.2.2]octan-1-yl}acetamide (Compound 353)

 The title compound was isolated by chiral preparative SFC of Example 246 as the first peak eluted off the column using the methodologies described in Example 198. ¹H NMR (501
25 MHz, DMSO-*d*₆) δ ppm 7.47 (dd, J = 17.2, 8.4 Hz, 2H), 7.19 (s, 1H), 7.15 – 7.06 (m, 2H), 7.00 (dd, J = 11.4, 2.9 Hz, 1H), 6.97 – 6.89 (m, 2H), 6.79 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 5.12 (d, J = 4.2 Hz, 1H), 4.43 – 4.32 (m, 4H), 3.98 (d, J = 9.5 Hz, 1H), 2.25 (ddd, J = 12.6, 9.5, 2.8 Hz, 1H), 2.18 – 2.06 (m, 1H), 1.91 – 1.71 (m, 8H); MS (ESI⁺) *m/z* 495.2 (M+H)⁺.

Example 255: 2-(4-chloro-3-fluorophenoxy)-*N*-{(3*S*)-4-[2-(4-fluorophenoxy)acetamido]-3-hydroxybicyclo[2.2.2]octan-1-yl}acetamide (Compound 354)

 The title compound was isolated by chiral preparative SFC of Example 246 as the second
30 peak eluted off the column using the methodologies described in Example 198. ¹H NMR (501 MHz, DMSO-*d*₆) δ ppm 7.47 (dd, J = 18.0, 9.1 Hz, 2H), 7.19 (s, 1H), 7.15 – 7.04 (m, 2H), 7.00 (dd, J = 11.4, 2.8 Hz, 1H), 6.99 – 6.89 (m, 2H), 6.79 (ddd, J = 9.0, 2.9, 1.2 Hz, 1H), 5.13 (s, 1H),

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 363

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 363

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHIER / FILE NAME :

1X

NOTE POUR LE TOME / VOLUME NOTE:


1

- 639 -

CLAIMS

We claim:

1. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein:

- D is a bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, bridged bicyclic cycloalkenyl, or cubanyl, wherein each bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, bridged bicyclic cycloalkenyl, or cubanyl is optionally substituted with 1-4 R^X groups; and wherein if the bridged bicyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen moiety may be optionally substituted by R^{N1} ;

- L^1 and L^2 are each independently C_1 - C_6 alkylene, C_2 - C_6 alkenylene, 2-7-membered heteroalkylene, O, or NR^C , wherein each C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or 2-7-membered heteroalkylene is optionally substituted with 1-5 R^L ;

R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_2 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, silyloxy- C_2 - C_6 alkyl, G^1 -O- C_2 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, or C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl;

- each R^L is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkoxy, halo- C_1 - C_6 alkyl, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, oxo, halo, cyano, - OR^A , - $NR^B R^C$, - $NR^B R^{CC}$, - $NR^B C(O)R^D$, - $C(O)NR^B R^C$, - $C(O)R^D$, - $C(O)OH$, - $C(O)OR^D$, - SR^E , - $S(O)R^D$, - $S(O)_2 R^D$, - $OS(O)R^D$, - $OS(O)_2 R^D$, and G^2 ; or

- 2 geminal R^L groups together with the carbon to which they are attached form a cyclopropyl moiety;

- R^{N1} is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, halo- C_2 - C_6 alkyl, amino- C_2 - C_6 alkyl, cyano- C_2 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, HO_2C - C_1 - C_6 alkyl, C_1 - C_6 alkyl- $C(O)_2$ - C_1 - C_6 alkyl, phenoxy- C_1 - C_6 alkyl (wherein phenoxy is optionally substituted with 1-3 halogens), - $C(O)NR^B R^C$, - $C(O)R^D$, - $C(O)OR^D$, and - $S(O)_2 R^D$;

- 640 -

A and W are each independently phenyl or 5-6-membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R^Y;

each R^X is independently selected from the group consisting of C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkyl-C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkoxy, oxo, halo, cyano, -OR^A, -NR^BR^C, -NR^BR^{CC}, -NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, =CHC(O)OR^D, =CHC(O)OH, -SR^E, -S(O)R^D, -S(O)₂R^D, -OS(O)R^D, -OS(O)₂R^D, and G²; or

2 geminal R^X groups together with the carbon to which they are attached form an oxirane moiety;

each R^Y is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, O-C₃-C₆ cycloalkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, hydroxy-C₁-C₆ alkoxy, halo-C₁-C₆ alkyl, halo-C₁-C₆ alkoxy, amino-C₁-C₆ alkyl, cyano-C₁-C₆ alkyl, oxo, halo, cyano, -OR^A, -NR^BR^C, -NR^BR^{CC}, -NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, -S(R^F)_m, -S(O)R^D, -S(O)₂R^D, and G¹; or

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl, heterocyclyl, aryl, or heteroaryl ring optionally substituted with 1-5 R^X;

each G¹ and G² is independently C₃-C₆ cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl, wherein each C₃-C₆ cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 R^Z;

each R^Z is independently selected from the group consisting of C₁-C₆ alkyl, hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, halo, cyano, -OR^A, -NR^BR^C, -NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, -C(O)OH, -C(O)OR^D, and -S(O)₂R^D;

each R^A is independently hydrogen, C₁-C₆ alkyl, halo-C₁-C₆ alkyl, -C(O)NR^BR^C, -C(O)R^D, or -C(O)OR^D;

each of R^B and R^C is independently hydrogen, C₁-C₆ alkyl, or halo-C₁-C₆ alkyl;

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with 1-3 R^Z;

each R^{CC} is independently selected from the group consisting of hydroxy-C₁-C₆ alkyl, halo-C₁-C₆ alkyl, HO₂C-C₁-C₆ alkyl, C₁-C₆ alkyl-C(O)₂-C₁-C₆ alkyl, (CO)-C₁-C₆alkyl-OH, (CO)-C₁-C₆alkyl-C₁-C₆alkoxy and 4-6 membered heterocyclyl; wherein the heterocyclyl may optionally be substituted with 1-3 R^Z;

- 641 -

each R^D is independently C₁-C₆ alkyl, 2-7-membered heteroalkyl, hydroxy-C₁-C₆ alkyl, or halo-C₁-C₆ alkyl, wherein each C₁-C₆ alkyl, 2-7-membered heteroalkyl, hydroxy-C₁-C₆ alkyl, or halo-C₁-C₆ alkyl is optionally substituted with 1-5 R^G;

each R^E is independently hydrogen, C₁-C₆ alkyl, or halo-C₁-C₆ alkyl;

5 each R^F is independently hydrogen, C₁-C₆ alkyl, or halo;

each R^G is independently aryl or 5-6 membered heteroaryl, wherein each aryl or 5-6 membered heteroaryl is optionally substituted with 1-5 R^H;

each R^H is independently C₁-C₆ alkyl or halo-C₁-C₆ alkyl;

10 m is 1 when R^F is hydrogen or C₁-C₆ alkyl, 3 when R^F is C₁-C₆ alkyl, or 5 when R^F is halo;
t is 0 or 1; and
s is 0 or 1.

2. The compound of claim 1, wherein D is a bridged bicyclic cycloalkyl, a bridged bicyclic heterocyclyl, or cubanyl, each of which is optionally substituted with 1-4 R^X groups.

15

3. The compound of any one of claims 1-2, wherein D is a bridged 5-8 membered bicyclic cycloalkyl or heterocyclyl, or cubanyl, each of which is optionally substituted with 1-4 R^X groups.


20

4. The compound of any one of claims 1-3, wherein D is selected from cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.2.2]oct-2-ene, bicyclo[2.1.1]hexane, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[3.2.1]octane, or 2-azabicyclo[2.2.2]octane, each of which is optionally substituted with 1-4 R^X groups.


25

5. The compound of any one of claims 1-4, wherein D is selected from:

- 642 -



6. The compound of any one of claims 1-5, wherein D is selected from:




7. The compound of any one of claims 1-6, wherein D is substituted with 1 or 2 R^X .

8. The compound of any one of claims 1-7, wherein R^X is independently C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkoxy, oxo, halo, cyano, $-OR^A$, $-OS(O)_2R^D$, $-S(O)_2R^D$, $-SR^E$, $NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $=CHC(O)OH$, $=CHC(O)OR^D$, $NR^B R^C$, $NR^B R^{CC}$, or G^2 ; or 2 geminal R^X groups together with the carbon to which they are attached form an oxirane moiety.

9. The compound of claim 8, wherein R^X is independently CH_3 , $-CH_2OH$, $-CH_2OCH_3$, $-CH_2CH_2CH_3$, $-C(CH_3)_2OH$, $-O-CH_2-O-CH_3$, CH_2CH_2OH , oxo, fluoro, bromo, OH, cyano,

- 643 -

OCH₃, NH₂, N(H)CH₂CF₃, N(H)CH₂CH₂OH, N(CH₃)₂, N(CH₃)CH₂CH₂OH, N(CH₃)CH₂CO₂H, N(CH₃)CH₂CH₂CO₂H, NHC(O)CH₃, OC(O)CH₃, C(O)NH₂, OS(O)₂CH₃, -S(O)₂CH₃, -S(O)₂CH₂CH₃, C(O)OH, C(O)OCH₃, OC(O)R^D, -C(O)CH₃, =CHC(O)OH, =CHC(O)OCH₂CH₃, -




5

10. The compound of claim 8, wherein G² is aryl or 5-6 membered heteroaryl.

11. The compound of claim 8, wherein G² is oxadiazolyl, or tetrazolyl.

10 12. The compound of any one of claims 1-6, wherein D is substituted with 0 R^X.



14. The compound of any one of claims 1-13, wherein at least one of L¹ and L² is
15 independently 2-7-membered heteroalkylene optionally substituted by 1-5 R^L.

15. The compound of any one of claims 1-14, wherein one of L¹ and L² is independently C₁-C₆ alkylene or C₂-C₆ alkenylene and the other of L¹ and L² is independently 2-7-membered heteroalkylene, and wherein each C₁-C₆ alkylene, C₂-C₆ alkenylene, and 2-7-membered
20 heteroalkylene is optionally substituted by 1-5 R^L.


16. The compound of any one of claims 14-15, wherein each R^L is independently C₁-C₆ alkyl, OH, oxo, -C(O)R^D, cyano, HO₂C-C₁-C₆ alkyl, C₁-C₆ alkyl-C(O)₂-C₁-C₆ alkyl, -C(O)OH, -NR^BR^C, -NR^BR^{CC}, -NR^BC(O)R^D, hydroxy-C₁-C₆ alkyl, or hydroxy-C₁-C₆ alkoxy.

25

- 644 -


17. The compound of any one of claims 14-16, wherein each R^L is independently CH_3 , oxo, or $C(O)CH_3$.

18. The compound of any one of claims 1-17, wherein each of L^1 and L^2 is independently selected from CH_2O^* , $CH_2CH_2^*$, $CH_2CH_2CH_2^*$, CH_2^* , $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, $NHCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $CH(OH)^*$, $CH(OH)CH_2CH_2^*$, $CH_2CH(OH)^*$, $CH_2NHC(O)^*$, $NHC(O)OCH_2^*$, O^* , NH^* , $S(O)_2CH^*$, $S(O)_2CH_2CH_2^*$, $S(O)_2CH_2CH_2O^*$, $CH_2C(O)^*$, $O-CH_2CH_2^*$, $CH_2N(CH_2CO_2H)^*$, $CH(CO_2H)CH_2CH_2O^*$, $CH_2N(CH_2CO_2C(CH_3)_3)^*$, $CH(CN)CH_2O^*$, $CH_2CH(NH(CH_3))^*$, $CH(OCH_2CH_2OH)^*$, $CH_2CH(NH(C(O)CH_2OH))^*$, $CH_2CH(NH_2)CH_2^*$, $CH(CH_2CH_2OH)O^*$



or , and “-*” indicates the attachment point to A and W, respectively.

19. The compound of any one of claims 1-18, wherein L^1 is independently selected from CH_2O^* , $CH_2CH_2O^*$ or $CH=CH^*$, L^2 is independently selected from CH_2O^* , $CH_2CH_2^*$, $CH_2CH_2CH_2^*$, CH_2^* , $CH_2C(O)^*$, $CH=CH^*$, $CH_2CH_2O^*$, $CH_2OCH_2^*$, $CH_2OCH_2CH_2^*$, $CH_2CH_2CH_2O^*$, $CH_2CH_2OCH_2^*$, $NHCH_2^*$, CH_2NH^* , $CH_2N(CH_3)^*$, $CH_2N(CH_3)C(O)^*$, $CH_2N(C(O)CH_3)^*$, $CH_2CH(OH)^*$, $CH(OH)^*$, $CH(OH)CH_2CH_2^*$, $CH_2CH(OH)^*$, $CH_2NHC(O)^*$, $NHC(O)OCH_2^*$, O^* , NH^* , $S(O)_2CH^*$, $S(O)_2CH_2CH_2^*$, $S(O)_2CH_2CH_2O^*$, $CH_2C(O)^*$, $CH_2N(CH_2CO_2H)^*$, $CH(CO_2H)CH_2CH_2O^*$, $CH_2N(CH_2CO_2C(CH_3)_3)^*$, $CH(CN)CH_2O^*$, $CH_2CH(NH(CH_3))^*$, $CH(OCH_2CH_2OH)^*$, $CH_2CH(NH(C(O)CH_2OH))^*$,

$CH_2CH(NH_2)CH_2^*$, $CH(CH_2CH_2OH)O^*$, $CH_2C(CH_3)_2O^*$ or , and “-*” indicates the attachment point to A and W, respectively.


20. The compound of any one of claims 1-19, wherein t is 1 and s is 1.

21. The compound of any one of claims 1-19, wherein s is 1 and t is 0.

- 645 -

22. The compound of any one of claims 1-19, wherein s is 0 and t is 0.
23. The compound of any one of claims 1-22, wherein R¹ and R² are each independently
 5 hydrogen, C₁-C₆ alkyl, hydroxyl-C₂-C₆ alkyl, or silyloxy-C₂-C₆ alkyl.
24. The compound of any one of claims 1-23, wherein one of R¹ and R² is independently
 hydrogen and the other of R¹ and R² is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ hydroxyl-C₂-
 C₆ alkyl, silyloxy-C₂-C₆ alkyl, HO₂C-C₁-C₆ alkyl, or C₁-C₆ alkyl-C(O)₂-C₁-C₆ alkyl.
 10
25. The compound of any one of claims 1-24, wherein R¹ and R² are each independently
 hydrogen, *-CH₃, *-CH₂CH₂OH, *-CH₂CH₂OSi(CH₃)₂C(CH₃)₃, *-CH₂CO₂H, or *-
 CH₂C(O)₂C(CH₃), and “*-” indicates the attachment point to the nitrogen atom.
- 15 26. The compound of any one of claims 1-25, wherein one of R¹ and R² is independently
 hydrogen and the other of R¹ and R² is independently hydrogen, *-CH₃, *-CH₂CH₂OH, *-
 CH₂CH₂OSi(CH₃)₂C(CH₃)₃, *-CH₂CO₂H, or *-CH₂C(O)₂C(CH₃), and “*-” indicates the
 attachment point to the nitrogen atom.
- 20 27. The compound of any one of claims 1-26, wherein R¹ and R² are each independently
 hydrogen.
28. The compound of any one of claims 1-27, wherein each A and W is independently a
 phenyl or 5-6-membered heteroaryl optionally substituted with 1-5 R^Y groups.
- 25 29. The compound of any one of claims 1-27, wherein each of A and W is independently
 phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, triazinyl, pyrazolyl, pyrimidinyl, triazolyl,
 oxadiazolyl, oxadiazolonyl, thiazolyl, imidazolyl, pyrimidin-2(1H)-onyl, 1H-
 benzo[d]imidazolyl, pyrazolo[1,5-a]pyridine, 1H-indazolyl or isoxazolyl, each of which is
 30 optionally substituted with 1-5 R^Y groups.


10




- 647 -

31. The compound of any one of claims 1-30, wherein A is phenyl and W is phenyl or 5-6-membered heteroaryl, each of A and W is optionally substituted with 1-5 R^Y , and each R^Y is independently C_1 - C_6 alkyl, O - C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, hydroxy- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B R^{CC}$, $-NR^B C(O)R^D$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)_2 R^D$, or G^1 .
32. The compound of any one of claims 1-31, wherein A is phenyl and W is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, pyrimidinyl, triazinyl, pyrazolyl, triazolyl, oxadiazolyl, oxadiazolonyl, thiazolyl, imidazolyl, or isoxazolyl, each of which is optionally substituted with 1-5 R^Y groups.


33. The compound of any one of claims 1-32, wherein A is selected from:



34. The compound of any one of claims 1-33, wherein W is selected from:




- 648 -



35. The compound of any one of claims 1-34, wherein each R^Y is independently hydrogen, bromo, chloro, fluoro, iodo, cyano, CF_3 , CHF_2 , CH_2CF_3 , CH_3 , CH_2CH_3 , OH, CH_2OH ,

10 $C(CH_3)_2OH$, OCH_3 , OCH_2CH_3 , $OCHF_2$, OCF_3 , OCH_2CF_3 , OCH_2CH_2OH , CH_2OCH_3 , $S(O)_2CH_3$, $S(O)_2CH_2CH_2CH_3$, CN, $N(CH_3)_2$, SF_5 , SCH_3 , NH_2 , $NH(C(O)CH_2OH)$, $NH(CH_2CH_2OH)$, $NH(CO)CH_2OCH_3$, $C(CH_3)_3$, $CH(CH_3)_2$, CH_2CN , CH_2NH_2 , $CH(OH)CH_3$, $C(OH)(CH_3)CF_3$,

$S(O)_2CH_3$, $C(O)CH_3$, $C(O)OCH_3$, $C(O)OH$, $OCHF_2$, G^1 , or .

15 36. The compound of any one of claims 1-35, wherein each A and W is independently substituted with 2 R^Y on adjacent atoms, and the 2 R^Y , together with the atoms to which they are

- 649 -

attached, form a 3-7-membered fused cycloalkyl, 3-7-membered fused heterocyclyl, fused aryl, or 5-6-membered fused heteroaryl ring optionally substituted with 1-5 R^X .

37. The compound of claim 36, wherein the 2 R^Y together with the atoms to which they are attached form a phenyl, pyridyl, pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, dioxanyl, dioxolanyl, pyrrolidin-2-onyl, or morpholin-3-onyl ring, each of which is optionally substituted with 1-5 R^X .


38. The compound of any one of claims 36-37, wherein each R^X is independently C_1 - C_6 alkyl, OR^A , or halo.

39. The compound of any one of claims 36-38, wherein each R^X is independently CH_3 , OH or fluoro.

40. The compound of any one of claims 1-39, wherein G^1 is cyclopropyl, isoxazolyl, piperidinyl, phenyl, or pyrazolyl, each of which is optionally substituted with 1-5 R^Z .

41. The compound of claim 40, wherein each R^Z is independently C_1 - C_6 alkyl or halo.

42. The compound of any one of claims 1-41, wherein the compound of Formula (I) is a compound of Formula (I-b):



Formula (I-b)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof,

wherein:

D is (1,2,3,4,6,7)-cubane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane, or 2-azabicyclo[2.2.2]octane, each of which is optionally substituted with 1-4 R^X groups; and wherein 2-azabicyclo[2.2.2]octane is substituted on nitrogen by hydrogen or CH_3 ;

- 650 -

L^1 and L^2 are each independently $\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{CH}_2-^*$, $\text{CH}_2\text{CH}_2\text{CH}_2-^*$, CH_2-^* , $\text{CH}_2\text{C}(\text{O})-^*$, $\text{CH}=\text{CH}-^*$, $\text{CH}_2\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{OCH}_2-^*$, $\text{CH}_2\text{OCH}_2\text{CH}_2-^*$, $\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-^*$, $\text{CH}_2\text{CH}_2\text{OCH}_2-^*$, NHCH_2-^* , $\text{CH}_2\text{NH}-^*$, $\text{CH}_2\text{N}(\text{CH}_3)-^*$, $\text{CH}_2\text{N}(\text{CH}_3)\text{C}(\text{O})-^*$, $\text{CH}_2\text{N}(\text{C}(\text{O})\text{CH}_3)-^*$, $\text{CH}_2\text{CH}(\text{OH})-^*$, $\text{CH}(\text{OH})-^*$, $\text{CH}(\text{OH})\text{CH}_2\text{CH}_2-^*$, $\text{CH}_2\text{CH}(\text{OH})-^*$, $\text{CH}_2\text{NHC}(\text{O})-^*$, $\text{NHC}(\text{O})\text{OCH}_2-^*$, $\text{O}-^*$, $\text{NH}-^*$, $\text{S}(\text{O})_2\text{CH}-^*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2-^*$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2\text{O}-^*$, or $\text{CH}_2\text{C}(\text{O})-^*$, and “ $-^*$ ” indicates the attachment point to A and W, respectively.

R^1 and R^2 are each independently hydrogen, CH_3 , $\text{CH}_2\text{CH}_2\text{OH}$, or $\text{CH}_2\text{CH}_2\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_3$;

A and W are each independently isoxazolyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyridazinonyl, pyrimidinyl, triazinyl, thiazolyl, triazolyl, oxadiazolyl, or oxadiazolonyl, each of which is optionally substituted with 1-5 R^Y groups;

each R^X is independently selected from CH_3 , $-\text{CH}_2\text{OH}$, $-\text{C}(\text{CH}_3)_2\text{OH}$, oxo, fluoro, bromo, OH, cyano, OCH_3 , NH_2 , $\text{N}(\text{CH}_3)_2$, $\text{NHC}(\text{O})\text{CH}_3$, $\text{OC}(\text{O})\text{CH}_3$, $\text{C}(\text{O})\text{NH}_2$, $\text{OS}(\text{O})_2\text{CH}_3$, $-\text{S}(\text{O})_2\text{CH}_3$, $-\text{S}(\text{O})_2\text{CH}_2\text{CH}_3$, $\text{C}(\text{O})\text{OH}$, $\text{OC}(\text{O})\text{R}^D$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{SCH}_3$, or G^2 ;

each R^Y is independently bromo, chloro, fluoro, iodo, CF_3 , CHF_2 , CH_2CF_3 , CH_3 , CH_2CH_3 , OH, CH_2OH , $\text{C}(\text{CH}_3)_2\text{OH}$, OCH_3 , OCH_2CH_3 , OCF_3 , $\text{S}(\text{O})_2\text{CH}_3$, $\text{S}(\text{O})_2\text{CH}_2\text{CH}_2\text{CH}_3$, CN, $\text{N}(\text{CH}_3)_2$, SF_5 , SCH_3 , NH_2 , $\text{C}(\text{CH}_3)_3$, $\text{CH}(\text{CH}_3)_2$, CH_2CN , CH_2NH_2 , $\text{CH}(\text{OH})\text{CH}_3$, $\text{C}(\text{OH})(\text{CH}_3)\text{CF}_3$, $\text{S}(\text{O})_2\text{CH}_3$, $\text{C}(\text{O})\text{CH}_3$, $\text{C}(\text{O})\text{OCH}_3$, $\text{C}(\text{O})\text{OH}$, OCHF_2 or G^1 ; or

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, furanyl, or dioxolanyl ring, each of which is optionally substituted with 1-2 R^X ;

G^1 and G^2 are cyclopropyl, isoxazolyl, phenyl, piperidinyl, oxadiazolyl, or tetrazolyl, or pyrazolyl, each of which is optionally substituted with 1-2 R^Z ;

each R^D is CH_2O optionally substituted with 1-5 R^G ;

each R^G is independently pyridyl optionally substituted with 1-5 R^H ;


each R^H is independently CF_3 ;

each R^Z is independently CH_3 ; and

t is 0 or 1.

43. The compound of any one of claims 1-42, wherein the compound of Formula (I) is a compound of Formula (I-c):

- 651 -




Formula (I-c)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

5

44. The compound of any one of claims 1-43, wherein the compound of Formula (I) is a compound of Formula (I-d):




Formula (I-d)

10

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

45. The compound of any one of claims 1-43, wherein the compound of Formula (I) is a compound of Formula (I-e):




15

Formula (I-e)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

20

46. The compound of any one of claims 1-43 and 45, wherein the compound of Formula (I) is a compound of Formula (I-f):




Formula (I-f)

- 652 -

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.


47. The compound of any one of claims 1-42, wherein the compound of Formula (I) is a compound of Formula (I-g):



Formula (I-g)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.


48. The compound of any one claims 1-42 and 47, wherein the compound of Formula (I) is a compound of Formula (I-h):



Formula (I-h)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

49. The compound of any one of claims 1-42 and 47-48, wherein the compound of Formula (I) is a compound of Formula (I-i):




Formula (I-i)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

50. The compound of any one of claims 1-42, wherein the compound of Formula (I) is a compound of Formula (I-j):

- 653 -




Formula (I-j)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

5

51. The compound of any one of claims 1-42 and 50, wherein the compound of Formula (I) is a compound of Formula (I-k):




Formula (I-k)

10

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

52. The compound of any one of claims 1-42 and 50-51, wherein the compound of Formula (I) is a compound of Formula (I-l):




Formula (I-l)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

20

53. A compound of Formula (II):



Formula (II)

- 654 -

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein:

D is a bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl, wherein each bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, or cubanyl is optionally substituted with 1-4 R^X groups; and wherein if the bridged bicyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen moiety may be optionally substituted by R^{N1} ;

L^1 is C_1 - C_6 alkylene, C_2 - C_6 alkenylene, 2-7-membered heteroalkylene, O, or NR^C , wherein C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or 2-7-membered heteroalkylene is optionally substituted with 1-5 R^X ;

L^2 is $-(C_0$ - C_2 alkylene)-O-(C_0 - C_2 alkylene)-;

R^1 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_2 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, and silyloxy- C_2 - C_6 alkyl;

R^{N1} is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_2 - C_6 alkyl, halo- C_2 - C_6 alkyl, amino- C_2 - C_6 alkyl, cyano- C_2 - C_6 alkyl, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OR^D$, and $-S(O)_2 R^D$;

A and W are each independently phenyl or 5-6-membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R^Y ;

each R^X is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-SR^E$, $-S(O)R^D$, $-S(O)_2 R^D$, $-OS(O)R^D$, $-OS(O)_2 R^D$, and G^2 ;

each R^Y is independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, amino- C_1 - C_6 alkyl, cyano- C_1 - C_6 alkyl, oxo, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, $-S(R^F)_m$, $-S(O)R^D$, $-S(O)_2 R^D$, and G^1 ; or

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl, heterocyclyl, aryl, or heteroaryl ring optionally substituted with 1-5 R^X ;

each G^1 and G^2 is independently C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl, wherein each C_3 - C_6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 R^Z ;

- 655 -

each R^Z is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxy- C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo, cyano, $-OR^A$, $-NR^B R^C$, $-NR^B C(O)R^D$, $-C(O)NR^B R^C$, $-C(O)R^D$, $-C(O)OH$, $-C(O)OR^D$, and $-S(O)_2 R^D$;

each R^A is independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, $-C(O)NR^B R^C$, $-C(O)R^D$, or $-C(O)OR^D$;

each of R^B and R^C is independently hydrogen or C_1 - C_6 alkyl; or

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocycl ring optionally substituted with 1-3 R^Z ;

each R^D is independently C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl, wherein each C_1 - C_6 alkyl, 2-7-membered heteroalkyl, or halo- C_1 - C_6 alkyl is optionally substituted with 1-5 R^G ;

each R^E is independently hydrogen, C_1 - C_6 alkyl, or halo- C_1 - C_6 alkyl;

each R^F is independently hydrogen, C_1 - C_6 alkyl, or halo;


each R^G is independently aryl or 5-6 membered heteroaryl, wherein each aryl or 5-6 membered heteroaryl is optionally substituted with 1-5 R^H ;

each R^H is independently C_1 - C_6 alkyl or halo- C_1 - C_6 alkyl;

m is 1 when R^F is hydrogen or C_1 - C_6 alkyl, 3 when R^F is C_1 - C_6 alkyl, or 5 when R^F is halo; and

t is 0 or 1.

54. The compound of claim 53, wherein D is selected from the group consisting of



55. The compound of claim 53 or 54, wherein each R^X is independently selected from the group consisting of oxo, $-OR^A$ (*e.g.*, OH or OCH_3), $-C(O)OH$, $-C(O)OR^D$ (*e.g.*, $-C(O)OCH_3$), halo, and hydroxy- C_1 - C_6 alkyl.


- 656 -

56. The compound of any one of claims 53-55, wherein L^1 is $\text{CH}_2\text{O}-^*$ or $\text{CH}_2\text{OCH}_2-^*$; wherein “ $-^*$ ” indicates the attachment point to A.


57. The compound of any one of claims 53-56, wherein L^2 is selected from the group consisting of $\text{O}-^*$, OCH_2-^* , $\text{CH}_2\text{O}-^*$, $\text{OCH}_2\text{CH}_2-^*$, $\text{CH}_2\text{OCH}_2-^*$, and $\text{CH}_2\text{CH}_2\text{O}-^*$; wherein “ $-^*$ ” indicates the attachment point to W.

58. The compound of any one of claims 53-57, wherein R^1 is hydrogen or CH_3 .

59. The compound of any one of claims 53-58, wherein A is selected from the group consisting of:



60. The compound of any one of claims 53-59, wherein W is selected from the group consisting of:




wherein R^{N4} is hydrogen or CH_3 .

- 657 -

61. The compound of any one of claims 53-60, wherein each R^Y is independently hydrogen, chloro, fluoro, CF_3 , CHF_2 , CH_3 , CH_2CH_3 , $CH(CH_3)_2$, OCH_3 , OCF_3 , $OCH(CH_3)_2$, or CN.

62. The compound of any one of claims 53-61, wherein the compound of Formula (II) is a compound of Formula (II-a):



Formula (II-a)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, wherein:

D is bicyclo[1.1.1]pentanyl or bicyclo[2.2.2]octanyl, each of which is optionally substituted with 1-4 R^X groups;

L^1 is CH_2O^* or $CH_2OCH_2^*$, wherein “-*” indicates the attachment point to A;

L^2 is selected from the group consisting of O^* , OCH_2^* , CH_2O^* , $OCH_2CH_2^*$, $CH_2OCH_2^*$, and $CH_2CH_2O^*$; wherein “-*” indicates the attachment point to W;

A is phenyl or pyridyl, each of which is optionally substituted with 1-5 R^Y groups;

W is phenyl, pyridyl, isoxazolyl, or pyrazolyl, each of which is optionally substituted on one or more available carbons with 1-5 R^Y groups; and wherein pyrazolyl may be optionally substituted on an available nitrogen with hydrogen or CH_3 ;

each R^X is independently fluoro, oxo, OH, OCH_3 , $C(O)OH$, or $C(O)OCH_3$;

each R^Y is independently chloro, fluoro, CF_3 , CH_3 , CH_2CH_3 , $CH(CH_3)_2$, OCH_3 , $OCH(CH_3)_2$, or CN; or

2 R^Y groups on adjacent atoms, together with the atoms to which they are attached form a furanyl, pyrrolyl, or dioxolanyl ring, each of which is optionally substituted with 1-2 R^X ; and

R^1 is hydrogen.

63. The compound of any one of claims 1-62, wherein the compound is selected from any compound set forth in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof.

- 658 -

64. A pharmaceutically acceptable composition comprising a compound of claims 1-63 and a pharmaceutically acceptable carrier.

65. A composition for use in treating a neurodegenerative disease, a leukodystrophy, a
5 cancer, an inflammatory disease, an autoimmune disease, a viral infection, a skin disease, a fibrotic disease, a hemoglobin disease, a kidney disease, a hearing loss condition, an ocular disease, a musculoskeletal disease, a metabolic disease, or a mitochondrial disease in a subject, wherein the composition comprises a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer
10 thereof as described in any one claims 1-63.

66. The composition of claim 65, wherein the neurodegenerative disease comprises a leukodystrophy, a leukoencephalopathy, a hypomyelinating or demyelinating disease, an intellectual disability syndrome, a cognitive impairment, a glial cell dysfunction, or a brain
15 injury (e.g., a traumatic brain injury or toxin induced brain injury).

67. The composition of any one of claims 65 or 66, wherein the neurodegenerative disease comprises vanishing white matter disease, childhood ataxia with CNS hypo myelination, Alzheimer's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, frontotemporal
20 dementia, Gerstmann-Straussler-Scheinker disease, Huntington's disease, dementia (e.g., HIV-associated dementia or Lewy body dementia), kuru, multiple sclerosis, Parkinson's disease, or a prion disease.

68. The composition of any one of claims 65-67, wherein the neurodegenerative disease
25 comprises vanishing white matter disease.

69. The composition of claim 65, wherein the cancer comprises pancreatic cancer, breast cancer, multiple myeloma, or a cancer of the secretory cells.

30 70. The composition of claim 65, wherein the inflammatory disease comprises postoperative cognitive dysfunction, arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis), systemic lupus erythematosus (SLE), myasthenia gravis, diabetes (e.g.,

- 659 -

juvenile onset diabetes or diabetes mellitus type 1), Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma (e.g., allergic asthma), acne vulgaris, celiac disease, chronic prostatitis, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, or atopic dermatitis.

71. The composition of claim 65, wherein the musculoskeletal disease comprises muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, distal muscular dystrophy, congenital muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, or myotonic muscular dystrophy), multiple sclerosis, amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy, spinal cord spasticity, spinal muscle atrophy, myasthenia gravis, neuralgia, fibromyalgia, Machado-Joseph disease, cramp fasciculation syndrome, Freidrich's ataxia, a muscle wasting disorder (e.g., muscle atrophy, sarcopenia, cachexia), an inclusion body myopathy, motor neuron disease, or paralysis.

72. The composition of claim 65, wherein the metabolic disease comprises non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, heart disease, atherosclerosis, arthritis, cystinosis, diabetes (e.g., Type I diabetes, Type II diabetes, or gestational diabetes), phenylketonuria, proliferative retinopathy, or Kearns-Sayre disease.

73. The composition of claim 65, wherein the mitochondrial disease is associated with or is a result of mitochondrial dysfunction, one or more mitochondrial protein mutations, or one or more mitochondrial DNA mutations.

74. The composition of claim 65 or 73, wherein the mitochondrial disease is a mitochondrial myopathy.

- 660 -

75. The composition of any one of claims 65 and 73-74, wherein the mitochondrial disease is selected from the group consisting of Barth syndrome, chronic progressive external ophthalmoplegia (cPEO), Kearns-Sayre syndrome (KSS), Leigh syndrome (e.g., MILS, or maternally inherited Leigh syndrome), mitochondrial DNA depletion syndromes (MDDS, e.g.,
 5 Alpers syndrome), mitochondrial encephalomyopathy (e.g., mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)), mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), myoclonus epilepsy with ragged red fibers (MERRF), neuropathy, ataxia, retinitis pigmentosa (NARP), Leber's hereditary optic neuropathy (LHON), and Pearson syndrome.

10

76. The composition of claim 65, wherein the autoimmune disease is selected from the group consisting of Achalasia, Addison's disease, Adult Still's disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome, Autoimmune angioedema, Autoimmune dysautonomia,
 15 Autoimmune encephalomyelitis, Autoimmune hepatitis, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune urticaria, Axonal & neuronal neuropathy (AMAN), Baló disease, Behcet's disease, Benign mucosal pemphigoid, Bullous pemphigoid, Castleman disease (CD), Celiac disease, Chagas disease, Chronic inflammatory demyelinating
 20 polyneuropathy (CIDP), Chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), Cicatricial pemphigoid, Cogan's syndrome, Cold agglutinin disease, Congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn's disease, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressler's syndrome, Endometriosis, Eosinophilic
 25 esophagitis (EoE), Eosinophilic fasciitis, Erythema nodosum, Essential mixed cryoglobulinemia, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura (HSP), Herpes gestationis or pemphigoid gestationis (PG),
 30 Hidradenitis Suppurativa (HS) (Acne Inversa), Hypogammaglobulinemia, IgA Nephropathy, IgG4-related sclerosing disease, Immune thrombocytopenic purpura (ITP), Inclusion body myositis (IBM), Interstitial cystitis (IC), Juvenile arthritis, Juvenile diabetes (Type 1 diabetes),

- 661 -

Juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus, Lyme disease chronic, Meniere's disease, Microscopic polyangiitis (MPA), Mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multifocal

5 Motor Neuropathy (MMN) or MMNCB, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neonatal Lupus, Neuromyelitis optica, Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism (PR), PANDAS, Paraneoplastic cerebellar degeneration (PCD), Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis (peripheral uveitis), Parsonage-Turner syndrome, Pemphigus, Peripheral neuropathy,

10 Perivenous encephalomyelitis, Pernicious anemia (PA), POEMS syndrome, Polyarteritis nodosa, Polyglandular syndrome type I, Polyglandular syndrome type II, Polyglandular syndrome type III, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Primary biliary cirrhosis, Primary sclerosing cholangitis, Progesterone dermatitis, Psoriasis, Psoriatic arthritis, Pure red cell aplasia (PRCA), Pyoderma

15 gangrenosum, Raynaud's phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Relapsing polychondritis, Restless legs syndrome (RLS), Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjögren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome (SPS), Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia (SO), Takayasu's arteritis,

20 Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), Transverse myelitis, Type 1 diabetes, Ulcerative colitis (UC), Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vitiligo, Vogt-Koyanagi-Harada Disease, and Wegener's granulomatosis (or Granulomatosis with Polyangiitis (GPA)).

25 77. The composition of claim 65, wherein the viral infection is selected from the group consisting of influenza, human immunodeficiency virus (HIV) and herpes.

78. The composition of claim 65, wherein the skin disease is selected from the group consisting of acne, alopecia areata, basal cell carcinoma, Bowen's disease, congenital

30 erythropoietic porphyria, contact dermatitis, Darier's disease, disseminated superficial actinic porokeratosis, dystrophic epidermolysis bullosa, eczema (atopic eczema), extra-mammary Paget's disease, epidermolysis bullosa simplex, erythropoietic protoporphyria, fungal infections

- 662 -

of nails, Hailey-Hailey disease, herpes simplex, hidradenitis suppurativa, hirsutism, hyperhidrosis, ichthyosis, impetigo, keloids, keratosis pilaris, lichen planus, lichen sclerosus, melanoma, melasma, mucous membrane pemphigoid, pemphigoid, pemphigus vulgaris, pityriasis lichenoides, pityriasis rubra pilaris, plantar warts (verrucae), polymorphic light eruption, psoriasis, plaque psoriasis, pyoderma gangrenosum, rosacea, scabies, scleroderma, shingles, squamous cell carcinoma, Sweet's syndrome, urticaria and angioedema and vitiligo.

79. The composition of claim 65, wherein the fibrotic disease is selected from the group consisting of adhesive capsulitis, arterial stiffness, arthrofibrosis, atrial fibrosis, cardiac fibrosis, cirrhosis, congenital hepatic fibrosis, Crohn's disease, cystic fibrosis, Dupuytren's contracture, endomyocardial fibrosis, glial scar, hepatitis C, hypertrophic cardiomyopathy, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, interstitial lung disease, keloid, mediastinal fibrosis, myelofibrosis, nephrogenic systemic fibrosis, non-alcoholic fatty liver disease, old myocardial infarction, Peyronie's disease, pneumoconiosis, pneumonitis, progressive massive fibrosis, pulmonary fibrosis, radiation-induced lung injury, retroperitoneal fibrosis, scleroderma/systemic sclerosis, silicosis and ventricular remodeling.

80. The composition of claim 65, wherein the hemoglobin disease is selected from the group consisting of "dominant" β -thalassemia, acquired (toxic) methemoglobinemia, carboxyhemoglobinemia, congenital Heinz body hemolytic anemia, HbH disease, HbS/ β -thalassemia, HbE/ β -thalassemia, HbSC disease, homozygous α^+ -thalassemia (phenotype of α^0 -thalassemia), Hydrops fetalis with Hb Bart's, sickle cell anemia/disease, sickle cell trait, sickle β -thalassemia disease, α^+ -thalassemia, α^0 -thalassemia, α -Thalassemia associated with myelodysplastic syndromes, α -Thalassemia with mental retardation syndrome (ATR), β^0 -Thalassemia, β^+ -Thalassemia, δ -Thalassemia, γ -Thalassemia, β -Thalassemia major, β -Thalassemia intermedia, $\delta\beta$ -Thalassemia, and $\epsilon\gamma\delta\beta$ -Thalassemia.

81. The composition of claim 65, wherein the kidney disease is selected from the group consisting of Abderhalden–Kaufmann–Lignac syndrome (Nephropathic Cystinosis), Abdominal Compartment Syndrome, Acetaminophen-induced Nephrotoxicity, Acute Kidney Failure/Acute Kidney Injury, Acute Lobar Nephronia, Acute Phosphate Nephropathy, Acute Tubular Necrosis,

- 663 -

Adenine Phosphoribosyltransferase Deficiency, Adenovirus Nephritis, Alagille Syndrome, Alport Syndrome, Amyloidosis, ANCA Vasculitis Related to Endocarditis and Other Infections, Angiomyolipoma, Analgesic Nephropathy, Anorexia Nervosa and Kidney Disease, Angiotensin Antibodies and Focal Segmental Glomerulosclerosis, Antiphospholipid Syndrome, Anti-TNF- α

5 Therapy-related Glomerulonephritis, APOL1 Mutations, Apparent Mineralocorticoid Excess Syndrome, Aristolochic Acid Nephropathy, Chinese Herbal Nephropathy, Balkan Endemic Nephropathy, Arteriovenous Malformations and Fistulas of the Urologic Tract, Autosomal Dominant Hypocalcemia, Bardet-Biedl Syndrome, Bartter Syndrome, Bath Salts and Acute Kidney Injury, Beer Potomania, Beeturia, β -Thalassemia Renal Disease, Bile Cast Nephropathy,

10 BK Polyoma Virus Nephropathy in the Native Kidney, Bladder Rupture, Bladder Sphincter Dyssynergia, Bladder Tamponade, Border-Crossers' Nephropathy, Bourbon Virus and Acute Kidney Injury, Burnt Sugarcane Harvesting and Acute Renal Dysfunction, Byetta and Renal Failure, C1q Nephropathy, C3 Glomerulopathy, C3 Glomerulopathy with Monoclonal Gammopathy, C4 Glomerulopathy, Calcineurin Inhibitor Nephrotoxicity, Callilepsis Laureola

15 Poisoning, Cannabinoid Hyperemesis Acute Renal Failure, Cardiorenal syndrome, Carfilzomib-Induced Renal Injury, CFHR5 nephropathy, Charcot-Marie-Tooth Disease with Glomerulopathy, Chinese Herbal Medicines and Nephrotoxicity, Cherry Concentrate and Acute Kidney Injury, Cholesterol Emboli, Churg-Strauss syndrome, Chyluria, Ciliopathy, Cocaine and the Kidney, Cold Diuresis, Colistin Nephrotoxicity, Collagenofibrotic Glomerulopathy,

20 Collapsing Glomerulopathy, Collapsing Glomerulopathy Related to CMV, Combination Antiretroviral (cART) Related-Nephropathy, Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), Congenital Nephrotic Syndrome, Congestive Renal Failure, Conorenal syndrome (Mainzer-Saldino Syndrome or Saldino-Mainzer Disease), Contrast Nephropathy, Copper Sulphate Intoxication, Cortical Necrosis, Crizotinib-related Acute Kidney Injury,

25 Cryocrystalglobulinemia, Cryoglobulinemia, Crystalglobulin-Induced Nephropathy, Crystal-Induced Acute Kidney injury, Crystal-Storing Histiocytosis, Cystic Kidney Disease, Acquired, Cystinuria, Dasatinib-Induced Nephrotic-Range Proteinuria, Dense Deposit Disease (MPGN Type 2), Dent Disease (X-linked Recessive Nephrolithiasis), DHA Crystalline Nephropathy, Dialysis Disequilibrium Syndrome, Diabetes and Diabetic Kidney Disease, Diabetes Insipidus,

30 Dietary Supplements and Renal Failure, Diffuse Mesangial Sclerosis, Diuresis, Djenkol Bean Poisoning (Djenkolism), Down Syndrome and Kidney Disease, Drugs of Abuse and Kidney Disease, Duplicated Ureter, EAST syndrome, Ebola and the Kidney, Ectopic Kidney, Ectopic

- 664 -

Ureter, Edema, Swelling, Erdheim-Chester Disease, Fabry's Disease, Familial Hypocalciuric Hypercalcemia, Fanconi Syndrome, Fraser syndrome, Fibronectin Glomerulopathy, Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy, Fraley syndrome, Fluid Overload, Hypervolemia, Focal Segmental Glomerulosclerosis, Focal Sclerosis, Focal Glomerulosclerosis, Galloway Mowat syndrome, Giant Cell (Temporal) Arteritis with Kidney Involvement, Gestational Hypertension, Gitelman Syndrome, Glomerular Diseases, Glomerular Tubular Reflux, Glycosuria, Goodpasture Syndrome, Green Smoothie Cleanse Nephropathy, HANAC Syndrome, Harvoni (Ledipasvir with Sofosbuvir)-Induced Renal Injury, Hair Dye Ingestion and Acute Kidney Injury, Hantavirus Infection Podocytopathy, Heat Stress Nephropathy, Hematuria (Blood in Urine), Hemolytic Uremic Syndrome (HUS), Atypical Hemolytic Uremic Syndrome (aHUS), Hemophagocytic Syndrome, Hemorrhagic Cystitis, Hemorrhagic Fever with Renal Syndrome (HFRS, Hantavirus Renal Disease, Korean Hemorrhagic Fever, Epidemic Hemorrhagic Fever, Nephropathis Epidemica), Hemosiderinuria, Hemosiderosis related to Paroxysmal Nocturnal Hemoglobinuria and Hemolytic Anemia, Hepatic Glomerulopathy, Hepatic Veno-Occlusive Disease, Sinusoidal Obstruction Syndrome, Hepatitis C-Associated Renal Disease, Hepatocyte Nuclear Factor 1 β -Associated Kidney Disease, Hepatorenal Syndrome, Herbal Supplements and Kidney Disease, High Altitude Renal Syndrome, High Blood Pressure and Kidney Disease, HIV-Associated Immune Complex Kidney Disease (HIVICK), HIV-Associated Nephropathy (HIVAN), HNF1B-related Autosomal Dominant Tubulointerstitial Kidney Disease, Horseshoe Kidney (Renal Fusion), Hunner's Ulcer, Hydroxychloroquine-induced Renal Phospholipidosis, Hyperaldosteronism, Hypercalcemia, Hyperkalemia, Hypermagnesemia, Hyponatremia, Hyperoxaluria, Hyperphosphatemia, Hypocalcemia, Hypocomplementemic Urticarial Vasculitic Syndrome, Hypokalemia, Hypokalemia-induced renal dysfunction, Hypokalemic Periodic Paralysis, Hypomagnesemia, Hyponatremia, Hypophosphatemia, Hypophosphatemia in Users of Cannabis, Hypertension, Hypertension, Monogenic, Iced Tea Nephropathy, Ifosfamide Nephrotoxicity, IgA Nephropathy, IgG4 Nephropathy, Immersion Diuresis, Immune-Checkpoint Therapy-Related Interstitial Nephritis, Infliximab-Related Renal Disease, Interstitial Cystitis, Painful Bladder Syndrome (Questionnaire), Interstitial Nephritis, Interstitial Nephritis, Karyomegalic, Ivemark's syndrome, JC Virus Nephropathy, Joubert Syndrome, Ketamine-Associated Bladder Dysfunction, Kidney Stones, Nephrolithiasis, Kombucha Tea Toxicity, Lead Nephropathy and Lead-Related Nephrotoxicity, Lecithin Cholesterol Acyltransferase Deficiency (LCAT Deficiency),

- 665 -

Leptospirosis Renal Disease, Light Chain Deposition Disease, Monoclonal Immunoglobulin Deposition Disease, Light Chain Proximal Tubulopathy, Liddle Syndrome, Lightwood-Albright Syndrome, Lipoprotein Glomerulopathy, Lithium Nephrotoxicity, LMX1B Mutations Cause Hereditary FSGS, Loin Pain Hematuria, Lupus, Systemic Lupus Erythematosus, Lupus Kidney Disease, Lupus Nephritis, Lupus Nephritis with Antineutrophil Cytoplasmic Antibody Seropositivity, Lupus Podocytopathy, Lyme Disease-Associated Glomerulonephritis, Lysinuric Protein Intolerance, Lysozyme Nephropathy, Malarial Nephropathy, Malignancy-Associated Renal Disease, Malignant Hypertension, Malakoplakia, McKittrick-Wheelock Syndrome, MDMA (Molly; Ecstasy; 3,4-Methylenedioxymethamphetamine) and Kidney Failure, Meatal Stenosis, Medullary Cystic Kidney Disease, Urolodulin-Associated Nephropathy, Juvenile Hyperuricemic Nephropathy Type 1, Medullary Sponge Kidney, Megaureter, Melamine Toxicity and the Kidney, MELAS Syndrome, Membranoproliferative Glomerulonephritis, Membranous Nephropathy, Membranous-like Glomerulopathy with Masked IgG Kappa Deposits, MesoAmerican Nephropathy, Metabolic Acidosis, Metabolic Alkalosis, Methotrexate-related Renal Failure, Microscopic Polyangiitis, Milk-alkalai syndrome, Minimal Change Disease, Monoclonal Gammopathy of Renal Significance, Dysproteinemia, Mouthwash Toxicity, MUC1 Nephropathy, Multicystic dysplastic kidney, Multiple Myeloma, Myeloproliferative Neoplasms and Glomerulopathy, Nail-patella Syndrome, NARP Syndrome, Nephrocalcinosis, Nephrogenic Systemic Fibrosis, Nephroptosis (Floating Kidney, Renal Ptosis), Nephrotic Syndrome, Neurogenic Bladder, 9/11 and Kidney Disease, Nodular Glomerulosclerosis, Non-Gonococcal Urethritis, Nutcracker syndrome, Oligomeganephronia, Orofaciodigital Syndrome, Orotic Aciduria, Orthostatic Hypotension, Orthostatic Proteinuria, Osmotic Diuresis, Osmotic Nephrosis, Ovarian Hyperstimulation Syndrome, Oxalate Nephropathy, Page Kidney, Papillary Necrosis, Papillorenal Syndrome (Renal-Coloboma Syndrome, Isolated Renal Hypoplasia), PARN Mutations and Kidney Disease, Parvovirus B19 and the Kidney, The Peritoneal-Renal Syndrome, POEMS Syndrome, Posterior Urethral Valve, Podocyte Infolding Glomerulopathy, Post-infectious Glomerulonephritis, Post-streptococcal Glomerulonephritis, Post-infectious Glomerulonephritis, Atypical, Post-Infectious Glomerulonephritis (IgA-Dominant), Mimicking IgA Nephropathy, Polyarteritis Nodosa, Polycystic Kidney Disease, Posterior Urethral Valves, Post-Obstructive Diuresis, Preeclampsia, Propofol infusion syndrome, Proliferative Glomerulonephritis with Monoclonal IgG Deposits (Nasr Disease), Propolis (Honeybee Resin) Related Renal Failure, Proteinuria (Protein in Urine), Pseudohyperaldosteronism,

- 666 -

Pseudohypobicarbonatemia, Pseudohypoparathyroidism, Pulmonary-Renal Syndrome, Pyelonephritis (Kidney Infection), Pyonephrosis, Pyridium and Kidney Failure, Radiation Nephropathy, Ranolazine and the Kidney, Refeeding syndrome, Reflux Nephropathy, Rapidly Progressive Glomerulonephritis, Renal Abscess, Peripnephric Abscess, Renal Agenesis, Renal Arcuate Vein Microthrombi-Associated Acute Kidney Injury, Renal Artery Aneurysm, Renal Artery Dissection, Spontaneous, Renal Artery Stenosis, Renal Cell Cancer, Renal Cyst, Renal Hypouricemia with Exercise-induced Acute Renal Failure, Renal Infarction, Renal Osteodystrophy, Renal Tubular Acidosis, Renin Mutations and Autosomal Dominant Tubulointerstitial Kidney Disease, Renin Secreting Tumors (Juxtaglomerular Cell Tumor), Reset Osmostat, Retrocaval Ureter, Retroperitoneal Fibrosis, Rhabdomyolysis, Rhabdomyolysis related to Bariatric Sugery, Rheumatoid Arthritis-Associated Renal Disease, Sarcoidosis Renal Disease, Salt Wasting, Renal and Cerebral, Schistosomiasis and Glomerular Disease, Schimke immuno-osseous dysplasia, Scleroderma Renal Crisis, Serpentine Fibula-Polycystic Kidney Syndrome, Exner Syndrome, Sickle Cell Nephropathy, Silica Exposure and Chronic Kidney Disease, Sri Lankan Farmers' Kidney Disease, Sjögren's Syndrome and Renal Disease, Synthetic Cannabinoid Use and Acute Kidney Injury, Kidney Disease Following Hematopoietic Cell Transplantation, Kidney Disease Related to Stem Cell Transplantation, TAFRO Syndrome, Tea and Toast Hyponatremia, Tenofovir-Induced Nephrotoxicity, Thin Basement Membrane Disease, Benign Familial Hematuria, Thrombotic Microangiopathy Associated with Monoclonal Gammopathy, Trench Nephritis, Trigonitis, Tuberculosis, Genitourinary, Tuberous Sclerosis, Tubular Dysgenesis, Immune Complex Tubulointerstitial Nephritis Due to Autoantibodies to the Proximal Tubule Brush Border, Tumor Lysis Syndrome, Uremia, Uremic Optic Neuropathy, Ureteritis Cystica, Ureterocele, Urethral Caruncle, Urethral Stricture, Urinary Incontinence, Urinary Tract Infection, Urinary Tract Obstruction, Urogenital Fistula, Uromodulin-Associated Kidney Disease, Vancomycin-Associated Cast Nephropathy, Vasomotor Nephropathy, Vesicointestinal Fistula, Vesicoureteral Reflux, VGEF Inhibition and Renal Thrombotic Microangiopathy, Volatile Anesthetics and Acute Kidney Injury, Von Hippel-Lindau Disease, Waldenstrom's Macroglobulinemic Glomerulonephritis, Warfarin-Related Nephropathy, Wasp Stings and Acute Kidney Injury, Wegener's Granulomatosis, Granulomatosis with Polyangiitis, West Nile Virus and Chronic Kidney Disease, Wunderlich syndrome, Zellweger Syndrome, or Cerebrohepatorenal Syndrome.

- 667 -

82. The composition of claim 65, wherein the hearing loss condition is selected from the group consisting of mitochondrial nonsyndromic hearing loss and deafness, hair cell death, age-related hearing loss, noise-induced hearing loss, genetic or inherited hearing loss, hearing loss experienced as a result of ototoxic exposure, hearing loss resulting from disease, and hearing loss resulting from trauma.

83. The composition of claim 65, wherein the ocular disease cataracts, glaucoma, endoplasmic reticulum (ER) stress, autophagy deficiency, age-related macular degeneration (AMD), or diabetic retinopathy.

84. The composition of any one of claims 65-83, comprising administering a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof, or a composition thereof, to a subject in combination with a second agent (e.g., agent for treating a neurodegenerative disease, a leukodystrophy, a cancer, an inflammatory disease, an autoimmune disease, a viral infection, a skin disease, a fibrotic disease, a hemoglobin disease, a kidney disease, a hearing loss condition, an ocular disease, a musculoskeletal disease, a metabolic disease, a mitochondrial disease or a disease or disorder associated with impaired function of eIF2B, eIF2 α , or a component of the eIF2 pathway or ISR pathway).

85. A composition for use in treating a disease related to a modulation of eIF2B activity or levels, eIF2 α activity or levels, or the activity or levels of a component of the eIF2 pathway or the ISR pathway, wherein the composition comprises a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide or stereoisomer thereof as described in any one of claims 1-63.

86. The composition of claim 85, wherein the modulation comprises an increase in eIF2B activity or levels, increase in eIF2 α activity or levels, or increase in activity or levels of a component of the eIF2 pathway or the ISR pathway.

87. The composition of claim 85, wherein the disease may be caused by a mutation to a gene or protein sequence related to a member of the eIF2 pathway (e.g., the eIF2 α signaling pathway).

- 668 -

88. A method of treating cancer in a subject, the method comprising administering to the subject a compound of formula (I) or formula (II) in combination with an immunotherapeutic agent.